<SEC-DOCUMENT>0001437749-23-022879.txt : 20230810
<SEC-HEADER>0001437749-23-022879.hdr.sgml : 20230810
<ACCEPTANCE-DATETIME>20230810080434
ACCESSION NUMBER:		0001437749-23-022879
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230810
DATE AS OF CHANGE:		20230810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UroGen Pharma Ltd.
		CENTRAL INDEX KEY:			0001668243
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38079
		FILM NUMBER:		231157256

	BUSINESS ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
		BUSINESS PHONE:		972 9 770 7601

	MAIL ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>urgn20230630_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:urgn="http://www.urogen.com/20230630" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>urgn20230630_10q.htm</title>
  <!-- Generated by ThunderDome Portal - 8/9/2023 4:47:50 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="padding: 0in 0.1in; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001668243</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">UroGen Pharma Ltd. </ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
<ix:nonFraction id="c101504776" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c101504777" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c101504781" contextRef="i_2023-06-30" unitRef="ILSPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c101504782" contextRef="i_2022-12-31" unitRef="ILSPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c101504783" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000,000</ix:nonFraction>
<ix:nonFraction id="c101504784" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000,000</ix:nonFraction>
<ix:nonFraction id="c101504785" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">23,498,617</ix:nonFraction>
<ix:nonFraction id="c101504787" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">23,498,617</ix:nonFraction>
<ix:nonFraction id="c101504786" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">23,129,953</ix:nonFraction>
<ix:nonFraction id="c101504788" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">23,129,953</ix:nonFraction>
<ix:nonFraction id="c101504890" contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">490,744</ix:nonFraction>
<ix:nonFraction id="c101504891" contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">607,317</ix:nonFraction>
<ix:nonFraction id="c101504892" contextRef="i_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45</ix:nonFraction>
<ix:nonFraction id="c101504893" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">116,554</ix:nonFraction>
<ix:nonFraction id="c101504896" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction>
<ix:nonFraction id="c101504897" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">143</ix:nonFraction>
<ix:nonFraction id="c101504916" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">24,136</ix:nonFraction>
<ix:nonFraction id="c101504918" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">24,136</ix:nonFraction>
<ix:nonFraction id="c101504926" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">62</ix:nonFraction>
<ix:nonFraction id="c101504927" contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">478,646</ix:nonFraction>
<ix:nonFraction id="c101504928" contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">495,713</ix:nonFraction>
<ix:nonFraction id="c101504930" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">17,074</ix:nonFraction>
<ix:nonFraction id="c101504933" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction>
<ix:nonFraction id="c101504934" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">16</ix:nonFraction>
<ix:nonFraction id="c101504937" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">16</ix:nonFraction>
<ix:nonFraction id="c101504948" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3">13</ix:nonFraction>
<ix:nonFraction id="c101504949" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3">13</ix:nonFraction>
<ix:nonFraction id="c101504982" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">487,787</ix:nonFraction>
<ix:nonFraction id="c101504983" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">577,104</ix:nonFraction>
<ix:nonFraction id="c101504984" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">107</ix:nonFraction>
<ix:nonFraction id="c101504985" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">89,361</ix:nonFraction>
<ix:nonFraction id="c101504988" contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction>
<ix:nonFraction id="c101504989" contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">814</ix:nonFraction>
<ix:nonFraction id="c101505008" contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,349</ix:nonFraction>
<ix:nonFraction id="c101505010" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,349</ix:nonFraction>
<ix:nonFraction id="c101505018" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">61</ix:nonFraction>
<ix:nonFraction id="c101505019" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">475,698</ix:nonFraction>
<ix:nonFraction id="c101505020" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">467,321</ix:nonFraction>
<ix:nonFraction id="c101505022" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">8,413</ix:nonFraction>
<ix:nonFraction id="c101505025" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction>
<ix:nonFraction id="c101505026" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">15</ix:nonFraction>
<ix:nonFraction id="c101505029" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">16</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c101505219" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c101505494" contextRef="i_2023-06-30_CounterpartyNameAxis-RTWInvestmentsMember" unitRef="USD" name="urgn:PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" scale="6" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember" name="us-gaap:LongTermDebtTerm" id="c101505520" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-01-31_CounterpartyNameAxis-MDAndersonMember" name="urgn:CollaborationAgreementTerm" id="c101505661" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c101505676" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="6" format="ixt:numdotdecimal" decimals="-8">100.0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c101505697" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c101505703" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c101505707" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:footnote xml:lang="en-us" id="f77a016e4-dc74-4be3-af47-01f1c1cc61c6">$1.5 million and $1.0 million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, respectively.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fdbc58e92-bcbc-4c05-93c1-815a65a63318">$2.7 million and $2.3 million of the Amounts paid and payable are included as current portion of the prepaid
forward obligation within other current liabilities on the condensed consolidated balance sheets as of June 30,
2023 and December 31, 2022, respectively.</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="urgn-20230630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2023-01-01_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-08-07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="ILSPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2023-04-01_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-26</xbrli:startDate><xbrli:endDate>2023-07-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:FurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:FurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ManufacturingEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ManufacturingEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:FurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:FurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOfUpTo200MillionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesOfUpTo200MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesBetween200MillionAnd300MillionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesBetween200MillionAnd300MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOver300MillionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesOver300MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_CounterpartyNameAxis-RTWInvestmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-UGN102Member_StatementScenarioAxis-SalesUpTo200MillionWithFDAApprovalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:UGN102Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesUpTo200MillionWithFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesBetween200MillionAnd300MillionWithFDAApprovalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesBetween200MillionAnd300MillionWithFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesOver300MillionWithFDAApprovalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesOver300MillionWithFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-01_2021-05-31_CounterpartyNameAxis-RTWInvestmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-03-07_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember_VariableRateAxis-LondonInterbankOfferedRateLibor1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">urgn:LondonInterbankOfferedRateLibor1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2023-07-31_LongtermDebtTypeAxis-SecuredDebtMember_SubsequentEventTypeAxis-SubsequentEventMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">urgn:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-01_DebtInstrumentAxis-PharmakonLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_LeaseContractualTermAxis-CompanyOfficesInIsraelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:CompanyOfficesInIsraelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-10-01_2020-10-31_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInLosAngelesCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInLosAngelesCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInLosAngelesCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2019-11-29_LeaseContractualTermAxis-LeaseAgreementForOfficeInPrincetonNewJerseyMember_LegalEntityAxis-UroGenPharmaIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInPrincetonNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInPrincetonNewJerseyMember_LegalEntityAxis-UroGenPharmaIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInPrincetonNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_ProductOrServiceAxis-JelmytoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_ProductOrServiceAxis-JelmytoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_ProductOrServiceAxis-JelmytoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_ProductOrServiceAxis-JelmytoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:GovernmentSponsoredProgramsReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:GovernmentSponsoredProgramsReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:GovernmentSponsoredProgramsReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-01-31_CounterpartyNameAxis-MDAndersonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:MDAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_CounterpartyNameAxis-MDAndersonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:MDAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-03-31_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-01-01_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-01-01_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-10-12_2018-10-12_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-12</xbrli:startDate><xbrli:endDate>2018-10-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-10-12_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-08_2020-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-08</xbrli:startDate><xbrli:endDate>2020-06-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-07_2021-06-07_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-07</xbrli:startDate><xbrli:endDate>2021-06-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-07_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-06-08_2022-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-31_PlanNameAxis-The2019InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:The2019InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-12-01_2021-12-31_PlanNameAxis-The2019InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:The2019InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-26</xbrli:startDate><xbrli:endDate>2023-07-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:PrefundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:MonographCapitalPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-26</xbrli:startDate><xbrli:endDate>2023-07-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001668243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:MonographCapitalPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-26</xbrli:startDate><xbrli:endDate>2023-07-26</xbrli:endDate></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f77a016e4-dc74-4be3-af47-01f1c1cc61c6" fromRefs="c101505270 c101505271"></ix:relationship>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fdbc58e92-bcbc-4c05-93c1-815a65a63318" fromRefs="c101505507 c101505510"></ix:relationship></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 6pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>WASHINGTON, DC 20549</b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 6pt auto 6pt auto;" />
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2023-01-01_2023-06-30">10-Q</ix:nonNumeric></b></p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 6pt auto 6pt auto;" />
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; margin: 0pt;"><b>(Mark One)</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 2.4%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-06-30">&#x2612;</ix:nonNumeric></p> </td><td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
</tbody></table>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2023-01-01_2023-06-30">June 30, 2023</ix:nonNumeric></b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>OR</b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 2.4%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-06-30">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
</tbody></table>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>For the transition period from</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b> to </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Commission file number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2023-01-01_2023-06-30">001-38079</ix:nonNumeric></b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 6pt auto 6pt auto;" />
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 24pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UROGEN PHARMA LTD.</b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Exact Name of Registrant as Specified in its Charter)</b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 6pt auto 6pt auto;" />
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: bottom; width: 26.7%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" contextRef="d_2023-01-01_2023-06-30">Israel</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 26.7%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2023-01-01_2023-06-30">98-1460746</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: bottom; width: 26.7%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(State or other jurisdiction of</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>incorporation or organization)</b></p> </td><td style="vertical-align: bottom; width: 26.7%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(I.R.S. Employer</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identification No.)</b></p> </td></tr>
<tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: bottom; width: 26.7%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2023-01-01_2023-06-30">400 Alexander Park Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2023-01-01_2023-06-30">Princeton</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2023-01-01_2023-06-30">New Jersey</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 26.7%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2023-01-01_2023-06-30">08540</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: bottom; width: 26.7%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Address of principal executive offices)</b></p> </td><td style="vertical-align: bottom; width: 26.7%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Zip Code)</b></p> </td></tr>
</tbody></table>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2023-01-01_2023-06-30">646</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2023-01-01_2023-06-30">768-9780</ix:nonNumeric></b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Registrant</b>&#x2019;<b>s telephone number, including area code</b></p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 6pt auto 6pt auto;" />
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>N/A</b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Former name, former address and former fiscal year, if changed since last report)</b></p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<table cellpadding="3" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"><td style="vertical-align: bottom; width: 40%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="text-decoration: underline; ">Title of each class</span></p> </td><td style="vertical-align: bottom; width: 20%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="text-decoration: underline; ">Trading Symbol</span></p> </td><td style="vertical-align: bottom; width: 40%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="text-decoration: underline; ">Name of exchange on which registered</span></p> </td></tr>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"><td style="vertical-align: bottom; width: 40%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2023-01-01_2023-06-30">Ordinary Shares, par value NIS 0.01 per share</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 20%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2023-01-01_2023-06-30">URGN</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 40%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2023-01-01_2023-06-30">Nasdaq</ix:nonNumeric> Stock Market LLC</p> </td></tr>
</tbody></table>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2023-01-01_2023-06-30">Yes</ix:nonNumeric>&#xa0;&#xa0;&#x2612;&#xa0;&#xa0;&#xa0;&#xa0;No&#xa0;&#xa0;&#x2610;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2023-01-01_2023-06-30">Yes</ix:nonNumeric>&#xa0;&#xa0;&#x2612;&#xa0;&#xa0;&#xa0;&#xa0;No&#xa0;&#xa0;&#x2610;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Large&#xa0;accelerated&#xa0;filer</p> </td><td style="vertical-align: top; width: 47%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x2610;</p> </td><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Accelerated&#xa0;filer</p> </td><td style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x2610;</p> </td></tr>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td><td colspan="1" style="vertical-align: top; width: 47%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td><td colspan="1" style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td><td colspan="1" style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2023-01-01_2023-06-30">Non-accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 47%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x2612;</p> </td><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Smaller&#xa0;reporting&#xa0;company</p> </td><td style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-06-30">&#x2612;</ix:nonNumeric></p> </td></tr>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 47%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Emerging growth company</p> </td><td style="vertical-align: top; width: 47%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-06-30">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#xa0;&#x2610;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#xa0;&#xa0;&#xa0;&#xa0;Yes&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-06-30">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;No&#xa0;&#xa0;&#x2612;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">As of August 7, 2023, the registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2023-08-07">30,282,880</ix:nonFraction>&#xa0;ordinary shares, par value NIS 0.01 per share, outstanding.</p>
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">&#xa0;</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="toc" title="toc" href="#"></a>UroGen Pharma Ltd.</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Index</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <table cellpadding="1" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
    <tbody>
     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 7pt;"><b>Page</b></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PART I.</b></p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#pi" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">FINANCIAL INFORMATION</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#pi">1</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 1.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#pi" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Financial Statements (Unaudited)</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#pi">1</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#pi" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Condensed Consolidated Balance Sheets</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#pi">1</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#income" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#income">2</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#she" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Condensed Consolidated Statements of Shareholders</span>&#x2019;<span style="text-decoration: underline; ">&#xa0;Equity (Deficit)</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#she">3</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#cfs" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Condensed Consolidated Statements of Cash Flows</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#cfs">5</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#notes" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#notes">6</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 2.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#mda" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Management</span>&#x2019;<span style="text-decoration: underline; ">s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#mda">20</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 3.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#qqdmr" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Quantitative and Qualitative Disclosures About Market Risk</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#qqdmr">32</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 4.</p> </td>
      <td style="vertical-align: top; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#cps" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Controls and Procedures</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#cps">34</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PART II.</b></p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#pii" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">OTHER INFORMATION</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#pii">35</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 1.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#legal" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Legal Proceedings</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#legal">35</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 1A.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#risks" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Risk Factors</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#risks">35</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 2.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#uses" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#uses">80</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 3.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#duss" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Defaults Upon Senior Securities</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#duss">80</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 4.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#msd" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Mine Safety Disclosures</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#msd">80</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 5.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#oi" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Other Information</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#oi">80</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Item 6.</p> </td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#ex" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Exhibits</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#ex">81</a></p> </td>
     </tr>

     <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
      <td style="vertical-align: middle; width: 8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 87%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#sigs" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Signatures</span></a></p> </td>
      <td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><a class="tocPGNUM" href="#sigs">82</a></p> </td>
     </tr>

    </tbody>
   </table>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Trademarks and Trade Names</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unless the context requires otherwise, references in this Quarterly Report to the &#x201c;Company,&#x201d;&#xa0;"UroGen," &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to UroGen Pharma Ltd. and its subsidiary, UroGen Pharma, Inc.<i> </i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen<sup style="vertical-align:top;line-height:120%;">&#xae;</sup>, <i>RTGel</i><sup style="vertical-align:top;line-height:120%;">&#xae;</sup>, and&#xa0;<i>Jelmyto</i><sup style="vertical-align:top;line-height:120%;">&#xae;</sup>&#xa0;are trademarks of ours that we use in this Quarterly Report. This Quarterly Report also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Quarterly Report appear without the &#xae; or &#x2122; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames. We do not intend our use or display of other companies&#x2019; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row" style="font-family: Arial, Helvetica, sans-serif;font-size: 10pt;">
     <div class="hf-cell PGNUM">
       i
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="pi" title="pi" href="#"></a>Part I</b>&#x2014;<b>Financial Information</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Item 1. Financial Statements.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UroGen Pharma Ltd.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Balance Sheets</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(unaudited; in thousands, except share amounts and par value)</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Assets</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504727" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">20,127</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504728" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">55,408</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504729" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">27,174</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504730" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">44,556</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Restricted cash</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504731" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:RestrictedCashCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">816</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504732" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RestrictedCashCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">813</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504733" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">15,505</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504734" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">12,704</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Inventories</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504735" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">4,988</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504736" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">4,325</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504737" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">12,723</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504738" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">11,101</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current assets</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504739" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">81,333</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504740" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">128,907</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-current assets:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504742" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-4">910</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504743" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,297</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Restricted deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504744" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">224</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504745" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">223</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Right of use assets</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504746" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">2,107</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504747" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">2,452</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504748" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">7,970</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504749" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other non-current assets</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504750" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,817</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504751" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">2,740</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Assets</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504752" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">95,361</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504753" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">135,619</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Liabilities and Shareholders' Deficit</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504756" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">16,403</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504757" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">12,383</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Employee related accrued expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504758" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">6,721</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504759" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8,257</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504760" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,641</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504761" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,276</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current liabilities:</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504762" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">26,765</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504763" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">23,916</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-current liabilities:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid forward obligation</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504765" contextRef="i_2023-06-30" unitRef="USD" name="urgn:PrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">104,507</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504766" contextRef="i_2022-12-31" unitRef="USD" name="urgn:PrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">98,923</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Long-term debt</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101504767" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">98,296</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101504768" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">97,537</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Long-term lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504769" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,209</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504770" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,586</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Uncertain tax positions liability</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504771" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,018</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504772" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,018</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504773" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">233,795</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504774" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-4">224,980</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commitments and Contingencies (Note 18)</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c101504776">&#xa0;</span></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c101504777">&#xa0;</span></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Shareholders' Deficit:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Ordinary shares, NIS <span style="-sec-ix-hidden:c101504781"><span style="-sec-ix-hidden:c101504782">0.01</span></span> par value, <span style="-sec-ix-hidden:c101504783"><span style="-sec-ix-hidden:c101504784">100,000,000</span></span> shares authorized at June 30, 2023 and December 31, 2022; <span style="-sec-ix-hidden:c101504785"><span style="-sec-ix-hidden:c101504787">23,498,617</span></span> and <span style="-sec-ix-hidden:c101504786"><span style="-sec-ix-hidden:c101504788">23,129,953</span></span> shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504779" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">64</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504780" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">63</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504789" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">493,109</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504790" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">487,787</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504791" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">631,453</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504792" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">577,104</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504793" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">154</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504794" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">107</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Shareholders' Deficit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504795" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">138,434</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504796" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">89,361</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Liabilities and Shareholders' Deficit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504797" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">95,361</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504798" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">135,619</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="income" title="income" href="#"></a>UroGen Pharma Ltd.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Statements of Operations and Comprehensive Loss</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(unaudited; in thousands, except share and per share amounts)</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">For the Three Months Ended June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">For the Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 52%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504799" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">21,139</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504800" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">16,604</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504801" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">38,331</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504802" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">30,168</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenue</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504803" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:CostOfRevenue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,443</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504804" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:CostOfRevenue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,846</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504805" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:CostOfRevenue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,708</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504806" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:CostOfRevenue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,371</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross profit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504807" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:GrossProfit" scale="3" format="ixt:numdotdecimal" decimals="-3">18,696</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504808" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:GrossProfit" scale="3" format="ixt:numdotdecimal" decimals="-3">14,758</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504809" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:GrossProfit" scale="3" format="ixt:numdotdecimal" decimals="-3">33,623</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504810" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:GrossProfit" scale="3" format="ixt:numdotdecimal" decimals="-3">26,797</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504812" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">11,584</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504813" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">12,640</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504814" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">24,082</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504815" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">25,336</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504816" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">22,494</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504817" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">20,833</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504818" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">46,968</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504819" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">42,133</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504820" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">15,382</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504821" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">18,715</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504822" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,427</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504823" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,672</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504824" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="urgn:FinancingOnPrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">5,344</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504825" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="urgn:FinancingOnPrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">5,833</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504826" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:FinancingOnPrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">10,568</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504827" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="urgn:FinancingOnPrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">11,659</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense on long-term debt</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504828" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:InterestExpenseLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">3,761</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504829" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:InterestExpenseLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">2,239</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504830" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:InterestExpenseLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">7,314</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504831" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:InterestExpenseLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">2,521</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest and other income (expense), net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504832" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="urgn:InterestAndOtherIncomeNet" scale="3" format="ixt:numdotdecimal" decimals="-3">405</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504833" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="urgn:InterestAndOtherIncomeNet" scale="3" format="ixt:numdotdecimal" decimals="-3">128</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504834" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:InterestAndOtherIncomeNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,035</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504835" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="urgn:InterestAndOtherIncomeNet" scale="3" format="ixt:numdotdecimal" decimals="-3">126</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504836" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">24,082</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504837" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">26,659</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504838" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,274</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504839" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,726</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504840" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">54</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504841" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">32</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504842" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">75</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504843" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">357</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504844" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">24,136</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504845" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">26,691</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504846" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,349</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504847" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">55,083</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Statements of Comprehensive Loss</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504849" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">24,136</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504850" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">26,691</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504851" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,349</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504852" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">55,083</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other comprehensive loss</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Unrealized gain (loss) on investments</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504854" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">109</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101504855" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">13</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504856" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">47</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504857" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">31</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive Loss</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504858" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">24,245</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504859" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">26,678</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504860" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,396</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504861" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">55,114</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per ordinary share - basic and diluted</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504862" contextRef="d_2023-04-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.03</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504863" contextRef="d_2022-04-01_2022-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.18</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504864" contextRef="d_2023-01-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2.33</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504865" contextRef="d_2022-01-01_2022-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2.43</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504866" contextRef="d_2023-04-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">23,462,016</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504867" contextRef="d_2022-04-01_2022-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">22,703,572</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504868" contextRef="d_2023-01-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">23,371,878</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504869" contextRef="d_2022-01-01_2022-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">22,667,825</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="she" title="she" href="#"></a>UroGen Pharma Ltd.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Statements of Shareholders</b>&#x2019;<b>&#xa0;Deficit</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(unaudited; in thousands, except share amounts)</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <div>
   <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Ordinary Shares</em></em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Additional paid-in</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated other comprehensive</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">capital</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Deficit</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">loss</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 34%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of April 1, 2023</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504888" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">23,440,521</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504889" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">64</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504890">490,744</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504891">(607,317</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504892">(45</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504893">(116,554</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes During the Three Months Ended June 30, 2023</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercise of options into ordinary shares</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504895" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">58,096</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504896">&#x2014;</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504897">143</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><ix:nonFraction id="c101504898" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><ix:nonFraction id="c101504899" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504900" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">143</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Share-based compensation</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504903" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,222</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504906" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,222</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other comprehensive loss</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504911" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">109</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504912" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">109</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net loss</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c101504916">(24,136</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c101504918">(24,136</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2023</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504919" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">23,498,617</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504920" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">64</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504921" contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">493,109</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504922" contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">631,453</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504923" contextRef="i_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">154</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504924" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">138,434</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of April 1, 2022</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504925" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">22,682,221</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504926">62</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504927">478,646</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504928">(495,713</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101504929" contextRef="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">69</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504930">(17,074</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Changes During the Three Months Ended June 30, 2022</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercise of options into ordinary shares</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504932" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">45,670</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504933">-</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504934">16</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504937">16</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Share-based compensation</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504940" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,823</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504943" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,823</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other comprehensive income</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504948">13</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504949">13</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net loss</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504953" contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">26,691</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101504955" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">26,691</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2022</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504956" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">22,727,891</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504957" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">62</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101504958" contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">481,485</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504959" contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">522,404</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504960" contextRef="i_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">56</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101504961" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,913</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UroGen Pharma Ltd.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Statements of Shareholders</b>&#x2019;<b>&#xa0;Deficit</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(unaudited; in thousands, except share amounts)</b></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Ordinary Shares</em></em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Additional paid-in</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Accumulated other comprehensive</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Amount</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">capital</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Deficit</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">loss</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 34%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of January 1, 2023</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504980" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">23,129,953</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504981" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">63</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504982">487,787</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504983">(577,104</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504984">(107</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504985">(89,361</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes During the Six Months Ended June 30, 2023</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercise of options into ordinary shares</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504987" contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">368,664</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504988">1</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101504989">814</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><ix:nonFraction id="c101504990" contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><ix:nonFraction id="c101504991" contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504992" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">815</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Share-based compensation</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504995" contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,508</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101504998" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,508</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other comprehensive loss</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505003" contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">47</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505004" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">47</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net loss</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c101505008">(54,349</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c101505010">(54,349</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2023</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505011" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">23,498,617</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505012" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">64</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505013" contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">493,109</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101505014" contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">631,453</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101505015" contextRef="i_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">154</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101505016" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">138,434</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of January 1, 2022</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505017" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">22,462,995</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101505018">61</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101505019">475,698</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101505020">(467,321</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505021" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">25</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101505022">8,413</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes During the Six Months Ended June 30, 2022</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercise of options into ordinary shares</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505024" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">264,896</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101505025">1</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101505026">15</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c101505029">16</span></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Share-based compensation</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505032" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,772</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505035" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,772</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other comprehensive loss</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><ix:nonFraction id="c101505037" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><ix:nonFraction id="c101505038" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><ix:nonFraction id="c101505039" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505040" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">31</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505041" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">31</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net loss</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505045" contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">55,083</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505047" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">55,083</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2022</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505048" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">22,727,891</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505049" contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">62</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505050" contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">481,485</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101505051" contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">522,404</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101505052" contextRef="i_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">56</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101505053" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,913</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="cfs" title="cfs" href="#"></a>UroGen Pharma Ltd.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Condensed Consolidated Statements of Cash Flow</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(unaudited; in thousands)</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Flows From Operating Activities</b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505059" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,349</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505060" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">55,083</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Adjustment to reconcile net loss to net cash from operating activities:</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Depreciation and amortization</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505062" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">426</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505063" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">449</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 45pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Inventory Obsolescence</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505064" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505065" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="3" format="ixt:numdotdecimal" decimals="-3">265</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Accrued financing on prepaid forward obligation</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505066" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:AccruedFinancingOnPrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">5,982</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c101505067" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="urgn:AccruedFinancingOnPrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">8,359</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Amortization (accretion) on marketable securities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505068" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">664</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505069" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">169</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Share-based compensation</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505070" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">4,508</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505071" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">5,772</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 45pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Amortization of discount on long-term debt</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505072" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" format="ixt:numdotdecimal" decimals="-3">759</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505073" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" format="ixt:numdotdecimal" decimals="-3">403</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Amortization of right of use assets</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505074" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">440</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505075" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">483</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Inventory</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505077" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3">663</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505078" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-4">480</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Accounts receivable</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505079" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">2,801</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505080" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">122</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Prepaid expenses and other current assets</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505081" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">1,622</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505082" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">2,958</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Other non-current assets</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505083" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">77</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c101505084" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">444</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Accounts payable and accrued expenses</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505085" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-4">4,020</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505086" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,454</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Employee related accrued expenses</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505087" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,536</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505088" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">520</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Other current liabilities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505089" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c101505090" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">704</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Lease liabilities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505091" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">504</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505092" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">574</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net cash used in operating activities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505093" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">46,081</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505094" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">48,195</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Flows From Investing Activities</b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 45pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Purchases of marketable securities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c101505096" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">24,176</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505097" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Maturities of marketable securities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505098" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">34,204</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505099" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">13,533</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Purchases of property and equipment</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505100" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">38</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505101" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">88</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net cash provided by investing activities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505102" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-4">9,990</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505103" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">13,445</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Flows From Financing Activities</b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Proceeds from exercise of options into ordinary shares</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505105" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">814</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c101505106" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">16</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 45pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Proceeds from issuance of long-term debt</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505107" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505108" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">70,793</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Issuance cost related to at-the-market issuances</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505109" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505110" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">144</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net cash provided by financing activities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505111" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">814</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505112" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">70,665</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Increase (Decrease) in Cash and Cash Equivalents</b></p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505113" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,277</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505114" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3">35,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash, Cash Equivalents and Restricted Cash at Beginning of Period</b></p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505115" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-4">56,220</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505116" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">45,586</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash, Cash Equivalents and Restricted Cash at End of Period</b></p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505117" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">20,943</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505118" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">81,501</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Supplemental Disclosures of Non-Cash Activities</b></p> </td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -45pt;">Right of use assets obtained in exchange for new operating lease liabilities</p> </td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505120" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:NonCashNewLeaseLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">95</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505121" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="urgn:NonCashNewLeaseLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,419</ix:nonFraction></td>
      <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="notes" title="notes" href="#"></a>UroGen Pharma Ltd.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Notes to the Unaudited Condensed Consolidated Financial Statements</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:NatureOfOperations" id="c2444542" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>&#x2013;<b> Business and Nature of Operations</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in&#xa0;<em style="font: inherit;"> April 2004 (</em>&#x201c;UPL&#x201d;).</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma,&#xa0;Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in&#xa0;<em style="font: inherit;"> October 2015&#xa0;</em>and began operating in&#xa0;<em style="font: inherit;"> February 2016 (</em>&#x201c;UPI&#x201d;).</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the &#x201c;Company&#x201d;) is a biotechnology company dedicated to developing and commercializing&#xa0;innovative&#xa0;solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company&#x2019;s&#xa0;<em style="font: inherit;">first</em>&#xa0;commercial product,&#xa0;<i>Jelmyto</i>&#xa0;(mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em>&#xa0;clinical development of UGN-<em style="font: inherit;">102,</em>&#xa0;and raising capital to support and expand these activities.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On&#xa0;<em style="font: inherit;"> April 15, 2020,&#xa0;</em>the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) granted expedited approval for&#xa0;<i>Jelmyto</i>, a&#xa0;<em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (&#x201c;low-grade UTUC&#x201d;).&#xa0;<i>Jelmyto</i>&#xa0;consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release&#xa0;<i>RTGel</i>&#xa0;technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
  </ix:nonNumeric>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:BasisOfAccounting" id="c2444543" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>&#x2013;<b> Basis of Presentation</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company&#x2019;s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company&#x2019;s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> as filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on <em style="font: inherit;"> March 24, 2023.</em></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color:#ffffff;">f $<ix:nonFraction id="c101505137" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">631.5</ix:nonFraction>&#xa0;</span>million and $<ix:nonFraction id="c101505138" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">577.1</ix:nonFraction>&#xa0;million as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan.&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for the next <em style="font: inherit;">12</em> months from the date the financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a&#xa0;going&#xa0;concern. The Company&#x2019;s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from <i>Jelmyto</i> product sales and develop UGN-<em style="font: inherit;">102.</em>&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> July&#xa0;</em><em style="font: inherit;">26,</em> <em style="font: inherit;">2023,</em> the Company entered into a private placement transaction with certain institutional and other accredited investors pursuant to which the Company agreed to sell its ordinary shares and pre-funded warrants to purchase ordinary shares to the investors, for aggregate&#xa0;gross proceeds of $<ix:nonFraction id="c101505146" contextRef="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" format="ixt:numdotdecimal" decimals="-7">120.0</ix:nonFraction> million.&#xa0; See Note <em style="font: inherit;">19</em> for further discussion regarding the private placement transaction.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on the Company's cash, cash equivalents and marketable securities as of <em style="font: inherit;"> June 30, 2023, </em>together with management&#x2019;s cash flow projections and the net proceeds to the Company from its private placement transaction in <em style="font: inherit;"> July 2023, </em>the Company believes that it has sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these financial statements. The Company will&#xa0;need to raise additional capital in the future. There can be&#xa0;<em style="font: inherit;">no</em>&#xa0;assurances that the Company will be able to secure such additional financing if at all, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is&#xa0;<em style="font: inherit;">not</em>&#xa0;successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">6</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2444544" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">3</em> </b>&#x2013;<b> Significant Accounting Policies</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ConsolidationPolicyTextBlock" id="c101508147" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Principles of Consolidation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company's condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:UseOfEstimates" id="c101508148" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="c101508149" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Functional Currency</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The U.S. dollar (&#x201c;Dollar&#x201d;) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the condensed consolidated statements of operations as &#x201c;Interest and other income (expense), net.&#x201d;</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" id="c101508150" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cash and Cash Equivalents; Marketable Securities</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company presents all highly liquid investments with an original maturity of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents. Cash and cash equivalents generally consist of money market funds and bank money market accounts and are stated at cost, which approximates fair value.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents and marketable securities totaled $<ix:nonFraction id="c101505156" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:numdotdecimal" decimals="-5">55.3</ix:nonFraction>&#xa0;million as of <em style="font: inherit;"> June 30, 2023</em>. The Company accounts for its investments, which include&#xa0;cash equivalents and marketable securities,&#xa0;as available-for-sale in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic <em style="font: inherit;">320,</em> &#x201c;Investments &#x2014; Debt and Equity Securities&#x201d;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#x2019; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certain short-term investments are valued using models or other valuation methodologies that use Level <em style="font: inherit;">2</em> inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has <em style="font: inherit;">not</em> been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash is related primarily to cash held to secure corporate credit cards; restricted deposits are related to cash held to secure leases.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ConcentrationRiskCreditRisk" id="c101508151" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#x2019;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#x2019;s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:IncomeTaxPolicyTextBlock" id="c101508152" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the United States. Deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than <em style="font: inherit;">not</em> that the deferred taxes will <em style="font: inherit;">not</em> be realized in the foreseeable future.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company follows a <em style="font: inherit;">two</em>-step approach in recognizing and measuring uncertain tax positions. After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-<em style="font: inherit;">not</em> chance of being sustained), ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">30</em>-<em style="font: inherit;">7</em> requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than <em style="font: inherit;">50%</em> likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. See Note <em style="font: inherit;">16</em>&#xa0;for further discussion related to income taxes.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:InventoryPolicyTextBlock" id="c101508153" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Inventory</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#xa0;For <i>Jelmyto</i>, the Company commenced capitalization of inventory at the receipt of FDA approval.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company values its inventory at the lower of cost or net realizable value.&#xa0;The Company measures inventory approximating actual cost under a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories<i>.</i></p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i></i></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c101508154" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment are depreciated over the following useful lives (in years):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="c2444545" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Useful Lives</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computers and software</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c101505219">3</span></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c101505221" format="ixt-sec:duryear">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c101505223" format="ixt-sec:duryear">6.5</ix:nonNumeric></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c101505224" format="ixt-sec:duryear">5</ix:nonNumeric> - <ix:nonNumeric contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c101505226" format="ixt-sec:duryear">16.5</ix:nonNumeric></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c101505227" format="ixt-sec:duryear">2</ix:nonNumeric> - <ix:nonNumeric contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c101505229" format="ixt-sec:duryear">10</ix:nonNumeric></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note <em style="font: inherit;">8</em> for further discussion regarding property and equipment.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:PrepaidForwardObligationPolicyPolicyTextBlock" id="c101508155" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Prepaid Forward Obligation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is party to a transaction with RTW Investments (the &#x201c;RTW Transaction&#x201d;) in which the Company received funds to support the continued launch of <i>Jelmyto</i> and the development of UGN-<em style="font: inherit;">102</em> in return for tiered, future cash payments based on net sales of <i>Jelmyto</i> and UGN-<em style="font: inherit;">102,</em> if approved by the FDA. The net proceeds received under the RTW Transaction were recognized as a long-term liability. The Company recognizes the current cash payable amounts under the arrangement within other current liabilities on the condensed consolidated balance sheets. The subsequent measurement for the liability follows the accounting&#xa0;principles defined in ASC Topic <em style="font: inherit;">835</em>-<em style="font: inherit;">30,</em> &#x201c;Imputation of Interest&#x201d;. See Note <em style="font: inherit;">9</em> for further discussion related to the prepaid forward obligation.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:DebtPolicyTextBlock" id="c101508156" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Long-Term Debt</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is party to a loan agreement with funds managed by Pharmakon Advisors, L.P. (&#x201c;Pharmakon&#x201d;). The Company recognizes interest expense in current earnings, and accrued interest within other current liabilities on the condensed consolidated balance sheets. The Company recognizes capitalized financing expenses as a direct offset to the long-term debt on the Company's condensed consolidated balance sheets, and amortizes them over the term of the debt using the effective interest method. See Note <em style="font: inherit;">10</em> for further discussion related to long-term debt.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c101508157" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Leases</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has <em style="font: inherit;">no</em> finance leases.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company accounts for leases in accordance with ASC Topic <em style="font: inherit;">842,</em> &#x201c;Leases&#x201d;<i>.</i> The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right-of-use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#x2019;s lease terms <em style="font: inherit;"> may </em>include options to extend the lease. The lease extensions are included in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise that option.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Because most of the Company&#x2019;s leases do <em style="font: inherit;">not</em> provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ROU assets for operating leases are periodically reviewed for impairment losses under ASC <em style="font: inherit;">360</em>-<em style="font: inherit;">10,</em> &#x201c;Property, Plant, and Equipment&#x201d;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c101508158" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Revenue</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Product sales from <i>Jelmyto</i> are recognized as revenue under ASC <em style="font: inherit;">606</em> at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of <i>Jelmyto</i> are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. Net revenue recognized includes gross revenue and management&#x2019;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to <em style="font: inherit;">340b</em> drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company&#x2019;s copay assistance program, and Medicare refund for discarded drug, which are estimated based on the Company&#x2019;s historical experience.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c101508159" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Research and Development Expenses</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to <em style="font: inherit;">third</em> parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when such development milestone results are achieved.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="c101508160" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Selling,</i></b> <b><i>General and Administrative Expenses</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses consist&#xa0;primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services&#xa0;and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by <em style="font: inherit;">third</em> parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" id="c101508161" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Share-Based Compensation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#x201c;RSU&#x201d;) equaled the closing price of the Company&#x2019;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic <em style="font: inherit;">718,</em> &#x201c;Compensation&#x2014;Stock Compensation&#x201d;.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c101508162" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Net Loss per Ordinary Share</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c101508163" escape="true"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Recently Adopted Issued Pronouncements</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are <em style="font: inherit;">not</em> applicable to the Company.</p></ix:nonNumeric><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:OtherFinancialInformationTextBlock" id="c2444546" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">4</em> </b>&#x2013;<b> Other Financial Information</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Accounts Payable and Accrued Expenses</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable and accrued expenses consisted&#xa0;of the following as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>&#xa0;(in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="c2444547" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505236" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4,659</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505237" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,527</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued sales reserves</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505238" contextRef="i_2023-06-30" unitRef="USD" name="urgn:AccruedSalesReserveCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,721</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505239" contextRef="i_2022-12-31" unitRef="USD" name="urgn:AccruedSalesReserveCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">618</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505240" contextRef="i_2023-06-30" unitRef="USD" name="urgn:AccruedClinicalExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,054</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505241" contextRef="i_2022-12-31" unitRef="USD" name="urgn:AccruedClinicalExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,853</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued research and development expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505242" contextRef="i_2023-06-30" unitRef="USD" name="urgn:AccruedResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,003</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505243" contextRef="i_2022-12-31" unitRef="USD" name="urgn:AccruedResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,285</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505244" contextRef="i_2023-06-30" unitRef="USD" name="urgn:AccruedSellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,836</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505245" contextRef="i_2022-12-31" unitRef="USD" name="urgn:AccruedSellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,609</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued other expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505246" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">3,130</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505247" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">491</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505248" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">16,403</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505249" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">12,383</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Interest and Other Income (Expense), Net</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest and other income (expense), net consisted of the following as of <em style="font: inherit;"> June 30, 2023 </em>and <em style="font: inherit;">2022</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="c2444548" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505254" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">1,080</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505255" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">28</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense), net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505256" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505257" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">98</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total interest and other income (expense), net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505258" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:InterestAndOtherIncomeNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,035</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505259" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="urgn:InterestAndOtherIncomeNet" scale="3" format="ixt:numdotdecimal" decimals="-3">126</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:InventoryDisclosureTextBlock" id="c2444549" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">5</em> </b>&#x2013;<b> Inventories</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inventories consisted of the following as of&#xa0;<em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="c2444550" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505270" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">5,363</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505271" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">4,676</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505272" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">2,072</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505273" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">2,019</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505274" contextRef="i_2023-06-30" unitRef="USD" name="urgn:InventoryCurrentAndNoncurrentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,435</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505275" contextRef="i_2022-12-31" unitRef="USD" name="urgn:InventoryCurrentAndNoncurrentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">6,695</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 2%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p> </td><td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#xa0;$<ix:nonFraction id="c101505262" contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" format="ixt:numdotdecimal" decimals="-5">2.4</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c101505263" contextRef="i_2022-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" format="ixt:numdotdecimal" decimals="-5">2.4</ix:nonFraction>&#xa0;million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023</em>&#xa0;and <em style="font: inherit;"> December 31, 2022, </em>respectively. Changes in non-current assets are reflected on the condensed consolidated statements of cash flows within the caption of other non-current assets.&#xa0;</p> </td></tr>
</tbody></table>
  </ix:nonNumeric>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:FairValueDisclosuresTextBlock" id="c2444551" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">6</em> </b>&#x2013;<b> Fair Value Measurements</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As a basis for considering such assumptions, a <em style="font: inherit;">three</em>-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td><td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Level <em style="font: inherit;">1:</em></p> </td><td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td><td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Level <em style="font: inherit;">2:</em></p> </td><td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are <em style="font: inherit;">not</em> active.</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td><td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Level <em style="font: inherit;">3:</em></p> </td><td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The carrying amounts of the Company&#x2019;s cash, restricted cash, other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these assets and liabilities.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The carrying value of the prepaid forward obligation (See Note <em style="font: inherit;">9</em> - Prepaid Forward Obligation) approximates its fair value.&#xa0;The Company estimated&#xa0;the fair value of the prepaid forward obligation using Level <em style="font: inherit;">3</em> inputs, including internally developed financial forecasts and management's estimate of&#xa0;probability of success related to product candidates, and determined&#xa0;that the effective interest rate in the obligation approximates market rates for loans with similar terms and risk characteristics.&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company estimated the fair value of&#xa0;long-term debt (see Note <em style="font: inherit;">10</em> - Long-Term Debt)&#xa0;using the income approach with Level <em style="font: inherit;">3</em> inputs. The Company estimated future floating rate interest payments using a forward curve of a <em style="font: inherit;">three</em>-month benchmark rate, and estimated fair value based on publicly available data reported in the financial statements of publicly traded venture lending companies. Based on a reasonable range of yields for debt instruments of similar tenor in a similar industry, the Company determined that the carrying value of the long-term debt on the Company's balance sheet approximates its fair value.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">No</em> transfers between levels have occurred during the periods presented.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets measured at fair value on a recurring basis based on Level <em style="font: inherit;">1</em> and Level <em style="font: inherit;">2</em> fair value measurement criteria as of <em style="font: inherit;"> June 30, 2023</em> are as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="c1F7EBBFA-1B58-42FB-9522-6D14AC70DD5C" escape="true" continuedAt="c5FB1A74E-F851-435F-B174-E2CE1CA35074">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements Using</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Quoted Prices</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Significant</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">in Active</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Balance as of</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Markets for</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Observable</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Identical Assets</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Inputs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Assets:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Cash equivalents</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Money market funds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505316" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">596</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505317" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">596</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505318" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Marketable securities</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505320" contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">18,915</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505321" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">18,915</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505322" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505323" contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">6,485</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505324" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505325" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">6,485</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"><ix:nonFraction id="c101505326" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">2,011</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"><ix:nonFraction id="c101505327" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"><ix:nonFraction id="c101505328" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">2,011</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505329" contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">7,733</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505330" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505331" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">7,733</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505332" contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">35,144</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505333" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">18,915</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505334" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">16,229</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Total assets at fair value</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505335" contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-4">35,740</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505336" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">19,511</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505337" contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">16,229</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets measured at fair value on a recurring basis based on Level <em style="font: inherit;">1</em> and Level <em style="font: inherit;">2</em> fair value measurement criteria as of <em style="font: inherit;"> December 31, 2022</em> are as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:continuation id="c5FB1A74E-F851-435F-B174-E2CE1CA35074">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements Using</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Quoted Prices</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Significant</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">in Active</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Balance as of</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Markets for</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Observable</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Identical Assets</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Inputs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505357" contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">28,693</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505358" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">28,693</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505359" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505360" contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">2,387</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c101505361" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505362" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">2,387</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505363" contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">9,392</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505364" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505365" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">9,392</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505366" contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">4,084</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505367" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505368" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">4,084</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505369" contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">44,556</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505370" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">28,693</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505371" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">15,863</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#x2019;s investments in U.S. government bonds and money market funds are measured based on publicly available quoted market prices for identical securities as of <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023</em> and <em style="font: inherit;"> December 31, 2022. </em>The Company's investments in corporate bonds, commercial paper and certificates of deposits are measured based on quotes from market makers for similar items in active markets.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="c2444554" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">7</em> </b>&#x2013;<b>&#xa0;Investments</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table summarizes the Company&#x2019;s investments as of <em style="font: inherit;"> June 30, 2023</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:MarketableSecuritiesTextBlock" id="c2444555" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Amortized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Cost Basis</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Gains</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Losses</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 48%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Cash equivalents</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505388" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">596</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505389" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember" unitRef="USD" name="urgn:CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505390" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember" unitRef="USD" name="urgn:CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505391" contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">596</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Marketable securities:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505393" contextRef="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">18,991</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505394" contextRef="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505395" contextRef="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">76</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505396" contextRef="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">18,915</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505397" contextRef="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">6,548</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505398" contextRef="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505399" contextRef="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">63</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505400" contextRef="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">6,485</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505401" contextRef="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">2,014</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c101505402" contextRef="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505403" contextRef="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505404" contextRef="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">2,011</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505405" contextRef="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">7,745</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c101505406" contextRef="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505407" contextRef="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">13</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505408" contextRef="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">7,733</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505409" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">35,298</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505410" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505411" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">155</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505412" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">35,144</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets at fair value</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505413" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">35,894</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505414" contextRef="i_2023-06-30" unitRef="USD" name="urgn:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c101505415" contextRef="i_2023-06-30" unitRef="USD" name="urgn:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">155</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505416" contextRef="i_2023-06-30" unitRef="USD" name="urgn:CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-4">35,740</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company classifies its investments as available-for-sale, and they consist entirely of debt securities. As of <em style="font: inherit;"> June 30, 2023</em>, the amortized cost of investments included an immaterial amount of accrued interest. As of <em style="font: inherit;"> June 30, 2023</em>, marketable securities were&#xa0;in a net unrealized loss position.&#xa0;Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss.&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of&#xa0;<em style="font: inherit;"> June 30, 2023</em>, the aggregate fair value of investments held by the Company in an unrealized loss position was $<ix:nonFraction id="c101505373" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" format="ixt:numdotdecimal" decimals="-5">33.9</ix:nonFraction> million&#xa0;which consisted of&#xa0;<em style="font: inherit;">38</em> securities.&#xa0;The unrealized loss was primarily driven by rising interest rates. The Company does <em style="font: inherit;">not</em> expect to settle the debentures at a price less than the amortized cost basis of the investment; the Company expects to recover the entire amortized cost basis of the security. In accordance with the Company&#x2019;s general investment strategy, the Company does <em style="font: inherit;">not</em> intend to sell the investments before maturity. As of&#xa0;<em style="font: inherit;"> June 30, 2023</em>, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and <em style="font: inherit;">no</em> allowance for credit losses were recognized in the period.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#x2019;s investments&#xa0;as of <em style="font: inherit;"> June 30, 2023</em> mature at various dates through <em style="font: inherit;"> January 2026. </em>The fair values of investments&#xa0;by contractual maturity consist of the following (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="c2444556" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturities within one year</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505421" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" format="ixt:numdotdecimal" decimals="-4">27,770</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505422" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" format="ixt:numdotdecimal" decimals="-3">44,556</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturities after one year through three years</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505423" contextRef="i_2023-06-30" unitRef="USD" name="urgn:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" scale="3" format="ixt:numdotdecimal" decimals="-4">7,970</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505424" contextRef="i_2022-12-31" unitRef="USD" name="urgn:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505425" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:Investments" scale="3" format="ixt:numdotdecimal" decimals="-4">35,740</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505426" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Investments" scale="3" format="ixt:numdotdecimal" decimals="-3">44,556</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</p>
   <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2444557" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">8</em> </b>&#x2013;<b> Property and Equipment</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, consists of the following as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2444558" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505441" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">456</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505442" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">452</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505443" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">2,195</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505444" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">2,168</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505445" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-4">610</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505446" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">602</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505447" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">617</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505448" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">617</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505449" contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">607</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505450" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">608</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505451" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">4,485</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505452" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">4,447</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505453" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">3,575</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505454" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-4">3,150</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505455" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-4">910</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505456" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,297</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization expense was $<ix:nonFraction id="c101505428" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c101505429" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million for the&#xa0;<em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em> and $<ix:nonFraction id="c101505432" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c101505433" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em>.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:PrepaidForwardObligationDisclosureTextBlock" id="c2444559" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">9</em> </b>&#x2013;<b> Prepaid Forward Obligation</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2021, </em>the Company entered into a prepaid forward agreement with RTW Investments (&#x201c;RTW&#x201d;). Under the terms of the RTW Transaction, the Company received $<ix:nonFraction id="c101505458" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember" unitRef="USD" name="urgn:ProceedsFromPrepaidForwardObligation" scale="6" format="ixt:numdotdecimal" decimals="-6">75.0</ix:nonFraction> million (<span style="background-color:#ffffff;">$<ix:nonFraction id="c101505459" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember" unitRef="USD" name="urgn:ProceedsFromPrepaidForwardArrangementNet" scale="6" format="ixt:numdotdecimal" decimals="-5">72.4</ix:nonFraction></span>&#xa0;million net of transaction&#xa0;costs) to support the continued launch of <i>Jelmyto</i> and the development of UGN-<em style="font: inherit;">102.</em> In return for the transferred funds, RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of <i>Jelmyto</i> in an amount equal to: (i) <ix:nonFraction id="c101505461" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOfUpTo200MillionMember" unitRef="Pure" name="urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" scale="-2" format="ixt:numdotdecimal" decimals="3">9.5</ix:nonFraction>% of annual net sales up to <em style="font: inherit;">$200</em> million, (ii) <ix:nonFraction id="c101505463" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesBetween200MillionAnd300MillionMember" unitRef="Pure" name="urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" scale="-2" format="ixt:numdotdecimal" decimals="2">3.0</ix:nonFraction>% of annual net sales for annual net sales between <em style="font: inherit;">$200</em> million and <em style="font: inherit;">$300</em> million, and (iii) <ix:nonFraction id="c101505466" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOver300MillionMember" unitRef="Pure" name="urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" scale="-2" format="ixt:numdotdecimal" decimals="2">1.0</ix:nonFraction>% of annual net sales for annual net sales above <em style="font: inherit;">$300</em> million. If certain revenue thresholds for <i>Jelmyto</i> aggregate worldwide annual net sales are <em style="font: inherit;">not</em> met, the future cash payments to RTW with respect to <i>Jelmyto</i> annual net sales up to <em style="font: inherit;">$200</em> million will increase by <ix:nonFraction id="c101505470" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOfUpTo200MillionMember" unitRef="Pure" name="urgn:PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" scale="-2" format="ixt:numdotdecimal" decimals="3">3.5</ix:nonFraction>%, and <em style="font: inherit;"> may </em>decrease back to <em style="font: inherit;">9.5%</em> dependent on the Company meeting certain subsequent <i>Jelmyto</i> aggregate worldwide annual net sales thresholds. The&#xa0;rate in effect for the <em style="font: inherit;">six</em>&#xa0;months ended <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023</em>&#xa0;for annual net sales up to $<ix:nonFraction id="c101505475" contextRef="i_2023-06-30_CounterpartyNameAxis-RTWInvestmentsMember" unitRef="USD" name="urgn:PrepaidForwardAgreementMinimumFutureCashFlows" scale="6" format="ixt:numdotdecimal" decimals="-8">200</ix:nonFraction> million was <ix:nonFraction id="c101505476" contextRef="i_2023-06-30_CounterpartyNameAxis-RTWInvestmentsMember" unitRef="Rate" name="urgn:PrepaidForwardAgreementMinimumFutureCashFlowsRate" scale="-2" format="ixt:numdotdecimal" decimals="2">13.0</ix:nonFraction>%.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, subject to FDA approval of UGN-<em style="font: inherit;">102,</em> RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of UGN-<em style="font: inherit;">102</em> in an amount equal to: (i) <ix:nonFraction id="c101505479" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-UGN102Member_StatementScenarioAxis-SalesUpTo200MillionWithFDAApprovalMember" unitRef="Pure" name="urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" scale="-2" format="ixt:numdotdecimal" decimals="3">2.5</ix:nonFraction>% of annual net sales up to <em style="font: inherit;">$200</em> million, (ii) <ix:nonFraction id="c101505481" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesBetween200MillionAnd300MillionWithFDAApprovalMember" unitRef="Pure" name="urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" scale="-2" format="ixt:numdotdecimal" decimals="2">1.0</ix:nonFraction>% of annual net sales for annual net sales between <em style="font: inherit;">$200</em> million and <em style="font: inherit;">$300</em> million, and (iii) <ix:nonFraction id="c101505484" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesOver300MillionWithFDAApprovalMember" unitRef="Pure" name="urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" scale="-2" format="ixt:numdotdecimal" decimals="3">0.5</ix:nonFraction>% of annual net sales for annual net sales above <em style="font: inherit;">$300</em> million. If the Company does <em style="font: inherit;">not</em> receive FDA approval for UGN-<em style="font: inherit;">102</em> by a specified date, the future cash payments to RTW with respect to aggregate worldwide annual net sales of <i>Jelmyto</i> across all <i>Jelmyto</i> annual net sales tiers will increase by <ix:nonFraction id="c101505488" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesOver300MillionWithFDAApprovalMember" unitRef="Pure" name="urgn:PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" scale="-2" format="ixt:numdotdecimal" decimals="3">1.5</ix:nonFraction>%. &#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the prepaid forward agreement, the Company will be required to make payments of amounts owed to RTW each calendar quarter, through and until the quarter in which the aggregate cash payments received by RTW are equal to or greater than <em style="font: inherit;">$300</em> million. As security for the payment and fulfilment of these amounts throughout the arrangement, the Company has granted RTW a <em style="font: inherit;">first</em> priority security interest in <i>Jelmyto</i> and UGN-<em style="font: inherit;">102,</em> including the regulatory approvals, intellectual property, material agreements, proceeds and accounts receivable related to these products.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In&#xa0;<em style="font: inherit;"> May 2021</em><i>,</i>&#xa0;following the receipt of necessary regulatory approvals, the Company received the $<ix:nonFraction id="c101505492" contextRef="d_2021-05-01_2021-05-31_CounterpartyNameAxis-RTWInvestmentsMember" unitRef="USD" name="urgn:ProceedsFromPrepaidForwardObligation" scale="6" format="ixt:numdotdecimal" decimals="-6">75.0</ix:nonFraction>&#xa0;million prepaid forward payment ($<ix:nonFraction id="c101505493" contextRef="d_2021-05-01_2021-05-31_CounterpartyNameAxis-RTWInvestmentsMember" unitRef="USD" name="urgn:ProceedsFromPrepaidForwardArrangementNet" scale="6" format="ixt:numdotdecimal" decimals="-5">72.4</ix:nonFraction>&#xa0;million net of transaction costs) from RTW and recognized an associated prepaid forward obligation liability. Each period the Company makes a payment to RTW, an expense is recognized related to financing on the prepaid forward obligation based on an imputed rate derived from the expected future payments. Management reassesses the effective rate each period based on the current carrying value of the obligation and the revised estimated future payments. Changes in future payments from previous estimates are included in&#xa0;future financing expense.&#xa0;The Company does <span style="-sec-ix-hidden:c101505494">not</span> expect to make any principal payments in the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table shows the activity with respect to the carrying value of the prepaid forward liability for the year ended <em style="font: inherit;"> December 31, 2022 </em>and for the <em style="font: inherit;">six</em>&#xa0;months ended <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023,</em> in thousands:</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" id="c2444560" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 87%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of prepaid forward obligation as of December 31, 2021</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505505" contextRef="i_2021-12-31" unitRef="USD" name="urgn:PrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">85,713</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505506" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="urgn:FinancingOnPrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">21,559</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amounts paid and payable (1)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505507" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="urgn:DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">8,349</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Carrying value of prepaid forward obligation as of December 31, 2022</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505508" contextRef="i_2022-12-31" unitRef="USD" name="urgn:PrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">98,923</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Financing on prepaid forward obligation</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505509" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:FinancingOnPrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">10,568</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Amounts paid and payable (1)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505510" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">4,984</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of prepaid forward obligation as of June 30, 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505511" contextRef="i_2023-06-30" unitRef="USD" name="urgn:PrepaidForwardObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">104,507</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup> $<ix:nonFraction id="c101505500" contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember" unitRef="USD" name="urgn:PrepaidForwardObligation" scale="6" format="ixt:numdotdecimal" decimals="-5">2.7</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c101505501" contextRef="i_2022-12-31_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember" unitRef="USD" name="urgn:PrepaidForwardObligation" scale="6" format="ixt:numdotdecimal" decimals="-5">2.3</ix:nonFraction>&#xa0;million&#xa0;of the Amounts paid and payable are included as current portion of the prepaid forward obligation within other current liabilities on the condensed consolidated balance sheets as of <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023</em>&#xa0;and <em style="font: inherit;"> December 31, 2022, </em>respectively.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:DebtDisclosureTextBlock" id="c2444561" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">10</em> &#x2013; Long-Term Debt</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On&#xa0;<em style="font: inherit;"> March 7,&#xa0;</em><em style="font: inherit;">2022,</em>&#xa0;the Company entered into a loan&#xa0;agreement with Pharmakon&#xa0;for a&#xa0;senior secured term loan of up to $<ix:nonFraction id="c101505514" contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:SecuredLongTermDebt" scale="6" format="ixt:numdotdecimal" decimals="-8">100</ix:nonFraction>&#xa0;million in&#xa0;<em style="font: inherit;">two</em>&#xa0;tranches. The&#xa0;<em style="font: inherit;">first</em>&#xa0;tranche of $<ix:nonFraction id="c101505517" contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="urgn:SecuredLongTermDebtFirstTranche" scale="6" format="ixt:numdotdecimal" decimals="-6">75</ix:nonFraction>&#xa0;million was funded in&#xa0;<em style="font: inherit;"> March 2022. </em>The <em style="font: inherit;">second</em> tranche of&#xa0;$<ix:nonFraction id="c101505519" contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="urgn:SecuredLongTermDebtAdditionalDraw" scale="6" format="ixt:numdotdecimal" decimals="-6">25</ix:nonFraction>&#xa0;million was funded in&#xa0;<em style="font: inherit;"> December 2022. </em>The facility will mature&#xa0;<span style="-sec-ix-hidden:c101505520">five</span>&#xa0;years from initial funding and can be prepaid in whole at the Company's&#xa0;discretion, at any time, subject to prepayment premiums and make-whole amounts.&#xa0;The loan will require interest-only payments for the&#xa0;<em style="font: inherit;">first</em>&#xa0;<em style="font: inherit;">48</em>&#xa0;months followed by principal and interest payments with interest accruing using&#xa0;<em style="font: inherit;">3</em>-month London Inter-Bank Offered Rate (&#x201c;LIBOR&#x201d;) (with a&#xa0;<ix:nonFraction id="c101505524" contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="Pure" name="urgn:DebtInstrumentLIBORFloor" scale="-2" format="ixt:numdotdecimal" decimals="4">1.25</ix:nonFraction>% floor) plus&#xa0;<ix:nonFraction id="c101505525" contextRef="d_2022-03-07_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember_VariableRateAxis-LondonInterbankOfferedRateLibor1Member" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="4">8.25</ix:nonFraction>%. On <em style="font: inherit;"> June 29, 2023, </em>the loan agreement with Pharmakon was amended to replace&#xa0;the benchmark governing the interest rate with a rate based on the secured overnight financing rate ("SOFR") published by the Federal Reserve Bank of New York.&#xa0; Effective <em style="font: inherit;"> July 2023, </em>the loan&#xa0;will accrue interest using a benchmark rate of <em style="font: inherit;">3</em>-month SOFR plus a&#xa0;<ix:nonFraction id="c101505527" contextRef="d_2023-07-01_2023-07-31_LongtermDebtTypeAxis-SecuredDebtMember_SubsequentEventTypeAxis-SubsequentEventMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="7">0.26161</ix:nonFraction>% adjustment. The Company is <em style="font: inherit;">not</em> required to maintain any financial covenants.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company incurred financing expenses of $<ix:nonFraction id="c101505529" contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsGross" scale="6" format="ixt:numdotdecimal" decimals="-5">4.2</ix:nonFraction> million which are recognized as a direct offset to the long-term debt on the Company's condensed consolidated balance sheets. These debt issuance costs are&#xa0;amortized over the term of the debt using the&#xa0;effective interest method, and are&#xa0;recorded in the condensed consolidated statements of operations as "Interest expense".</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table shows the activity with respect to the carrying value of the long-term debt, in thousands:</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="c2444562" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 81%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt at closing of Pharmakon loan</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505530" contextRef="i_2022-01-01_DebtInstrumentAxis-PharmakonLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-8">100,000</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized costs and discounts</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505531" contextRef="i_2022-01-01_DebtInstrumentAxis-PharmakonLoanMember" unitRef="USD" name="urgn:DebtInstrumentCapitalizedCostsAndDiscounts" scale="3" format="ixt:numdotdecimal" decimals="-3">4,217</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505532" contextRef="d_2022-01-01_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember" unitRef="USD" name="us-gaap:InterestExpenseLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">8,438</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amounts paid</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505533" contextRef="i_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember" unitRef="USD" name="urgn:DebtInstrumentPaidAndPayableAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">6,685</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Carrying value of Pharmakon loan as of December 31, 2022</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505534" contextRef="i_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">97,537</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Interest expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505535" contextRef="d_2023-01-01_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember" unitRef="USD" name="us-gaap:InterestExpenseLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">7,314</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Amounts paid</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505536" contextRef="i_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember" unitRef="USD" name="urgn:DebtInstrumentPaidAndPayableAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">6,555</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of Pharmakon loan as of June 30, 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505537" contextRef="i_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">98,296</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:LesseeOperatingLeasesTextBlock" id="c2444563" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">11</em>&#xa0;</b>&#x2013;<b> Leases </b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Operating Leases</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company had&#xa0;the following office and laboratory facility leases as of <em style="font: inherit;"> June 30, 2023</em>:</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td><td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> April 2016, </em>UPL signed an addendum to its <em style="font: inherit;"> November 2014 </em>lease agreement for the Company&#x2019;s&#xa0;offices located in Israel, in order to increase the office space rented and to extend the rent period for an additional <em style="font: inherit;">three</em> years until <em style="font: inherit;"> August 2022. </em>In&#xa0;<em style="font: inherit;"> July 2022,&#xa0;</em>the Company signed a lease extension agreement for the Company&#x2019;s&#xa0;offices located in Israel, extending the term of the lease through&#xa0;<em style="font: inherit;"> September 2025.&#xa0;&#xa0;</em>The Company's remaining contractual obligation under this lease is approximately $<ix:nonFraction id="c101505540" contextRef="i_2023-06-30_LeaseContractualTermAxis-CompanyOfficesInIsraelMember" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" format="ixt:numdotdecimal" decimals="-5">0.6</ix:nonFraction>&#xa0;million as of <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023.</em>&#xa0;</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td><td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> April 2018, </em>UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was <em style="font: inherit;"> July 10, 2018 </em>and terminates in <em style="font: inherit;"> March 2024. </em>The landlord provided a tenant allowance for leasehold improvements of $<ix:nonFraction id="c101505543" contextRef="d_2020-10-01_2020-10-31_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember" unitRef="USD" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction> million that was accounted for as a lease incentive. The Company&#x2019;s remaining contractual obligation under this lease is approximately $<ix:nonFraction id="c101505544" contextRef="i_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction>&#xa0;million as of <em style="font: inherit;"> June 30, 2023</em>. In <em style="font: inherit;"> November 2019, </em>UPI entered into a sublease for this office space, with a lease commencement date of&#xa0;<em style="font: inherit;"> January 1, 2020 </em>and continuing until the end of the lease term in <em style="font: inherit;"> March 2024. </em>The subtenants exercised their early access clause and moved into the premises at the end of <em style="font: inherit;"> November 2019.&#xa0;</em>The remaining rental payments to be received over the lease term is approximately $<ix:nonFraction id="c101505545" contextRef="d_2023-01-01_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember" unitRef="USD" name="us-gaap:SubleaseIncome" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction>&#xa0;million as of <em style="font: inherit;"> June 30, 2023</em>. The Company accounts for the sublease as an operating lease in accordance with ASC <em style="font: inherit;">842.</em></p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td><td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> November 2019, </em>UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was <em style="font: inherit;"> November 29, 2019&#xa0;</em>with an original lease term of <ix:nonNumeric contextRef="i_2019-11-29_LeaseContractualTermAxis-LeaseAgreementForOfficeInPrincetonNewJerseyMember_LegalEntityAxis-UroGenPharmaIncMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c101505547" format="ixt-sec:durmonth">38</ix:nonNumeric> months, expiring <em style="font: inherit;"> January 31, 2023. </em>In <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">2022,</em> the Company signed a lease extension for the Princeton office, extending the term of the lease through <em style="font: inherit;"> January 31, 2026.&#xa0;</em>The Company&#x2019;s remaining contractual obligation under this lease is approximately $<ix:nonFraction id="c101505549" contextRef="i_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInPrincetonNewJerseyMember_LegalEntityAxis-UroGenPharmaIncMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="6" format="ixt:numdotdecimal" decimals="-5">1.5</ix:nonFraction>&#xa0;million as of <em style="font: inherit;"> June 30, 2023</em>.</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, the Company has other operating office equipment and vehicle leases. The Company&#x2019;s operating leases <em style="font: inherit;"> may </em>require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company&#x2019;s leases do <em style="font: inherit;">not</em> contain any residual value guarantees or material restrictive covenants. The Company&#x2019;s leases expire at various dates from <em style="font: inherit;">2023</em>&#xa0;through <em style="font: inherit;">2026,</em> with varying renewal and termination options.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The components of lease cost for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em>&#xa0;and <em style="font: inherit;">2022</em>&#xa0;were as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:LeaseCostTableTextBlock" id="c2444564" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505573" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">257</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505574" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">257</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505575" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">485</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505576" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">516</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505577" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:SubleaseIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">56</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505578" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:SubleaseIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">56</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505579" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:SubleaseIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">112</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c101505580" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:SubleaseIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">112</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Variable lease cost</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505581" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505582" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505583" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">38</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505584" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">36</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505585" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-4">220</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505586" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-4">220</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505587" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">411</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505588" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-4">440</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The amounts recognized as of <em style="font: inherit;"> June 30, 2023</em> and&#xa0;<em style="font: inherit;"> December 31, 2022</em> were as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:AssetsAndLiabilitiesLesseeTableTextBlock" id="c2444565" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Right-of-use assets</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505593" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">2,107</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505594" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">2,452</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505595" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,209</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505596" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,586</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505597" contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">910</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505598" contextRef="i_2022-12-31_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">941</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> June 30, 2023</em>, <em style="font: inherit;">no</em> impairment losses have been recognized.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Supplemental information related to leases for the <em style="font: inherit;">six</em> months ended&#xa0;<em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;">2022</em> is as follows (in thousands, except for lease terms and discount rate amounts):</p> &#xa0;
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" id="c2444566" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505606" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="3" format="ixt:numdotdecimal" decimals="-3">587</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505607" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="3" format="ixt:numdotdecimal" decimals="-4">590</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Right-of-use assets obtained in exchange for new operating lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505608" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">95</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c101505609" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">1,419</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term of operating leases (in years)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2023-06-30" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c101505610" format="ixt-sec:duryear">2.23</ix:nonNumeric></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2022-06-30" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c101505611" format="ixt-sec:duryear">3.01</ix:nonNumeric></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate of operating leases</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505612" contextRef="i_2023-06-30" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="4">10.16</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505613" contextRef="i_2022-06-30" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="4">9.93</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> June 30, 2023</em>,&#xa0;maturities of lease liabilities were as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c2444567" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Leases</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505617" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" format="ixt:numdotdecimal" decimals="-3">581</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505618" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-3">923</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505619" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">811</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505620" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:numdotdecimal" decimals="-3">52</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027 and thereafter</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505621" contextRef="i_2023-06-30" unitRef="USD" name="urgn:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505622" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,367</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: Interest</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505623" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">248</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505624" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">2,119</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Subleases</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> June 30, 2023</em>, undiscounted cash flows to be received under the Company&#x2019;s operating sublease on an annual basis were as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="c2444568" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating Leases</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 14%;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505627" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" scale="3" format="ixt:numdotdecimal" decimals="-3">126</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505628" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-3">49</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025 and thereafter</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505629" contextRef="i_2023-06-30" unitRef="USD" name="urgn:LessorOperatingLeasePaymentToBeReceivedAfterNextYear" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505630" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="3" format="ixt:numdotdecimal" decimals="-3">175</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="c2444569" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">12</em>&#xa0;</b>&#x2013;<b> Revenue From Product Sales</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net product sales consist of the following for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;">2022</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="c2444570" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Jelmyto</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505636" contextRef="d_2023-04-01_2023-06-30_ProductOrServiceAxis-JelmytoMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">21,139</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505637" contextRef="d_2022-04-01_2022-06-30_ProductOrServiceAxis-JelmytoMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">16,604</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505638" contextRef="d_2023-01-01_2023-06-30_ProductOrServiceAxis-JelmytoMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">38,331</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505639" contextRef="d_2022-01-01_2022-06-30_ProductOrServiceAxis-JelmytoMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">30,168</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">Net revenue recognized includes gross revenue and management&#x2019;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to&#xa0;<em style="font: inherit;">340b</em>&#xa0;drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company&#x2019;s copay assistance program, and Medicare refund for discarded drug, which are estimated based on the Company&#x2019;s historical experience. Reserves related to items that are contractually able to be net settled are recognized as contra accounts receivable while other remaining reserves are recognized within other current liabilities on the condensed consolidated balance sheets.&#xa0;The following table shows the activity with respect to sales reserves for period ended&#xa0;of <em style="font: inherit;"> June 30, 2023</em>&#xa0;(in thousands):</p>
   <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="urgn:ScheduleOfSalesReservesTableTextBlock" id="c2444571" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Reserves related to government sponsored programs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other reserves</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total accrued sales reserves</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 43%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance as of December 31, 2022</b></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505643" contextRef="i_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember" unitRef="USD" name="urgn:AccruedSalesReserve" scale="3" format="ixt:numdotdecimal" decimals="-4">590</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505644" contextRef="i_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember" unitRef="USD" name="urgn:AccruedSalesReserve" scale="3" format="ixt:numdotdecimal" decimals="-3">847</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505645" contextRef="i_2022-12-31" unitRef="USD" name="urgn:AccruedSalesReserve" scale="3" format="ixt:numdotdecimal" decimals="-3">1,437</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accruals</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505646" contextRef="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember" unitRef="USD" name="urgn:SalesReserveAccruals" scale="3" format="ixt:numdotdecimal" decimals="-3">5,392</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505647" contextRef="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember" unitRef="USD" name="urgn:SalesReserveAccruals" scale="3" format="ixt:numdotdecimal" decimals="-3">6,052</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505648" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:SalesReserveAccruals" scale="3" format="ixt:numdotdecimal" decimals="-3">11,444</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Utilizations</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505649" contextRef="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember" unitRef="USD" name="urgn:SalesReserveUtilization" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">5,182</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505650" contextRef="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember" unitRef="USD" name="urgn:SalesReserveUtilization" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,756</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c101505651" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="urgn:SalesReserveUtilization" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,938</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance as of June 30, 2023</b></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505652" contextRef="i_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember" unitRef="USD" name="urgn:AccruedSalesReserve" scale="3" format="ixt:numdotdecimal" decimals="-5">800</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505653" contextRef="i_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember" unitRef="USD" name="urgn:AccruedSalesReserve" scale="3" format="ixt:numdotdecimal" decimals="-3">3,143</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505654" contextRef="i_2023-06-30" unitRef="USD" name="urgn:AccruedSalesReserve" scale="3" format="ixt:numdotdecimal" decimals="-3">3,943</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c2444572" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">13</em>&#xa0;</b>&#x2013;<b> License and Collaboration Agreements</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Agenus Agreement</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> November 2019, </em>the Company entered into a license agreement with Agenus Inc., pursuant to which Agenus granted to the Company an exclusive, worldwide (<em style="font: inherit;">not</em> including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus&#x2019;s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary monoclonal antibody of Agenus known as <em style="font: inherit;">AGEN1884</em> (zalifrelimab), an anti-CTLA-<em style="font: inherit;">4</em> antagonist, for the treatment of cancers of the urinary tract via intravesical delivery. UGN-<em style="font: inherit;">301</em> is a formulation of zalifrelimab administered using <i>RTGel</i>&#xa0;technology&#xa0;that is in Phase <em style="font: inherit;">1</em> clinical&#xa0;development for high-grade non-muscle invasive bladder cancer ("high-grade NMIBC").&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>MD Anderson Agreement</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> January 2021, </em>the Company announced that it entered into a <span style="-sec-ix-hidden:c101505661">three</span>-year strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-<em style="font: inherit;">201</em> and UGN-<em style="font: inherit;">301</em>&#xa0;as an investigational treatment for high-grade NMIBC. Pursuant to the agreement, the Company has made&#xa0;bi-annual payments totaling $<ix:nonFraction id="c101505664" contextRef="d_2023-01-01_2023-06-30_CounterpartyNameAxis-MDAndersonMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="6" format="ixt:numdotdecimal" decimals="-6">2.0</ix:nonFraction> million to MD Anderson to fund the collaboration, recognized evenly over the associated period through research and development expenses. In <em style="font: inherit;"> July 2022, </em>the Company determined that it had achieved the objectives that it established when the agreement was initiated, and notified MD Anderson that it was exercising its right to conclude the collaboration in <em style="font: inherit;">2022</em> as the Company did <em style="font: inherit;">not</em> foresee initiating further development activities as part of the collaboration, although the Company will continue to collaborate on existing joint projects. As a result of this notification, the Company is <em style="font: inherit;">not</em> responsible for any further&#xa0;fixed bi-annual funding payments in <em style="font: inherit;">2023,</em> although the Company will be responsible for costs related to existing joint projects to the extent they&#xa0;exceed the payments already made to MD Anderson.&#xa0;&#xa0;</p>
  </ix:nonNumeric>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2444573" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">14</em>&#xa0;</b>&#x2013;<b> Shareholders</b>&#x2019;<b> Equity </b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company had <ix:nonFraction id="c101505670" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="6" format="ixt:numdotdecimal" decimals="-8">100.0</ix:nonFraction> million ordinary shares authorized for issuance as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>. The Company had <ix:nonFraction id="c101505671" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="6" format="ixt:numdotdecimal" decimals="-5">23.5</ix:nonFraction>&#xa0;million and <ix:nonFraction id="c101505672" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="6" format="ixt:numdotdecimal" decimals="-5">23.1</ix:nonFraction>&#xa0;million ordinary shares issued and outstanding as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>, respectively. Each ordinary share is entitled to <em style="font: inherit;">one</em> vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors (the &#x201c;Board&#x201d;). Since its inception, the Board has <em style="font: inherit;">not</em> declared any dividends.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2444574" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">15</em>&#xa0;</b>&#x2013;<b> Share-Based Compensation</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> October 2010, </em>the Board approved a share option plan (the <em style="font: inherit;">"2010</em> Plan") for grants to Company employees, consultants, directors, and other service providers. Subsequently, in <em style="font: inherit;"> March 2017, </em>the Board adopted the <em style="font: inherit;">2017</em> Equity Incentive Plan (the <em style="font: inherit;">"2017</em> Plan" and, together with the <em style="font: inherit;">2010</em> Plan, the "Plans"), which was approved by the shareholders in <em style="font: inherit;"> April 2017. </em>The <em style="font: inherit;">2017</em> Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance share awards, performance cash awards, and other forms of share awards to the Company's employees, directors and consultants.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The grant of options to Israeli employees under the Plans is subject to the terms stipulated by Section <em style="font: inherit;">102</em> of the Israeli Income Tax Ordinance (&#x201c;Section <em style="font: inherit;">102&#x201d;</em>). The option grants are subject to the track chosen by the Company, either the &#x201c;regular income&#x201d; track or the &#x201c;capital gains&#x201d; track, as set out in Section <em style="font: inherit;">102.</em> The Company registered the Plans under the capital gains track, which offers more favorable tax rates to the employees. As a result, and pursuant to the terms of Section <em style="font: inherit;">102,</em> the Company is <em style="font: inherit;">not</em> allowed to claim as an expense for tax purposes the amounts credited to the employees in respect of options granted to them under the Plans, including amounts recorded as salary benefits in the Company&#x2019;s accounts, with the exception of the work-income benefit component, if any, determined on grant date. For non-employees and for non-Israeli employees, the Plans is&#xa0;subject to Section <em style="font: inherit;">3</em>(i) of the Israeli Income Tax Ordinance.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employees are typically granted stock options and/or restricted stock units&#xa0;("RSUs"), upon commencement of employment. Also, eligible employees <em style="font: inherit;"> may </em>receive an annual grant of options or RSUs. Non-employee members of the Board typically receive a grant of stock options upon initial appointment to the Board, and/or stock options annually. The term of any option granted under the Plans cannot exceed <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c101505694" format="ixt-sec:duryear">10</ix:nonNumeric> years. Options shall <em style="font: inherit;">not</em> have an exercise price less than <ix:nonFraction id="c101505696" contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>% of the fair market value of the Company&#x2019;s ordinary shares on the grant date, and generally vest over a period of <span style="-sec-ix-hidden:c101505697">three</span> years. If the individual possesses more than <ix:nonFraction id="c101505698" contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember" unitRef="Pure" name="urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">10</ix:nonFraction>% of the combined voting power of all classes of equity of the Company, the exercise price shall <em style="font: inherit;">not</em> be less than <ix:nonFraction id="c101505700" contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MinimumMember" unitRef="Pure" name="urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" scale="-2" format="ixt:numdotdecimal" decimals="1">110</ix:nonFraction>% of the fair market value of an ordinary share&#xa0;on the date of grant.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#x2019;s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a <ix:nonFraction id="c101505701" contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">33</ix:nonFraction>% increment upon the <em style="font: inherit;">first</em> anniversary of grant, and in either equal quarterly or annual amounts for the <span style="-sec-ix-hidden:c101505703">two</span> years following the <em style="font: inherit;">one</em>-year anniversary of the grant date. Options generally vest in a <ix:nonFraction id="c101505705" contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">33</ix:nonFraction>% increment upon the <em style="font: inherit;">first</em> anniversary of the grant date, and in either equal quarterly or annual amounts for the <span style="-sec-ix-hidden:c101505707">two</span> years following the <em style="font: inherit;">one</em>-year anniversary of the grant date.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The expected volatility is based on a mix of the Company&#x2019;s historical volatility, and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted. The expected term is the length of time until the expected dates of exercising the options and is estimated for employees using the simplified method due to insufficient specific historical information of employees&#x2019; exercise behavior, and for non-employees, and directors using the contractual term.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The maximum number of ordinary shares that was initially authorized for issuance under the <em style="font: inherit;">2017</em> Plan was&#xa0;<ix:nonFraction id="c101505710" contextRef="i_2017-03-31_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,400,000</ix:nonFraction>.&#xa0;On <em style="font: inherit;"> January 1, 2018, </em>the share reserve increased by <ix:nonFraction id="c101505711" contextRef="d_2018-01-01_2018-01-01_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">250,167</ix:nonFraction> to <ix:nonFraction id="c101505712" contextRef="i_2018-01-01_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,650,167</ix:nonFraction> shares. On <em style="font: inherit;"> October 12, 2018, </em>the Company increased the number&#xa0;of ordinary shares authorized for issuance under the <em style="font: inherit;">2017</em> Plan by <ix:nonFraction id="c101505714" contextRef="d_2018-10-12_2018-10-12_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,900,000</ix:nonFraction> to <ix:nonFraction id="c101505715" contextRef="i_2018-10-12_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">3,550,167</ix:nonFraction> shares. On <em style="font: inherit;"> June 8, 2020, </em>the Company&#x2019;s shareholders approved an increase to the number&#xa0;of&#xa0;ordinary shares authorized for issuance under&#xa0;the <em style="font: inherit;">2017</em> Plan by <ix:nonFraction id="c101505717" contextRef="d_2020-06-08_2020-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">400,000</ix:nonFraction> to <ix:nonFraction id="c101505718" contextRef="i_2020-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">3,950,167</ix:nonFraction> shares. On <em style="font: inherit;"> June 7, 2021, </em>the Company&#x2019;s shareholders approved an increase to the number&#xa0;of ordinary shares authorized for issuance under the <em style="font: inherit;">2017</em> Plan by <ix:nonFraction id="c101505720" contextRef="d_2021-06-07_2021-06-07_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">400,000</ix:nonFraction> to <ix:nonFraction id="c101505721" contextRef="i_2021-06-07_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">4,350,167</ix:nonFraction> shares. On <em style="font: inherit;"> June 8, 2022, </em>the Company's shareholders approved an increase to the number&#xa0;of ordinary shares authorized for issuance under the <em style="font: inherit;">2017</em>&#xa0;Plan by <ix:nonFraction id="c101505723" contextRef="d_2022-06-08_2022-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">400,000</ix:nonFraction> to <ix:nonFraction id="c101505724" contextRef="i_2022-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">4,750,167</ix:nonFraction> shares.&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> May 2019, </em>the Company adopted the UroGen Pharma Ltd. <em style="font: inherit;">2019</em> Inducement Plan (the &#x201c;Inducement Plan&#x201d;). Under the Inducement Plan, the Company is authorized to issue up to <ix:nonFraction id="c101505726" contextRef="i_2019-05-31_PlanNameAxis-The2019InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">900,000</ix:nonFraction> ordinary shares pursuant to inducement awards. The only persons eligible to receive grants under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule <em style="font: inherit;">5635</em>(c)(<em style="font: inherit;">4</em>) and the related guidance under Nasdaq IM&#xa0;<em style="font: inherit;">5635</em>-<em style="font: inherit;">1,</em>&#xa0;including individuals who were <em style="font: inherit;">not</em> previously an employee or director of the Company or are following a bona fide period of&#xa0;non-employment,&#xa0;in each case as an inducement material to such individual&#x2019;s agreement to enter into employment with the Company. In <em style="font: inherit;"> December 2021, </em>the Board approved a <ix:nonFraction id="c101505732" contextRef="d_2021-12-01_2021-12-31_PlanNameAxis-The2019InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction> increase in the share reserve of the Inducement Plan.&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> June 30, 2023</em><span style="background-color:#ffffff;">, </span><ix:nonFraction id="c101505733" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">3,493,724</ix:nonFraction>&#xa0;<span style="background-color:#ffffff;">ordinary shares are subject to outstanding awards under the Company's share-based compensation plans and <ix:nonFraction id="c101505734" contextRef="i_2023-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">941,759</ix:nonFraction>&#xa0;ordinary shares remain available for future awards.</span></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table illustrates the effect of share-based compensation on the condensed consolidated statements of operations (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2444575" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505750" contextRef="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">496</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505751" contextRef="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">673</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505752" contextRef="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,021</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101505753" contextRef="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,398</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505754" contextRef="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,726</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505755" contextRef="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">2,150</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505756" contextRef="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,487</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101505757" contextRef="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,374</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total share-based compensation expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505758" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,222</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505759" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,823</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505760" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,508</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c101505761" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">5,772</ix:nonFraction></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The total unrecognized compensation cost of options and RSUs at <em style="font: inherit;"> June 30, 2023</em> is&#xa0;$<ix:nonFraction id="c101505736" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">12.6</ix:nonFraction>&#xa0;million with a weighted average recognition period of <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c101505737" format="ixt-sec:duryear">2.0</ix:nonNumeric>&#xa0;years.</p>
  </ix:nonNumeric>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2444576" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">16</em>&#xa0;</b>&#x2013;<b> Income Taxes </b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is taxed under Israeli tax laws. As of <em style="font: inherit;"> June 30, 2023</em>, the Company continues to maintain a full valuation allowance against deferred tax assets for all jurisdictions. In evaluating the need for a valuation allowance, the Company considers all sources of taxable income available to realize the deferred tax asset, including the future reversal of existing temporary differences, forecasts of future taxable income, and tax planning strategies. The Company has cumulative global pretax losses for the years ended <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em>&#xa0;and&#xa0;<em style="font: inherit;">2020,</em> and for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em>. The Company will continue to assess the extent to which its deferred tax assets <em style="font: inherit;"> may </em>be realized in the future and will adjust the valuation allowance as needed.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has a liability for uncertain tax positions of $<ix:nonFraction id="c101505767" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:numdotdecimal" decimals="-6">3.0</ix:nonFraction>&#xa0;million as of <em style="font: inherit;"> June 30, 2023</em>, for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of <em style="font: inherit;"> June 30, 2023</em>, the Company&#x2019;s liability for uncertain tax positions includes $<ix:nonFraction id="c101505768" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" format="ixt:numdotdecimal" decimals="-5">1.1</ix:nonFraction>&#xa0;million of accrued interest and penalties.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company operates on a global basis and is subject to tax laws and regulations in the United States&#xa0;and Israel. The estimate of the Company&#x2019;s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that <em style="font: inherit;"> may </em>result from its uncertain tax positions. Based upon the information currently available, the Company does <em style="font: inherit;">not</em> reasonably expect changes in its existing uncertain tax positions in the next <em style="font: inherit;">12</em> months and has recorded the gross uncertain tax positions as a long-term liability.</p>
  </ix:nonNumeric>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="c2444577" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">17</em>&#xa0;</b>&#x2013;<b> Related Parties</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">There were <em style="font: inherit;">no</em> related party transactions for the&#xa0;<em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em> or <em style="font: inherit;">2022</em>.</p>
  </ix:nonNumeric>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2444578" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">18</em>&#xa0;</b>&#x2013;<b> Commitments and Contingencies </b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these arrangements is unknown as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>. The Company does <em style="font: inherit;">not</em> anticipate recognizing any significant losses relating to these arrangements.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Leases</i></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">See Note <em style="font: inherit;">11</em>&#xa0;for further discussion regarding lease commitments.</p>
  </ix:nonNumeric>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-06-30" name="us-gaap:SubsequentEventsTextBlock" id="c2444579" escape="true">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">19</em>&#xa0;</b>&#x2013;<b> Subsequent Events</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> July&#xa0;</em><em style="font: inherit;">26,</em> <em style="font: inherit;">2023,</em> the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional and other accredited investors (the &#x201c;Purchasers&#x201d;), pursuant to which the Company agreed to sell and issue to the Purchasers <ix:nonFraction id="c101505781" contextRef="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">12,579,156</ix:nonFraction> ordinary shares of the Company (&#x201c;Shares&#x201d;) (or in lieu of Shares,&#xa0;pre-funded&#xa0;warrants to purchase ordinary shares of the Company) at a purchase price of $<ix:nonFraction id="c101505782" contextRef="i_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">9.54</ix:nonFraction> per Share (or $<ix:nonFraction id="c101505783" contextRef="i_2023-07-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="urgn:ClassOfWarrantsOrRightsIssuancePricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">9.539</ix:nonFraction> for each ordinary share underlying a&#xa0;pre-funded&#xa0;warrant), in a private placement transaction (the &#x201c;Private Placement&#x201d;) for aggregate gross proceeds of $<ix:nonFraction id="c101505784" contextRef="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" format="ixt:numdotdecimal" decimals="-7">120.0</ix:nonFraction> million, before deducting fees to placement agents and financial advisors and before other expenses payable by the Company. Each&#xa0;pre-funded&#xa0;warrant has&#xa0;an exercise price of $<ix:nonFraction id="c101505785" contextRef="i_2023-07-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> per ordinary share, subject to customary adjustments, became&#xa0;exercisable upon original issuance and will <em style="font: inherit;">not</em> expire until exercised in full. The&#xa0;pre-funded&#xa0;warrants <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be exercised if the aggregate number of ordinary shares beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation. The aggregate fee payable by the Company to placement agents and financial advisors is&#xa0;$<ix:nonFraction id="c101505788" contextRef="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="urgn:PlacementAgentsAndFinancialAdvisorsFees" scale="6" format="ixt:numdotdecimal" decimals="-5">3.6</ix:nonFraction> million, plus the reimbursement of certain expenses.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Monograph Capital Partners I, L.P. (&#x201c;Monograph&#x201d;), a life sciences venture firm that is affiliated with Fred Cohen, M.D., a director of the Company, purchased <ix:nonFraction id="c101506847" contextRef="d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,572,327</ix:nonFraction> of the Shares in the Private Placement, for an aggregate purchase price of $<ix:nonFraction id="c101506848" contextRef="d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" format="ixt:numdotdecimal" decimals="-6">15.0</ix:nonFraction>&#xa0;million. Dr.&#xa0;Cohen is the Chair and Chief Investment Officer of Monograph.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin: 0pt; text-align: left;"><b><a id="mda" title="mda" href="#"></a>Item 2. Management</b>&#x2019;<b>s Discussion and Analysis of Financial Condition and Results of Operations.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report and</i>&#xa0;<i>the audited financial statements and notes thereto as of and for the year ended December</i>&#xa0;<i>31, 2022&#xa0;and the related Management</i>&#x2019;<i>s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2022&#xa0;(</i>&#x201c;<i>Annual Report</i>&#x201d;<i>), which was filed with the SEC&#xa0;</i><i>on March 24, 2023. The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended (</i>&#x201c;<i>Securities Act</i>&#x201d;<i>), and Section 21E of the Securities Exchange Act of 1934, as amended&#xa0;(</i>&#x201c;<i>Exchange Act</i>&#x201d;<i>), which are subject to the </i>&#x201c;<i>safe harbor</i>&#x201d;<i> created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, trends, seasonality, projected costs, prospects and plans and objectives of management. The words </i>&#x201c;<i>anticipates,</i>&#x201d;<i> </i>&#x201c;<i>believes,</i>&#x201d;<i> </i>&#x201c;<i>estimates,</i>&#x201d;<i> </i>&#x201c;<i>expects,</i>&#x201d;<i> </i>&#x201c;<i>intends,</i>&#x201d;<i> </i>&#x201c;<i>may,</i>&#x201d;<i> </i>&#x201c;<i>plans,</i>&#x201d;<i> </i>&#x201c;<i>projects,</i>&#x201d;<i> </i>&#x201c;<i>will,</i>&#x201d;<i> </i>&#x201c;<i>would</i>&#x201d;<i> and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, </i>&#x201c;<i>Risk Factors</i>&#x201d;<i> in this Quarterly Report. In addition, statements that </i>&#x201c;<i>we believe</i>&#x201d;<i> and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.&#xa0;</i><i>The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Overview</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed&#xa0;<i>RTGel</i>&#xa0;reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based&#xa0;technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our approved product&#xa0;<i>Jelmyto</i>&#xa0;(mitomycin) for pyelocalyceal solution, and our investigational candidate, UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer (&#x201c;low-grade UTUC&#x201d;) and low-grade intermediate risk non-muscle invasive bladder cancer (&#x201c;low-grade intermediate risk NMIBC&#x201d;), respectively. In addition, our immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, which we intend to study as both monotherapy and in&#xa0;combination therapy.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We estimate that the annual treatable patient population of low-grade UTUC in the United States is approximately 6,000 to 7,000 and&#xa0;the annual treatable population of low-grade intermediate risk NMIBC is approximately 80,000.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>RTGel</i>&#xa0;is a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology, which, unlike the general characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when warmed to body temperature. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urinary tract, forming a transient reservoir of drug that dissolves over time while preventing rapid excretion, providing for increased dwell time. <i>RTGel</i>&#xa0;leverages the physiologic flow of urine to provide a natural exit from the body.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We believe that <i>RTGel</i>, when formulated with an active drug, may allow for the improved efficacy of treatment of various types of urothelial and specialty cancers and urologic diseases without compromising the safety of the patient or interfering with the natural flow of fluids in the urinary tract. <i>RTGel</i> achieves this by:</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">increasing the exposure of active drugs in the bladder and upper urinary tract by significantly extending the dwell time of the active drug while conforming to the anatomy of the bladder and the upper urinary tract, which allows for enhanced drug tissue coverage. For example, the average dwell time of the standard aqueous mitomycin formulation, currently used as adjuvant treatment, in the upper urinary tract is approximately five minutes, compared to up to&#xa0;six hours when mitomycin is formulated with <i>RTGel</i>;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations. For instance, it is only possible to dissolve 0.5 mg of mitomycin in 1 mL of water while it is possible to formulate up to 8 mg of mitomycin with 1 mL of <i>RTGel</i>; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">maintaining the active drug&#x2019;s molecular structure and mode of action.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">These characteristics of <i>RTGel</i>&#xa0;enable sustained release of mitomycin in the urinary tract for both <i>Jelmyto</i> and UGN-102. Further, <i>RTGel</i> may be particularly effective in the bladder and upper urinary tract where tumor visibility and access are challenging, and where there exists a significant amount of urine flow and voiding. We believe that these characteristics of <i>RTGel</i> may prove useful for the local delivery of active drugs to other bodily cavities in addition to the bladder and upper urinary tract.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Jelmyto</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On April 15, 2020, the U.S. F<span style="font-family:Arial,Helvetica,sans-serif;">ood and Drug Administration ("FDA") appro</span>ved our new drug application (&#x201c;NDA&#x201d;) for <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-101, for the treatment of adult patients with low-grade UTUC. <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to prolong exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. New product exclusivity for <i>Jelmyto</i> exists through April 15, 2023, and&#xa0;Orphan Drug exclusivity applies through April 15, 2027, as well as a composition of matter patents set to expire in early&#xa0;2031.&#xa0;The main patents that protect <i>Jelmyto</i>&#xa0;in the United States are set to expire in&#xa0;January 2031. These patents were listed in the FDA's Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations).</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Low-grade UTUC is a rare cancer that develops in the lining of the upper urinary tract, ureters and kidneys. In the United States, there are approximately 6,000 - 7,000 new or recurrent low-grade UTUC patients annually. It is a challenging condition to treat due to the complex anatomy of the urinary tract system. Prior to <i>Jelmyto</i>, the&#xa0;current standard of care included endoscopic resection(s)&#xa0;and radical nephroureterectomy, the latter which involves the removal of the renal pelvis, kidney, ureter and bladder cuff. Treatment is further complicated by the fact that low-grade UTUC is most commonly diagnosed in patients over 70 years of age, who may already have compromised kidney function and may suffer further complications as a result of a major surgery. We are focused on changing the way urothelial cancers are treated, an area in which&#xa0;there has been no significant advancements in recent years.&#xa0;<i>Jelmyto</i><i>&#xa0;</i>is the first drug therapy of its kind,&#xa0;providing&#xa0;an alternative to&#xa0;endoscopic resection(s)&#xa0;and/or radical nephroureterectomy.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The FDA approval is based on results from our Phase 3 OLYMPUS trial showing <i>Jelmyto</i> achieved clinically significant disease eradication in adults with low-grade UTUC. Findings from the final study results include:</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Complete response (&#x201c;CR&#x201d;) (primary endpoint) of 58% (41/71) in the intent-to-treat population and in the sub-population of patients who were deemed not capable of surgical removal at diagnosis.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">At the 12-month time point for assessment of durability, 23 patients remained in CR of a total of 41 patients, eight had experienced recurrence of disease and ten patients were unable to be evaluated.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Durability of response was estimated to be 81.8% at 12 months by Kaplan-Meier analysis. The median duration of response was not reached.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The most commonly reported adverse events (&#x2265;&#xa0;20%) were ureteric obstruction, flank pain, urinary tract infection, hematuria, abdominal pain, fatigue, renal dysfunction, nausea, dysuria and vomiting. Most adverse events were mild to moderate and manageable. No treatment-related deaths occurred.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In December 2022, we presented new data from a follow up study to the OLYMPUS trial designed to obtain long&#x2010;term&#xa0;data on <i>Jelmyto</i>. Based on data available for 16 of the 23 patients who had remained in CR at the end of the OLYMPUS study, the median duration of response in that subset of patients was 28.9 months. Thirteen patients remained in CR, two patients had recurrence of low grade&#x2010;UTUC on the same side as treated in OLYMPUS, and one patient underwent RNU due to ureteral stricture without evidence of UTUC at the time of surgery. No patient had progressed to high&#x2010;grade disease.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In June 2020, we initiated our commercial launch of <i>Jelmyto</i> in the United States. We have staffed, trained and prepared a customer-facing team that includes&#xa0;territory business managers with deep experience in both urology and oncology. These territory business managers&#xa0;are led by seven regional business directors, who are in turn supported by three regional operations managers.&#xa0;Each region is additionally supported by one to two clinical nurse educators to provide education and training around instillation, as well as a field reimbursement manager to help ensure access and reimbursement for appropriate patients. In addition, our organization currently includes several&#xa0;medical science liaisons who appropriately engage with physicians interested in learning more about UroGen,&#xa0;<i>Jelmyto</i>&#xa0;and our technology, both in person and virtually. In total, our customer-facing team comprises approximately 80 representatives.&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We are committed to helping patients access <i>Jelmyto</i>. Our market access teams have laid the foundation for coverage and reimbursement, meeting multiple times with payors. Medicare patients are covered and the vast majority of commercial plans have policies in place, in whole covering over 150 million lives. In addition to reimbursement and access, we have also been focused on ensuring seamless integration into physician practices. We have implemented processes to help make <i>Jelmyto</i> preparation and administration seamless for practitioners and patients, including entering into an agreement with a major national specialty pharmacy under which the pharmacy, following receipt of a patient prescription, prepares and dispenses the <i>Jelmyto</i> admixture on our behalf. In September 2022, the FDA authorized an extension of the in-use period for Jelmyto admixture from eight hours to 96 hours (four days) following reconstitution of the product, adding convenience and flexibility in managing patient care.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In October 2020, a Medicare C-Code was issued for <i>Jelmyto</i>. The Centers for Medicare &amp; Medicaid Services established a permanent and product-specific J-code for <i>Jelmyto</i> that took effect on January 1, 2021&#xa0;and replaced the C-Code.&#xa0;We have also launched a registry to capture data and evaluate real world outcomes in patients with low-grade UTUC that have been or will be treated with <i>Jelmyto</i>. The purpose of the registry is to study the use of <i>Jelmyto</i> in clinical practice in the United States and address specific clinical questions.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In the first two&#xa0;full fiscal years following the initiation of our commercial launch of <i>Jelmyto </i>in June 2020, we have experienced a moderate decline in revenue during the third quarter from the preceding quarter. We believe this result is primarily attributable to the nature of low-grade disease, which does not require immediate treatment and therefore we believe there is an impact in the summer months. However, it is too early to say with confidence whether this seasonality trend will continue in future periods. Moreover, our future <i>Jelmyto </i>revenue will be impacted by various factors and we expect our <i>Jelmyto</i> revenue to fluctuate quarter-to-quarter for the foreseeable future.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>UGN-102&#xa0;</i></b><b><i>(mitomycin) for intravesical solution</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UGN-102 is our sustained-release formulation of mitomycin that we are developing for the treatment of low-grade intermediate risk NMIBC.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In October 2021, we reported final&#xa0;data from the Phase 2b OPTIMA II trial.&#xa0;The single-arm, open label trial completed enrollment of 63 patients at clinical sites across the United States and Israel in September 2019. Patients were treated with six weekly instillations of UGN-102 and underwent assessment of&#xa0;CR (the primary endpoint) four to six weeks following the last instillation; 65%, or 41 out of 63 patients, treated with UGN-102 achieved a complete response three months after the start of therapy. In this subset of patients,&#xa0;39 (95%), 30 (73%), and 25 (61%) remained disease-free at six, nine, and 12 months after treatment initiation, respectively. The probability of durable response nine months after CR (12 months after treatment initiation) was estimated to be 72.5% by Kaplan-Meier analysis.&#xa0;Thirteen patients had documented recurrences. Fifty-seven of 63 (90%) patients completed all six instillations of UGN-102 according to the study protocol. Median duration of response was not reached. The most common adverse events, greater than 10%, were most often reported as mild to moderate in severity and include dysuria, hematuria, urinary frequency, fatigue, urgency and urinary tract infection.&#xa0;The final data was published online in The Journal of Urology in October 2021 and was&#xa0;included in the January 2022 print edition.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In December 2022 we presented new data from a follow up study to the OPTIMA II study designed to obtain long-term data on UGN-102 that shows median duration of response of 24.4 months&#xa0;based on available data for 15 out of 25 patients who achieved a complete response in OPTIMA II.&#xa0;Seven patients remained in CR, six patients had recurrence of low-grade&#xa0;disease, one patient had progression to high-grade disease and one patient withdrew consent but remained in CR at the last evaluation prior to discontinuation. All patients were alive at the last contact, and five patients were known to have had post-study treatment with transurethral resection of the bladder tumors or fulguration.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UGN-102 is administered locally using the standard practice of intravesical instillation directly into the bladder via a catheter. The instillation into the bladder is expected to take place in a physician&#x2019;s office as a non-operative same-day treatment, in comparison with trans-urethral resection of bladder tumor&#xa0;("TURBT") or similar surgical procedures, which are operations conducted under general anesthesia and may require an overnight stay. Surgical tumor removal often has limited success due to the inability to properly identify, reach and resect all tumors. We believe that an effective chemoablation agent can potentially provide better eradication of tumors irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated with surgery.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We initiated our&#xa0;Phase 3 ATLAS trial in December 2020 and until November 2021,&#xa0;were enrolling patients in this trial comparing&#xa0;UGN-102 with or without TURBT to standard of care, TURBT. In parallel, we&#xa0;continued to engage in discussions with the FDA&#xa0;and&#xa0;based on this dialogue, we designed a trial in order to demonstrate the efficacy and safety of UGN-102. This Phase 3 ENVISION trial is a single-arm, multinational, multicenter study evaluating the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with low-grade intermediate risk NMIBC. The design of the&#xa0;Phase 3 ENVISION trial&#xa0;is similar to our Phase 2 OPTIMA II trial in that the patient population has similar&#xa0;clinical characteristics, receives the same investigational treatment regimen and&#xa0;undergoes similar efficacy and safety assessments and qualitative follow-up. Study participants receive&#xa0;six&#xa0;once-weekly intravesical instillations of UGN-102. The primary endpoint is complete response rate at three months after the first instillation, and the key secondary endpoint is durability of response in patients who achieve complete response at the three-month assessment.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In February 2022, we announced the initiation of the Phase 3 ENVISION trial, targeting&#xa0;enrollment of&#xa0;220 patients across 90 sites. In December 2022, we completed our target enrollment of the Phase 3 ENVISION trial. As a result of the FDA's acceptance of a single arm approach, we stopped enrollment of the Phase 3 ATLAS trial.&#xa0;However, at the time enrollment was stopped, any patients who had signed an informed consent were able to complete screening, and if eligible were randomized into the trial.&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On July&#xa0;27, 2023, we announced topline data from our Phase 3 trials, ATLAS and ENVISION. In the ATLAS trial,&#xa0;UGN-102&#xa0;met its primary endpoint of disease-free survival, reducing risk of recurrence, progression, or death by 55%.&#xa0;UGN-102&#xa0;also showed a 64.8% complete response rate at three months for patients who only received&#xa0;UGN-102,&#xa0;compared to a 63.6% complete response rate at three months for patients who only received a TURBT. The ENVISION trial met its primary endpoint by demonstrating that patients treated with&#xa0;UGN-102&#xa0;had a 79.2% rate of complete response at&#xa0;3-months&#xa0;following the initial treatment. Additional data evaluating the secondary endpoint of duration of response from ENVISION is anticipated in 2024. In both trials,&#xa0;UGN-102&#xa0;was generally well-tolerated, with a side effect profile similar to that of previous clinical trials of&#xa0;UGN-102.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We also initiated a Phase 3b study with&#xa0;the objective of demonstrating whether UGN-102 can be administered at home by a qualified home health professional, avoiding the need for repeated visits to a healthcare setting for instillation. As per the study design, patients in this study received six once-weekly intravesical instillations of UGN-102 with the initial treatment visit occurring at the investigative site and instillation performed by a qualified physician. Treatment visits two to six took place at the patient's home and instillation were&#xa0;performed by a properly trained and qualified home health professional. The primary endpoints of the study include safety and tolerability, discontinuations from at home study treatment and feedback from patients, home health professionals and investigators via standardized questionnaires. The study completed enrollment with a total of eight&#xa0;patients across four centers and all study visits for these enrolled patients have been completed. Preliminary results were reported through a press release in February 2023,&#xa0;finding that UGN-102 was suitable to administer at home by a visiting nurse under the supervision of a treating physician and resulted in 75% of patients achieving a complete response, defined as no detectable disease three&#xa0;months after starting treatment. Patients, nurses and investigators also completed home instillation feasibility questionnaires. These standardized feasibility questionnaires highlighted that all eight&#xa0;patients preferred at-home to in-office treatment, and five&#xa0;of six&#xa0;patients recommended UGN-102 home instillation instead of TURBT. Home instillation was reported as feasible for visiting nurses, and three&#xa0;of four&#xa0;investigators considered at-home treatment &#x201c;not different&#x201d; than in-office treatment. We believe establishing the precedent for a convenient at home solution may facilitate access to care and address quality of life issues that certain patients may face with the current standard of care.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>UGN-301 (zalifrelimab) intravesical solution</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Our immuno-uro-oncology pipeline includes UGN-301, an anti-CTLA-4 monoclonal antibody, which we intend to study as a standalone agent and as a combination therapy. Non-human primate toxicity studies supported the initiation of a multi-arm&#xa0;Phase 1 study of UGN-301 in&#xa0;combination with other agents. We believe that this approach leverages our unique drug delivery technology and provides an opportunity to evaluate&#xa0;intravesical delivery of UGN-301&#xa0;in combination with other immuno-modulators, chemotherapies, gene therapy and innate immune stimulators.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">High-grade non-muscle invasive bladder cancer ("high-grade NMIBC") is a highly aggressive form of bladder cancer. TURBT followed by adjuvant intravesical immunotherapy with Bacillus of Calmette and Guerin ("BCG") is the current standard of care therapy for high-grade NMIBC.&#xa0;However, the high rates of recurrence and significant risk of progression to muscle-invasive tumors are particularly dangerous. Radical cystectomy, or bladder removal is strongly advocated in patients with BCG-unresponsive NMIBC (i.e., patients with BCG-refractory and BCG-relapsing tumors in whom further BCG therapy is not recommended) or for patients who cannot tolerate BCG.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The first combination we are seeking to investigate clinically involves the sequential use of UGN-201 (imiquimod), a toll-like receptor-7 ("TLR 7") agonist, and UGN-301 in high-grade NMIBC. UGN-201 is a liquid formulation of imiquimod for intravesical administration that has been optimized for delivery in the urinary tract. We believe that UGN-201 may elicit an innate immune response in the presence of released bladder cancer antigens, which may translate into a long lasting acquired immune response. We believe the combination of UGN-301 and UGN-201 could elicit an innate as well as adaptive immune response and potentially represent a valid post-TURBT adjuvant treatment of high-grade NMIBC.&#xa0;UGN-301&#xa0;is delivered using our proprietary&#xa0;<i>RTGel</i>&#xa0;technology, which has been designed to significantly improve the effectiveness of certain intravesical therapy. In November 2019, we entered into a worldwide license agreement with Agenus Inc. to develop and commercialize zalifrelimab&#xa0;via intravesical delivery&#xa0;for the treatment of urinary tract cancers, initially in high-grade NMIBC. We believe that the combination of UGN-301 and UGN-201 makes local therapy a potentially more effective treatment option while minimizing systemic exposure and potential side effects.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In March 2022, we announced FDA clearance of our Investigational New Drug application&#xa0;("IND")&#xa0;to begin a novel Phase 1 clinical study of UGN-301 in patients with recurrent NMIBC.&#xa0;The novel study design utilizes a Master Protocol that we believe&#xa0;is a more efficient and streamlined approach to development. It will provide more flexibility to add study arms as the trial progresses and is expected to increase efficiency and potentially reduce&#xa0;costs. We expect&#xa0;the Master Protocol will allow us to more quickly evaluate safety, tolerability and dosing of UGN-301 in combination with additional immunomodulators and chemotherapies, with the goal of developing optimized treatment regimens for patients.&#xa0;The multi-arm Phase 1 study, which is expected to support the development of UGN-301 in high-grade NMIBC, was initiated in April 2022 and is actively enrolling.&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Our Research and Development and License Agreements</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Agenus Agreement</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In November 2019, we entered into a license agreement with Agenus Inc. ("Agenus"),&#xa0;pursuant to which Agenus granted us&#xa0;an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus&#x2019;s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary monoclonal antibody of Agenus known as AGEN1884 (zalifrelimab), an anti-CTLA-4 antagonist, for the treatment of cancers of the urinary tract via intravesical delivery. UGN-301 is a formulation of zalifrelimab administered using <i>RTGel</i> technology&#xa0;that is in Phase 1 clinical&#xa0;development for high-grade NMIBC.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>MD Anderson Agreement</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In January 2021, we announced that we had&#xa0;entered into a three-year strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301&#xa0;as an investigational treatment for high-grade NMIBC. Pursuant to the agreement, we have made bi-annual payments totaling $2.0 million to MD Anderson to fund the collaboration,&#xa0;recognized evenly over the associated period through research and development expenses. In July 2022, we determined that we had achieved the objectives that we&#xa0;established when the agreement was initiated, and notified MD Anderson that we were exercising our right to conclude the collaboration in 2022 as we&#xa0;did not foresee initiating further development activities as part of the collaboration, although we&#xa0;will continue to collaborate on existing joint projects. As a result of this notification, we are&#xa0;not responsible for any further fixed bi-annual funding payments in 2023, although we will be responsible for costs related to existing joint projects to the extent they&#xa0;exceed the payments already made to MD Anderson.&#xa0;&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">For additional information regarding our research and development and license agreements, see Note 13&#xa0;to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Components of Operating Results</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Revenue</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">During the three and six months ended June 30, 2023, we recognized&#xa0;$21.1&#xa0;million and $38.3&#xa0;million of revenue, respectively from sales of our product, <i>Jelmyto</i>.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cost of Revenue</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenue consists primarily of inventory and related costs associated with the manufacturing, distribution, warehousing and preparation of <i>Jelmyto,&#xa0;</i>including inventory write-downs. In periods prior to receiving FDA approval for <i>Jelmyto</i>, we recognized inventory and related costs associated with the manufacture of <i>Jelmyto</i> as research and development expense.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Research and Development Expenses</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses, net consists primarily of:</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">salaries and related costs, including share-based compensation expense, for our personnel in research and development functions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">expense incurred under agreements with third parties, including clinical research organizations (&#x201c;CROs&#x201d;), subcontractors, suppliers and consultants, nonclinical studies and clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">expense&#xa0;incurred to acquire, develop and manufacture nonclinical study and clinical trial materials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Courier New&quot;, Courier, monospace; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">expense&#xa0;incurred to purchase active pharmaceutical ingredient (&#x201c;API&#x201d;) in support of R&amp;D activities and other related manufacturing costs; and</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">facility and equipment costs, including depreciation expense, maintenance and allocated direct and indirect overhead costs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We expense all research and development costs as incurred. We estimate nonclinical study and clinical trial expense based on the services performed pursuant to contracts with research institutions and contract research organizations that conduct and manage nonclinical studies and clinical trials on our behalf based on actual time and expense incurred by them.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We recognize&#xa0;costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Where at risk contingent milestone payments are due to third parties under research and development and collaboration agreements, the milestone payment obligations are expensed when such development milestone results are achieved.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We are currently focused on advancing our product candidates, and our future research and development expense&#xa0;will depend on their clinical success. Research and development expense&#xa0;will continue to be significant.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We do not believe that it is possible at this time to accurately project total expenses required for us to reach commercialization of our product candidates. Due to the inherently unpredictable nature of nonclinical and clinical development, we are unable to estimate with certainty the costs we will incur and the timelines that will be required in the continued development and approval of our product candidates. Clinical and nonclinical development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, if and when such arrangements will be entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We expect our research and development expense&#xa0;to increase over the next several years as our clinical programs progress and as we seek to initiate clinical trials of additional product candidates. We also expect to incur increased research and development expense&#xa0;as we selectively identify and develop additional product candidates.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">per patient trial costs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the number of patients that participate in the trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the number of sites included in the trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the countries in which the trials are conducted;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the length of time required to enroll eligible patients;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the number of doses that patients receive;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the drop-out or discontinuation rates of patients;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">potential additional safety monitoring or other studies requested by regulatory agencies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the duration of patient follow-up; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the efficacy and safety profile of the product candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#x2019;s commercial potential.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other than <i>Jelmyto</i>, which was approved by the FDA in April 2020, we have not received approval of any of our product candidates. UGN-102 and UGN-301&#xa0;are still in clinical development. As such, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">License fees and development milestone payments related to in-licensed products and technology are expensed as incurred, or achieved&#xa0;in the case of milestones, if it is determined at that point that they have no established alternative future use.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Selling and Marketing Expenses</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">To date, selling and marketing expenses consist&#xa0;primarily of commercial personnel costs (including share-based compensation) along with pre-commercialization and commercialization activities related to <i>Jelmyto,&#xa0;</i>formerly known as UGN-101.&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>General and Administrative Expenses</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative expenses consist&#xa0;primarily of personnel costs (including share-based compensation related to directors, executives, finance, medical affairs, business development, investor relations, and human resource functions). Other significant costs include medical affairs services, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Financing on Prepaid Forward Obligation</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation is comprised of financing expense related to the RTW Transaction (see Note 9 to our condensed consolidated financial statements appearing elsewhere&#xa0;in this Quarterly Report).</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>Interest Expense</b></i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense is comprised of interest related to our long-term debt with Pharmakon (see Note 10 to our condensed consolidated financial statements appearing elsewhere&#xa0;in this Quarterly Report).</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Interest and Other Income (Expense), Net</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest and other income (expense), net, consisted primarily of interest income, net losses on foreign exchange&#xa0;and bank commissions.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Income Taxes</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We have yet to generate taxable income in Israel. We have historically incurred operating losses resulting in carry forward tax losses totaling approximately $419.1&#xa0;million as of December 31, 2022. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses. We have provided a full valuation allowance with respect to the deferred tax assets related to these carry forward losses. Income tax expense also consists of our estimate of uncertain tax positions, and related interest and penalties. See Note 16&#xa0;to our&#xa0;condensed consolidated financial statements appearing elsewhere in this Quarterly&#xa0;Report for further information.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Critical Accounting Policies and Estimates</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of our unaudited condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the revenue and expense incurred during the reported periods. In accordance with U.S. generally accepted accounting principles ("GAAP"), we base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ from these estimates under different assumptions or conditions. We discussed the critical accounting policies used in the preparation of our financial statements in <i>Management</i>&#x2019;<i>s Discussion and Analysis of Financial Condition and Results of Operations</i> included in our Annual Report as well as in the Note 3 to the condensed consolidated financial statements included in this Quarterly Report.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Results of Operations</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Comparison of the three months ended June 30, 2023 and 2022</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table sets forth our results of operations for the three months ended June 30, 2023 and 2022.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="10" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="10" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">21,139</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">16,604</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,535</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenue</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,443</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,846</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">597</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross profit</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">18,696</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">14,758</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">3,938</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">11,584</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">12,640</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(1,056</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Selling and marketing</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">13,930</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">12,841</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,089</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,564</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,992</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">572</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,078</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,473</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">605</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(15,382</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(18,715</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">3,333</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(5,344</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(5,833</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">489</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Interest expense on long-term debt</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">(3,761</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">(2,239</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">(1,522</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest and other income (expense), net</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">405</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">128</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">277</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(24,082</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(26,659</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,577</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(32</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(22</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(24,136</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(26,691</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,555</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revenue</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue was&#xa0;$21.1 million and&#xa0;$16.6&#xa0;million for the three&#xa0;months ended June 30, 2023 and 2022, respectively. The increase&#xa0;in revenue of $4.5&#xa0;million primarily reflects the increased volume of sales of <i>Jelmyto</i>.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cost of Revenue</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenue was&#xa0;$2.4 million and&#xa0;$1.8 million for the three&#xa0;months ended June 30, 2023 and 2022, respectively. In periods prior to receiving FDA approval for <i>Jelmyto</i>, we recognized inventory and related costs associated with the manufacture of <i>Jelmyto</i> as research and development expenses.&#xa0;The overall increase of $0.6&#xa0;million&#xa0;is primarily attributable to the full depletion of inventories that we had expensed prior to receiving FDA approval and increased volume of sales of our product <i>Jelmyto</i>.&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Research and Development Expenses</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses&#xa0;were&#xa0;$11.6 million and&#xa0;$12.6 million for the three months ended June 30, 2023 and 2022, respectively. The overall&#xa0;decrease of&#xa0;$1.0 million is primarily attributable to lower&#xa0;research and development expenses due to the conclusion of the ATLAS trial&#xa0;and lower cost related to the Phase 3 ENVISION trial&#xa0;for UGN-102, partially offset by higher&#xa0;research and development expenses related to our Phase 1 study for UGN-301.&#xa0; Additionally, research and development expenses decreased due to the ending of our collaboration with MD Anderson, lower cost incurred related to research into ingredient scale-up and production efficiency for <i>Jelmyto </i>and&#xa0;lower clinical compensation&#xa0;expenses.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Selling and Marketing Expenses</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling and marketing expenses were&#xa0;$13.9 milli<span style="background-color:#ffffff;">on and&#xa0;$12.8 million for the three months ended </span>June 30, 2023 and 2022<span style="background-color:#ffffff;">, respectively. The&#xa0;increase&#xa0;in selling and marketing expenses of&#xa0;$1.1 million is primarily attributable to&#xa0;</span>brand marketing related expenses and&#xa0;commercial operation advertisement, data management and trainings, partially offset by lower market research&#xa0;related expenses.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>General and Administrative Expenses</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and <span style="background-color:#ffffff;">administrative expenses were&#xa0;$8.6 million and&#xa0;$8.0 million for the three months ended </span>June 30, 2023 and 2022<span style="background-color:#ffffff;">, respectively. The&#xa0;increase in general and administrative expenses of&#xa0;$0.6 million resulted primarily from professional services and ongoing managed services.</span></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Financing on Prepaid Forward Obligation</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation was&#xa0;$5.3 million and $5.8&#xa0;million for the three months ended June 30, 2023 and 2022, respectively. The measurement of financing on&#xa0;prepaid forward obligation is an accounting estimate under the "imputed interest method" of accounting (see Note 3 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report) which is affected by estimated future payments to RTW, which are based on a percentage of revenues. The decrease&#xa0;in financing on prepaid forward obligation of $0.5&#xa0;million was driven primarily by changes in underlying assumptions&#xa0;for remeasuring the effective rate.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Interest Expense on Long-term Debt</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense was $3.8&#xa0;million and $2.2&#xa0;million&#xa0;for the three months ended June 30, 2023 and 2022,&#xa0;respectively. The increase was primarily driven by increase in interest rates related to the&#xa0;Pharmakon loan and the funding of the second tranche of the Pharmakon loan in December 2022.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Interest and Other Income (Expense), Net</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest and other income (expense), net was $0.4&#xa0;million and $0.1&#xa0;million&#xa0;for the three months ended June 30, 2023 and 2022, respectively. The increase in interest and other income (expense), net was primarily due to interest earned on investments due to changes in the overall interest rate environment.</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Comparison of the six months ended June 30, 2023 and 2022</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table sets forth our results of operations for the six months ended June 30, 2023 and 2022.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="10" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 27%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended June 30,</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="10" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 27%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">38,331</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">30,168</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">8,163</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenue</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,708</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,371</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,337</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross profit</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">33,623</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">26,797</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">6,826</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">24,082</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">25,336</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(1,254</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Selling and marketing</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">28,073</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">26,192</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,881</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,895</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,941</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,954</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">71,050</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,469</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,581</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(37,427</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(40,672</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">3,245</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(10,568</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(11,659</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,091</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense on long-term debt</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(7,314</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(2,521</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(4,793</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest and other income (expense), net</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,035</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">126</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">909</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(54,274</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(54,726</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">452</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(75</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(357</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">282</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 61%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(54,349</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(55,083</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">734</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revenue</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue was&#xa0;$38.3&#xa0;million and&#xa0;$30.2&#xa0;million for the six months ended June 30, 2023 and 2022, respectively. The&#xa0;increase&#xa0;in revenue of&#xa0;$8.1&#xa0;million primarily reflects the increased volume of sales of <i>Jelmyto</i>.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cost of Revenue</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenue was&#xa0;$4.7&#xa0;million and&#xa0;$3.4&#xa0;million for the six months ended June 30, 2023 and 2022, respectively. In periods prior to receiving FDA approval for <i>Jelmyto</i>, we recognized inventory and related costs associated with the manufacture of <i>Jelmyto</i> as research and development expenses.&#xa0;The overall increase of $1.3&#xa0;million&#xa0;is primarily attributable to the full depletion of inventories that we had expensed prior to receiving FDA approval and increased volume of sales of our product <i>Jelmyto</i>.&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Research and Development Expenses</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses&#xa0;were&#xa0;$24.1&#xa0;million and&#xa0;$25.3&#xa0;million for the six months ended June 30, 2023 and 2022, respectively. The overall&#xa0;decrease of&#xa0;$1.2&#xa0;million is primarily attributable to lower&#xa0;research and development expenses due to the conclusion of the ATLAS trial&#xa0;and lower cost related to the Phase 3 ENVISION trial&#xa0;for UGN-102, partially offset by higher&#xa0;research and development expenses related to our Phase 1 study for UGN-301.&#xa0; Additionally, research and development expenses decreased due to the ending of our collaboration with MD Anderson, lower cost incurred related to research into ingredient scale-up and production efficiency for <i>Jelmyto </i>and&#xa0;lower clinical compensation&#xa0;expenses.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Selling and Marketing Expenses</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling and marketing expenses were&#xa0;$28.1&#xa0;milli<span style="background-color:#ffffff;">on and&#xa0;$26.2&#xa0;million for the </span> six <span style="background-color:#ffffff;">months ended </span>June 30, 2023 and 2022<span style="background-color:#ffffff;">, respectively. The&#xa0;increase&#xa0;in selling and marketing expenses of&#xa0;$1.9&#xa0;million is primarily attributable to&#xa0;</span>brand marketing related expenses and&#xa0;commercial operation advertisement, data management and trainings, partially offset by lower market research&#xa0;related expenses.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>General and Administrative Expenses</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and <span style="background-color:#ffffff;">administrative expenses were&#xa0;$18.9&#xa0;million and&#xa0;$15.9&#xa0;million for the </span> six <span style="background-color:#ffffff;">months ended </span>June 30, 2023 and 2022<span style="background-color:#ffffff;">, respectively. The&#xa0;increase&#xa0;in general and administrative expenses of&#xa0;$3.0&#xa0;million resulted primarily from third-party advisory providers, professional services, and ongoing managed services.</span></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Financing on Prepaid Forward Obligation</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation was&#xa0;$10.6&#xa0;million and&#xa0;$11.7&#xa0;million for the six months ended June 30, 2023 and 2022, respectively. The measurement of financing on&#xa0;prepaid forward obligation is an accounting estimate under the "imputed interest method" of accounting (see Note 3 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report) which is affected by estimated future payments to RTW, which are based on a percentage of revenues. The decrease&#xa0;in financing on prepaid forward obligation of $1.1&#xa0;million was driven primarily by changes in underlying assumptions&#xa0;for remeasuring the effective rate.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Interest Expense on Long-term Debt</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense was&#xa0;$7.3&#xa0;million and $2.5&#xa0;million&#xa0;for the six months ended June 30, 2023 and 2022,&#xa0;respectively. The cost in 2023&#xa0;relates to interest expense on the Pharmakon loan for&#xa0;two full quarters versus the prior year given the loan&#xa0;closed in March 2022.&#xa0; In addition, the increase was attributable to&#xa0;increase in interest rates related to the&#xa0;Pharmakon loan and the funding of the second tranche of the Pharmakon loan in December 2022.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Interest and Other Income (Expense), Net</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest and other income (expense), net was&#xa0;$1.0&#xa0;million and $0.1&#xa0;million&#xa0;for the six months ended June 30, 2023 and 2022, respectively. The increase in interest and other income (expense), net was primarily due to interest earned on investments due to changes in the overall interest rate environment.</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of June 30, 2023, we had&#xa0;$55.3&#xa0;million in cash and cash equivalents and marketable securities. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation, and is held primarily in U.S. dollars.&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Through June 30, 2023, we funded our operations primarily through public equity offerings, private placements of equity securities and our funding arrangements with RTW and Pharmakon.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In December 2019, we entered into a sales agreement (the &#x201c;ATM Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) pursuant to which we may from time to time offer and sell our ordinary shares having an aggregate offering price of up to $100.0 million. The remaining capacity under the ATM Sales Agreement is approximately $83.4 million as of June&#xa0;30, 2023. The shares will be offered and sold pursuant to our shelf registration statement on Form S-3 filed with the SEC on November 15, 2022, which was declared effective on November 29, 2022.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In March 2021, we entered into a prepaid forward agreement with RTW, pursuant to which RTW agreed to provide us with an upfront cash payment of $75.0 million to support the launch of <i>Jelmyto</i> and the development of UGN-102, and we agreed to provide RTW with tiered future payments based on global annual net product sales of <i>Jelmyto</i> and UGN-102, if approved. In May 2021, following the receipt of necessary regulatory approvals, we received the $75.0 million prepaid forward payment ($<span style="background-color:#ffffff;">72.4</span>&#xa0;million net of transaction costs) from RTW.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On&#xa0;March 7,&#xa0;2022, we&#xa0;entered into a loan&#xa0;agreement ("Loan Agreement") with Pharmakon for a&#xa0;senior secured term loan of up to $100.0 million in&#xa0;two&#xa0;tranches. The&#xa0;first&#xa0;tranche of $75.0 million ($72.6&#xa0;million of proceeds were received, $70.8&#xa0;million net of additional transaction costs) was funded in&#xa0;March 2022, and the second tranche of $25.0 million was funded in December 2022.&#xa0;The Pharmakon loan will mature&#xa0;five&#xa0;years from initial funding and can be prepaid in whole at our discretion, at any time, subject to prepayment premiums and make-whole amounts.&#xa0;The Pharmakon loan will require interest-only payments for the&#xa0;first&#xa0;48&#xa0;months followed by principal and interest payments with interest accruing using&#xa0;3-month LIBOR (with a&#xa0;1.25% floor) plus&#xa0;8.25%. On June 29, 2023, the Loan Agreement was amended to replace&#xa0;the benchmark governing the interest rate with a rate based on the secured overnight financing rate ("SOFR") published by the Federal Reserve Bank of New York.&#xa0; Effective&#xa0;July 2023, the loan&#xa0;will accrue interest using a benchmark rate of 3-month SOFR plus a&#xa0;0.26161% adjustment.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On July&#xa0;26, 2023, we entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional and other accredited investors (the &#x201c;Purchasers&#x201d;), pursuant to which we agreed to sell and issue to the Purchasers 12,579,156 ordinary shares of the Company (&#x201c;Shares&#x201d;) (or in lieu of Shares,&#xa0;pre-funded&#xa0;warrants to purchase ordinary shares of the Company) at a purchase price of $9.54 per Share (or $9.539 for each ordinary share underlying a&#xa0;pre-funded&#xa0;warrant), in a private placement transaction (the &#x201c;Private Placement&#x201d;) for aggregate gross proceeds of $120.0 million, before deducting fees to placement agents and financial advisors and before other expenses payable by us. Each&#xa0;pre-funded&#xa0;warrant has an exercise price of $0.001 per ordinary share, subject to customary adjustments, and became exercisable upon original issuance and will not expire until exercised in full. The&#xa0;pre-funded&#xa0;warrants may not be exercised if the aggregate number of ordinary shares beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation. The aggregate fee payable by us to&#xa0;placement agents and financial advisors is&#xa0;$3.6 million, plus the reimbursement of certain expenses.&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We have incurred losses since our inception and negative cash flows from our operations, and as of June 30, 2023 we had an accumulated deficit of $631.5&#xa0;million. We anticipate that we will continue to incur losses for the reasonably foreseeable future. Our primary uses of capital are, and we expect will continue to be, commercialization activities, research and development expense, including third-party clinical research and development services, laboratory and related supplies, clinical costs, including manufacturing costs, legal and other regulatory expense and general and administrative costs, partially offset by proceeds from sales of <i>Jelmyto</i>.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We routinely evaluate our liquidity needs, including assessment of our&#xa0;current financial condition, sources of liquidity including current cash and cash equivalents and marketable securities and management&#x2019;s cash flow projections. Our ability to continue as a going concern is expected to be impacted by our ability to raise additional capital to fund our operations, produce cash inflows from <i>Jelmyto</i> product sales and develop UGN-102.&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We cannot estimate the actual amounts necessary to successfully commercialize any approved products, or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Funding and Material Cash Requirements</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;">Our present and future funding and material cash requirements will depend on many factors, including, among other things:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Arial; font-size: 10pt;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="width: 76pt; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the progress, timing and completion of clinical trials for UGN-102 and UGN-301;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Arial; font-size: 10pt;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="width: 76pt; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">nonclinical studies and clinical trials for any of our other product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Arial; font-size: 10pt;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="width: 76pt; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the costs related to obtaining regulatory approval UGN-102 and UGN-301 and any of our other product candidates, and any delays we may encounter as a result of regulatory requirements or adverse clinical trial results with respect to any of these product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Arial; font-size: 10pt;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="width: 76pt; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">selling, marketing and patent-related activities undertaken in connection with the commercialization of <i>Jelmyto</i> and UGN-102 and any of our other product candidates, and costs involved in the continued development of an effective sales and marketing organization;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Arial; font-size: 10pt;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="width: 76pt; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other amounts we may be required to pay to obtain rights to third party intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Arial; font-size: 10pt;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="width: 76pt; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">potential new product candidates we identify and attempt to develop;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Arial; font-size: 10pt;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="width: 76pt; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">revenues we may derive either directly or in the form of royalty payments from future sales of <i>Jelmyto</i>, UGN-102, UGN-301, <i>RTGel </i>reverse thermal hydrogel technology and any other product candidates; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Arial; font-size: 10pt;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="width: 76pt; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the repayment of outstanding debt.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Accordingly, we will&#xa0;need to obtain additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We may finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of any additional securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, may involve agreements that include covenants that further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, the terms of the&#xa0;Forward Contract with RTW and the Loan Agreement limit our ability to take certain actions, including incurring additional indebtedness.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">For more information as to the risks associated with our future funding needs, see Part II, Item 1A &#x2013; Risk Factors. We will require additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Contractual Obligations and Commitments</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In April 2016, we signed an addendum to our November 2014 lease agreement for our executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, we utilized the agreement extension option and extended the rent period for an additional three years until August 2022. In July 2022, we signed a lease extension agreement extending the term of the lease through September 2025.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In April 2018, we entered into a new lease agreement for an office in Los Angeles, CA. The lease commencement date was July 10, 2018 and terminates in March 2024.&#xa0;In November 2019, we subleased our offices in Los Angeles, CA. The lease commencement date was January 1, 2020 and terminates in March 2024. The subtenants exercised their early access clause and moved into the premises at the end of November 2019.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Also, in November 2019, we entered into a new lease agreement, dated effective October 31, 2019, for an office in Princeton, NJ. The lease commencement date was November 29, 2019 and the lease term is 38 months.&#xa0;In June&#xa0;2022, we&#xa0;signed an amendment to our&#xa0;November 2019 lease agreement to extend the term for an additional three years through January 31, 2026.&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The total obligation for future minimum lease payments under our operating leases is $2.4&#xa0;million as of June&#xa0;30, 2023.&#xa0;See Note 11 to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report&#xa0;for further information.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In March 2022, UroGen Pharma Ltd., UroGen Pharma, Inc., as the borrower ("Borrower"), and certain direct and indirect subsidiaries of the Company party thereto from time to time, as guarantors ("Guarantors" and, collectively with UroGen Pharma Ltd. and Borrower, "Credit Parties"), entered into the Loan Agreement with funds managed by Pharmakon Advisors, L.P., including BPCR Limited Partnership (as a "Lender"), BioPharma Credit Investments V (Master) LP (as a "Lender"), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, "Collateral Agent"), pursuant to which the Lenders agreed to make the Term Loans to the Borrower in an aggregate principal amount of up to $100.0 million to be funded in two tranches: (i) the Tranche A Loan of $75.0 million was advanced in March&#xa0;2022 and (ii) the Tranche B Loan of $25.0 million was advanced in December&#xa0;2022. The Term Loans will mature on the fifth-year anniversary of the Tranche A Closing Date (the &#x201c;Maturity Date&#x201d;). The Term Loans bear interest at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.25%. On June 29, 2023, the Loan Agreement&#xa0;was amended ("Amended Loan Agreement") to replace&#xa0;the benchmark governing the interest rate with a rate based on the SOFR&#xa0;published by the Federal Reserve Bank of New York.&#xa0; Effective&#xa0;July 2023, the loan&#xa0;will accrue interest using a benchmark rate of 3-month SOFR plus a&#xa0;0.26161% adjustment as described in the Amended Loan Agreement.&#xa0; Interest is payable quarterly in arrears. Repayment of outstanding principal of the Term Loans will be made in four equal quarterly payments of principal commencing after the 17th-quarter anniversary of the Tranche A Closing Date. The obligations of the Borrower under the Loan Agreement are guaranteed on a full and unconditional basis by UroGen Pharma Ltd. and the other Guarantor and are secured by substantially all of the respective Credit Parties&#x2019; tangible and intangible assets and property, including intellectual property, subject to certain exceptions.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cash Flows</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table sets forth the significant sources and uses of cash for the periods set forth below:&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six Months Ended June 30,</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(in thousands)</b></p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash (used in) provided by:</p> </td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating activities</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(46,081</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(48,195</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Investing activities</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">9,990</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">13,445</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Financing activities</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">814</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70,665</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net change in cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(35,277</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,915</td>
     <td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Operating Activities</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities was $46.1&#xa0;million during the six months ended June 30, 2023, compared to $48.2&#xa0;million during the six months ended June 30, 2022. The $2.1&#xa0;million decrease&#xa0;was attributable primarily to timing of certain accruals, as well as increase in net sales of our product<i> Jelmyto</i> during 2023, partially offset by increase in interest on long-term debt.&#xa0;&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Investing Activities</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by&#xa0;investing activities was $10.0&#xa0;million during the six months ended June 30, 2023, compared to $13.5&#xa0;million&#xa0;during the six months ended June 30, 2022. The net change of $3.5&#xa0;million is attributable primarily to more reinvestment of marketable securities in 2023 as compared to 2022.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Financing Activities</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by financing activities was $0.8&#xa0;million during the six months ended June 30, 2023, compared to $70.7 million during the six months ended June 30, 2022. The decrease of $69.9&#xa0;million is attributable primarily to proceeds from the Pharmakon loan in the prior&#xa0;year.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="qqdmr" title="qqdmr" href="#"></a>Item 3. Quantitative and Qualitative Disclosures About Market Risk.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Interest Rate Fluctuation Risk</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Some of the securities in which we invest have market risk in that a change in prevailing interest rates may cause the principal amount of the marketable securities to fluctuate. Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of&#xa0;June 30, 2023, we had $55.3&#xa0;million in&#xa0;cash,&#xa0;cash equivalents and marketable securities. We invest our cash primarily in money market accounts, but from time to time may&#xa0;invest in commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our marketable securities without significantly increasing risk. We have established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity. If a 10% change in interest rates were to have occurred on June 30, 2023, this change would not have had a material effect on the fair value of our cash, cash equivalents and marketable securities as of that date.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Inflation Risk</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inflation generally may affect us by increasing our cost of labor and clinical trial costs. Inflation has not had a material effect on our business, financial condition or results of operations during the three and six&#xa0;months ended June 30, 2023&#xa0;or 2022.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Foreign Currency Exchange Risk</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in the New Israeli Shekel ("NIS"). As a result, we are exposed to the risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation, if any, of the NIS against the dollar. For example, the dollar appreciated against the NIS during 2022&#xa0;by a total of 11.9%. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected. Our operations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future. If a 10% change in NIS-to-Dollar exchange rates were to have occurred during the three months ended June&#xa0;30, 2023, this change would not have had a material effect on our operating expenses.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We do not currently engage in currency hedging activities in order to reduce this currency exposure, but we may begin to do so in the future. Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="cps" title="cps" href="#"></a>Item 4. Controls and Procedures.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Evaluation of Disclosure Controls and Procedures</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Our management, with the participation of our chief executive and financial officers (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosures controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June 30, 2023. The term &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Changes in Internal Control over Financial Reporting</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in our internal control over financial reporting may include such activities as implementing new, more efficient systems, consolidating activities, and migrating processes. There were no changes in our internal control over financial reporting during the quarter ended June&#xa0;30, 2023&#xa0;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="pii" title="pii" href="#"></a>Part II</b>&#x2014;<b>Other Information</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="legal" title="legal" href="#"></a>Item 1. Legal Proceedings.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="risks" title="risks" href="#"></a>Item 1A. Risk Factors.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risk Factor Summary</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Below is a summary of the material&#xa0;factors that make an investment in our ordinary shares speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading </i>&#x201c;<i>Risk Factors,</i>&#x201d;<i> and should be carefully considered, together with other information in this Quarterly Report and our other filings with the U.S. Securities and Exchange Commission ("</i><i>SEC") before making investment decisions regarding our ordinary shares.</i></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We will require additional financing to fund our operations and achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are highly dependent on the successful commercialization of our only approved product, <i>Jelmyto</i>.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We have limited experience as an organization in marketing and distributing products and are therefore subject to certain risks in relation to the commercialization of <i>Jelmyto</i>&#xa0;and any of our product candidates that receive regulatory approval.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The market opportunities for <i>Jelmyto</i>&#xa0;and our product candidates may be smaller than we anticipate or limited to those patients who are ineligible for established therapies or for whom prior therapies have failed and may be small.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Jelmyto</i>&#xa0;and any of our product candidates that receive regulatory approval may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Jelmyto</i>&#xa0;and our product candidates, if approved, will face significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition to <i>Jelmyto</i>, we are dependent on the success of our lead product candidate, UGN-102, and our other product candidates, including obtaining regulatory approval to market our product candidates in the United States.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;">UGN-102 may not meet its secondary endpoint in the ongoing Phase 3 ENVISION trial.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We have entered into collaboration and licensing agreements and in the future may enter into collaboration and licensing arrangements with other third parties for the development or commercialization of our product candidates. If our collaboration and licensing arrangements are not successful, we may not be able to capitalize on the market potential of these product candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce <i>Jelmyto</i>&#xa0;for commercial use, and to produce UGN-102,&#xa0;UGN-201 and UGN-301 for nonclinical studies and clinical trials, and expect to continue to do so to support commercial scale production of UGN-102 and UGN-201, if approved, as well as UGN-301 if approved as a monotherapy or for any approved product that includes UGN-301.&#xa0;There are significant risks associated with the manufacture of pharmaceutical products and contracting with contract manufacturers, including single-source suppliers. Furthermore, our existing third-party subcontractors and single-source suppliers may not be able to meet the increased need for certain raw materials, compounds and components that may result from our commercialization efforts. This increases the risk that we will not have sufficient quantities of <i>Jelmyto</i>, UGN-102, UGN-201 or UGN-301 or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any of our other products we develop.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If we fail to attract and keep senior management and key personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize any of the products we develop.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our indebtedness resulting from our Loan Agreement could adversely affect our financial condition or restrict our future operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not adequate, we may not be able to compete effectively, and we otherwise may be harmed.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If the FDA does not conclude that UGN-102 satisfies the requirements under 505(b)(2), or if the requirements for our product candidates are not as we expect, the approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;">We expect current and future legislation affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase limitations on reimbursement, rebates and other payments, which could adversely affect third-party coverage of our products, our operations, and/or how much or under what circumstances healthcare providers will prescribe or administer our products, if approved.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Jelmyto</i>&#xa0;and any of our product candidates that receive regulatory approval will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor policies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risk Factors</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>You should carefully consider the following risk factors, as well as the other information in this Quarterly Report, before deciding whether to purchase, hold or sell shares of our ordinary shares. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from&#xa0;those contained in forward-looking statements we have made in this Quarterly Report and those we may make from time to time. When evaluating our business, you should consider all of the factors described as well as the other information in our Annual Report and this Quarterly Report, including our financial statements and the related notes,</i>&#xa0;&#x201c;<i>Management</i>&#x2019;<i>s Discussion and Analysis of Financial Condition and Results of Operation</i>&#x201d;&#xa0;<i>and</i>&#xa0;<i>Item 1A,</i>&#xa0;&#x201c;<i>Risk Factors.</i>&#x201d;<i> We have marked with an asterisk (*) those risk factors that did not appear as risk factors in, or contain changes to the similarly titled risk factors included in, Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our ordinary shares would likely decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</i></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are a biotechnology company with a limited operating history upon which you can evaluate our business and prospects. We are not profitable and have incurred net losses in each period since we commenced operations in 2004, including net losses of $109.8&#xa0;million for the year&#xa0;ended December 31, 2022&#xa0;and a net loss of $24.1 million for the quarter ended June&#xa0;30, 2023.&#xa0;As of June&#xa0;30, 2023, we had an accumulated deficit of&#xa0;$631.5&#xa0;million.&#xa0;We expect to continue to incur significant expenses and&#xa0;operating losses for the foreseeable future. Our ability to ultimately achieve recurring revenues and profitability is dependent upon our ability to successfully complete the development of our product candidates and obtain necessary regulatory approvals for and successfully manufacture, market and commercialize our products.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We believe that we will continue to expend substantial resources in the foreseeable future for the clinical development of our current product candidates or any additional product candidates and indications that we may choose to pursue in the future. These expenditures will include costs associated with research and development, conducting nonclinical studies and clinical trials, and payments for third-party manufacturing and supply, as well as sales and marketing of any of our product candidates that are approved for sale by regulatory agencies. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our clinical stage and nonclinical drug candidates and any other drug candidates that we may develop in the future. Other unanticipated costs may also arise.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our future capital requirements depend on many factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the timing of, and the costs involved in, clinical development and obtaining regulatory approvals for our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in regulatory requirements during the development phase that can delay or force us to stop our activities related to any of our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the cost of commercialization activities for <i>Jelmyto</i>&#xa0;and any other products approved for sale, including marketing, sales and distribution costs;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our degree of success in commercializing <i>Jelmyto</i>;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the cost of third-party manufacturing of our products candidates and any approved products;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the number and characteristics of any other product candidates we develop or acquire;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements, and the terms and timing of such arrangements;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the extent and rate of market acceptance of any approved products;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the expenses needed to attract and retain skilled personnel;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the costs associated with being a public company;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent and other intellectual property claims, including potential litigation costs, and the outcome of such litigation;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the timing, receipt and amount of sales of, or royalties on, future approved products, if any;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#x2022;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">the repayment of outstanding debt;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">any product liability or other lawsuits related to our products or business arrangements;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">scientific breakthroughs in the field of urothelial cancer treatment and diagnosis that could significantly diminish the demand for our product candidates or make them obsolete; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in reimbursement or other laws, regulations or policies that could have a negative impact on our future revenue stream.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     37
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology&#xa0;industry. Drug development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have not obtained regulatory approval for or commercialized any product except <i>Jelmyto</i>.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We will require additional financing to fund our operations and achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.*</i></b></p>
  <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">We are not profitable and have had negative cash flow from operations since our inception. Since our inception, almost all our resources have been dedicated to the nonclinical and clinical development of our first commercial product, <i>Jelmyto</i>, and our lead product candidate UGN-102. As of June&#xa0;30, 2023, we had cash and cash equivalents and marketable securities of $55.3&#xa0;million. This amount does not include the proceeds from our $120.0 million private placement of ordinary shares and pre-funded warrants, $115.0 million of which closed on August 2, 2023 and the remaining $5.0 million of which closed on August 9, 2023. Fees to placement agents and financial advisors for the private placement are 3.0% of the gross proceeds, plus the reimbursement of certain expenses. To fund our operations and develop our product candidates and commercialize <i>Jelmyto</i>, we have relied primarily on equity and debt financings and, following the launch of <i>Jelmyto </i>in June 2020, revenue generated from sales of&#xa0;<i>Jelmyto</i>. In March 2021, we announced a transaction with RTW Investments ("RTW") totaling $75 million in funding for our company, which was received in May 2021, to support the launch of <i>Jelmyto</i> and the development of UGN-102. In return for the upfront cash payment, RTW is entitled to receive tiered future payments based on global annual net product sales of <i>Jelmyto</i> and UGN-102, if approved.&#xa0;In March 2022, we entered into the Loan Agreement, pursuant to which the Lenders agreed to make the Term Loans to Borrower in an aggregate principal amount of up to $100 million to be funded in two tranches. The&#xa0;first&#xa0;tranche of $75.0 million ($72.6&#xa0;million of proceeds were received, $70.8&#xa0;million net of additional transaction costs) was funded in&#xa0;March 2022, and the second tranche of $25.0 million was funded in December 2022.&#xa0;&#xa0;</p>
  <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><span style="font-family:Arial,Helvetica,sans-serif;">We will&#xa0;require additional capital to complete clinical trials, obtain regulatory approval for and commercialize our product candidates, and otherwise fund our operations. Our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity financings, convertible debt or debt financings, third-party funding, marketing and distribution arrange</span>ments, as well as other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. In any event, we will require additional capital to pursue nonclinical and clinical activities, and pursue regulatory approval for, and to commercialize, our pipeline product candidates.</p>
  <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">Any additional fundraising efforts may divert the attention of our management from day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on favorable terms, if at all. Moreover, the terms of any financing may negatively impact the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than would be desirable and we may be required to relinquish rights to some of our technologies, intellectual property or product candidates or otherwise agree to terms unfavorable to us, any of which may harm our business, financial condition, cash flows, operating results and prospects.</p>
  <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">If adequate funds are not available to us on a timely basis, we may be required or choose to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">delay, limit, reduce or terminate nonclinical studies, clinical trials or other development activities for our product candidates or any of our future product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">delay, limit, reduce or terminate our other research and development activities; or</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">delay, limit, reduce or terminate our establishment or expansion of manufacturing, sales and marketing or distribution capabilities or other activities that may be necessary to commercialize <i>Jelmyto</i>&#xa0;or any of our product candidates that obtain marketing approval.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We may also be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could harm our business, financial condition, cash flows and results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our indebtedness resulting from our Loan Agreement could adversely affect our financial condition or restrict our future operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On March 7, 2022, UroGen Pharma Ltd., UroGen Pharma, Inc., as the borrower (&#x201c;Borrower&#x201d;), and certain direct and indirect subsidiaries of the Company party thereto from time to time, as guarantors (&#x201c;Guarantors&#x201d;) and, collectively with UroGen Pharma Ltd. and Borrower&#xa0;(&#x201c;Credit Parties&#x201d;) entered into a loan agreement (&#x201c;Loan Agreement&#x201d;) with funds managed by Pharmakon Advisors, L.P., including BPCR Limited Partnership (as a &#x201c;Lender&#x201d;), BioPharma Credit Investments V (Master) LP (as a &#x201c;Lender&#x201d;), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, "Collateral Agent"), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $100 million ("Term Loans"), to be funded in two tranches: (i) the first tranche (&#x201c;Tranche A Loan&#x201d;) was advanced in the amount of $75 million, in March&#xa0;2022 (&#x201c;Tranche A Closing Date&#x201d;) and (ii) the second tranche (&#x201c;Tranche B Loan&#x201d;) of $25 million was advanced in December 2022.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The obligations of the Borrower under the Loan Agreement are guaranteed on a full and unconditional basis by UroGen Pharma Ltd. and the other Guarantor and are secured by substantially all of the respective Credit Parties&#x2019; tangible and intangible assets and property, including intellectual property, subject to certain exceptions.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Loan Agreement contains negative covenants that, among other things and subject to certain exceptions, restrict our ability to:</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 44pt; text-indent: 0pt;">&#x2022; sell or dispose of assets, including certain intellectual property;<br /> &#x2022; amend, modify or waive certain agreements or organizational documents;<br /> &#x2022; consummate certain change in control transactions;<br /> &#x2022; incur certain additional indebtedness;<br /> &#x2022; incur any non-permitted lien or other encumbrance on the Credit Parties&#x2019; assets;<br /> &#x2022; pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests; and<br /> &#x2022; make payments of certain subordinated indebtedness.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, we are required under the Loan Agreement to comply with various operating covenants and default clauses that may restrict our ability to finance our operations, engage in business activities or expand or fully pursue our business strategies. A breach of any of these covenants or clauses could result in a default under the Loan Agreement, which could cause all of the outstanding indebtedness under the facility to become immediately due and payable, including a make whole amount and prepayment premium.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">If we are unable to generate sufficient cash to repay our debt obligations when they become due and payable, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively affect our business operations and financial condition.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Covenants under our Prepaid Forward Contract with RTW restrict our ability to borrow additional capital.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In March 2021, we entered into a Prepaid Forward Contract (the &#x201c;Forward Contract&#x201d;) with RTW, pursuant to which we are obligated to make tiered cash payments to RTW, based on the worldwide annual net product sales of <i>Jelmyto</i> and, subject to FDA approval, UGN-102 (together, the &#x201c;Products&#x201d;), subject to an aggregate revenue cap of $300 million.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Until the earlier of such time that (i) our aggregate worldwide annual net product sales of the Products reach a certain threshold or (ii) our market capitalization reaches a certain threshold, (a) we have granted RTW a security interest in the Products and the regulatory approvals, intellectual property, material agreements, proceeds and accounts receivable related to the Products (the &#x201c;Product Collateral&#x201d;), (b) we are subject to a negative pledge in respect of the Product Collateral and (c) we may not incur additional indebtedness secured by Product Collateral without such secured debt provider entering into a intercreditor agreement with RTW. Upon the occurrence of an insolvency event, as defined in the Forward Contract, any remaining payment obligations under the Forward Contract will be automatically accelerated.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The Forward Contract requires us to use a significant portion of our cash flow to make payments to RTW, limits our ability to borrow additional funds for working capital, capital expenditures or other general business purposes, limits our flexibility to plan for, or react to, changes in our business and industry, places us at a competitive disadvantage compared to our competitors not subject to similar restrictions and increases our vulnerability to the impact of adverse economic industry conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     39
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity, convertible debt or debt financings, as well as selectively continuing to enter into collaborations, strategic alliances and licensing arrangements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including pursuant to the ATM Sales Agreement, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring and distributing dividends, and may be secured by all or a portion of our assets.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If we raise funds by selectively continuing to enter into additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish additional valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity, convertible debt or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If we are unable to raise additional funds through other collaborations, strategic alliances or licensing arrangements, we may be required to terminate product development or future commercialization efforts or to cease operations altogether.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Risks Related to Our Business and Strategy </b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We are highly dependent on the successful commercialization of our only approved product, Jelmyto.*</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Jelmyto </i>is our first product, which we commercially launched in the United States in June 2020. We have not commercialized any other product candidates. We have invested significant efforts and financial resources in the research and development of <i>Jelmyto</i>, our first and only product approved for commercial sale. We are focusing a significant portion of our activities and resources on <i>Jelmyto</i>, and we believe our prospects are highly dependent on, and a significant portion of the value of our company relates to, our ability to successfully commercialize <i>Jelmyto</i> in the United States.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Successful commercialization of <i>Jelmyto</i> is subject to many risks. We initiated our commercial launch of <i>Jelmyto</i> in June 2020, and prior to that, we had never, as an organization, launched or commercialized any product. There is no guarantee that our ongoing commercial launch of <i>Jelmyto</i> or our future commercialization efforts will be successful, or that we will be able to successfully launch and commercialize any other product candidates that receive&#xa0;regulatory approval. There are numerous examples of unsuccessful product launches and failures to meet high expectations of market potential, including by pharmaceutical companies with more experience and resources than us. While we have established our commercial team and have hired our U.S. sales force, we will need to maintain, further train and develop our team in order to be prepared to successfully coordinate the ongoing launch and commercialization of <i>Jelmyto</i>. Even if we are successful in maintaining and further developing our commercial team, there are many factors that could cause the ongoing launch and commercialization of <i>Jelmyto</i> to be unsuccessful, including a number of factors that are outside our control. We must also properly educate physicians and nurses on the skillful preparation and administration of <i>Jelmyto</i>, and develop a broad experiential knowledge base of aggregated clinician feedback from which we can refine appropriate procedures for product administration, without which there could be a risk of adverse events.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Because no drug has previously been approved by the FDA for the treatment of low-grade UTUC, it is especially difficult to estimate <i>Jelmyto</i>&#x2019;s market potential. The commercial success of <i>Jelmyto</i> depends on the extent to which patients and physicians accept and adopt <i>Jelmyto</i> as a treatment for low-grade UTUC, and we do not know whether our or others&#x2019; estimates in this regard will be accurate. For example, if the patient population suffering from low-grade UTUC is smaller than we estimate or if physicians are unwilling to prescribe or patients are unwilling to be treated with <i>Jelmyto</i> due to label warnings, adverse events associated with product administration or other reasons, the commercial potential of <i>Jelmyto</i> will be limited. Physicians may not prescribe <i>Jelmyto</i> and patients may be unwilling to be treated with <i>Jelmyto</i> if coverage is not provided or reimbursement is inadequate to cover a significant portion of the cost.&#xa0;Additionally, any negative development for <i>Jelmyto</i> in our post-marketing commitments, or in regulatory processes in other jurisdictions, may adversely impact the commercial results and potential of <i>Jelmyto</i>. Thus, significant uncertainty remains regarding the commercial potential of <i>Jelmyto</i>.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, our ongoing commercial launch of <i>Jelmyto</i> and subsequent commercialization efforts could be hindered by pandemics, epidemics or public health emergencies, although we are currently not able to predict or quantify any such potential impact with any degree of certainty.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">If the launch or commercialization of <i>Jelmyto</i> is unsuccessful or perceived as disappointing, our share price could decline significantly and the long-term success of the product and our company could be harmed.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Jelmyto has only been studied in a limited number of patients and in limited populations. Following the initiation of our commercial launch in June 2020, Jelmyto is now available to a much larger number of patients and in broader populations, and we do not know whether the results of Jelmyto use in such larger number of patients and broader populations will be consistent with the results from our clinical studies.*</i></b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Jelmyto</i> has been administered only to a limited number of patients and in limited populations in clinical studies, including our successful pivotal Phase 3 OLYMPUS clinical trial for the treatment of adult patients with low-grade UTUC. While the FDA granted approval of <i>Jelmyto</i> based on the data included in the NDA&#xa0;including data from the Phase 3 OLYMPUS clinical trial, and we have subsequently published new long-term data from OLYMPUS trial, we do not know whether the results when a large number of patients and broader populations are exposed to <i>Jelmyto</i>, including results related to safety and efficacy, will be consistent with the results from earlier clinical studies of&#xa0;<i>Jelmyto</i> that served as the basis for the approval of <i>Jelmyto</i>. New data relating to <i>Jelmyto</i>, including from spontaneous adverse event reports and post-marketing studies in the United States, and from other ongoing clinical studies, may result in changes to the product label and may adversely affect sales, or result in withdrawal of <i>Jelmyto</i> from the market. The FDA and regulatory authorities in other jurisdictions may also consider the new data in reviewing potential marketing applications in other jurisdictions, or imposing post&#x2011;approval requirements. If any of these actions were to occur, it could result in significant expense and delay or limit our ability to generate sales revenues.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We have limited experience as an organization in marketing and distributing products and are therefore subject to certain risks in relation to the commercialization of Jelmyto and any of our</i></b>&#xa0;<b><i>product candidates that receive</i></b>&#xa0;<b><i>regulatory approval.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our strategy is to build and maintain a fully integrated biotechnology company to successfully execute the commercialization of <i>Jelmyto</i> in the United States. <i>Jelmyto</i> is our only product that has been approved for sale by any regulatory body, and it became available in the United States in June 2020. While we have established a commercial management team and have also established a field-based organization comprised of a sales team, reimbursement support team, clinical nurse educators, national account managers and medical science liaisons, we currently have&#xa0;limited experience commercializing pharmaceutical products as an organization. In order to successfully commercialize <i>Jelmyto</i>, we must continue to develop our sales, marketing, managerial, compliance and related capabilities or make arrangements with third parties to perform these services. This involves many challenges, such as recruiting and retaining talented personnel, training employees, setting the appropriate system of incentives, managing additional headcount and integrating new business units into an existing corporate infrastructure. These efforts will continue to be expensive and time-consuming, and we cannot be certain that we will be able to successfully further develop these capabilities. Additionally, we will need to maintain and further develop our sales force, and we will be competing with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. In the event we are unable to effectively develop and maintain our commercial team, including our sales force, our ability to effectively commercialize <i>Jelmyto</i> would be limited, and we would not be able to generate product revenues successfully. If we fail to establish and maintain an effective sales and marketing infrastructure, we will be unable to successfully commercialize our product candidates, which in turn would have an adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we are unable to effectively train and equip our sales force, our ability to successfully commercialize Jelmyto will be harmed.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">None of the members of our sales force had ever promoted <i>Jelmyto</i> prior to its launch in June 2020. In addition, <i>Jelmyto</i> is the first drug approved by the FDA for the treatment of low-grade UTUC. As a result, we are and will continue to be required to expend significant time and resources to train our sales force to be credible, persuasive, and compliant with applicable laws in marketing <i>Jelmyto</i> for the treatment of low-grade UTUC to physicians and nurses. In addition, we must train our sales force to ensure that a consistent and appropriate message about <i>Jelmyto</i> is being delivered to our customers. If we are unable to effectively train our sales force and equip them with effective materials, including medical and sales literature to help them inform and educate customers about the benefits and risks of <i>Jelmyto</i> and its proper administration, our efforts to successfully commercialize <i>Jelmyto</i> could be put in jeopardy, which would negatively impact our ability to generate product revenues.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">There can be no assurance that our territory business managers will continue to have in-person access to physicians as a result of pandemics, epidemics or public health emergencies, or that digital materials and virtual engagement will be effective at growing and sustaining prescription levels of <i>Jelmyto</i>. Disruptions in the prescription volume of <i>Jelmyto</i> could also occur:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">if patients are physically quarantined or are unable or unwilling to visit healthcare providers;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">if physicians restrict access to their facilities for a material period of time;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">if healthcare providers prioritize treatment of acute or communicable illnesses over treatment of low-grade UTUC;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">if pharmacies are closed or suffering staff shortages or supply chain disruptions;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">if patients lose access to employer-sponsored health insurance due to periods of high unemployment; or</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">as a result of general disruptions in the operations of payors, distributors, logistics providers and other third parties that are necessary for <i>Jelmyto</i>&#xa0;to be prescribed, reconstituted, instilled and reimbursed.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>The market opportunities for Jelmyto and our product candidates may be smaller than we anticipate or limited to those patients who are ineligible for established therapies or for whom prior therapies have failed and may be small.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancer therapies are sometimes characterized as first-line, second-line or third-line. When cancer is detected early enough, first-line therapy, often chemotherapy, hormone therapy, surgery, radiotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life. Second- and third-line therapies are administered to patients when prior therapy is not or is no longer effective. For urothelial cancers, the current first-line standard of care is surgery designed to remove one or more tumors. Chemotherapy is currently used in treating urothelial cancer only as an adjuvant, or supplemental therapy, after tumor resection. We are designing our lead product candidate UGN-102 as an alternative to&#xa0;surgery as the standard of care for certain urothelial cancers. However, there is no guarantee that this product candidate will be approved or that we will not have to conduct additional clinical trials. Even if approved, the market opportunity for UGN-102 may be smaller than we anticipate or limited to those patients who are ineligible for established therapies or for whom prior therapies have failed. Our other or future product candidates may face similar risks.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     41
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers who have previously failed prior treatments, and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or third-party market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, our pivotal Phase 3 OLYMPUS clinical trial for <i>Jelmyto</i> was designed to evaluate the use of <i>Jelmyto</i> for the treatment of tumors in the renal pelvis (the funnel-like dilated part of the ureter in the kidney) and was not designed to evaluate the use of <i>Jelmyto</i> for the treatment of tumors in the ureter (the tube that connects the kidneys to the bladder). Even though <i>Jelmyto</i> is approved for the treatment of low-grade UTUC, physicians may choose to only use it to treat tumors in the renal pelvis and not tumors in the ureter, which would limit the degree of physician adoption and market acceptance of <i>Jelmyto</i>. Even if we obtain significant market share, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including the use of the products as first- or second-line therapy. For example, low-grade UTUC is a rare malignant tumor of the cells lining the urinary tract and there is limited scientific literature or other research on the incidence and prevalence of low-grade UTUC. If our estimates of the incidence and prevalence of low-grade UTUC are incorrect, <i>Jelmyto</i>&#x2019;s commercial viability may prove to be limited, which may negatively affect our financial results.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Jelmyto and any of our product candidates that receive</i></b>&#xa0;<b><i>regulatory approval may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The commercial success of <i>Jelmyto</i> and any other product candidates that receive&#xa0;regulatory approval will depend significantly on their broad adoption and use by physicians&#xa0;for approved indications, including, in the case of <i>Jelmyto</i>, for the treatment of low-grade UTUC, and in the case of UGN-102, for the treatment of low-grade intermediate risk NMIBC, and for other therapeutic indications that we may seek to pursue with any of our product candidates. Physicians treating low-grade UTUC and low-grade intermediate risk NMIBC have never had to consider treatments other than surgery. The degree and rate of physician and patient adoption of <i>Jelmyto</i>, UGN-102 or any of our other product candidates, if approved, will depend on a number of factors, including:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the clinical indications for which the product is approved;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the safety and efficacy data from the clinical trial(s) supporting the approved clinical indications;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the approved labeling and packaging for our products, including the degree of product preparation and administration convenience and ease of use that is afforded to physicians by the approved labeling and product packaging;&#xa0;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the prevalence and severity of adverse side effects and the level of benefit/risk observed in our clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">sufficient patient satisfaction with the results and administration of our products and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the extent to which physicians recommend our products to patients;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">physicians&#x2019;&#xa0;and patients&#x2019;&#xa0;willingness to adopt new therapies in lieu of other products or treatments, including willingness to adopt <i>Jelmyto</i>, and our lead product candidate UGN-102 as locally-administered drug replacements to current surgical standards of care;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the cost of treatment, safety and efficacy of our products in relation to alternative treatments, including the recurrence rate of our treatments;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the extent to which the costs of our products are covered and reimbursed by third-party payors, including the availability of a physician reimbursement code for our treatments, and patients&#x2019;&#xa0;willingness to pay for our products;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">whether treatment with our products, including the treatment of low-grade UTUC with <i>Jelmyto</i>&#xa0;and the treatment of low-grade intermediate risk NMIBC with UGN-102, if approved, will be deemed to be an elective procedure by third- party payors; if so, the cost of treatment would be borne by the patient and would be less likely to be broadly adopted;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">proper education of physicians or nurses for the skillful administration of our approved product, <i>Jelmyto</i>, and UGN-102, if approved, and development of a broad experiential knowledge base of aggregated clinician feedback from which we can refine appropriate procedures for product administration, without which there could be a risk of adverse events;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the effectiveness of our sales and marketing efforts, especially the success of any targeted marketing efforts directed toward physicians and clinics and any direct-to-consumer marketing efforts we may initiate; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#x2022;</td>
     <td style="vertical-align: top; width: auto; font-family: Arial;">third-party clinical practice guidelines.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If <i>Jelmyto</i>, UGN-102 or any of our other product candidates are approved for use but fail&#xa0;to achieve the broad degree of physician adoption and market acceptance necessary for commercial success, our operating results and financial condition would be adversely affected.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Jelmyto and our product candidates, if approved, will face significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target or seek to have existing drugs approved for use for the treatment of the indications that we target.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     42
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are aware of several pharmaceutical companies that are developing drugs in the general fields of urology and uro-oncology, such as AADi, LLC, Biocancell Ltd.,&#xa0;Bristol Myers Squibb, CG Oncology Inc., Ferring Pharmaceuticals, FKD Therapies Oy, GSK,&#xa0;ImmunityBio, Janssen, Merck Sharp&#xa0;&amp; Dohme Corp,&#xa0;Roche,&#xa0;Samyang Biopharma, Seagen Inc., Steba Biotech Ltd., SURGE Therapeutics, Viralytics Limited and Vyriad. We are aware that Ferring Pharmacuticals plans to begin production of its Adstiladrin, approved by the FDA for the treatment of high-risk BCG-unresponsive NMIBC, in the second half of 2023. In January 2023, SURGE Therapeutics received FDA clearance on an IND to proceed with a Phase 1/2a study of its SURGERx platform with&#xa0;resiquimod for prevention of recurrence and/or progression after TURBT in patients previously diagnosed with high-grade NMIBC that experience recurrence. We are aware of a company called Steba Biotech with an IND granted in December 2020 which&#xa0;has initiated a Phase 3 study of padeliporfin ImPACT for the treatment of adult patients&#xa0;with low-grade and unifocal high-grade UTUC in the first quarter of 2021. We have also entered into a Phase 1 study to support the development of UGN-301 in high-grade NMIBC. We are also aware that other companies, such as Janssen and Lipac are conducting, or have recently conducted clinical trials for product candidates for the treatment of low-grade intermediate risk NMIBC. Outside of these indications where we are developing products, we are aware of other companies doing work in both bladder and upper tract cancers, but these are with agents or on targets in high-grade, metastatic, or muscle invasive cancers. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing products that are more effective, easier to administer or less costly than our product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, we face competition from existing standards of treatment, surgical tumor resection procedures. If we are not able to demonstrate that our product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates in replacement of the existing standard of care. Generic mitomycin injectable drug products, while approved by FDA for gastric and pancreatic cancers, are neither approved for low-grade UTUC nor reconstituted with hydrogel in an FDA-approved product as <i>Jelmyto</i> is, although they may be used off-label by physicians for the treatment of low-grade UTUC, as they have been prior to the approval of <i>Jelmyto</i>.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our ability to market Jelmyto and any of our product candidates that receive marketing approval is and will be limited to certain indications. If we want to expand the indications for which we may market our products, we will need to obtain additional regulatory approvals, which may not be granted.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Jelmyto</i> is indicated for adult patients with low-grade UTUC. We are currently developing UGN-102, UGN-201 and UGN-301 for the treatment of various forms of bladder cancer. The FDA and other applicable regulatory agencies will restrict our ability to market or advertise our products to the scope of the approved label for the applicable product and for no other indications, which could limit physician and patient adoption. We may attempt to develop and, if approved, promote and commercialize new treatment indications for our products in the future, but we cannot predict when or if we will receive the regulatory approvals required to do so. Failure to receive such approvals will prevent us from promoting or commercializing new treatment indications. In addition, we would be required to conduct additional clinical trials or studies to support approvals for additional indications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our business will be limited.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we are found to have improperly promoted off-label uses of Jelmyto or any of our</i></b>&#xa0;<b><i>product candidates that receive</i></b>&#xa0;<b><i>regulatory approval, or if physicians misuse our products, we may become subject to prohibitions on the sale or marketing of our products, significant sanctions, and product liability claims, and our image and reputation within the industry and marketplace could be harmed.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling and may not be promoted based on overstated efficacy or omission of important safety information. For example, we cannot promote the use of our product <i>Jelmyto</i> in a manner that is inconsistent with the approved label, but we are permitted to share truthful and non-misleading information that is otherwise consistent with the product&#x2019;s FDA approved labeling. However, physicians are able, in their independent medical judgment, to use <i>Jelmyto</i> on their patients in an off-label manner, such as for the treatment of other urology indications. If we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would harm our business. The federal government has levied large administrative, civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would harm our business. In addition, management&#x2019;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our reputation with physicians, patients and caregivers, and our position within the industry.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Physicians may also misuse our products or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our products are misused or used with improper technique, we may become subject to costly litigation. Product liability claims could divert management&#x2019;s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. We currently carry product liability insurance covering our clinical trials with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. In addition, while we have established product liability insurance relating to our commercialization of <i>Jelmyto</i>, there can be no assurance that we will be able to maintain this insurance on commercially reasonable terms or that this insurance will be sufficient. Furthermore, the use of our products for conditions other than those approved by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     43
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>In addition to Jelmyto, we are dependent on the success of our lead product candidate, UGN-102, and our other product candidates, including obtaining regulatory approval to market our product candidates in the United States.*</i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA and by foreign regulatory authorities. These regulations differ from country to country. To gain approval to market our product candidates, we must provide clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication. Other than <i>Jelmyto</i>, all of our product candidates, including our lead product candidate, UGN-102, remain in clinical development and have not yet received regulatory approval from the FDA or any other regulatory agency in the United States or any other country. Our business depends upon obtaining these regulatory approvals. There are no drugs that have been approved by the FDA for the primary treatment of low-grade intermediate risk NMIBC, and only a limited number of drugs have been approved by the FDA as adjuvant treatment for BCG unresponsive&#xa0;NMIBC. The FDA can delay, limit or deny approval of our product candidates for many reasons.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The success of our product candidates is subject to significant risks, including risks associated with successfully completing current and future clinical trials, such as:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s acceptance of our parameters for regulatory approval relating to UGN-102 and our other product candidates, including our proposed indications, primary and secondary endpoint assessments and measurements, safety evaluations and regulatory pathways, and proposed labeling and packaging;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to successfully complete the FDA requirements related to chemistry, manufacturing and controls ("CMC"), for UGN-102 and our other product candidates, and if completed, their sufficiency to support an NDA;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s timely acceptance of our INDs, for our product candidates and our inability&#xa0;to commence clinical trials in the United States without such IND acceptances;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s acceptance of the design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from nonclinical studies or clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s acceptance of the population studied in our clinical trials being sufficiently large, broad and representative to assess efficacy and safety in the patient population for which we seek approval;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to successfully complete the clinical trials of our product candidates, including timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate the safety and efficacy of the product candidates undergoing such clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to demonstrate meaningful clinical or other benefits which outweigh any safety or other perceived risks, through the completion of our clinical trials for our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s need to schedule an advisory committee meeting, and to conduct such meeting, in a timely manner to evaluate and decide on the approval of our potential future NDA for UGN-102;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">if applicable, the recommendation of the FDA&#x2019;s advisory committee to approve our applications to market UGN-102 and our other product candidates in the United States, without limiting the approved labeling, specifications, distribution or use of the products, or imposing other restrictions;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s determination of safety and efficacy of our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s determination that the Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act ("FDCA") regulatory pathway&#xa0;(&#x201c;505(b)(2)&#x201d;)&#xa0;is available for our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the prevalence and severity of adverse events associated with our product candidates, including UGN-102, as there are no drugs and related drug administration procedures approved for the primary treatment of low-grade NMIBC, that are based on <i>RTGel</i>&#xa0;technology;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the timely and satisfactory performance by third-party contractors of their obligations in relation to our clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our success in educating physicians and patients about the benefits, risks, administration and use of our product candidates, if approved, particularly in light of the fact that there are no drugs that have been approved by the FDA for the primary treatment of low-grade NMIBC, and only a limited number of drugs have been approved by the FDA as adjuvant treatment for high-grade NMIBC;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the effectiveness of our marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s acceptance of the quality of our drug substance or drug product, formulation, labeling, packaging, or the specifications of our product candidates is sufficient for approval;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with cGMP;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     44
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#x2019;s acceptance of the manufacturing processes or facilities of third-party manufacturers with which we contract;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to secure supplies&#xa0;for our product candidates to support clinical trials and commercial use;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to manufacture or secure finished product from third-party suppliers for product candidates, including UGN-102, if approved;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to obtain, maintain, protect and enforce our intellectual property rights with respect to our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#x2022;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">the extent to which the costs of our products, once approved, are covered and reimbursed by third-party payors, including the availability of a physician reimbursement code for our treatments, and patients&#x2019; willingness to pay for our products; and</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to properly train physicians or nurses for the skillful preparation and administration of any of our product candidates that receive approval, including UGN-102, and our ability to develop a broad experiential knowledge base of aggregated clinician feedback from which we can refine appropriate procedures for product administration, without which there could be a risk of adverse events.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Many of these clinical, regulatory and commercial risks are beyond our control. Further, these risks and uncertainties impact all of&#xa0;our clinical programs that we pursue and may be amplified by&#xa0;pandemics, epidemics or public health emergencies, as described below. Accordingly, we cannot assure you that we will be able to advance any more of our product candidates through clinical development, or to obtain additional regulatory approval of any of our product candidates. To the extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our product candidates and would thus negatively impact our business, results of operations and prospects. Even if we receive approval of any of the product candidates in our pipeline or future product candidates, there is no assurance that we will be able to successfully commercialize any of them.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>UGN-102 may not meet its secondary endpoint in the ongoing Phase 3 ENVISION trial.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">On July&#xa0;27, 2023, we announced that UGN-102 met its primary endpoints in the Phase 3 ATLAS and ENVISION trials. Additional data evaluating the secondary endpoint of duration of response from ENVISION are anticipated in 2024. If UGN-102 does not meet its secondary endpoint or we receive other data that negatively impacts the efficacy and safety profile of UGN-102, then our ability to seek and potentially obtain regulatory approval of UGN-102 on the timeline we currently expect may be adversely affected.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as patient data become available and following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. In particular, interim data may reflect small sample sizes, be subject to substantial variability and may not be indicative of either future interim results or final results. Publications based on interim data may differ from FDA approved product labeling. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our ordinary shares. See the description of risks under the heading &#x201c;Risks Related to Ownership of our Ordinary Shares&#x201d; for additional disclosures related to the risk of volatility in the price of our ordinary shares.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. Furthermore, we may report interim analyses of only certain endpoints rather than all endpoints. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, UGN-102 or any other investigational product candidate may be harmed, which could harm our business, financial condition, results of operations and prospects.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We have limited experience in conducting clinical trials and obtaining approval for product candidates and may be unable to do so successfully. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">As a company, we have limited experience in conducting clinical trials and have progressed only one product candidate through to regulatory approval. In part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot be certain that the planned clinical trials will begin or conclude on time, if at all. Large-scale trials will require significant additional financial and management resources. Third-party clinical investigators do not operate under our control. Any performance failure on the part of such third parties could delay the clinical development of our product candidates or delay or prevent us from obtaining regulatory approval or commercializing our current or future product candidates, depriving us of potential product revenue and resulting in additional losses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>We have not yet applied for regulatory approvals to market UGN-102 or the other product candidates in our pipeline, and we may be delayed in obtaining or failing to obtain such regulatory approvals and to commercialize our product candidates.</i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The process of developing, obtaining regulatory approval for and commercializing our product candidates is long, complex, costly and uncertain, and delays or failure can occur at any stage. The research, testing, manufacturing, labeling, marketing, sale and distribution of drugs are subject to extensive and rigorous regulation by the FDA and foreign regulatory agencies, as applicable. These regulations are agency-specific and differ by jurisdiction. We are not permitted to market any product candidate in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from the respective regulatory agencies in such countries. To gain approval of an NDA or other equivalent regulatory approval, we must provide the FDA or relevant foreign regulatory authority with nonclinical and clinical data that demonstrates the safety and efficacy of the product for the intended indication.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Before we can submit an NDA to the FDA or comparable similar applications to foreign regulatory authorities, we must conduct Phase 3 clinical trials, or a pivotal/registration trial equivalent, for each product candidate. After submission of an NDA, the FDA may raise additional questions on any data contained in the application. These questions may come in the form of information requests or in the NDA 74-day letter as review issues. We must address these questions during the review, but we do not know whether our responses will be acceptable to the FDA. We cannot assure you that the FDA will not decide to require us to perform additional clinical trials, including potentially requiring us to perform an additional pivotal study with a control arm, before approving, or as a condition of approving, NDAs for our product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Phase 3 clinical trials often produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical trials may be unsatisfactory to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful. The FDA or applicable foreign regulatory agencies may suspend one or all of our clinical trials or require that we conduct additional clinical, nonclinical, manufacturing, validation or drug product quality studies and submit that data before considering or reconsidering any NDA or comparable foreign regulatory application that we may submit. Depending on the extent of these additional studies, approval of any applications that we submit may be significantly delayed or may cause the termination of such programs or may require us to expend more resources than we have available.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If any of these outcomes occur, we may not receive regulatory approval for the corresponding product candidates, and our business would not be able to generate revenue from the sale of any such product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Changes in funding for the</i></b>&#xa0;<b><i>FDA, the SEC</i></b>&#xa0;<b><i>and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The ability of the&#xa0;FDA&#xa0;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Disruptions at the&#xa0;FDA&#xa0;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the&#xa0;FDA and the SEC, have had to furlough critical&#xa0;FDA, SEC and other government&#xa0;employees and stop critical activities. If a prolonged&#xa0;government&#xa0;shutdown&#xa0;occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may not be able to advance our nonclinical product candidates into clinical development and through regulatory approval and commercialization.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Certain of our product candidates are currently in nonclinical development and are therefore currently subject to the risks associated with nonclinical development, including the risks associated with:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">generating adequate and sufficient nonclinical safety and efficacy data in a timely fashion to support the initiation of clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">obtaining regulatory approval to commence clinical trials in any jurisdiction, including the submission and acceptance of INDs;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">contracting with the necessary parties to conduct a clinical trial;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">enrolling sufficient numbers of patients in clinical trials in timely fashion, if at all; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">timely manufacture of sufficient quantities of the product candidate for use in clinical trials.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     46
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">These risks and uncertainties impact all of&#xa0;our nonclinical programs that we pursue. If we are unsuccessful in advancing our nonclinical product candidates into clinical trials in a timely fashion, our business may be harmed. Even if we are successful in advancing our nonclinical product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this Quarterly Report and our other filings with the SEC. Accordingly, we cannot assure you that we will be able to develop, obtain regulatory approval for, commercialize or generate significant revenue from our product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur at any time during the clinical trial process. We do not know whether our ongoing and future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including failure to:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">generate sufficient nonclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">obtain regulatory approval or feedback on trial design, in order to commence a trial;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">identify, recruit and train suitable clinical investigators;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">reach agreement on acceptable terms with prospective contract research organizations ("CROs")&#xa0;and clinical trial sites, and have such CROs and sites effect the proper and timely conduct of our clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">obtain and maintain institutional review board&#xa0;("IRB") approval at each clinical trial site;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">identify, recruit, enroll and retain suitable patients to participate in a trial;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">have a sufficient number of patients enrolled, complete a trial or return for post-treatment follow-up;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">ensure clinical investigators and clinical trial sites observe trial protocol or continue to participate in a trial;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">address any patient safety concerns that arise during the course of a trial;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">address any conflicts with new or existing laws or regulations;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">add a sufficient number of clinical trial sites;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">manufacture sufficient quantities at the required quality of product candidate for use in clinical trials; or</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">raise sufficient capital to fund a trial.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Patient enrollment is a significant factor in the timing and success of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians&#x2019; and patients&#x2019; or caregivers&#x2019; perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be developed or approved for the indications we are investigating.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the trial&#x2019;s data safety monitoring board, by the FDA or by the applicable foreign regulatory authorities. Such authorities may suspend or terminate one or more of our clinical trials due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If we experience delays in carrying out or completing any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     47
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Jelmyto or any of our product candidates may produce undesirable side effects that we may not have detected in our previous nonclinical studies and clinical trials or that are not expected with mitomycin treatment or inconsistent with catheter administration procedures. This could prevent us from gaining marketing approval or market acceptance for these product candidates, or from maintaining such approval and acceptance, and could substantially increase commercialization costs and even force us to cease operations.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">As with most pharmaceutical products, <i>Jelmyto</i> and our product candidates may be associated with side effects or adverse events that can vary in severity and frequency. Side effects or adverse events associated with the use of <i>Jelmyto</i> or any of our product candidates, including UGN-102, may be observed at any time, including in clinical trials or once a product is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory approval or market our product candidates. To date, in our nonclinical testing,&#xa0;Compassionate Use Program for <i>Jelmyto,</i> clinical trials and post-marketing experience, we have observed several adverse events and serious adverse events ("SAEs"), including ureteric obstruction, ureteral stenosis, inhibition of urine flow, rash, flank pain, kidney swelling, kidney infection, renal dysfunction, hematuria, fatigue, nausea, abdominal pain, dysuria, vomiting, urinary tract infection, urgency in urination and pain during urination. In addition, we have observed transient perturbation of laboratory measures of renal and hematopoietic function. These adverse events are known mitomycin or procedure-related adverse events and many are indicated as potential side effects of mitomycin usage on the mitomycin label. However, we cannot assure you that we will not observe additional drug or procedure-related adverse events or SAEs in the future or that the FDA will not determine them as such. Side effects such as toxicity or other safety issues associated with the use of <i>Jelmyto</i> or our product candidates could require us to perform additional studies or halt development or sale of <i>Jelmyto</i> or our product candidates or expose us to product liability lawsuits, which will harm our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Furthermore, our Phase 2b clinical trial for UGN-102 involved larger patient bases than in our prior studies of these candidates, and the commercial marketing of <i>Jelmyto</i> and, if approved, UGN-102, will further expand the clinical exposure of the drugs to a wider and more diverse group of patients than those participating in the clinical trials, which may identify undesirable side effects caused by these products that were not previously observed or reported.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date upon which we become aware of the adverse event as well as the nature and severity of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action including enforcing a hold on or cessation of clinical trials, withdrawal of approved drugs from the market, criminal prosecution, the imposition of civil monetary penalties or seizure of our products.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Additionally, in the event we discover the existence of adverse medical events or side effects caused by one of our products or product candidates, a number of other potentially significant negative consequences could result, including:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our inability to submit an NDA or similar application for our product candidates because of insufficient risk-reward, or the denial of such application by the FDA or foreign regulatory authorities;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA or foreign regulatory authorities suspending or terminating our clinical trials or suspending or withdrawing their approval of the product;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA or foreign regulatory authorities requiring the addition of labeling statements, such as boxed or other warnings or contraindications or distribution and use restrictions;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA or foreign regulatory authorities requiring us to issue specific communications to healthcare professionals, such as letters alerting them to new safety information about our product, changes in dosage or other important information;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA or foreign regulatory authorities issuing negative publicity regarding the affected product, including safety communications;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our being limited with respect to the safety-related claims that we can make in our marketing or promotional materials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our being required to change the way the product is administered, conduct additional nonclinical studies or clinical trials or restrict or cease the distribution or use of the product; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our being sued and held liable for harm caused to patients.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     48
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Any of these events could prevent us from achieving market acceptance or approval of the affected product or product candidate and could substantially increase development or commercialization costs, force us to withdraw from the market any approved product, or even force us to cease operations. We cannot assure you that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may face future developmental and regulatory difficulties related to Jelmyto and any of our product candidates that receive marketing approval. In addition, we are subject to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are subject to certain post-marketing commitments related to <i>Jelmyto</i>, including a requirement for a period of five years to provide annual updates for the duration of response for all patients with ongoing complete responses enrolled in the Phase 3 OLYMPUS trial. With respect to our current and future candidates, even if we complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA or applicable foreign regulatory agency may grant approval contingent on the performance of additional costly post-approval clinical trials, risk mitigation requirements and surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues or increasing expenses, and cause the approved product candidate not to be commercially viable. Absence of long-term safety data may further limit the approved uses of our products, if any.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The FDA or applicable foreign regulatory agency also may approve our product candidates for a more limited indication or a narrower patient population than we originally requested or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Furthermore, any such approved product will remain subject to extensive regulatory requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If we fail to comply with the regulatory requirements of the FDA or other applicable foreign regulatory authorities, or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">regulatory agency refusal to approve pending applications or supplements to applications;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">suspension of any ongoing clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">suspension or withdrawal of marketing approval;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">an injunction or imposition of civil or criminal penalties or monetary fines;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">seizure or detention of products;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">bans or restrictions on imports and exports;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">issuance of warning letters or untitled letters;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">refusal of regulatory authorities to approve pending applications or supplements to applications.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     49
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, various aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention and, consequently, could adversely affect our business, financial condition, cash flows and results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we are not successful in developing, receiving regulatory approval for and commercializing our nonclinical and clinical product candidates, our ability to expand our business and achieve our strategic objectives could be impaired.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Although we have received FDA approval of <i>Jelmyto</i> for pyelocalyceal solution, for the treatment of adult patients with low-grade UTUC, and we plan to devote a substantial portion of our resources to the continued clinical testing and potential approval of UGN-102 for the treatment of low-grade intermediate risk NMIBC.&#xa0;Another key element of our strategy is to discover, develop and commercialize a portfolio of products to serve additional therapeutic markets. We are seeking to do so through our internal research programs, but our resources are limited, and those that we have are geared towards clinical testing and seeking regulatory approval of UGN-102 and our other existing product candidates. We may also explore strategic collaborations for the development or acquisition of new products, but we may not be successful in entering into such relationships. Research programs to identify product candidates require substantial technical, financial and human resources, regardless of whether any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the research methodology used may not be successful in identifying potential product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">competitors may develop alternatives that render our product candidates obsolete or less attractive;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a product candidate may in a subsequent trial be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">intellectual property or other proprietary rights of third parties for product candidates we develop may potentially block our entry into certain markets or make such entry economically impracticable.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed, and our business will be more vulnerable to any problems that we encounter in developing and commercializing our product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>W</b></i><i style="font-weight: bold;"><i><b>e</b></i> have entered into collaboration and licensing agreements and in the future may enter into</i>&#xa0;<b><i>collaboration and licensing arrangements with other third parties for the development or commercialization of our product candidates. If our collaboration and licensing arrangements are not successful, we may not be able to capitalize on the market potential of these product candidates.</i></b>&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We may utilize a variety of types of licensing, collaboration, distribution and other marketing arrangements with third parties to develop our product candidates and commercialize our approved product candidates, if any. We are not currently party to any such arrangement that we consider material. Our ability to generate revenues from these arrangements will depend on our collaborators&#x2019; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     50
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Any&#xa0;collaborations that we enter into&#xa0;may pose a number of risks, including the following:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">collaborators may not perform their obligations as expected;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">product candidates developed by collaborators may not perform sufficiently in clinical trials to be determined to be safe and effective, thereby delaying or terminating the drug approval process and reducing or eliminating milestone payments to which we would otherwise be entitled if the product candidates had successfully met their endpoints and/or received FDA approval;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">clinical trials conducted by collaborators could give rise to new safety concerns;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">collaborators may not pursue development and commercialization of our product candidates that receive marketing approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#x2019;&#xa0;strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would divert management attention and resources, be time-consuming and expensive;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Collaborations may not lead to development or commercialization of product candidates in the most efficient manner, or at all, and may otherwise experience challenges. For example, in August 2020, we announced that the Phase&#xa0;2&#xa0;APOLLO trial of BOTOX/<i>RTGel </i>for the treatment of overactive bladder, which was conducted by Allergan Pharmaceuticals Limited (&#x201c;Allergan&#x201d;), did&#xa0;not&#xa0;meet the primary endpoint.&#xa0;The data suggested that this result&#xa0;may&#xa0;have been due to BOTOX&#xa0;not&#xa0;effectively permeating the urothelium. In November 2021 our&#xa0;arrangement with Allergan was terminated.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If any future material collaborations that we enter into&#xa0;do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed, and we may need additional resources to develop our product candidates. All the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our collaborators.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Additionally, subject to its contractual obligations to us, if a collaborator of ours were to be involved in a business combination, it might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and perception of us in the business and financial communities could be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     51
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce Jelmyto for commercial use, and to produce UGN-102,</i></b>&#xa0;<b><i>UGN-201 and UGN-301 for nonclinical studies and clinical trials, and expect to continue to do so to support commercial scale production of UGN-102 and UGN-201, if approved, as well as UGN-301 if approved as a monotherapy or for any approved product that includes UGN-301. There are significant risks associated with the manufacture of pharmaceutical products and contracting with contract manufacturers, including</i></b>&#xa0;<b><i>single-source suppliers. Furthermore, our existing third-party subcontractors and single-source suppliers may not be able to meet the increased need for certain raw materials, compounds and components that may result from our commercialization efforts. This increases the risk that we will not have sufficient quantities of Jelmyto, UGN-102,</i></b>&#xa0;<b><i>UGN-201 or UGN-301 or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We currently rely on third party subcontractors and suppliers for certain compounds and components necessary to produce <i>Jelmyto</i> for commercial use and UGN-102, UGN-201 and UGN-301 for our nonclinical studies and&#xa0;clinical trials, and expect to rely on third party subcontractors and suppliers for commercial use for any of our drug candidates that receive regulatory approval. We currently depend on Teva Pharmaceuticals Industries Ltd&#xa0;("Teva"), as our single-source supplier of mitomycin active pharmaceutical ingredient ("API")&#xa0;for <i>Jelmyto</i> and UGN-102. We rely on Cenexi-Laboratories Thissen s.a., and Isotopia Molecular Imaging Ltd. as our single contracted suppliers for the mitomycin and gel contained in <i>Jelmyto</i> and UGN-102, respectively. We also currently depend on a single source supplier for imiquimod for UGN-201 and zalifrelimab for UGN-301. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce <i>Jelmyto</i> for commercial sale and our product candidates for our clinical trials and their subsequent commercial sale, if approved. Even if we are able to engage alternate suppliers on reasonable terms, we may face delays or increased costs in our supply chain that could jeopardize the commercialization of <i>Jelmyto&#xa0;</i>and the development of UGN-102. We do not have any control over the availability of these compounds and components beyond our existing contractual arrangements. If we or our suppliers and manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development and commercialization of our product candidates or any future product candidates, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of <i>Jelmyto</i> or any other approved products.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We expect to continue to rely on these or other subcontractors and suppliers to support our commercial requirements for <i>Jelmyto</i>, as well as UGN-102 or any of our other product candidates if approved for marketing by the FDA or foreign regulatory authorities. We also rely on a single third-party manufacturer to produce our proprietary drug product, or final mitomycin formulation, necessary for our clinical trial and commercial requirements. We plan to continue to rely on third parties for the production of mitomycin API, the gel contained in <i>Jelmyto,</i>&#xa0;UGN-102 and UGN-301, and for imiquimod for UGN-201, and for zalifrelimab for UGN-301, as well as for the raw materials, compounds and components necessary to produce our product candidates and for nonclinical studies and clinical trials.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Even though we are approved as a commercial supplier of <i>Jelmyto</i>, we have limited experience as a company in the commercial supply of drugs and may never be successful as a commercial supplier of drug products containing mitomycin. In addition, cost-overruns, unexpected delays, equipment failures, logistics breakdowns, labor shortages, natural disasters, power failures, production failures or product recalls, and numerous other factors could prevent us from realizing the intended benefits of our sales strategy and have a material adverse effect on our business. Further, although we commercially supply <i>Jelmyto</i>, further build-out is required and establishing such commercial-scale supply capabilities requires additional investment, is time-consuming and may be subject to delays, including because of shortage of labor, compliance with regulatory requirements or receipt of necessary regulatory approvals. In addition, building out our <i>Jelmyto</i> commercial supply capabilities may cost more than we currently anticipate, and delays or problems may adversely impact our ability to provide sufficient quantities of <i>Jelmyto</i> to support our commercialization of <i>Jelmyto</i> and planned future commercialization of UGN-102, if approved, as well as our financial condition.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">While we currently have over 12 months of mitomycin API and/or <i>Jelmyto</i> finished product on hand to continue our commercial and clinical operations as planned, we may face such delays or costs in future years. Although we believe we have sufficient quantities of mitomycin API for planned manufacturing operations during 2023, a prolonged supply interruption of certain components could adversely affect our ability to conduct commercialization activities and planned clinical trials. If any third party in our supply or distribution chain for materials or finished product is adversely impacted by restrictions resulting from pandemics, epidemics or public health emergencies, including staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to manufacture and distribute <i>Jelmyto</i> for commercial sales and our product candidates for our clinical trials and research and development operations.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     52
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, before we can begin to commercially manufacture any product candidates that receive&#xa0;regulatory approval in the future other than <i>Jelmyto</i>, whether in a third-party facility or in our own facility, once established, we must obtain regulatory approval from the FDA for our manufacturing process and facility in order to sell such products in the United States. A manufacturing authorization would also have to be obtained from the appropriate European Union regulatory authorities in order to sell such products in the European Union. In order to obtain approval, we will need to ensure that all of the processes, methods and equipment of such manufacturing facilities are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any vendors, contract laboratories or suppliers are found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that we may develop.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our continuing reliance on third party subcontractors and suppliers entails a number of risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing or supply agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third party subcontractors and suppliers may not be able to comply with cGMP or quality system regulation ("QSR")&#xa0;or similar regulatory requirements outside the United States. If any of these risks transpire, we may be unable to timely retain alternate subcontractors or suppliers on acceptable terms and with sufficient quality standards and production capacity, which may disrupt and delay our clinical trials or the manufacture and commercial sale of our in-line or investigational product candidates, if approved.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our failure or the failure of our third-party subcontractors and suppliers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of <i>Jelmyto</i>, UGN-102 or any of our other product candidates that we may develop. Any failure or refusal to supply or any interruption in supply of the components for <i>Jelmyto</i>, UGN-102 or any other product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We currently use single source suppliers relative to production of the <i>RTGel</i>&#xa0;products, the ureteral catheter and injector which are required to be used with <i>Jelmyto</i>. Both the ureteral catheter and injector are used as part of the delivery of <i>Jelmyto</i>. We are assessing second source suppliers regarding certain components of <i>Jelmyto</i> and are advancing these conversations as a means to ensure both a second source and potential future reductions in cost of revenues. However, there can be no assurance that we will be able to secure any second-source suppliers for these key components on a timely basis, on favorable terms, or at all.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We rely on third party transportation to deliver materials to our facilities and ship products to our customers. Transport operators are exposed to various risks, such as extreme weather conditions, natural disasters, work stoppages, personnel shortages, and operating hazards, as well as interstate and international transportation requirements. In addition, transport operators were affected by the impact of COVID-19 and the related shipping crisis and backlog, which&#xa0;led to increased shipping costs and supply chain disruptions, and a resurgence of COVID-19 or other pandemics, epidemics or public health emergencies may cause similar disruptions that may impact our operations in the future.&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If we experience transportation problems, or if there are other significant changes in the cost of these services, we may not be able to arrange efficient alternatives and timely means to obtain materials or ship products to our customers. Our failure to obtain such materials, ship products or maintain sufficient buffer inventory could materially and adversely impact our business, financial condition and results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We may need to enter into agreements with additional distributors or suppliers, and there is no guarantee that we will be able to do so on commercially reasonable terms or at all. If we are unable to maintain and, if needed, expand, our network of specialty distributors or suppliers, this would expose us to substantial risk in our clinical development or commercialization efforts.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Failure to obtain marketing approval in international jurisdictions would prevent our approved product, Jelmyto, and our product candidates from being marketed abroad.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In order to market and sell our products in the European Union and other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. Regulatory approval processes outside the United States generally include all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be commercialized in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to submit for marketing approvals and may not receive the necessary approvals to commercialize our product candidates in any particular market. For example, we have entered into an exclusive license agreement with Neopharm Ltd. ("Neopharm"), pursuant to which Neopharm is leading the process for seeking regulatory approval of <i>Jelmyto</i> in Israel. Neopharm initiated the regulatory approval process in June 2021 and the Israeli Ministry of Health has issued a registration certificate for the product. Additional analytical testing of proposed commercial materials is required to be completed before full clearance to market. Even if <i>Jelmyto</i> is fully approved for marketing in Israel, there can be no assurance that it will achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     53
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>We rely on third parties and consultants to assist us in conducting our clinical trials for our product candidates. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize UGN-102 or any of our other product candidates.</i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We do not have the ability to independently conduct many of our nonclinical studies or our clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs to conduct clinical trials on our product candidates. Third parties play a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies available to us under our agreements, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. Due to the limited drug development for non-muscle invasive urothelial cancers over the past 15 years, neither we nor any third-party clinical investigators, CROs and/or consultants are likely to have extensive experience conducting clinical trials for the indications we are targeting. If our CROs or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, or if they otherwise perform in a substandard manner, our clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete development of, obtain regulatory approval for, or successfully commercialize UGN-102 or any of our other product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We and the third parties upon whom we rely are required to comply with Good Clinical Practice ("GCP"), regulations, which are regulations and guidelines enforced by regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or our third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed, or the regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, a regulatory authority will determine that any of our clinical trials comply or complied with applicable GCP regulations. In addition, our clinical trials must be conducted with material produced under current GMP regulations, which are enforced by regulatory authorities. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be impacted if our CROs, clinical investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations; healthcare privacy and security laws; and bribery and anti-corruption laws.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In order for our clinical trials to be carried out effectively and efficiently, it is imperative that our CROs and other third parties communicate and coordinate with one another. Moreover, our CROs and other third parties may also have relationships with other commercial entities, some of which may compete with us. Our CROs and other third parties may terminate their agreements with us upon as few as 30 days&#x2019; notice under certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs, clinical investigators or other third parties on commercially reasonable terms, or at all. Switching or adding CROs, clinical investigators or other third parties can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship with our CROs, clinical investigators and other third parties, there can be no assurance that we will not encounter such challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, prospects, financial condition or results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If in the future we acquire or in-license technologies or product candidates, we may incur various costs, may have integration difficulties and may experience other risks that could harm our business and results of operations.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In the future, we may acquire or in-license additional product candidates and technologies. Any product candidate or technologies we in-license or acquire will likely require additional development efforts prior to commercial sale, including extensive nonclinical or clinical testing, or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective for approval by regulatory authorities. If intellectual property related to product candidates or technologies we in-license is not adequate, we may not be able to commercialize the affected products even after expending resources on their development. In addition, we may not be able to economically manufacture or successfully commercialize any product candidate that we develop based on acquired or in-licensed technology that is granted regulatory approval, and such products may not gain wide acceptance or be competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may be materially harmed.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     54
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We will need to continue to increase the size of our organization. If we fail to manage our growth effectively, our business could be disrupted.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">As of June&#xa0;30, 2023, we had 193&#xa0;employees, of whom 41&#xa0;are based in Israel and 152&#xa0;are based in the United States. We will need to continue to expand our development, quality, managerial, operational, finance, marketing, sales and other resources to manage our operations and clinical trials, continue our development activities and commercialize our product candidates, if approved. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our expansion strategy requires that we:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">manage our clinical trials effectively;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">identify, recruit, retain, incentivize and integrate additional employees;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">continue to improve our operational, financial and management controls, reporting systems and procedures.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">As we continue to grow as an organization, including by expanding our development efforts and building out and developing our commercial capabilities to support our ongoing commercial launch of <i>Jelmyto</i>, we will evaluate, and may implement, changes to our organization that may be appropriate in order to properly manage and direct our growth and transformation into a commercial-stage company. Due to our limited financial resources and our limited experience in managing a larger company, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage expansion or other significant changes to our organization could delay the execution of our development, commercialization and strategic objectives or disrupt our operations; and if we are not successful in commercializing our approved product or any of our product candidates that may receive regulatory approval, either on our own or through collaborations with one or more third parties, our revenues will suffer, and we would incur significant additional losses.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any of our other products we develop.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and face or will face an even greater risk with the commercialization of <i>Jelmyto</i> and any investigational product candidates that receive&#xa0;marketing approval. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">decreased demand for <i>Jelmyto</i>&#xa0;and our investigational product candidates we develop;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">injury to our reputation and significant negative media attention;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">withdrawal of clinical trial participants or cancellation of clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">costs to defend the related litigation, which may be only partially recoverable even in the event of successful defenses;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">a diversion of management&#x2019;s time and our resources;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">substantial monetary awards to trial participants or patients;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">loss of revenues;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">exhaustion of any available insurance and our capital resources; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the inability to commercialize any product we develop.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of products we may develop. We currently carry general clinical trial product liability insurance in an amount that we believe is adequate to cover the scope of our ongoing clinical programs. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. As a result of receiving marketing approval of <i>Jelmyto</i>, we have expanded our insurance coverage to include the commercialization of <i>Jelmyto</i>; however, we may be unable to continue to obtain this liability insurance on commercially reasonable terms and such insurance may be insufficient to cover our exposure. In addition, if and when we obtain approval for marketing UGN-102 or any other product candidate, we intend to further expand our insurance coverage to include the commercialization of UGN-102 or any other approved product; however, we may be unable to obtain this additional liability insurance on commercially reasonable terms.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     55
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>If we fail to attract and keep senior management and key personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize any of the products we develop.</i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical, scientific and other personnel. We believe that our future success is highly dependent upon the contributions of members of our senior management, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Although we have not historically experienced unique difficulties in attracting and retaining qualified employees, we could experience such problems in the future. For example, competition for qualified personnel in the pharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If our</i></b>&#xa0;<b><i>information technology systems or data, or those of third parties</i></b>&#xa0;<b><i>upon whom we rely, are or were compromised,</i></b> <b><i>this could result in adverse consequences resulting from such compromise including but not limited to regulatory investigations or actions; litigation; fines and penalties;</i></b> <b><i>a material disruption of our drug development program;</i></b>&#xa0;<b><i>compromise sensitive information related to our business;</i></b>&#xa0;<b><i>harm our reputation;</i></b>&#xa0;<b><i>triggering our breach notification obligations;</i></b>&#xa0;<b><i>prevent us from accessing critical information;</i></b>&#xa0;<b><i>disruptions of our business operations; loss of revenue or profits; loss of customers or sales</i></b>&#xa0;<b><i>and expose us to liability or other adverse effects to our business.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In the ordinary course of our business, we, and the third parties upon which we rely, process&#xa0;proprietary, confidential and sensitive information, including personal data (such as&#xa0;health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties (collectively, sensitive information).</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We, our CROs and other contractors, consultants, third-party vendors, and other third parties on which we rely, depend on information technology, telecommunication systems and data processing for significant elements of our operations, including, for example, systems handling human resources, financial reporting and controls, regulatory compliance and other infrastructure operations. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology&#xa0;systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#x201c;hackers,&#x201d; threat actors, &#x201c;hacktivists,&#x201d; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fake, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In particular, ransomware attacks are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, disruption of clinical trials, loss of data (including data related to clinical trials), loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the financial, operational and reputational impact of a ransomware attack, ransomware attack victims may prefer to make payment demands, but if we were to be a victim of such an attack, we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach or disruption of our systems and networks or the systems or networks of third parties&#xa0;that support us. Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#x2019; systems and technologies.&#xa0;Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions.&#xa0;Our ability to monitor these third parties&#x2019; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to operate our business. Additionally, our sensitive information could be leaked, disclosed, or revealed as a result of or in connection with our employee&#x2019;s, personnel&#x2019;s, or vendor&#x2019;s use of generative AI technologies.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive information. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps to detect and remediate vulnerabilities, but we may be unable to detect and remediate all vulnerabilities in our information technology systems because such threats and techniques used to exploit the vulnerability change frequently and&#xa0;are often sophisticated in nature. Despite our efforts to identify and address vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Therefore, such vulnerabilities could be exploited but may not be detected until after a security incident has occurred. These vulnerabilities pose material risks to our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Additionally, applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. For example, failures or significant downtime of our information technology or telecommunication systems or those used by our third-party service providers could cause significant interruptions in our operations and adversely impact the confidentiality, integrity and availability of sensitive information, including preventing us from conducting clinical trials, tests or research and development activities and preventing us from managing the administrative aspects of our business. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. If the information technology systems of our third-party vendors and other contractors become subject to disruptions or security incidents, we may have insufficient recourse against such third parties and may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><br /> Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Under applicable employment laws, we may not be able to enforce covenants not to compete.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We generally enter into non-competition agreements as part of our employment agreements with our employees. These agreements generally prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work, and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while working for us.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">For example, Israeli labor courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts as justification for the enforcement of non-compete undertakings, such as the protection of a company&#x2019;s trade secrets or other intellectual property.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Additionally, on July 9, 2021, President Biden signed an executive order encouraging the Federal Trade Commission (&#x201c;FTC&#x201d;) to curtail unfair use of non-compete agreements and other agreements that may unfairly limit worker mobility. While we cannot predict how the initiatives set forth in the executive order will be implemented or, as a result, the impact that the executive order will have on our operations, there is now increased uncertainty regarding the long-term enforceability of our non-compete agreements. In January 2023, the FTC proposed a rule that, if enacted, would prohibit employers from entering into non-compete clauses with workers and require employers to rescind existing non-complete clauses. Moreover, the law governing non-compete agreements and other forms of restrictive covenants varies from state to state within the U.S. and some states are reluctant to strictly enforce non-compete agreements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>Our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;">We are exposed to the risk that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, breach of contract or other unauthorized activities that violate: FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws; buying or selling of our ordinary shares while in possession of material non-public information; or laws that require the reporting of financial information or data accurately.</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;">Specifically, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. Activities subject to these laws also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Corporate Code of Ethics and Conduct and a Compliance Program, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, even if we are successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of such laws subject us to numerous penalties, including, but not limited to, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations</span>.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Most states also have statutes or regulations similar to these federal laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. We and/or our future partners may be subject to administrative, civil and criminal sanctions for violations of any of these federal and state laws. Pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, improper consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in&#xa0;off-label&#xa0;promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations, which could have a significant impact on the conduct of our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our research and development activities and our third-party subcontractors&#x2019; and suppliers&#x2019; activities involve the controlled storage, use, transportation and disposal of hazardous materials owned by us, including mitomycin, key components of our product candidates, and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Despite our efforts, we cannot eliminate the risk of contamination. This could cause an interruption of our commercialization efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our subcontractors and suppliers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exchange rate fluctuations between the U.S.</i></b>&#xa0;<b><i>Dollar and the New Israeli Shekel may negatively affect our earnings. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in New Israeli Shekels ("NIS"), which is the lawful currency of the State of Israel. As a result, we are exposed to the risks that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. For example, the dollar appreciated&#xa0;against the NIS during 2022&#xa0;by a total of 11.9%. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the dollar. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our business could be adversely affected by the effects of health pandemics, epidemics or other public health emergencies.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">A pandemic, epidemic or other public health emergencies, including a resurgence of COVID-19, poses the risk that we or our employees, contractors, suppliers, customers, and other partners may be prevented from conducting certain business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. For example, COVID-19 and mitigation measures to slow its spread had an adverse impact on global economic conditions. While it is not possible at this time to estimate the impact that any such pandemic, epidemic or other public health emergency could have on our business, if such an event were to occur, it could have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The measures that may be taken by various governments, in response to a pandemic, epidemic or other public health emergency, including a resurgence of COVID-19, could disrupt the supply chain of material needed for our product candidates and our approved product, <i>Jelmyto</i>, interrupt healthcare services, delay coverage decisions from Medicare and third party payors, delay ongoing and planned clinical trials involving our product candidates and have a material adverse effect on our business, financial condition and results of operations. In addition, we and many of our potential customers and partners worldwide have in the past and may in the future be subject to stay-at-home orders as a result of COVID-19 or future pandemics, epidemics or public health emergencies, including a resurgence of COVID-19. In addition, our ongoing commercial launch of <i>Jelmyto</i> and subsequent commercialization activities could be hindered by a pandemic, epidemic or other public health emergency, including a resurgence of COVID-19, although we are currently not able to predict or quantify any such potential impact with any degree of certainty. The worldwide spread of the COVID-19 virus previously resulted in and a future pandemic, epidemic or public health emergency, including a resurgence of COVID-19, may in the future result in a varying degree&#xa0;of interruption or slowdown of economic activity, thereby impacting demand for a broad variety of goods and services, including potentially for <i>Jelmyto</i>, while also disrupting sales channels and marketing activities for an unknown period of time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     58
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The timelines and conduct of our ongoing clinical trials may be affected by future pandemics, epidemics or public health emergencies, including a resurgence of COVID-19. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward any such pandemic, epidemic or public health emergency and patients&#x2019; ability or willingness to participate in clinical trials. For those patients who are enrolled and desire to continue in the clinical trials, some patients may not be able or willing to comply with clinical trial protocols if quarantines or governmental orders impede patient movement or interrupt healthcare services. Similarly, we may face increased challenges with the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to diseases, which could adversely impact our clinical trial operations, timelines and outcomes. While we remain in close contact with our&#xa0;clinical sites and suppliers to attempt to assess the impacts future pandemics, epidemics or public health emergencies, including a resurgence of COVID-19, may have on our clinical trials and projected timelines and we have reviewed and acknowledged recent FDA guidance in our protocols, and follow such guidance where possible, with an effort to ensure the ongoing safety of the patients in our clinical trials and the continued collection of high quality data, there is no guarantee that such efforts will be successful. As challenging as conducting clinical trials is during normal times, the risks, operational challenges and costs of conducting clinical trials have&#xa0;increased substantially following COVID-19.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="font-family:Arial,Helvetica,sans-serif;">Additionally, during most of the COVID-19 pandemic, our sales force had physical access to hospitals, surgery centers, clinics, healthcare providers and pharmacies curtailed, which we believe affected our sales and any future pandemics, epidemics or public health emergencies, including a resurgence of COVID-19, may in the future have a material adverse effect on our future sales. Beginning in the second quarter of 2021, our territory business managers have been able to engage in higher levels of in-person physician interaction than they were previously during the COVID-19 pandemic. However, there can be no assurance that our territory business managers will continue to have in-person access to physicians if any future pandemics, epidemics or public health emergencies, including a resurgence of COVID-19, were to occur. In addition, while we have developed digital materials and programs for our sales force to use in order to engage virtually with their target physici</span>ans&#xa0;when in-person engagement is not safe or feasible, digital materials and virtual engagement may not be effective at growing and maintaining prescription levels of <i>Jelmyto</i>. Additionally, patients who are currently using <i>Jelmyto</i> or who are eligible to use <i>Jelmyto</i>, may be unable to meet with their healthcare providers in person, which may reduce the number of&#xa0;new patient starts and hinder the ability of healthcare providers to complete the recommended number of <i>Jelmyto</i>&#xa0;instillations, affecting our revenues both in our currently approved indication and potentially impacting our anticipated launches in other indications, if approved.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">To the extent any future pandemics, epidemics or public health emergencies, including a resurgence of COVID-19, adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in the &#x201c;Risk Factors&#x201d; section of this report.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Certain of our clinical trials and other significant operations (including our Israeli corporate offices and contract manufacturers) are located outside of the United States&#xa0;and, therefore, our results may be adversely affected by geopolitical, economic and military instability</i></b><b><i>.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Certain of our clinical trials, such as the Phase 3 ATLAS trial, are operated outside of the United States, including in the Ukraine and Russia. We continue to follow patients in ATLAS, in the region. However, due to the ongoing war, we have experienced difficulty in following up with patients in the region, and we may not have the ability to continue follow up of these patients. The failure to identify and operationalize any alternative clinical sites may have an adverse effect on patient enrollment, and could result in delays in enrolling, carrying out, and/or completing our clinical trials.&#xa0;If<i> </i>we experience delays in achieving our development objectives within a timeframe that meets our prospective customers&#x2019; expectations, our business, prospects, financial results and reputation could be harmed.&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Geopolitical, economic and military conditions around the world may directly affect our business. Any hostilities involving any of the countries in which we operate, including terrorist activities, political instability or violence in the region or the interruption or curtailment of trade or transport between such country and its trading partners could adversely affect our operations and results of operations and adversely affect the market price of our ordinary shares.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our business activities may be subject to the U.S. Foreign Corrupt Practices Act ("</i></b><b>FCPA"</b><b><i>) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We currently dedicate certain resources to comply with numerous laws and regulations in each jurisdiction in which we operate outside of the United States. Our business activities in these foreign countries may be subject to the&#xa0;FCPA&#xa0;and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The&#xa0;FCPA&#xa0;generally prohibits companies and their employees and third party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a&#xa0;non-U.S.&#xa0;government official in order to influence official action or otherwise obtain or retain business. The&#xa0;FCPA&#xa0;also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of&#xa0;non-U.S.&#xa0;governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the&#xa0;FCPA. Recently the SEC and U.S. Department of Justice have increased their&#xa0;FCPA&#xa0;enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our product in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     59
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, our product and activities may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our product, or our failure to obtain any required import or export authorization for our product, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our product may create delays in the introduction of our product in international markets or, in some cases, prevent the export of our product to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or product targeted by such regulations, could result in decreased use of our product by, or in our decreased ability to export our product to existing or potential customers with international operations. Any decreased use of our product or limitation on our ability to export or sell access to our product would likely significantly harm our business, financial condition, results of operations and prospects.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>Risks Related to Our Intellectual Property </b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not adequate, we may not be able to compete effectively, and we otherwise may be harmed.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our commercial success depends in part upon our ability to obtain and maintain patent protection and utilize trade secret protection for our intellectual property and proprietary technologies, our products and their uses, as well as our ability to operate without infringing upon the proprietary rights of others. We rely upon a combination of patents, trade secret protection and confidentiality agreements, assignment of invention agreements and other contractual arrangements to protect the intellectual property related to hydrogel-based pharmaceutical compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating cancer, in particular&#xa0;urothelial and bladder cancer using hydrogel-based compositions, the method for treating overactive bladder topically without the need for injections, including an in-dwelling ureter catheter system for optimal delivery of a drug into the renal cavity.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We seek patent protection for our product candidates, and we hold a broad collection of intellectual property comprised of issued patents,&#xa0;pending patent applications and trademarks&#xa0;covering our proprietary <i>RTGel</i>&#xa0;technology, the pharmaceutical compositions, methods of use and manufacturing aspects of our product candidates. In the United States, we currently hold approximately 19&#xa0;granted patents that are directed to protect our approved product, <i>Jelmyto</i> and our lead product candidate, UGN-102, a proprietary <i>RTGel</i> technology,&#xa0;local compositions comprising different active ingredients, inter alia compositions comprising a Botulinum Toxin, UGN-201, the sequential use of UGN-201 and UGN-301,&#xa0;and our future product candidates that are under company research. These IP rights relate to certain aspects of cancer treatment. These issued patents are set to expire between 2024 and 2037. In total, our IP portfolio includes 42&#xa0;granted patents worldwide, and more than 45 pending patent applications filed in the U.S., Europe, Israel, Japan, Canada, China, Mexico and Australia that are directed to cover various methods, systems and compositions for treating cancer locally, by intravesical means, utilize various active ingredients and the combinations thereof. These patent applications, if issued, are set to expire between 2031 and 2041.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Limitations on the scope of our intellectual property rights may limit our ability to prevent third parties from designing around such rights and competing against us. For example, our patents do not claim a new compound. Rather, the active pharmaceutical ingredients of our products are known compounds and our&#xa0;patents and pending patent applications are directed inter alia to novel formulations of these known compounds with our proprietary <i>RTGel</i>&#xa0;technology. Accordingly, other parties may compete with us, for example, by independently developing or obtaining competing topical formulations that design around our patent claims, but which may contain the same active ingredients, or by seeking to invalidate our patents. Any disclosure of or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in the market.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We will not necessarily seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">One or more of the patent applications that we filed, or license may fail to result in granted patents in the United States or foreign jurisdictions, or if granted may fail to prevent a potential infringer from marketing its product or be deemed invalid and unenforceable by a court. Competitors in the field of reverse thermal gel therapies have created a substantial amount of scientific publications, patents and patent applications and other materials relating to their technologies. Our ability to obtain and maintain valid and enforceable patents depends on various factors, including interpretation of our technology and the prior art and whether the differences between them allow our technology to be patentable. Patent applications and granted patents are complex, lengthy and highly technical documents that are often prepared under limited time constraints and may not be free from errors that make their interpretation uncertain. The existence of errors in a patent may have an adverse effect on the patent, its scope and its enforceability. Our pending patent applications may not issue, and the scope of the claims of patent applications that do issue may be too narrow to adequately protect our competitive advantage. Also, our granted patents may be subject to challenges or narrowly construed and may not provide adequate protection.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     60
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>We may be subject to claims that we infringe, misappropriate or otherwise violate the intellectual property rights of third parties. </i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Even if our patents do successfully issue, third parties may challenge the validity, enforceability or scope of such granted patents or any other granted patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant. Also, patents granted by the USPTO may be subject to reexamination and other challenges.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceutical patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. There is significant litigation activity in the pharmaceutical industry regarding patent and other intellectual property rights. Such litigation could result in substantial costs and be a distraction to management and other employees.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. Furthermore, even if they are not challenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. To meet such challenges, which are part of the risks and uncertainties of developing and marketing product candidates, we may need to evaluate third party intellectual property rights and, if appropriate, to seek licenses for such third party intellectual property or to challenge such third party intellectual property, which may be costly and may or may not be successful, which could also have an adverse effect on the commercial potential for <i>Jelmyto</i>, UGN-102 and any of our other&#xa0;product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may receive only limited protection, or no protection, from our issued patents and patent applications. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">There can be no assurance that the patent applications will be granted. The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The patent application process, also known as patent prosecution, is expensive and time consuming, and we or any future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or any future licensors or licensees will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc., although we are unaware of any such defects that we believe are of material import. If we or any future licensors or licensees fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If any future licensors or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or in-license may fail to result in issued patents in the United States or foreign countries with claims that cover our product candidates. Even if patents do successfully issue from the patent applications that we own or in-license, third parties may challenge the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be challenged, also known as opposed, by any person within nine months from the publication of their grant. Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our product candidates, provide exclusivity for our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop or threaten our ability to commercialize our product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be open to competition from generic versions of our product candidates. Further, if we encounter delays in our development efforts, including our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">A considerable number of our patents and patent applications are entitled to effective filing dates prior to March&#xa0;16, 2013. For U.S. patent applications in which patent claims are entitled to a priority date before March&#xa0;16, 2013, an interference proceeding can be provoked by a third party, for example a competitor, or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by those patent claims. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     61
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>Our trade secrets may not have sufficient intellectual property protection. </i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary know-how that may not be patentable or that we elect not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product candidates, and our product development processes (such as manufacturing and formulation technologies) that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have an adverse effect on our business. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. The FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#x2019;s disclosure policies may change in the future, if at all.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, advisors, and any other third parties that have access to our proprietary know-how, information or technology, for example, third parties involved in the formulation and manufacture of our product candidates, and third parties involved in our clinical trials to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#x2019;s relationship with us is kept confidential and not disclosed to third parties. However, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed despite having such confidentiality agreements. Adequate remedies may not exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by third parties in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could harm our business, operating results and financial condition.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">For our U.S. patent applications containing a claim not entitled to priority before March&#xa0;16, 2013, there is a greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act, or the America Invents Act&#xa0;("AIA"), was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business and financial condition.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">An important change introduced by the AIA is that, as of March&#xa0;16, 2013, the United States transitioned to a &#x201c;first-to-file&#x201d; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even&#xa0;if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i)&#xa0;file any patent application related to our product candidates or (ii)&#xa0;invent any of the inventions claimed in our patents or patent applications.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#xa0;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in a United States federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     62
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Periodic maintenance fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our product candidates, our competitors might be able to enter the market earlier than should otherwise have been the case, which could harm our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may not be able to protect our intellectual property rights throughout the world. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we are unable to protect our trademarks from infringement, our business prospects may be harmed. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We filed applications for trademarks (<i>Jelmyto</i><sup style="vertical-align:top;line-height:120%;">&#xae;</sup>, <i>RTGel</i><sup style="vertical-align:top;line-height:120%;">&#xae;</sup>, and UroGen<sup style="vertical-align:top;line-height:120%;">&#xae;</sup>) that identify our branding elements, such as <i>Jelmyto</i> and our unique technology in the United States, Europe, Japan and China. Although we take steps to monitor the possible infringement or misuse of our trademarks, it is possible that third parties may infringe, dilute or otherwise violate our trademark rights. Any unauthorized use of our trademarks could harm our reputation or commercial interests. In addition, our enforcement against third-party infringers or violators may be unduly expensive and time-consuming, and the outcome may be an inadequate remedy.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights or the patents of our licensors, which could be expensive and time consuming. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the future, or the patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. Further, we may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against such a generic drug manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors&#x2019; patents, requiring us and/or our licensors to engage in complex, lengthy and costly litigation or other proceedings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     63
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">For example, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions, regarding patent and other intellectual property rights in the pharmaceutical industry. Recently, the AIA introduced new procedures including inter partes review and post grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future, including challenges by competitors who perceive our patents as blocking entry into the market for their products, and the outcome of such challenges.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates. They may also put our pending patent applications at risk of not issuing or issuing with limited and potentially inadequate scope to cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Additionally, it is also possible that prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administrative panel to affect the validity or enforceability of a claim. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a negative impact on our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Enforcing our or our licensors&#x2019; intellectual property rights through litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of litigation or administrative proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our ordinary shares could be significantly harmed.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">A significant portion of our intellectual property has been developed by our employees during their employment. Our employees execute agreements that assign to us&#xa0;any ownership interest in a patent or patent application created in the scope of the employee&#x2019;s employment. In Israel, the Israeli Patent Law, 5727-1967, or the Patent Law, provides that inventions conceived by an employee during the scope of his or her employment with a company are regarded as &#x201c;service inventions.&#x201d; Accordingly, our employees in Israel also enter into agreements that, among other things, waive the right to special remuneration for service inventions created in the scope of their employment or engagement. The Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, has previously held, in certain cases, that employees may be entitled to remuneration for service inventions that they develop during their service for a company despite their explicit waiver of such right. Therefore, although we enter into agreements with our Israeli employees that waive their right to special remuneration for service inventions created in the scope of their employment or engagement, we may nonetheless face claims by employees demanding remuneration beyond their regular salary and benefits.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Third-party claims alleging intellectual property infringement may adversely affect our business. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, the intellectual property rights of competitors. Our&#xa0;commercialization activities may be subject to claims that we infringe or otherwise violate patents owned or controlled by third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our product candidates may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates will not infringe existing or future patents. We may unknowingly infringe existing patents by commercialization of our product candidates. It is also possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless be found to be infringed by our product candidates. Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing our product candidates, if approved. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     64
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Third parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial expenses, and would be a substantial diversion of management time and employee resources from our business. In the event of a successful claim of infringement against us by a third party, we may have to (i)&#xa0;pay substantial damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed the third party&#x2019;s patents; (ii)&#xa0;obtain one or more licenses from the third party; (iii)&#xa0;pay royalties to the third party; and/or (iv)&#xa0;redesign any infringing products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditures. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop and commercialize our product candidates, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Defending ourselves or our licensors in litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#x2019; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a negative impact on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><span style="font-family:Arial;"><b>Risks Related to Government Regulation </b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If the FDA does not conclude that UGN-102 satisfies the requirements under 505(b)(2)</i></b>&#xa0;<b><i>or if the requirements for our product candidates are not as we expect, the approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The Drug Price Competition and Patent Term Restoration Act of 1984&#xa0;(the "Hatch-Waxman Act"), added&#xa0;505(b)(2) to the FDCA.&#xa0;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant, and for which the applicant has not received a right of reference, which could expedite the development program for UGN-102 and our other product candidates by potentially decreasing the amount of nonclinical and clinical data that we would need to generate in order to obtain FDA approval. However, while we believe that our product candidates are reformulations of existing drugs and, therefore, will not be treated as NCEs, the submission of an NDA under the&#xa0;505(b)(2) pathway does not preclude the FDA from determining that the product candidate that is the subject of such submission is an NCE and therefore not eligible for review under such regulatory pathway.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If the FDA does not allow us to pursue the&#xa0;505(b)(2) pathway as anticipated, we may need to conduct additional nonclinical experiments and clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely increase significantly. Moreover, inability to pursue the&#xa0;505(b)(2) pathway could result in new competitive products reaching the market more quickly than our product candidates, which would likely harm our competitive position and prospects. Even if we are allowed to pursue the&#xa0;505(b)(2) pathway, our product candidates may not receive the requisite approvals for commercialization.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     65
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, notwithstanding the approval of a number of products by the FDA under&#xa0;505(b)(2) certain competitors and others have objected to the FDA&#x2019;s interpretation of&#xa0;505(b)(2). If the FDA&#x2019;s interpretation of&#xa0;505(b)(2) is successfully challenged, the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under&#xa0;505(b)(2). In addition, the pharmaceutical industry is highly competitive, and&#xa0;505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a&#xa0;505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the&#xa0;505(b)(2) regulatory pathway for our product candidates, there is no guarantee this would ultimately lead to faster product development or earlier approval.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Moreover, even if these product candidates are approved under the&#xa0;505(b)(2) pathway, as the case may be, the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We expect current and future legislation affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase limitations on reimbursement, rebates and other payments, which could adversely affect third-party coverage of our products, our operations, and/or how much or under what circumstances healthcare providers will prescribe or administer our products, if approved.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#x201c;ACA&#x201d;), laws intended, among other things, to broaden access to health insurance, improve quality of care, and reduce or constrain the growth of healthcare spending.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     66
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">There have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#x201c;IRA&#x201d;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear any such challenges, other litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which started in 2013 and, due to subsequent legislative amendments to the statute, including the BBA, and the Consolidated Appropriations Act of 2023, will stay in effect until&#xa0;2032, unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.&#xa0;Further, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s AMP, for single source and innovator multiple source drugs, beginning January 1, 2024.&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Additionally, there have been several recent U.S. presidential executive orders, Congressional inquiries and proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, for example, in July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services&#xa0;("HHS") released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Further, on November 15, 2021, President Biden signed into law the Infrastructure Investment and Jobs Act. Beginning on January 1, 2023, manufacturers will be required to pay quarterly refunds to CMS for discarded amounts of certain single-dose container and single-use package drugs payable under part B of the Medicare program. Refunds are based on the discarded volume above 10% of the total allowed amount. However, in unique circumstances, CMS will increase the applicable threshold to 35%. At this time, CMS has determined that <i>Jelmyto</i> fits within this unique circumstance classification. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently&#xa0;subject to legal challenges. HHS has and will continue to issue and update guidance as these programs are implemented. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#x2019;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. If healthcare policies or reforms intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to the pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">These laws may result in additional reductions in healthcare funding, which could have an adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether regulations, guidance or interpretations will be changed, or what the impact of such changes on our operations, including the marketing approvals of UGN-102 or our other product candidates may be.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislation pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our products could adversely affect how much or under what circumstances healthcare providers will prescribe or administer our products. This could adversely affect our business by reducing our ability to generate revenues, raise capital, obtain additional licensees and market our products. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact product sales.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may be unable to obtain Orphan Drug Designation or exclusivity for future product candidates we may develop. If our competitors are able to obtain orphan drug exclusivity for their products that are for the same indication as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Under the Orphan Drug Act of 1983&#xa0;(the "Orphan Drug Act"), the FDA may designate a product as an orphan drug if it is intended to treat an orphan disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has Orphan Drug Designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. Although the FDA has granted orphan drug exclusivity to <i>Jelmyto</i> for the treatment of UTUC, we may not receive orphan drug exclusivity for any of our other product candidates that have received orphan designation.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Although the FDA has granted Orphan Drug Designation to <i>Jelmyto</i> and UGN-201 for treatment of UTUC and CIS, respectively, we may not receive Orphan Drug Designation for any of our other product candidates. If our competitors are able to obtain orphan drug exclusivity for their products that are the same or similar to our product candidates before our drug candidates are approved, we may not be able to have competing product candidates approved by the FDA for a significant period of time. Any delay in our ability to bring our product candidates to market would negatively impact our business, revenue, cash flows and operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Orphan Drug Designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug exclusivity for our product candidates, we may be subject to earlier competition and our potential revenue will be reduced. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages, user-fee waivers and market exclusivity for certain periods of time.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Jelmyto</i> and UGN-201 have been granted Orphan Drug Designation for the treatment of UTUC and CIS, respectively, in the United States. Even if we obtain Orphan Drug Designation for our other product candidates, we may not be the first to obtain regulatory approval for any particular orphan indication due to the uncertainties associated with developing biotechnology products. Further, even if we obtain Orphan Drug Designation for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate we are pursuing for the same indication, approval of our product candidate would be blocked during the period of marketing exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved product. Conversely, even if we are granted orphan exclusivity, a competitor that demonstrates clinical superiority with the same active moiety may obtain approval prior to expiration of our exclusivity. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate, we are pursuing for a different orphan indication, this may negatively impact the market opportunity for our product candidate. There have been legal challenges to aspects of the FDA&#x2019;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges could lead to changes that affect the protections afforded our product candidates in ways that are difficult to predict.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     68
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>Jelmyto and any of our product candidates that receive</i></b>&#xa0;<b><i>regulatory approval will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements. </i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Jelmyto</i> and any of our product candidates that receive&#xa0;regulatory approval will be subject to continual regulatory review by the FDA and/or foreign regulatory authorities. Additionally, <i>Jelmyto</i> and any of our product candidates that receive regulatory approval will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The FDA approval of <i>Jelmyto</i> is, and any regulatory approvals that we receive for our product candidates may be, subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval. In addition, any regulatory approvals that we receive for our current or future product candidates may contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for <i>Jelmyto</i> is, and any of our&#xa0;product candidates that receive&#xa0;regulatory approval will be, subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Later discovery of previously unknown problems with our products or product candidates, including adverse events of unanticipated severity or frequency, or problems with our third-party manufacturers&#x2019; processes, or failure to comply with regulatory requirements, may result in, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">fines, warning letters or holds on clinical trials;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us, or suspension or revocation of product license approvals; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">product seizure or detention, or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our relationships with healthcare professionals, independent contractors, clinical investigators, CROs, consultants and vendors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face significant penalties.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are&#xa0;subject to various U.S. federal, state and foreign health care laws, including those intended to prevent health care fraud and abuse. These laws may impact, among other things, our clinical research, sales and marketing activities, and constrain the business or financial arrangements with healthcare providers, physicians, and other parties that have the ability to directly or indirectly influence the prescribing, ordering, marketing, or distribution of products for which we obtain marketing approval.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The federal Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program such as Medicare and Medicaid. Remuneration has been broadly defined to include anything of value, including, but not limited to, cash, improper discounts, and free or reduced-price items and services.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal false claims laws, including the federal civil False Claims Act (the&#xa0;"FCA"),&#xa0;and civil monetary penalties law impose penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. The FCA has been used to, among other things, prosecute persons and entities submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     69
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Many states have similar fraud and abuse statutes and regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. State and federal authorities have aggressively targeted pharmaceutical companies for, among other things, alleged violations of these anti-fraud statutes, based on among other things, unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional practices, including certain marketing arrangements that rely on volume-based pricing and off-label promotion of FDA-approved products.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), among other things, imposes civil and criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including public and private payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Additionally, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#x201c;HITECH&#x201d;), and their implementing regulations, impose, among other things, specified requirements on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their business associates as well as their covered subcontractors relating to the privacy, security and transmission of individually identifiable health information, including mandatory contractual terms and required implementation of certain safeguards of such information. Among other things, HITECH makes HIPAA&#x2019;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways, may not have the same effect and may not be preempted by HIPAA, thus complicating compliance efforts.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our operations are also subject to the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section&#xa0;6002 of the ACA and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments and other transfers of value provided to physicians&#xa0;(defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members to CMS. We may also be subject to state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, drug pricing, and/or state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidelines promulgated by the federal government.&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor, including commercial insurers. In addition, we may be subject to certain foreign healthcare laws that are analogous to the U.S. healthcare laws described above. If any of our business activities, including but not limited to our relationships with healthcare providers, are found to violate any of the aforementioned laws, we may be subject to significant administrative, civil and criminal penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, diminished profits and future earnings and curtailment or restructuring of our operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Also, the FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Legislative or regulatory healthcare reforms in the United States or abroad may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">From time to time, legislation is drafted and introduced in Congress in the United States or by governments in foreign jurisdictions that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA or foreign regulatory agency regulations and guidance are often revised or reinterpreted by the FDA or the applicable foreign regulatory agency in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates or any future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">changes to manufacturing methods;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">recall, replacement, or discontinuance of one or more of our products; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">additional recordkeeping.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Each of these would likely entail substantial time and cost and could harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     70
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We are subject to stringent and changing U.S. and foreign</i></b>&#xa0;<b><i>laws, regulations, rules, contractual obligations, self-regulatory schemes, government regulation, policies,</i></b>&#xa0;<b><i>standards, and other obligations related to data privacy and security. The actual or perceived failure by us, our customers, partners or vendors to comply with such obligations could lead to regulatory investigations or actions; litigation&#xa0;</i></b><b><i>(including class claims) and mass arbitration demands</i></b><b><i>; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales;</i></b>&#xa0;<b><i>or otherwise adversely affect our business.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In the ordinary course of our business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, "processing") proprietary, confidential, and sensitive data, including personal data, intellectual property, and trade secrets (collectively, "sensitive information"). Our data processing activities&#xa0;subject to numerous data privacy and security obligations, such as&#xa0;domestic and foreign laws and regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to privacy, data protection, and data security.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In the United States, federal, state, and local governments have enacted numerous privacy, data protection, and data security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, as further described above, HIPAA&#xa0;imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information and the California Consumer Privacy Act of 2018 (&#x201c;CCPA&#x201d;) applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights related to their personal data. The CCPA provides for civil penalties for noncompliance (up to $7,500 per violation) and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, the California Privacy Rights Act of 2020 (&#x201c;CPRA&#x201d;), expands the CCPA&#x2019;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new California Privacy Protection Agency to implement and enforce the CPRA, which could increase the risk of enforcement. Other states, such as Virginia, Colorado, Utah and Connecticut, have also passed comprehensive privacy laws, which have taken effect or will become effective in 2023, and additional similar laws are being considered at the federal, state, and local levels. While these laws, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts and increase legal risk and compliance costs for us, the third parties upon whom we rely. These laws demonstrate our vulnerability to the evolving regulatory environment related to personal data. As we expand our operations, these and similar laws may increase our compliance costs and potential liability.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Outside the United States, an increasing number of laws, regulations, and industry standards apply to privacy, data protection, and data security. For example, the European Union&#x2019;s General Data Protection Regulation (&#x201c;EU GDPR&#x201d;) and the United Kingdom&#x2019;s GDPR (&#x201c;UK GDPR&#x201d;) impose strict requirements for processing personal data. Our upcoming clinical trial will include sites in the EU, which will increase our exposure to potential liability under the EU GDPR. For example, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. We anticipate that over time we may expand our business to include additional operations outside of the United States and Israel. With such expansion, we would be subject to increased governmental regulation in other countries in which we might operate, including the EU GDPR. Assisting our customers, partners, and vendors in complying with the EU GDPR or other foreign laws, or complying with such laws ourselves, may cause us to incur substantial operational costs or require us to change our business practices. Additionally, under various privacy laws and other obligations, we may be required to obtain certain consents to process personal data. Our inability or failure to do so could result in adverse consequences, including class action litigation and mass arbitration demands.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Moreover, in the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#x2019;s standard contractual clauses, the UK&#x2019;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework (which allows for transfers for relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.&#xa0;Inability to import personal data from Europe to the United States may limit our ability to conduct clinical trial activities in Europe, limit our ability to collaborate with contract research organizations, service providers, contractors and other entities subject to European data protection laws, adversely impact our operations, product development and ability to provide our products, and require us to increase our data processing capabilities in Europe at significant expense. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR&#x2019;s cross-border data transfer limitations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     71
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Our employees and personnel may use generative artificial intelligence (&#x201c;AI&#x201d;) technologies to perform their work, and the disclosure and use of personal information in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and consumer lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages. We may also use AI/ML to assist us in making certain decisions, which is regulated by certain privacy laws. Due to inaccuracies or flaws in the inputs, outputs, or logic of the AI/ML, the model could be biased and could lead us to make decisions that could bias certain individuals (or classes of individuals), and adversely impact their rights, employment, and ability to obtain certain pricing, products, services, or benefits.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA, require our customers to impose specific contractual restrictions on their service providers. We publish privacy policies, marketing materials and other statements regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model. Our business model materially depends on our ability to process personal data, so we are particularly exposed to the risks associated with the rapidly changing legal landscape. For example, we may be at heightened risk of regulatory scrutiny, and any changes in the regulatory framework could require us to fundamentally change our business model. We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could negatively impact our business. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We maintain workers compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor policies.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition to any healthcare reform measures which may affect reimbursement, market acceptance and sales of <i>Jelmyto</i>, UGN-102 and our other product candidates, if approved, will depend on the coverage and reimbursement policies of third-party payors, like government authorities, private health insurers, and managed care organizations. Third-party payors decide which medications they will cover and separately establish reimbursement levels. In October 2020, a Medicare C-Code was issued for <i>Jelmyto</i> and we have obtained pass-through status for two years, no more than three. CMS has established a permanent and product-specific J-code for <i>Jelmyto</i> that took effect on January 1, 2021. Our existing pass-through status is set to expire in the fourth quarter of&#xa0;2023. Loss of pass-through status may result in Medicare beneficiaries losing access to <i>Jelmyto</i> in the hospital outpatient setting and <i>Jelmyto</i> becomes packaged into a comprehensive ambulatory payment classification. This loss of pass-through status could adversely affect our <i>Jelmyto </i>revenues.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government and other third-party payors are increasingly challenging the prices charged for health care products, examining the cost effectiveness of drugs in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement for prescription drugs. Although our experience to date has demonstrated coverage for <i>Jelmyto</i>, we cannot be sure that adequate coverage will be available for UGN-102 or our other product candidates, if approved, or, if coverage is available, the level of reimbursement will be adequate to make our products affordable for patients or profitable for us. In addition, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass price increases on to our customers due to the process by which healthcare providers are reimbursed for our product candidates.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, decisions about reimbursement for new medicines under Medicare are made by CMS, as the administrator for the Medicare program. Private third-party payors often use CMS as a model for their coverage and reimbursement decisions, but also have their own methods and approval process apart from CMS&#x2019;s determinations. Our experience to date has demonstrated coverage with CMS and commercial payors for <i>Jelmyto</i>, and we have established written policies with certain commercial providers. However, it is difficult to predict what CMS as well as other third-party payors will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     72
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our products. Moreover, for products administered under the supervision of a physician, obtaining and maintaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or applicable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Reimbursement by a third-party payor may depend upon a number of factors including the third-party payor&#x2019;s determination that use of a product is:</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="margin: 0pt; font-family: Arial; font-size: 10pt;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">a covered benefit under its health plan;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">safe, effective and medically necessary;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">appropriate for the specific patient;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">cost-effective; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">neither experimental nor investigational.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Obtaining and maintaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We may not be able to provide data sufficient to gain acceptance with respect to coverage and/or sufficient reimbursement levels.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Although we have obtained&#xa0;written policy coverage in commercial plans as well as coverage for government plans for <i>Jelmyto</i> to date, we cannot be sure that adequate coverage or reimbursement will continue to be available for <i>Jelmyto</i>, or be available for UGN-102 or any of our other product candidates, if approved. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize <i>Jelmyto</i>, UGN-102 or our other product candidates, or achieve profitably at all, even if approved. Additionally, coverage policies and reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for any of our products or product candidates that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. For example, beginning on January 1, 2023, manufacturers will be required to pay quarterly refunds to CMS for discarded amounts of single-dose container and single-use package drugs covered under Medicare Part B.&#xa0;Rebates will be based on the discarded volume above 10% of the total allowed amount. However, in unique circumstances, CMS will increase the applicable threshold to 35%. At this time, CMS has determined that <i>Jelmyto</i> fits within this unique circumstance classification. If we are unable to obtain and maintain sufficient third&#x2011;party coverage and adequate reimbursement for our products, the commercial success of our products may be greatly hindered and our financial condition and results of operations may be materially and adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     73
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>Risks Related to Ownership of Our Ordinary Shares </b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>The market price of our ordinary shares has been and may continue to be subject to fluctuation and you could lose all or part of your investment.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The stock market in general has been, and the market price of our ordinary shares in particular has been and may continue to be, subject to fluctuation, whether due to, or irrespective of, our operating results and financial condition. The market price of our ordinary shares on the Nasdaq Global Market may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the success of our ongoing launch and commercialization of <i>Jelmyto</i>;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">actual or anticipated variations in our and our competitors&#x2019;&#xa0;results of operations and financial condition;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">physician and market acceptance of <i>Jelmyto</i>&#xa0;or any other approved product;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the mix of products that we sell;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">any voluntary or mandatory recall of <i>Jelmyto</i>&#xa0;or any other approved product, or the imposition of any additional labeling, marketing or promotional restrictions;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our success or failure to obtain approval for and commercialize our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in the structure of healthcare payment systems;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">development of technological innovations or new competitive products by others;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">announcements of technological innovations or new products by us;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">publication of the results of nonclinical or clinical trials for <i>Jelmyto</i>, UGN-102 or our other product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">failure by us to achieve a publicly announced milestone;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">delays between our expenditures to develop and market new or enhanced product candidates and the generation of sales from those products;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">developments concerning intellectual property rights;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the announcement of, or developments in, any litigation matters, including any product liability claims related to <i>Jelmyto</i>&#xa0;or any of our product candidates;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in our expenditures to promote our products;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">our sale or proposed sale, or the sale by our significant shareholders, of our ordinary shares or other securities in the future;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in key personnel;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">success or failure of our research and development projects or those of our competitors;</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">the trading volume of our ordinary shares; and</p> </td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-family: Arial;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial;">
     <td style="vertical-align: top; width: 4%; font-family: Arial;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x2022;</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">general economic and market conditions and other factors, including factors unrelated to our operating performance.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">These factors and any corresponding price fluctuations may negatively impact the market price of our ordinary shares and result in substantial losses being incurred by our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities class action litigation. If we were to become involved in securities litigation, it could impose a substantial cost upon us and divert the resources and attention of our management from our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Future sales of our ordinary shares could reduce the market price of our ordinary shares.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If our existing shareholders, particularly our directors, their affiliates, or our executive officers, sell a substantial number of our ordinary shares in the public market, the market price of our ordinary shares could decrease significantly. The perception in the public market that our shareholders might sell our ordinary shares could also depress the market price of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equity securities.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, our sale of additional ordinary shares or other&#xa0;securities in order to raise capital might have a similar negative impact on the share price of our ordinary shares. A decline in the price of our ordinary shares might impede our ability to raise capital through the issuance of additional ordinary shares or other equity securities and may cause you to lose part or all of your investment in our ordinary shares.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     74
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-family:Arial;"><b><i>Future equity offerings could result in future dilution and could cause the price of our ordinary shares to decline.*</i></b></span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In order to raise additional capital, we may in the future offer additional ordinary shares or other securities convertible into or exchangeable for our ordinary shares at prices that we determine from time to time, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders. We may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. On December 20, 2019, we entered into the ATM Sales Agreement pursuant to which we may from time to time offer and sell our ordinary shares, having an aggregate offering price of up to $100.0 million, to or through Cowen, acting as sales agent or principal, in any manner deemed to be an &#x201c;at-the market offering&#x201d;. As of June&#xa0;30, 2023, $83.4 million remain available for sale under the ATM Sales Agreement.&#xa0;The shares will be offered and sold pursuant to our shelf registration statement on Form S-3 filed with the SEC on November 15, 2022, which was declared effective on November 29, 2022.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>The significant share ownership position of our officers, directors and entities affiliated with certain of our directors may limit your ability to influence corporate matters. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our officers, directors and entities affiliated with certain of our directors beneficially own a significant portion of our outstanding ordinary shares. Accordingly, these persons are able to significantly influence, though not independently determine, the outcome of matters required to be submitted to our shareholders for approval, including decisions relating to the election of our board of directors, and the outcome of any proposed merger or consolidation of our company. These interests may not be consistent with those of our other shareholders. In addition, these persons&#x2019; significant interest in us may discourage third parties from seeking to acquire control of us, which may adversely affect the market price of our ordinary shares.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We have never declared or paid cash dividends on our share capital, nor do we anticipate paying any cash dividends on our share capital in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our ordinary shares will be investors&#x2019; sole source of gain for the foreseeable future. In addition, Israeli law limits our ability to declare and pay dividends and may subject our dividends to Israeli withholding taxes.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we are classified as a passive foreign investment company</i></b>&#xa0;<b><i>("PFIC"), our U.S. shareholders may suffer adverse tax consequences.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Generally, for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a PFIC for U.S. federal income tax purposes.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. In particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change. In addition, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of our ordinary shares from time to time, which may fluctuate considerably. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by how, and how quickly, we spend the cash we raise in any offering.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on our analysis of our income, assets, activities and market capitalization, we do not believe that we were a PFIC for the taxable&#xa0;year ended December 31, 2022.&#xa0;However, because the determination of whether or not we are a PFIC is a fact-intensive determination made on an annual basis, and because the applicable law is subject to varying interpretation, we cannot provide any assurances regarding our PFIC status for any past, current or future taxable years.&#xa0;Our U.S. tax counsel has not provided any opinion regarding our PFIC status in any taxable year.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who are U.S. shareholders who are individuals, having interest charges apply to distributions by us and gains from the sales of our shares, and additional reporting requirements under U.S. federal income tax laws and regulations. A U.S. Holder&#xa0;that (i) owns our ordinary shares at any point during a year in which we are characterized as a PFIC and (ii) does not timely make a QEF election (as described below) will treat such ordinary shares as stock in a PFIC for all subsequent tax years, even if we no longer qualify as a PFIC under the relevant tests in such subsequent tax years. A U.S. shareholder of a PFIC generally may mitigate these adverse U.S. federal income tax consequences by making a qualified electing fund (&#x201c;QEF&#x201d;) election, or, in some circumstances, a &#x201c;mark to market&#x201d; election. However, there is no assurance that we will provide the information required by the IRS in order to enable U.S. shareholders to make a timely QEF election. Moreover, there is no assurance that we will have timely knowledge of our status as a PFIC in the future. Accordingly, U.S. shareholders may be unable to make a timely QEF election with respect to our ordinary shares.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     75
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Changes to tax laws could have a material adverse effect on us and reduce net returns to our shareholders. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our tax treatment is subject to changes in tax laws, regulations and treaties, or the interpretation thereof, as well as tax policy initiatives and reforms under consideration and the practices of tax authorities in jurisdictions in which we operate, including those related to the Organisation for Economic Co-Operation and Development&#x2019;s&#xa0;("OECD")&#xa0;Base Erosion and Profit Shifting ("BEPS") Project (including "BEPS 2.0"), and the European Commission&#x2019;s state aid investigations and other initiatives.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or, in the specific context of withholding tax, dividends paid. The OECD has published a package of measures for reform as a product of BEPS, which include the reallocation of global profits of large multinational companies to market jurisdictions based on customer location as well as the introduction of a global minimum tax. Many of the package&#x2019;s proposed measures require amendments to the domestic tax legislation of various jurisdictions.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could affect our financial position and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders, and increase the complexity, burden and cost of tax compliance.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of our domestic and foreign earnings. For example, effective in 2022, the U.S. Tax Cuts and Jobs Act of 2017 eliminates the option to deduct research and development expenditures in the current period and requires U.S. taxpayers to capitalize and amortize them over five or fifteen years pursuant to Internal Revenue Code Section 174. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us.&#xa0;Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future tax expenses.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable nexus, often referred to as a &#x201c;permanent establishment&#x201d; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">If a &#x201c;United States person&#x201d; (as defined by the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;)) is treated as owning (directly, indirectly or constructively) at least 10% of the total combined&#xa0;voting power of all classes of our stock entitled to vote or 10% or more of the total value of all classes of our stock, such United States person may be treated as a &#x201c;United States shareholder&#x201d; with respect to each &#x201c;controlled foreign corporation&#x201d; ("CFC")&#xa0;in our group (if any). Each United States shareholder of a CFC may be required to annually report and include in its U.S. taxable income its pro rata share of &#x201c;Subpart F income,&#x201d; &#x201c;global intangible low-taxed income&#x201d; and investments in U.S. property by the CFC, regardless of whether the CFC makes any distributions. In addition, a United States shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain.&#xa0;An individual who is a United States shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if United States shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. Because our group includes at least one U.S. subsidiary (UroGen Pharma, Inc.), if we were to form or acquire any non-U.S. subsidiaries in the future, attribution rules could cause them to be treated as CFCs with respect to any United States person owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary shares.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We cannot provide any assurances that we will assist investors in determining whether we or any non-U.S. subsidiaries that we may form or acquire in the future would be treated as a CFC or whether such investor would be treated as a United States shareholder with respect to any such CFC.&#xa0;Further, we cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with the reporting and tax paying obligations discussed above. Failure to comply with these reporting obligations may subject you to significant monetary penalties and may prevent the statute of limitations with respect to your U.S. federal income tax return for the year for which reporting was due from starting. U.S. shareholders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     76
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our ability to use our U.S. net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be limited.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Under U.S. federal income tax law, federal net operating losses&#xa0;("NOLs")&#xa0;incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. In addition, under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#x201c;ownership change,&#x201d; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#x2019;s ability to utilize its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have not performed a detailed analysis to determine whether an ownership change under Section 382 of the Code has occurred for UroGen Pharma, Inc. If we undergo or have undergone an ownership change, our ability to utilize NOLs and other tax attributes could be limited by Sections 382 and 383 of the Code. Future changes in our share ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes, which could negatively impact our future cash flows. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>Risks Related to our Operations in Israel </b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our research and development facilities are located in Ra&#x2019;anana, Israel. If these or any future facilities in Israel were to be damaged, destroyed or otherwise unable to operate, whether due to war, acts of hostility, earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, pandemic, power outages or otherwise, or if performance of our research and development is disrupted for any other reason, such an event could delay our clinical trials or, if our product candidates are approved and we choose to manufacture all or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective customers will likely expect, or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our prospective customers&#x2019; expectations, our business, prospects, financial results and reputation could be harmed.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Political, economic and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, Hamas (an Islamist militia and political group that controls the Gaza Strip) and Hezbollah (an Islamist militia and political group based in Lebanon). In addition, several countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities, political instability or violence in the region or the interruption or curtailment of trade or transport between Israel and its trading partners could adversely affect our operations and results of operations and adversely affect the market price of our ordinary shares.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Additionally, the newly elected Israeli government has announced plans to significantly reduce the Israeli Supreme Court's judicial oversight, including reducing its ability to strike down legislation that it deems unreasonable, and plans to increase political influence over the selection of judges. These plans have prompted protests of Israeli citizens and criticism of leading Israeli business leaders as well as some foreign leaders. If such government plans are eventually enacted, they may cause operational challenges for us. In addition, if foreign policy is negatively impacted with regard to Israel, this could impact our business with suppliers and customers which could in turn adversely impact our reputation, results of operations or financial condition.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Further, our operations could be disrupted by the obligations of our employees to perform military service. As of June&#xa0;30, 2023, we had 41&#xa0;employees based in Israel. Of these employees, some may be military reservists, and may be called upon to perform military reserve duty of up to 36 days per year (and in some cases more) until they reach the age of 40 (and in some cases, up to the age of 45 or older). Additionally, they may be called to active duty at any time under emergency circumstances. In response to increased tension and hostilities in the region, there have been, at times, call-ups of military reservists, and it is possible that there will be additional call-ups in the future. Our operations could be disrupted by the absence of these employees due to military service. Such disruption could harm our business and operating results.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Provisions of Israeli law and our articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a tender offer for all of a company&#x2019;s issued and outstanding shares can only be completed if shareholders not accepting the tender offer hold less than 5% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless shareholders not accepting the tender offer hold less than 2% of the company&#x2019;s outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     77
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>It may be difficult to enforce a judgment of a U.S. court against us, our officers and directors or the Israeli experts named in our reports filed with the SEC in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on our officers and directors and these experts. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">We are incorporated in Israel. One of our directors resides outside of the United States, and most of the assets of this director are located outside of the United States. Therefore, a judgment obtained against us, or this director, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It may also be difficult for you to effect service of process on this director in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The rights and responsibilities of the holders of our ordinary shares are governed by our articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&#x2019;s articles of association, increases in a company&#x2019;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>Risks Related to Our Management and Employees </b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We depend on our executive officers and key clinical, technical and commercial personnel to operate our business effectively, and we must attract and retain highly skilled employees in order to succeed.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our success depends upon the continued service and performance of our executive officers who are essential to our growth and development. The loss of one or more of our executive officers could delay or prevent the continued successful implementation of our growth strategy, could affect our ability to manage our company effectively and to carry out our business plan, or could otherwise be detrimental to us. As of June&#xa0;30, 2023, we had 193&#xa0;employees. Therefore, knowledge of our product candidates and clinical trials is concentrated among a small number of individuals. Members of our executive team as well as key clinical, scientific, technical and commercial personnel may resign at any time and there can be no assurance that we will be able to continue to retain such personnel. If we cannot recruit suitable replacements in a timely manner, our business will be adversely impacted.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Our growth and continued success will also depend on our ability to attract and retain additional highly qualified and skilled research and development, operational, managerial and finance personnel. However, we face significant competition for experienced personnel in the pharmaceutical field. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to quality candidates than what we have to offer. If we cannot retain our existing skilled scientific and operational personnel and attract and retain sufficiently skilled additional scientific and operational personnel, as required, for our research and development and manufacturing operations on acceptable terms, we may not be able to continue to develop and commercialize our existing product candidates or new products. Further, any failure to effectively integrate new personnel could prevent us from successfully growing our company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Arial;">
     78
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>General Risk Factors </b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline. </i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The trading market for our ordinary shares relies in part on the research and reports that equity research analysts publish about us and our business, if at all. We do not have control over these analysts, and we do not have commitments from them to write research reports about us. The price of our ordinary shares could decline if no research reports are published about us or our business, or if one or more equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our business could be negatively affected as a result of actions of activist shareholders, and such activism could impact the trading value of our securities.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Shareholders may, from time to time, engage in proxy solicitations or advance shareholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our shareholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our share price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.*</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to bank failures and market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (&#x201c;SVB&#x201d;) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. In addition, on May 1, 2023, the FDIC seized First Republic Bank and sold its assets to JPMorgan Chase &amp; Co. While the U.S. Department of Treasury, FDIC and Federal Reserve Board have implemented a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program, there is no guarantee that such programs will be sufficient. Additionally, it is uncertain whether the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">While we have not experienced any adverse impact to our liquidity or to our current and projected business operations, financial condition or results of operations as a result of the matters relating to SVB, Signature Bank, Silvergate Capital Corp and First Republic Bank, uncertainty remains over liquidity concerns in the broader financial services industry, and our business, our business partners or industry as a whole may be adversely impacted in ways that we cannot predict at this time.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Although we assess our banking relationships as we believe necessary or appropriate, our access to cash in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we have banking relationships. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could also include factors involving financial markets or the financial services industry generally. The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Unstable market, economic and geo-political conditions may have serious adverse consequences on our business, financial condition and stock price.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">The global credit and financial markets have experienced extreme volatility and disruptions in the past, including due to recent bank failures.&#xa0;These disruptions can result in severely diminished liquidity and credit availability, increase in inflation, declines in consumer confidence, declines in economic growth, increases in unemployment rates, further bank failures and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment, higher inflation, bank failures or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our portfolio of corporate and government bonds could also be adversely impacted. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn or rising inflation, which could directly affect our ability to attain our operating goals on schedule and on budget.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">Other international and geo-political events could also have a serious adverse impact on our business. For instance, in February 2022, Russia initiated military action against Ukraine. In response, the United States and certain other countries imposed significant sanctions and trade actions against Russia and could impose further sanctions, trade restrictions, and other retaliatory actions. While we cannot predict the broader consequences, the conflict and retaliatory and counter-retaliatory actions could materially adversely affect global trade, currency exchange rates, inflation, regional economies, and the global economy, which in turn may increase our costs, disrupt our supply chain, impair our ability to raise or access additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition, and results of operations.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our business could be negatively impacted by environmental, social and corporate governance matters or our reporting of such matters.</i></b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">There is an increasing focus from certain investors, employees, partners, and other stakeholders concerning environmental, social and corporate governance&#xa0;("ESG") matters. We may be, or be perceived to be, not acting responsibly in connection with these matters, which could negatively impact us. For instance, the SEC has recently proposed climate change and ESG reporting requirements, which, if approved, would significantly increase our costs. In addition, we currently do not report our environmental emissions, and lack of reporting or future reporting could result in certain investors from declining to invest in our ordinary shares.&#xa0;</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#xa0;</p>
  <p style="margin: 0pt; font-family: Arial; font-size: 10pt;"><b><a id="uses" title="uses" href="#"></a>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</b></p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">None.</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="duss" title="duss" href="#"></a>Item 3. Defaults Upon Senior Securities.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">None.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="msd" title="msd" href="#"></a>Item 4. Mine Safety Disclosures.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">None.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="oi" title="oi" href="#"></a>Item 5. Other Information.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div style="font-size: 10pt;">
    None.
  </div>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       80
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="ex" title="ex" href="#"></a>Item 6. Exhibits.</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following exhibits are filed as part of this report:</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exhibit</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number</b></p> </td>
     <td style="vertical-align: bottom; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Description</b></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001668243/000119312517175069/d401998dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant</span>&#x2019;<span style="text-decoration: underline; ">s Form 6-K (File No. 001-38079), filed with the SEC on May 18, 2017).</span></a></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">4.1</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312523195560/d538950dex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of July 2023&#xa0;Pre-Funded</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">Warrant (incorporated by reference to Exhibit 4.1 to the Registrant</span><span style="text-decoration: underline; ">&#x2019;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K (File No. 001-38079), filed with the SEC on July 27, 2023).</span></a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">10.1+</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><a href="ex_553803.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Manufacturing and Supply Agreement - Amendment No. 2, dated May 19, 2023, by and between the Registrant and Isotopia Molecular Imaging Ltd.</span></a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">10.2</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><a href="ex_557241.htm" style="-sec-extract:exhibit;">Amendment to Loan Agreement, dated June 29, 2023, by and among the Company, UroGen Pharma, Inc., as the borrower, and certain direct and indirect subsidiaries of the Company party thereto from time to time, as guarantors, BPCR Limited Partnership, as a lender, BioPharma Credit Investments V (Master) LP, as a lender, and BioPharma Credit PLC, as collateral agent for the lenders.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">10.3</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312523195560/d538950dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Securities Purchase Agreement, dated July 26, 2023, by and among UroGen Pharma Ltd. and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K (File No. 001-38079), filed with the SEC on July 27, 2023).</span></a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">31.1</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><a href="ex_532896.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of&#xa0;2002.</span></a></td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">31.2</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_532897.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934,&#xa0;as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">32.1#</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_532898.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">32.2#</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_532899.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">101.INS</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inline XBRL Instance Document &#x2013;&#xa0;The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">101.SCH</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inline XBRL Taxonomy Extension Schema Document</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">101.CAL</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">101.DEF</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">101.LAB</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">101.PRE</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 3.8%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">104</p> </td>
     <td style="vertical-align: top; width: 0.5%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 49.1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The cover page from the Company&#x2019;s Quarterly Report on Form 10-Q has been formatted in Inline XBRL</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: top; width: 2%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">#</p> </td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The information in Exhibits 32.1 and 32.2 shall not be deemed &#x201c;filed&#x201d;&#xa0;for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 2%; font-family: Arial, Helvetica, sans-serif;">+</td>
     <td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">Certain portions of this exhibit are omitted because they are not material and are the type that the Registrant treats as private and confidential.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: Arial; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="sigs" title="sigs" href="#"></a>Signatures</b></p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: top; width: 24.3%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 26.4%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>UroGen Pharma Ltd.</b></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: middle; width: 24.3%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1.6%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 24.8%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: bottom; width: 24.3%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">August 10, 2023</p> </td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: top; width: 1.6%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 24.8%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/&#xa0;Elizabeth Barrett</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: bottom; width: 24.3%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1.6%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 24.8%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Elizabeth Barrett</b></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: bottom; width: 24.3%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1.6%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 24.8%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Chief Executive Officer</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Principal Executive Officer)</b></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: middle; width: 24.3%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1.6%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 24.8%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: bottom; width: 24.3%; font-family: Arial, Helvetica, sans-serif;">August 10, 2023</td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: top; width: 1.6%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 24.8%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/ Don Kim</p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: bottom; width: 24.3%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1.6%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 24.8%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Don Kim</b></p> </td>
    </tr>

    <tr style="font-family: Arial, Helvetica, sans-serif;">
     <td style="vertical-align: bottom; width: 24.3%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.7%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1.6%; font-family: Arial, Helvetica, sans-serif;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 24.8%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Chief Financial Officer</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Principal Financial and Accounting Officer)</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Arial;">
       82
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_553803.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_553803.htm</title>
	<!-- Generated by ThunderDome Portal - 8/4/2023 8:12:21 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: right;"><b>Exhibit 10.1</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">Execution Version</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MANUFACTURING AND SUPPLY AGREEMENT </b>&#8211;<b> AMENDMENT NO. 2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Wherea</b>s, <b>UroGen Pharma Ltd.</b>, with a principal place of business or an office at 9 HaTa&#8217;asiya Street, Ra&#8217;anana 4365007, Israel (the &#8220;<b>Buyer</b>&#8221;) and<b> Isotopia</b> <b>Molecular Imaging Ltd. </b>with its principal place of business located at Alexander Yanai 39 Street Segula Industrial Park Petach Tikva 49277, Israel. (the &#8220;<b>Supplier</b>&#8221;) (hereinafter referred to individually as a &#8220;<b>Party</b>&#8221; and collectively as the &#8220;<b>Parties</b>&#8221;) entered a Manufacturing and Supply Agreement with an Effective Date of May 26, 2020 (the &#8220;<b>Original Agreement</b>&#8221;); and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Whereas</b>, the Parties to the Original Agreement entered into a first amendment to the Original Agreement with an effective date of July 1, 2022, extending the term of the Original Agreement and providing for certain additional amendments to the Original Agreement (&#8220;<b>Amendment No. 1</b>&#8221;); and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Whereas</b>, the Parties agree that the &#8220;Original Agreement&#8221;, together with &#8220;Amendment No. 1&#8221;, hereinafter shall collectively be referred to as the &#8220;Agreement&#8221;; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Whereas</b>, the Parties desire to enter into this amendment (&#8220;<b>Amendment No. 2</b>&#8221;) of the Agreement providing for the pre-payment by Buyer of certain future fees due Supplier under the Agreement, Buyer&#8217;s right to certain off-invoice discounts as provided herein, and providing for certain other amendments to the Agreement, as set forth in more detail below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Now, therefore</b>, in consideration of the mutual promises and covenants contained herein, the parties hereby agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Interpretation</u></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 29pt;">Capitalized terms contained herein shall have the meaning ascribed to them in this Amendment No. 2. Capitalized terms which are not defined herein shall have the same meaning ascribed to them in the Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Amendments to the Agreement</u></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">New Section 10.5 shall be added to the Agreement. It shall provide as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 64pt;">&#8220;10.5.<b> </b><b><u>Pre-payment of Future Fees Due under the Agreement</u></b>. On the effective date of this Amendment No. 2, Buyer shall deliver to Supplier via wire transfer [***] (the &#8220;<b>Pre-Payment</b>&#8221;), constituting Buyer&#8217;s pre-payment of future fees that will become due under the Agreement.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">New Section 10.6 shall be added to the Agreement. It shall provide as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 64pt;">&#8220;10.6 <b><u>Off-Invoice Cumulative Discount to Buyer.</u></b> Supplier shall provide a discount to Buyer under the Agreement with a cumulative total of ILS [***]. (the &#8220;<b>Cumulative Discount</b>&#8221;). Commencing on the Effective Date of Amendment No. 2 and continuing to the end of the Term or until the Cumulative Discount has been satisfied in full, whichever is sooner, each Supplier invoices delivered to Buyer, except for invoices referring to payments made by Supplier to third parties in relation to Manufacturing (including Raw Materials and Services), shall include and shall reflect, without offset or a lesser discount percentage for any reason, a [***] discount off the fee otherwise payable by Buyer to Supplier under the Agreement, excluding Transfer Taxes (the &#8220;<b>Individual Invoice Discount</b>&#8221;). If any portion of the Cumulative Discount has not been fully satisfied by the sum of the Individual Invoice Discounts prior to the end of the Term, then Supplier shall pay via Wire Transfer prior to the end of the Term the unsatisfied balance of the Cumulative Discount that is owed to Buyer. By mutual prior written agreement, the Parties may elect to exempt certain Supplier invoices from the Individual Invoice Discount, except that [***] batch invoices and annual retainer invoices are not eligible for mutual exemption.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">New Section 10.7 shall be added to the Agreement. It shall provide as follows: &#8220;10.7 <b><u>Exclusive Dedication of Pre-Payment to Improvements</u></b>. Supplier undertakes to dedicate 100% the Pre-Payment exclusively toward the reasonable and necessary costs of certain mutually agreed capital equipment ([***]) and other improvements required by the applicable Regulatory Authority according to the Improvements Plan attached hereto as Exhibit A (collectively, the &#8220;<b>Improvements</b>&#8221;), that are intended for the Facility. Supplier agrees to complete the Improvements at the Facility no later than July 23, 2023. For clarity, Supplier shall be solely responsible for the costs of such Improvements and all payments to vendors and suppliers relating to such Improvements at the Facility.&#8221;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">New Section 13.3 shall be added to the Agreement. It shall provide as follows: &#8220;13.3. <b><u>Buyer</u></b><u>&#8217;</u><b><u>s Right to Receive Audited Financial Statements and to Audit Supplier</u></b><u>&#8217;</u><b><u>s Financial Good Standing</u></b>. For the period commencing January 1, 2023, through the end of the Term, Supplier shall provide Buyer with copies of its semiannual (e.g., quarterly) and annual audited financial statements (the &#8220;<b>Financial Statements</b>&#8221;). Such Financial Statements shall be delivered to Supplier within three (3) business days of Supplier&#8217;s receipt of such Financial Statements. For clarity, on or before the Effective Date of Amendment No. 2, Supplier shall provide Buyer with its Financial Statement for the first quarter (Q1) of 2023. In addition, Buyer (or any third party designated by Buyer), during the Term and at reasonable times and upon reasonable advance notice to Supplier, may audit the Books and Records and other mutually agreed financial records of Supplier to ensure Supplier is and remains in good financial standing sufficient to meet its commitments under and compliance with the Agreement; provided, however, that such audits by Buyer may not be conducted more than twice in any twelve (12)-month period, unless during a previous audit during such twelve (12)-month period Buyer identified and disclosed to Supplier a material risk relating to Supplier&#8217;s financial good standing. Buyer (or, as applicable, Buyer&#8217;s third-party designee) will be allowed to interview key Supplier employees, including its Chief Financial Officer, with respect to Supplier&#8217;s financial good standing and have access to, and be permitted to examine and copy (without charge), the Books and Records and mutually agreed financial records maintained by Supplier for the purposes of conducting such audit. The reasonable costs for any such audit of Supplier&#8217;s Financial Good Standing shall be borne by Supplier. Notwithstanding, as of July 31, 2023, Buyer (or any third party designated by Buyer), at its dole discretion and at reasonable times and upon reasonable advance notice to Supplier, may audit the Books and Records, Financial Statements and other mutually agreed financial records of Supplier to verify Supplier&#8217;s dedication of and use of the Pre-Payment solely for the Improvements.&#8221;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">New Section 18.8.1 shall be added to the Agreement. It shall provide as follows: &#8220;18.8.1 <b><u>Additional Change of Control Protections for Buyer.</u></b>&nbsp;&nbsp;Without limiting section 18.8 of the Agreement, or any of Buyer&#8217;s rights under the Agreement (e.g., Buyer&#8217;s right to deny consent to any assignment of the Agreement) or any of Supplier&#8217;s duties under the Agreement, or any of the protections or rights afforded Buyer under applicable law in the event of a change of control, in the event Supplier enters a transaction leading to a change of control of the Facility during the Term, then Supplier agrees that the written terms of such change of control agreement with such acquirer shall expressly provide for (i) the duly authorized assignment of the Agreement and the properly financed continuation of Manufacturing at the Facility and the continued, uninterrupted Manufacturing and supply of Product to Buyer consistent with the terms of the Agreement; (ii) written notice within ten (10) business days of the close of such transaction from acquirer to Buyer confirming the continuation of manufacturing at the Facility and confirming acquirer&#8217;s obligations under and performance under the Agreement; and (iii) receipt of Buyer&#8217;s prior written consent to such change of control agreement, which shall not be unreasonably withheld.&#8221;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.6.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Section 4.4 of the Agreement shall be amended. As amended, it shall provide as follows: &#8220;4.4 <b><u>Prompt Notification of Potential Product Supply Instability, Forecast Adjustment and Purchase Order Lead Time Adjustment</u></b>. Supplier shall notify Buyer in writing immediately upon learning any issue or event (e.g., Audit of the Facility; any Regulatory Authority action; material decrease in production capacity; material decrease in customer product orders/forecasts) that (i) may result in a Product supply interruption of greater than thirty (30) days; or (ii) may result in Supplier&#8217;s inability, financial or otherwise, to perform certain of its obligations under the Agreement; or (iii) may result in Supplier&#8217;s default under the Agreement; or (iv) may result in Supplier&#8217;s liquidation, whether voluntarily or otherwise, or its entering into any arrangement with its creditors or the appointment of a receiver (&#8220;<b>Instability Notification</b>&#8221;). Without limiting Buyer&#8217;s rights under Section 4.5 of the Agreement or Section 7 of the Agreement, following Buyer&#8217;s receipt of any such Instability Notification from Supplier, Buyer shall have the right (i) to request an increase in its then current &#8220;Safety Stock&#8221;&nbsp;of Raw Materials, without limitation, and Supplier shall order and maintain the requested increase in the &#8220;Safety Stock&#8221;&nbsp;of Raw Materials; (ii) to issue a new Forecast for Product; and (iii) to issue Purchase Orders for Product with delivery date lead times of thirty (30) or more calendar days after the date of the Purchase Order, or such other lead time as may be mutually agreed between Supplier and Buyer.&#8221;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.7.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">New Section 4.6 shall be added to the Agreement. It shall provide as follows: &#8220;4.6 <b><u>Prioritization of the Facility and Supplier</u></b><u>&#8217;</u><b><u>s Manufacture of the Product at the Facility.</u></b>&nbsp;&nbsp;Without limiting any of Buyer&#8217;s rights or Supplier&#8217;s duties under the Agreement, in the event Supplier elects during the Term to terminate, downsize, or reduce capacity at one or more of its various facilities or its Manufacturing activities at such facilities, either on account of financial hardship, market slowdowns, or for other business reasons, then Supplier agrees to prioritize the survival of and continued operation of the Facility and the Manufacture of Buyer&#8217;s Product at the Facility, at the expense of Supplier&#8217;s other facilities and operations therein.&#8221;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.8.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exhibit D to the Agreement (the &#8220;<b>Quote</b>&#8221;) shall be amended. As amended, the Quote is set forth as Exhibit B to this Amendment No. 2.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.9.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Except as amended above, all other terms of and exhibits to the Agreement shall remain unchanged.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Remaining Provisions</u></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless specifically stated otherwise in this Amendment No. 2, the remainder of the terms under the Agreement shall remain in full force and effect, <i>mutatis mutandis</i>. In any inconsistency between this Amendment No. 2 and the Agreement, this Amendment No. 2 shall prevail.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This Amendment No. 2 and the Agreement, together with all exhibits and schedules thereto, constitutes the full and entire understanding and agreements between the parties regarding the subject matters hereof and thereof, and the Agreement and Amendment No. 2 supersede all prior written or oral, and all contemporaneous written or oral, agreements, understandings and negotiations with respect to the subject matter hereof. No rights, duties or obligations hereunder may be waived, amended, modified or assigned, in any way, in whole or in part, including by operation of law, without the prior written consent of the parties and such rights, duties and obligations shall inure to the benefit of and be binding upon the successors, assigns and personal representatives of each of the parties hereto.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In case any provision of this Amendment No. 2 shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions of this Amendment No. 2 shall not in any way be affected or impaired thereby.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This Amendment No. 2 may be executed by separate signature pages or in any number of counterparts (including by facsimile or PDF attachment to e-mail), and each of such counterparts shall, for all purposes, constitute one agreement binding on the Parties, notwithstanding that the Parties are not signatories to the same counterpart.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Effective Date of Amendment No. 2.</u></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:29pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The effective date for this Amendment No. 2 shall be May 22, 2023.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IN WITNESS WHEREOF, this Amendment No. 2 has been signed by the following authorized representatives of the Parties hereto:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:51.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:49.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:51.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">UROGEN PHARMA LTD.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">By: <u>/s/ Keren Stotzky</u>______</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Name: Keren Stotzky</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Title: VP Manufacturing &amp; Supply Chain</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Date:_<u>5/18/2023</u>__________</p>
			</td>
			<td style="vertical-align:top;width:49.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;ISOTOPIA MOLECULAR IMAGING LTD.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">By: <u>/s/ Tzachi Levy</u>_______</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Name: Tzachi Levy</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Title: Head Of Sterile Plant</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Date:_<u>5/19/2023</u>_________&#8208;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex_557241.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html><head>
	<title>ex_557241.htm</title>
	<!-- Generated by ThunderDome Portal - 8/8/2023 9:46:55 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 10.2</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><i>Execution Version</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FIRST AMENDMENT TO LOAN AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This FIRST AMENDMENT TO LOAN AGREEMENT (this &#8220;<b>Amendment</b>&#8221;), dated and effective as of June 29, 2023 (the &#8220;<b>First Amendment Effective Date</b>&#8221;), is made by and among UROGEN PHARMA, INC., a Delaware corporation (as &#8220;<b>Borrower</b>&#8221; and a Credit Party), UROGEN PHARMA LTD., a company incorporated in Israel with company registration number 513537621 (as &#8220;<b>Parent</b>&#8221; and a Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the &#8220;<b>Collateral Agent</b>&#8221;), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a &#8220;<b>Lender</b>&#8221;), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a &#8220;<b>Lender</b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:center;margin:0pt;"><b>Recitals</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>A.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collateral Agent, Lenders and Borrower have entered into that certain Loan Agreement dated as of March 7, 2022 (the &#8220;<u>Loan Agreement</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>B.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with Section 11.5 of the Loan Agreement, Borrower (acting for its own behalf and on behalf of the other Credit Parties other than Parent), Collateral Agent and Lenders desire to amend the Loan Agreement on the terms and conditions set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:center;margin:0pt;"><b>Agreement</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:justify;margin:0pt;text-indent:36pt;">Now, Therefore, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>1.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</b> All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. The rules of interpretation set forth in the first paragraph of Section 13.1 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>2.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;Amendments to Loan Agreement.</b> With immediate effect from and as of the First Amendment Effective Date:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>a.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by adding as the fourth paragraph in Section 1 of the Loan Agreement the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;The Collateral Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to the Term SOFR Reference Rate, Adjusted Term SOFR or Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Term SOFR Reference Rate, Adjusted Term SOFR, Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Conforming Changes. The Collateral Agent and its affiliates or other related entities may engage in transactions that affect the calculation of the Term SOFR Reference Rate, Adjusted Term SOFR, Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to the Borrower. The Collateral Agent may select information sources or services in its reasonable discretion to ascertain the Term SOFR Reference Rate, Adjusted Term SOFR, Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no liability to Borrower, any Lender or any other Person for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>b.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in their entirety Section 2.2(b)(ii) of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Term Loans, including all unpaid principal thereunder (and, for the avoidance of doubt, all accrued and unpaid interest, all due and unpaid Lender Expenses and any and all other outstanding amounts payable under the Loan Documents), are due and payable in full on the Term Loan Maturity Date.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>c.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Section 2.2(c)(ii) of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon a Change in Control, Borrower shall promptly, and in any event no later than ten (10) days after the consummation of such Change in Control, notify the Collateral Agent in writing of the occurrence of a Change in Control, which notice shall include reasonable detail as to the nature, timing and other circumstances of such Change in Control (such notice, a &#8220;<b>Change in Control Notice</b>&#8221;). Borrower shall prepay in full all of the Term Loans advanced by Lenders under this Agreement, no later than three (3) Business Days after the delivery of such Change in Control Notice, in an amount equal to the sum of (A) all unpaid principal and any and all accrued and unpaid interest with respect to the Term Loans (such interest to be calculated based on Term SOFR for the Interest Period during which such Change in Control is consummated), and (B) any and all amounts payable with respect to the prepayment under this <u>Section 2.2(c)(ii)</u> pursuant to <u>Section 2.2(e)</u> and <u>Section 2.2(f)</u> (as applicable), together with any and all other amounts payable or accrued and not yet paid under this Agreement and the other Loan Documents (including pursuant to <u>Section 2.4</u>). The Collateral Agent will promptly notify each Lender of its receipt of the Change in Control Notice, and the amount of such Lender&#8217;s Applicable Percentage of such prepayment.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>d.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Section 2.2(g) of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any Makewhole Amount or Prepayment Premium payable as a result of any prepayment of the Term Loans pursuant to <u>Section 2.2(c)</u> or as a result of the acceleration of the maturity of the Term Loans pursuant to <u>Section 8.1(a)</u>, shall be presumed to be the liquidated damages sustained by each applicable Lender as the result of the early redemption and repayment of such Term Loan Notes and Borrower agrees that it is reasonable under the circumstances currently existing. BORROWER EXPRESSLY WAIVES (TO THE FULLEST EXTENT IT MAY LAWFULLY DO SO) THE PROVISIONS OF ANY PRESENT OR FUTURE REQUIREMENTS OF LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF ANY MAKEWHOLE AMOUNT OR PREPAYMENT PREMIUM IN CONNECTION WITH ANY SUCH PREPAYMENT OR ACCELERATION OR OTHERWISE. Borrower expressly agrees that (to the fullest extent it may lawfully do so) that: (i) each Makewhole Amount and Prepayment Premium is reasonable and is the product of an arm&#8217;s-length transaction among sophisticated business people, ably represented by counsel; (ii) each Makewhole Amount and Prepayment Premium shall be payable notwithstanding the then-prevailing market rates at the time payment thereof is made; (iii) there has been a course of conduct among Lenders and Borrower giving specific consideration in this transaction for such agreement to pay each Makewhole Amount and Prepayment Premium; and (iv) Borrower shall be estopped hereafter from claiming differently than as agreed to in this <u>Section 2.2(g)</u> and <u>Section 8.6</u>. Borrower expressly acknowledges that its agreement to pay the Makewhole Amount and Prepayment Premium, as the case may be, to applicable Lenders as herein described is a material inducement to such Lenders to make any Credit Extension. Without affecting any of any Lender&#8217;s rights or remedies hereunder or in respect hereof, if Borrower fails to pay the applicable Makewhole Amount or Prepayment Premium when due, then the amount thereof shall thereafter bear interest until paid in full at the Default Rate.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>e.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Section 2.3(a)(i) of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to <u>Section 2.3(b)</u> below, the principal amount outstanding under each Term Loan shall accrue interest at a <i>per annum</i> rate equal to Adjusted Term SOFR for the Interest Period therefor <i>plus</i> the Applicable Margin (the &#8220;<b>Term Loan Rate</b>&#8221;), which interest shall be payable quarterly in arrears in accordance with this <u>Section 2.3</u>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>f.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Section 2.3(e) of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conforming Changes</u>. In connection with the use or administration of Term SOFR, the Collateral Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Collateral Agent will promptly notify Borrower and Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>g.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by adding as Section 2.3(f) of the Loan Agreement the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Benchmark Replacement Setting</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Benchmark Replacement</u>. Notwithstanding anything to the contrary herein or in any other Loan Document, if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred prior any setting of the then-current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with <u>clause (a)</u> of the definition of &#8220;Benchmark Replacement&#8221; for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with <u>clause (b)</u> of the definition of &#8220;Benchmark Replacement&#8221; for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5<sup style="vertical-align:top;line-height:120%;">th</sup>) Business Day after the date notice of such Benchmark Replacement is provided to Borrower and the Lenders without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Collateral Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders. If the Benchmark Replacement is Daily Simple SOFR, all interest payments will be payable on a quarterly basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conforming Changes</u>. In connection with the implementation and administration of a Benchmark Replacement, the Collateral Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices; Standards for Decisions and Determinations</u>. The Collateral Agent will promptly notify Borrower and the Lenders of (A) the implementation of any Benchmark Replacement and (B) the effectiveness of any Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. The Collateral Agent will notify Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to <u>sub-clause (iv)</u> below and (y) the commencement of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Collateral Agent or, if applicable, any Lender (or group of Lenders) pursuant to this <u>Section 2.3(f)</u>, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this <u>Section 2.3(f)</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Unavailability of Tenor of Benchmark</u>. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (A) if the then-current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (1) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Collateral Agent in its reasonable discretion or (2) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Collateral Agent may modify the definition of &#8220;Interest Period&#8221; (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (B) if a tenor that was removed pursuant to <u>sub-clause (A)</u> above either (1) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (2) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Collateral Agent may modify the definition of &#8220;Interest Period&#8221; (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>h.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting the phrase &#8220;&#8230;the United States or any state thereof...&#8221; in Section 2.6(d)(i) of the Loan Agreement and replacing it with the phrase &#8220;&#8230;the United States&#8230;&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>i.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting Section 2.6(f) of the Loan Agreement in its entirety and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Status of Borrower</u>. Borrower is currently treated as a corporation for U.S. federal income tax purposes. Borrower shall provide the Required Lenders with a prior written notice as promptly as practicable, and in any event not less than ten (10) days, before taking any affirmative action (including making any election under Section 301.7701-3(c) of the Treasury Regulations (or any successor provision) by way of filing an IRS Form 8832) to change its U.S. entity tax classification.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>j.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Section 8.1(f) of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral. With respect to any and all Intellectual Property owned or held by any Credit Party and included in Collateral, each Credit Party hereby grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, as of the Tranche A Closing Date: (i) an irrevocable, non-exclusive, assignable, royalty-free license or other right to use (and for its agents or representatives to use), without charge, including the right to sublicense, use and practice, any and all such Intellectual Property in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, advertise for sale, sell, assign, license out, convey, transfer or grant options to purchase any Collateral, and access to all media in which any of the licensed items may be recorded or stored and to all Software and programs used for the compilation or printout thereof; and (ii) in connection with the Collateral Agent&#8217;s exercise of its rights or remedies under this <u>Section 8.1</u> (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, license out, convey, transfer or grant options to purchase any Collateral), each Credit Party&#8217;s rights under all licenses and all franchise Contracts inure to the benefit of all Secured Parties;&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>k.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Section 8.6 of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;"><b>&#8220;8.6</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Demand Waiver; Makewhole Amount; Prepayment Premium.</b> Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by the Collateral Agent on which Borrower is liable. Borrower acknowledges and agrees that if the maturity of all Obligations shall be accelerated pursuant to <u>Section 8.1(a)</u> by reason of the occurrence of an Event of Default, the applicable Makewhole Amount and Prepayment Premium that is payable pursuant to <u>Section 2.2(e)</u> and <u>Section 2.2(f)</u>, as applicable, shall become due and payable by Borrower upon such acceleration, whether such acceleration is automatic or is effected by the Collateral Agent&#8217;s or any Lender&#8217;s declaration thereof, as provided in <u>Section 8.1(a)</u>, and shall also become due and payable in the event the Obligations are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any other similar means, and Borrower shall pay the applicable Makewhole Amount and Prepayment Premium that is payable pursuant to <u>Section 2.2(e)</u> and <u>Section 2.2(f)</u>, as applicable, as compensation to Lenders for the loss of its investment opportunity and not as a penalty, and Borrower waives any right to object thereto in any voluntary or involuntary bankruptcy, insolvency or similar proceeding or otherwise.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>l.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety the Collateral Agent&#8217;s notice details in Section 9 of the Loan Agreement and replacing them as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">&#8220;BioPharma Credit Plc</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">c/o Link Group, Company Matters Ltd.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">6th Floor</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">65 Gresham Street</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">London EC2V 7NQ</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">United Kingdom</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Attn: Company Secretary</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Tel: +44 01 392 477 500</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Fax: +44 01 392 438 288</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Email: biopharmacreditplc@linkgroup.co.uk</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;text-indent:-36pt;">with copies (which shall not constitute notice) to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Pharmakon Advisors, LP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">110 East 59<sup style="vertical-align:top;line-height:120%;">th</sup> Street, #2800</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">New York, NY 10022</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Attn: Pedro Gonzalez de Cosio</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Phone: +1 (212) 883-2296</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Fax: +1 (917) 210-4048</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Email: pharmakon@pharmakonadvisors.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;text-indent:-36pt;">and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Akin Gump Strauss Hauer &amp; Feld LLP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">One Bryant Park</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">New York, NY 10036-6745</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Attn: Geoffrey E. Secol</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Phone: +1 (212) 872-8081</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Fax: +1 (212) 872-1002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Email: gsecol@akingump.com&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>m.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Section 11.2(a) of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#8220;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrower agrees to indemnify and hold harmless each of the Collateral Agent, Lenders and its and their respective Affiliates (and its or their respective successors and assigns) and each manager, member, partner, controlling Person, director, officer, employee, agent or sub-agent, advisor and affiliate thereof (each such Person, an &#8220;<b>Indemnified Person</b>&#8221;) from and against any and all Indemnified Liabilities; <u>provided</u>, <u>however</u>, that (i) Borrower shall have no obligation to any Indemnified Person hereunder with respect to any Indemnified Liabilities to the extent such Indemnified Liabilities arise from the bad faith, gross negligence or willful misconduct of such Indemnified Person (or any of such Indemnified Person&#8217;s Affiliates or controlling Persons or any of their respective directors, officers, managers, partners, members, agents, sub-agents or advisors), in each case, as determined by a final, non-appealable judgment of a court of competent jurisdiction, (ii) Borrower shall have no obligation to any Indemnified Person hereunder with respect to any Indemnified Liabilities if and to the extent such Indemnified Liabilities arise from a material breach of any obligation of such Indemnified Person hereunder, and (iii) Borrower shall have no obligation to any Indemnified Person hereunder with respect to any Indemnified Liabilities if and to the extent such Indemnified Liabilities arise from any claim by one Indemnified Person against another Indemnified Person that does not relate to any act or omission of Borrower or any Credit Party (other than against the Collateral Agent or any intercreditor agent in their respective capacities as such), and (iv) no Credit Party shall be liable for any settlement of any claim or proceeding effected by any Indemnified Person without the prior written consent of such Credit Party (which consent shall not be unreasonably withheld, conditioned or delayed), but if settled with such consent or if there shall be a final judgment against an Indemnified Person, each of the Credit Parties shall, jointly and severally with each other Credit Parties, indemnify and hold harmless such Indemnified Person from and against any loss or liability by reason of such settlement or judgment in the manner set forth in this Agreement. This <u>Section 11.2(a)</u> shall not apply with respect to Taxes other than any Taxes that represent liabilities, obligations, losses, damages, penalties, claims, costs, expenses and disbursements arising from any non-Tax claim.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>n.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Section 11.12 of the Loan Agreement and replacing it as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;11.12</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Electronic Execution of Documents</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">. The words &#8220;execution,&#8221; &#8220;execute,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in this Agreement and the other Loan Documents shall be deemed to include electronic signatures or electronic records, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any Requirements of Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform&nbsp;Electronic Transactions Act.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>o.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety each of the definitions of Available Tenor, Benchmark, Benchmark Replacement, Benchmark Transition Event, CCPA, Daily Simple SOFR, Data Protection Laws, Floor, Governmental Authority, Health Care Laws, Indemnified Liabilities, Interest Date, Interest Period, Lender Expenses, SOFR, Term SOFR, Tranche A Closing Date and Tranche B Closing Date in Section 13.1 of the Loan Agreement and replacing them, in alphabetical order, as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Adjusted Term SOFR</b>&#8221; means, for purposes of any calculation, the rate per annum equal to (a) Term SOFR for such calculation <u>plus</u> (b) the Term SOFR Adjustment; <u>provided</u> that if Adjusted Term SOFR as so determined shall ever be less than the Floor, then Adjusted Term SOFR shall be deemed to be the Floor.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Available Tenor</b>&#8221;<b><i> </i></b>means, as of any date of determination and with respect to the then-current Benchmark, as applicable, (a) if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement or (b) otherwise, any payment period for interest calculated with reference to such Benchmark (or component thereof) that is or may be used for determining any frequency of making payments of interest calculated with reference to such Benchmark pursuant to this Agreement, in each case, as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of &#8220;Interest Period&#8221; pursuant to <u>Section 2.3(e)</u>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Benchmark</b>&#8221;<b> </b>means, initially, the Term SOFR Reference Rate; <u>provided</u> that if a Benchmark Transition Event has occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then &#8220;Benchmark&#8221; means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to <u>Section 2.3(e)</u>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Benchmark Replacement</b>&#8221; means, with respect to any Benchmark Transition Event, the first alternative set forth in the order below that can be determined by the Collateral Agent for the applicable Benchmark Replacement Date:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the sum of (i) Daily Simple SOFR and (ii) 0.26161% (26.161 basis points); or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the sum of: (i) the alternate benchmark rate that has been selected by the Collateral Agent giving due consideration to (A) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (B) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities and (ii) the related Benchmark Replacement Adjustment;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><u>provided</u> that, if the Benchmark Replacement as determined pursuant to <u>clause (a)</u> or <u>(b)</u> above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Benchmark Transition Event</b>&#8221; means the occurrence of one or more of the following events with respect to the then-current Benchmark:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely; <u>provided</u> that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; <u>provided</u> that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">For the avoidance of doubt, a &#8220;Benchmark Transition Event&#8221; will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;CCPA</b>&#8221; means the provisions of the California Consumer Privacy Act, as amended by the California Privacy Rights Act and codified at Cal. Civ. Code &#167; 1798.100 et seq., with any implementing regulations.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Daily Simple SOFR</b>&#8221;<b><i> </i></b>means, for any day, SOFR, with the conventions for this rate (which will include a lookback) being established by the Collateral Agent in accordance with the conventions for this rate recommended by the Relevant Governmental Body for determining &#8220;Daily Simple SOFR&#8221; for Dollar-denominated bilateral business loans; <u>provided</u>, that if the Collateral Agent decides that any such convention is not administratively feasible for the Collateral Agent, then the Collateral Agent may establish another convention in its reasonable discretion.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Data Protection Laws</b>&#8221; means any and all applicable foreign or domestic (including U.S. federal, state and local), statutes, ordinances, orders, rules, regulations, judgments, Governmental Approvals, or any other requirements of Governmental Authorities relating to privacy, security, notification of breaches, or confidentiality of Personal Data that are applicable to the Parent or any of its Subsidiaries, including, to the extent applicable, HIPAA, Section 5 of the FTC Act and other consumer protection laws, Israeli Data Protection Law, GDPR, CCPA and other comprehensive state privacy laws, CMIA and other U.S. state medical information privacy laws and genetic testing laws.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Floor</b>&#8221; means a rate of interest equal to 1.25% <i>per annum</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Governmental Authority</b>&#8221; means any nation or government, any state or other political subdivision thereof, any agency (including Regulatory Agencies and data protection authorities), government department, authority, instrumentality, regulatory body, commission, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Health Care Laws</b>&#8221; means, collectively: (a) applicable federal, state or local laws, rules, regulations, codes, orders, ordinances, statutes and requirements issued under or in connection with Medicare, Medicaid or any other Government Payor Program; (b) applicable federal and state laws and regulations governing the privacy, security, confidentiality, or notification of breaches regarding health information, including HIPAA and Section 5 of the FTC Act; (c) applicable federal, state and local fraud and abuse laws of any Governmental Authority, including the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7(b)), the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes; (d) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. No. 108-173) and the regulations promulgated thereunder; (e) the Physician Payment Sunshine Act (42 U.S.C. &#167; 1320a-7h); (f) any applicable reporting and disclosure requirements, including any arising under Section 603 of the Veteran&#8217;s Health Care Act (Quarterly and Annual Non-Federal Average Manufacturer Price and Federal Ceiling Price), Best Price, Federal Supply Schedule Contract Prices and Tricare Retail Pharmacy Refunds, and Medicare Part D; (g) health care laws, rules, codes, statutes, regulations, orders, ordinances and requirements pertaining to Medicare or Medicaid; (h) federal, state or local laws, rules, regulations, ordinances, statutes and requirements relating to (x) the regulation of managed care, third party payors and Persons bearing the financial risk for the provision or arrangement of health care services, (y) billings to insurance companies, health maintenance organizations and other Managed Care Plans or otherwise relating to insurance fraud and (z) any insurance, health maintenance organization or managed care Requirements of Law; (i)&nbsp;the interoperability, information blocking, and health information technology certification regulations promulgated under the 21<sup style="vertical-align:top;line-height:120%;">st</sup> Century Cures Act (to the extent effective); (j)&nbsp;CDC regulations (including regulations implemented by the CDC Division of Select Agents and Toxins (&#8220;DSAT&#8221;) or otherwise relating to the Federal Select Agent Program (&#8220;FSAP&#8221;), such as 7 C.F.R. Part 331, 9 C.F.R. Part 121, and 42 C.F.R. Part 73); and (k) any other applicable domestic or foreign health care laws, rules, codes, regulations, manuals, orders, ordinances, and statutes relating to the research, development, testing, approval, licensure, post-approval or post-licensure monitoring, post-approval or post-licensure requirements, post-approval or post-licensure commitments, reporting, manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution or sale of or payment for Product.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Indemnified Liabilities</b>&#8221; means, collectively, any and all liabilities, obligations, losses, damages (including natural resource damages), penalties, claims, actions, judgments, suits, costs, reasonable and documented out-of-pocket fees, expenses and disbursements of any kind or nature whatsoever (including the reasonable and documented fees, expenses and disbursements of one counsel for Indemnified Persons plus, as applicable, one local legal counsel in each relevant material jurisdiction and one intellectual property legal counsel, and in the case of an actual or perceived conflict of interest, one additional counsel for such affected Indemnified Persons, in connection with any investigative, administrative or judicial proceeding or hearing commenced or threatened in writing by any Person, whether or not any such Indemnified Person shall have commenced such proceeding or hearing or be designated as a party or a potential party thereto, and any fees or expenses incurred by Indemnified Persons in enforcing any indemnity hereunder) whether direct, indirect or consequential and whether based on any federal, state or foreign laws, statutes, rules or regulations, on common law or equitable cause or on contract or otherwise, that may be imposed on, incurred by, or asserted against any such Indemnified Person, in any manner relating to or arising out of this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby (including any Lender&#8217;s agreement to make Credit Extensions or the use or intended use of the proceeds thereof, or any enforcement of any of the Loan Documents (including any sale of, collection from, or other realization upon any of the Collateral or the enforcement of any guaranty of the Obligations)).&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Interest Date</b>&#8221; means the last day of each calendar quarter, commencing with the last day of the calendar quarter during which the First Amendment Effective Date occurs.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Lender Expenses</b>&#8221; means, collectively:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all reasonable and documented out-of-pocket fees and expenses of the Collateral Agent and, as applicable, each Lender (and their respective successors and assigns) and their respective Related Parties (including the reasonable and documented out-of-pocket fees, expenses and disbursements of any legal counsel, manufacturing consultants or intellectual property experts (it being agreed that such consultant or expert fees, expenses and disbursements shall be limited to one such consultant and one such expert for the Collateral Agent, Lenders and such Related Parties, taken as a whole and in the case of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Person) therefor, (i) incurred in connection with developing, preparing, negotiating, syndicating, executing and delivering, and interpreting, investigating and administering, the Loan Documents (or any term or provision thereof), any commitment, proposal letter, letter of intent or term sheet therefor or any other document prepared in connection therewith, (ii) incurred in connection with the consummation and administration of any transaction contemplated therein, (iii) incurred in connection with the performance of any obligation or agreement contemplated therein, (iv) incurred in connection with any modification or amendment of any term or provision of, or any supplement to, or the termination (in whole or in part) of, any Loan Document, (v) incurred in connection with internal audit reviews and Collateral audits, or (vi) otherwise incurred with respect to the Credit Parties in connection with the Loan Documents, including any filing or recording fees and expenses; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all reasonable and documented out-of-pocket costs and expenses incurred by the Collateral Agent and each Lender (and their respective successors and assigns) and their respective Related Parties (including the reasonable and documented out-of-pocket fees, expenses and disbursements of any legal counsel therefor for the Collateral Agent, Lenders and such Related Parties taken as a whole and in the case of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Person) in connection with (i) any refinancing or restructuring of the credit arrangements provided hereunder in the nature of a &#8220;work-out,&#8221; (ii) the enforcement or protection or preservation of any right or remedy under any Loan Document, any Obligation, with respect to any of the Collateral or any other related right or remedy, or (iii) the commencement, defense, conduct of, intervention in, or the taking of any other action with respect to, any proceeding (including any Insolvency Proceeding) related to any Credit Party or any Subsidiary of any Credit Party in respect of any Loan Document or Obligation, or otherwise in connection with any Loan Document or Obligation (or the response to and preparation for any subpoena or request for document production relating thereto); provided, that, except with respect to an Insolvency Proceeding, to the extent such enforcement entails the Collateral Agent or any Lender commencing legal action of any sort against Borrower, any fees and expenses incurred in connection therewith shall only be payable by Borrower to the extent the Collateral Agent or any Lender is successful in such legal action.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;SOFR</b>&#8221; means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Term SOFR</b>&#8221; means, for any day in any calendar month, the Term SOFR Reference Rate for a tenor of three (3) months on the day (such day, the &#8220;<b>Periodic Term SOFR Determination Day</b>&#8221;) that is two (2) U.S. Government Securities Business Days&#8217; prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; <u>provided</u>, however, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Tranche A Closing Date</b>&#8221; means the date on which the Tranche A Loan is advanced by Lenders, which is March 16, 2022.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Tranche B Closing Date</b>&#8221; means the date on which the Tranche B Loan is advanced by Lenders, which is December 16, 2022.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>p.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety each of the definitions of Early Opt-in Effective Date, Early Opt-in Election, Interest Rate Determination Date and LIBOR Rate in Section 13.1 of the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>q.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by adding, in alphabetical order, each of the following definitions to Section 13.1 of the Loan Agreement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Applicable Margin</b>&#8221; means, for any day, as to any Term Loan, a rate <i>per annum</i> equal to eight and one-quarter percent (8.25%).&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Benchmark Replacement Adjustment</b>&#8221; means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Collateral Agent and Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities at such time.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Benchmark Replacement Date</b>&#8221; means a date and time determined by the Collateral Agent in its reasonable discretion, which date shall be no later than the earliest to occur of the following events with respect to the then-current Benchmark:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of <u>clause (a)</u> or <u>(b)</u> of the definition of &#8220;Benchmark Transition Event,&#8221; the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof); and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of <u>clause (c)</u> of the definition of &#8220;Benchmark Transition Event,&#8221; the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative; <u>provided</u> that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such <u>clause (c)</u> and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">For the avoidance of doubt, the &#8220;Benchmark Replacement Date&#8221; will be deemed to have occurred in the case of <u>clause (a)</u> or <u>(b)</u> above with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Benchmark Unavailability Period</b>&#8221; means, the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with <u>Section 2.3(e)</u> and (b) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with <u>Section 2.3(e)</u>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;CMIA</b>&#8221; means the California Confidentiality of Medical Information Act, codified at Cal. Civ. Code pt. 2.6 &#167; 56 et seq.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Conforming Changes</b>&#8221;<b> </b>means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#8220;Business Day,&#8221; the definition of &#8220;U.S. Government Securities Business Day,&#8221; the definition of &#8220;Interest Period&#8221; or any similar or analogous definition (or the addition of a concept of &#8220;interest period&#8221;), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods and other technical, administrative or operational matters) that the Collateral Agent decides (after consultation with Borrower) may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Collateral Agent in a manner substantially consistent with market practice (or, if the Collateral Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Collateral Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Collateral Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;First Amendment Effective Date</b>&#8221; means June __, 2023.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Periodic Term SOFR Determination Day</b>&#8221; has the meaning specified in the definition of Term SOFR.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;SOFR Administrator</b>&#8221; means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Term SOFR Adjustment</b>&#8221; means a percentage equal to 0.26161% <i>per annum</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Term SOFR Administrator</b>&#8221; means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Collateral Agent in its reasonable discretion).&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;Term SOFR Reference Rate</b>&#8221; means the forward-looking term rate based on SOFR.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"><b>&#8220;&#8220;U.S.</b>&nbsp;<b>Government Securities Business Day</b>&#8221; means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>r.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety the notice details of each Lender in Exhibit D of the Loan Agreement and replacing them as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">&#8220;BPCR LIMITED PARTNERSHIP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">c/o Link Group, Company Matters Ltd.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">6th Floor</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">65 Gresham Street</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">London EC2V 7NQ</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">United Kingdom</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Attn: Company Secretary</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Tel: +44 01 392 477 500</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Fax: +44 01 392 438 288</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Email: biopharmacreditplc@linkgroup.co.uk</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;text-indent:-36pt;">with copies (which shall not constitute notice) to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">PHARMAKON ADVISORS, LP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">110 East 59<sup style="vertical-align:top;line-height:120%;">th</sup> Street, #2800</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">New York, NY 10022</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Attn: Pedro Gonzalez de Cosio</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Phone: +1 (212) 883-2296</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Fax: +1 (917) 210-4048</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">Email: pharmakon@pharmakonadvisors.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;text-indent:-36pt;">and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">AKIN GUMP STRAUSS HAUER &amp; FELD LLP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">One Bryant Park</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">New York, NY 10036-6745</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Attn: Geoffrey E. Secol</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Phone: +1 (212) 872-8081</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Fax: +1 (212) 872-1002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Email: gsecol@akingump.com&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">&#8220;BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">c/o BioPharma Credit Investments V GP LLC</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">c/o Walkers Corporate Limited</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">190 Elgin Avenue,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">George Town, Grand Cayman KY1-9008</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Attn: Pedro Gonzalez de Cosio</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:-36pt;">with copies (which shall not constitute notice) to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">PHARMAKON ADVISORS, LP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">110 East 59th Street, #2800</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">New York, NY 10022</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Attn: Pedro Gonzalez de Cosio</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Phone: +1 (212) 883-2296</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Fax: +1 (917) 210-4048</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Email: pharmakon@pharmakonadvisors.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;text-indent:-36pt;">and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">AKIN GUMP STRAUSS HAUER &amp; FELD LLP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">One Bryant Park</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">New York, NY 10036-6745</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Attn: Geoffrey E. Secol</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Phone: +1 (212) 872-8081</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Fax: +1 (212) 872-1002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">Email: gsecol@akingump.com&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:90pt;"><b>s.</b>&nbsp;&nbsp;&nbsp;&nbsp;The Loan Agreement shall be amended by deleting in its entirety Exhibits B-1 and B-2 to the Loan Agreement and replacing them with <u>Exhibits B-1</u> and <u>B-2</u> attached to this Amendment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>3.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties; Reaffirmation; Covenant to Deliver. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;"><b>a.</b>&nbsp;&nbsp;&nbsp;&nbsp;Borrower hereby represents and warrants to each Lender and the Collateral Agent as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:99pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Borrower has all requisite power and authority to enter into this Amendment and to carry out the transactions contemplated hereby.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:99pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ii.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This Amendment has been duly executed and delivered by Borrower and is the legally valid and binding obligation of such Person, enforceable against such Person in accordance with its respective terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors&#8217;&nbsp;rights generally or by general principles of equity.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:99pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">iii.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The execution, delivery and performance by Borrower of this Amendment have been duly authorized and do not and will not: (A) contravene the terms of such Person&#8217;s Operating Documents; (B) violate any Requirements of Law, except to the extent that such violation could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (C) conflict with or result in any breach or contravention of, or require any payment to be made under any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or affecting such Person or the assets or properties of such Person or any of its Subsidiaries or any order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which such Person or any of its properties or assets are subject, except to the extent that such conflict, breach, contravention or payment could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (D) require any Governmental Approval, or other action by, or notice to, or filing with, any Governmental Authority (except such Governmental Approvals or other actions, notices and filings which have been duly obtained, taken, given or made on or before the First Amendment Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (E) require any approval, consent, exemption or authorization, or other action by, or notice to, or filing with, any Person other than a Governmental Authority, including such Person&#8217;s stockholders, members or partners, (except such approvals, consents, exemptions, authorizations, actions, notices and filings which have been or will be duly obtained, taken, given or made on or before the First Amendment Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; or (F) constitute a material breach of or a material default under (which such default has not been cured or waived) or an event of default (or the equivalent thereof, however described) under, or could reasonably be expected to give rise to the cancellation, termination or invalidation of or the acceleration of such Person&#8217;s or any Subsidiary&#8217;s obligations under, any Material Contract.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:99pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">iv.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Both before and immediately after giving effect to this Amendment, no Event of Default or Default has occurred and is continuing.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:36pt;"><b>b.</b>&nbsp;&nbsp;&nbsp;&nbsp;Borrower hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, Borrower acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>c.</b>&nbsp;&nbsp;&nbsp;&nbsp;Borrower hereby agrees to deliver to the Collateral Agent, within two (2) Business Days of the First Amendment Effective Date, originally-signed copies of the Amended and Restated Tranche A Notes and the Amended and Restated Tranche B Notes, in the forms attached as <u>Exhibit B-1</u> and <u>Exhibit B-2</u> hereto, respectively (collectively, the &#8220;<b><i>Replacement Notes</i></b>&#8221;), in replacement of the Tranche A Notes, dated March 16, 2022, and the Tranche B Notes, dated December 16, 2022, issued by Borrower to each Lender (the &#8220;<b><i>Existing Notes</i></b>&#8221;) whereupon the Lenders shall return all copies of the Existing Notes to Borrower to be destroyed and the Existing Notes shall from that moment be treated as cancelled and of no further force or effect. Failure of Borrower to deliver the Replacement Notes in accordance with this paragraph constitutes an Event of Default for all purposes under the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>4.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;References to and Effect on Loan Agreement</b>. Except as specifically set forth herein, this Amendment shall not modify or in any way affect any of the terms, conditions, covenants, representations and warranties contained in the Loan Agreement, or any of the rights of the Lenders and the Collateral Agent therein, which shall remain in full force and effect and are hereby ratified and confirmed in all respects. Except as specifically set forth herein, the execution, delivery and effectiveness of this Amendment shall not directly or indirectly (i) constitute a consent or waiver of any past, present or future breaches, violations or defaults of or under any provisions of the Loan Agreement nor constitute a novation of any of the Obligations under the Loan Agreement, (ii) amend, modify or operate as a waiver of any provision of the Loan Agreement or any right, power or remedy of any Lender or the Collateral Agent, or (iii) constitute a course of dealing or other basis for altering the Loan Agreement or any other Loan Document. Except as set forth herein, each of the Lenders and the Collateral Agent reserves all of its rights, powers, and remedies under the Loan Documents and Requirements of Law. On and after the First Amendment Effective Date, all references in the Loan Agreement to &#8220;this Agreement,&#8221; &#8220;hereto,&#8221; &#8220;hereof,&#8221; &#8220;hereunder,&#8221; or words of like import shall mean the Loan Agreement as amended by this Amendment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>5.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;Successors and Assigns.</b> This Amendment binds and is for the benefit of Borrower, the other Credit Parties, Lenders and Collateral Agent and each of their respective successors and permitted assigns.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>6.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;Governing Law; Venue; Jury Trial Waiver.</b> This Amendment shall be construed in accordance with and governed by the law of the State of New York. The provisions of Section 10 (<i>Choice of law, Venue and Jury Trial Waiver Etc</i>.) of the Loan Agreement shall apply hereto as if more fully set forth herein as if references therein to &#8220;this Agreement&#8221; were references to this Amendment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>7.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;Counterparts.</b> This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or other electronic imaging means (e.g. &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this Amendment. The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in this Amendment shall be deemed to include electronic signatures or electronic records, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for under any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform&nbsp;Electronic Transactions Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[Remainder of Page Intentionally Left Blank]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>IN WITNESS WHEREOF</b>, the undersigned hereto have caused this Amendment to be executed as of the date first written above by each of their officers thereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 216pt;text-indent:-18pt;"><b>UROGEN PHARMA, INC.,</b><br>
<b>as Borrower and a Credit Party on its own behalf and on behalf of each other Credit Party (other than Parent)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 216pt;text-indent:-18pt;">By <u> /s/ Don Kim</u>____________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 198pt;">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Don Kim</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 198pt;">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 216pt;text-indent:-18pt;"><b>UROGEN PHARMA LTD.,</b><br>
<b>as Parent and a Credit Party</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 198pt;">By <u> /s/ Don Kim</u>____________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 198pt;">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Don Kim</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 198pt;">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BIOPHARMA CREDIT PLC,</b><br>
<b>as Collateral Agent</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By: Pharmakon Advisors, LP,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">its Investment Manager</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">By: Pharmakon Management I, LLC,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">its General Partner</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By___<u>/s/ Pedro Gonzalez de Cosio</u>_______________<br>
Name: Pedro Gonzalez de Cosio</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title: Managing Member</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BPCR LIMITED PARTNERSHIP,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>as a Lender</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By: Pharmakon Advisors, LP,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">its Investment Manager</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">By: Pharmakon Management I, LLC,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">its General Partner</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By___<u>/s/ Pedro Gonzalez de Cosio</u>_______________<br>
Name: Pedro Gonzalez de Cosio<br>
Title: Managing Member</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP,</b><br>
<b>as Lender</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BioPharma Credit Investments V GP LLC,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">its general partner</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">By: Pharmakon Advisors, LP,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">its Investment Manager</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By___<u>/s/ Pedro Gonzalez de Cosio</u>_______________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name: Pedro Gonzalez de Cosio</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title: CEO and Managing Member</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT B-1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">THIS TRANCHE A NOTE HAS BEEN ISSUED WITH &#8220;ORIGINAL ISSUE DISCOUNT&#8221; (WITHIN THE MEANING OF SECTION 1273 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED). HOLDERS OF THIS TRANCHE A NOTE SHOULD CONTACT MOLLY HENDERSON, CHIEF FINANCIAL OFFICER, UROGEN PHARMA, 400 ALEXANDER PARK DRIVE, PRINCETON, NEW JERSEY 08540 IN WRITING TO OBTAIN (1) THE ISSUE PRICE AND ISSUE DATE OF THIS TRANCHE A NOTE, (2) THE AMOUNT OF ORIGINAL ISSUE DISCOUNT ON THIS TRANCHE A NOTE AND (3) THE YIELD TO MATURITY OF THIS TRANCHE A NOTE.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AMENDED AND RESTATED SECURED TRANCHE A LOAN PROMISSORY NOTE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$37,500,000.00&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dated: June __, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">FOR VALUE RECEIVED, the undersigned, UROGEN PHARMA, INC., a private limited company incorporated under the laws of England and Wales and limited by shares (&#8220;<b>Borrower</b>&#8221;), HEREBY PROMISES TO PAY to [BPCR LIMITED PARTNERSHIP] [BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP] (&#8220;<b>Lender</b>&#8221;), or its registered assignees, the principal amount of THIRTY-SEVEN MILLION FIVE HUNDRED THOUSAND DOLLARS AND NO CENTS ($37,000,000.00), plus interest on the aggregate unpaid principal amount of this Amended and Restated Secured Tranche A Loan Promissory Note (this &#8220;<b>Tranche A Note</b>&#8221;) at a <i>per annum</i> rate equal to Adjusted Term SOFR <i>plus</i> the Applicable Margin, and in accordance with the terms of the Loan Agreement dated as of March 7, 2022 by and among Borrower, Lender, BioPharma Credit PLC, as Collateral Agent, the other Lenders from time to time party thereto and the other parties thereto (as may be amended, restated, supplemented or otherwise modified from time to time, the &#8220;<b>Loan Agreement</b>&#8221;). If not sooner paid, the entire principal amount, all accrued and unpaid interest hereunder, all due and unpaid Lender Expenses and any other amounts payable under the Loan Documents shall be due and payable on the Term Loan Maturity Date; <u>provided</u>, <u>however</u>, that if such date is not a Business Day, the applicable principal (and any and all other outstanding amounts payable under the Loan Documents) shall be due and payable on the first Business Day immediately following such date. This Amended and Restated Secured Tranche A Loan Promissory Note amends and restates in its entirety that certain Secured Tranche A Loan Promissory Note, dated March 16, 2022, in the aggregate principal amount of Thirty-Seven Million and Five Hundred Thousand Dollars and Zero Cents ($37,500,000.00). Any capitalized term not otherwise defined herein shall have the meaning attributed to such term in the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Borrower shall make four (4) equal quarterly payments of principal of the Tranche A Loan commencing on the first Payment Date that occurs during or immediately after the 17th calendar quarter following the Tranche A Closing Date and continuing through the Term Loan Maturity Date; <u>provided</u>, <u>however</u>, that if any such date is not a Business Day, the applicable principal shall be due and payable on the first Business Day immediately following such date. All unpaid principal with respect to the Tranche A Loan (and, for the avoidance of doubt, all accrued and unpaid interest, all due and unpaid Lender Expenses and any other amounts payable under the Loan Documents) is due and payable in full on the Term Loan Maturity Date; <u>provided</u>, <u>however</u>, that if such date is not a Business Day, the applicable principal (and any and all other outstanding amounts payable under the Loan Documents) shall be due and payable on the first Business Day immediately following such date. Interest shall accrue on this Tranche A Note commencing on, and including, the date of this Tranche A Note, and shall accrue on this Tranche A Note, or any portion thereof, for the day on which this Tranche A Note or such portion is paid. Interest on this Tranche A Note shall be payable in accordance with <u>Section 2.3</u> of the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Principal, interest and all other amounts due with respect to this Tranche A Note are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Tranche A Note.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Loan Agreement, among other things, (a) provides for the making of secured Term Loans by Lender to Borrower, and (b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Tranche A Note may not be prepaid except as set forth in <u>Section 2.2(c)</u> of the Loan Agreement or as expressly provided in <u>Section 8.1</u> of the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Tranche A Note and the obligation of Borrower to repay the unpaid principal amount of this Tranche A Note, interest thereon, and all other amounts due Lender under the Loan Agreement are secured pursuant to the Collateral Documents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement of this Tranche A Note are hereby waived.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">THIS TRANCHE A NOTE SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Note Register; Ownership of Note</u>. The ownership of an interest in this Tranche A Note shall be registered on a record of ownership maintained by Borrower pursuant to <u>Section 2.8(a)</u> of the Loan Agreement. Notwithstanding anything else in this Tranche A Note to the contrary, the right to the principal of, and stated interest on, this Tranche A Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an interest in the obligation. Borrower shall be entitled to treat the registered holder of this Tranche A Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in this Tranche A Note on the part of any other Person.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>[Balance of Page Intentionally Left Blank]</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, Borrower has caused this Tranche A Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BORROWER:</b><br>
<br>
<b>UROGEN PHARMA, INC.,</b><br>
<b>as Borrower</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By: _________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name: _________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title: _________________________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT B-2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AMENDED AND RESTATED SECURED TRANCHE B LOAN PROMISSORY NOTE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$12,500,000.00&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dated: June __, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">FOR VALUE RECEIVED, the undersigned, UROGEN PHARMA, INC., a private limited company incorporated under the laws of England and Wales and limited by shares (&#8220;<b>Borrower</b>&#8221;), HEREBY PROMISES TO PAY to [BPCR LIMITED PARTNERSHIP] [BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP] (&#8220;<b>Lender</b>&#8221;), or its registered assignees, the principal amount of TWELVE MILLION FIVE HUNDRED THOUSAND DOLLARS AND NO CENTS ($12,500,000.00), plus interest on the aggregate unpaid principal amount of this Amended and Restated Secured Tranche B Loan Promissory Note (this &#8220;<b>Tranche B Note</b>&#8221;) at a <i>per annum</i> rate equal to Adjusted Term SOFR <i>plus</i> the Applicable Margin, and in accordance with the terms of the Loan Agreement dated as of March 7, 2022 by and among Borrower, Lender, BioPharma Credit PLC, as Collateral Agent, the other Lenders from time to time party thereto and the other parties thereto (as may be amended, restated, supplemented or otherwise modified from time to time, the &#8220;<b>Loan Agreement</b>&#8221;). If not sooner paid, the entire principal amount, all accrued and unpaid interest hereunder, all due and unpaid Lender Expenses and any other amounts payable under the Loan Documents shall be due and payable on the Term Loan Maturity Date; <u>provided</u>, <u>however</u>, that if such date is not a Business Day, the applicable principal (and any and all other outstanding amounts payable under the Loan Documents) shall be due and payable on the first Business Day immediately following such date. This Amended and Restated Secured Tranche B Loan Promissory Note amends and restates in its entirety that certain Secured Tranche B Loan Promissory Note, dated December 16, 2022, in the aggregate principal amount of twelve million five hundred thousand dollars and zero cents ($12,500,000.00). Any capitalized term not otherwise defined herein shall have the meaning attributed to such term in the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Borrower shall make four (4) equal quarterly payments of principal of the Tranche B Loan commencing on the first Payment Date that occurs during or immediately after the 17th calendar quarter following the Tranche A Closing Date and continuing through the Term Loan Maturity Date; <u>provided</u>, <u>however</u>, that if any such date is not a Business Day, the applicable principal shall be due and payable on the first Business Day immediately following such date. All unpaid principal with respect to the Tranche B Loan (and, for the avoidance of doubt, all accrued and unpaid interest, all due and unpaid Lender Expenses and any other amounts payable under the Loan Documents) is due and payable in full on the Term Loan Maturity Date; <u>provided</u>, <u>however</u>, that if such date is not a Business Day, the applicable principal (and any and all other outstanding amounts payable under the Loan Documents) shall be due and payable on the first Business Day immediately following such date.. Interest shall accrue on this Tranche B Note commencing on, and including, the date of this Tranche B Note, and shall accrue on this Tranche B Note, or any portion thereof, for the day on which this Tranche B Note or such portion is paid. Interest on this Tranche B Note shall be payable in accordance with <u>Section 2.3</u> of the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Principal, interest and all other amounts due with respect to this Tranche B Note are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Tranche B Note.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Loan Agreement, among other things, (a) provides for the making of secured Term Loans by Lender to Borrower, and (b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Tranche B Note may not be prepaid except as set forth in <u>Section 2.2(c)</u> of the Loan Agreement or as expressly provided in <u>Section 8.1</u> of the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Tranche B Note and the obligation of Borrower to repay the unpaid principal amount of this Tranche B Note, interest thereon, and all other amounts due Lender under the Loan Agreement are secured pursuant to the Collateral Documents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement of this Tranche B Note are hereby waived.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">THIS TRANCHE B NOTE SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Note Register; Ownership of Note</u>. The ownership of an interest in this Tranche B Note shall be registered on a record of ownership maintained by Borrower pursuant to <u>Section 2.8(a)</u> of the Loan Agreement. Notwithstanding anything else in this Tranche B Note to the contrary, the right to the principal of, and stated interest on, this Tranche B Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an interest in the obligation. Borrower shall be entitled to treat the registered holder of this Tranche B Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in this Tranche B Note on the part of any other Person.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>[Balance of Page Intentionally Left Blank]</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, Borrower has caused this Tranche B Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BORROWER:</b><br>
<br>
<b>UROGEN PHARMA, INC.,</b><br>
<b>as Borrower</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By: _________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name: _________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title: _________________________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex_532896.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_532896.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: col-resize;">
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt 0pt 0pt 8pt;"><b>Exhibit 31.1</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">I, Elizabeth Barrett, certify that:</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">I have reviewed this quarterly report on Form 10-Q of UroGen Pharma&nbsp;Ltd.;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">3.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(c)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(d)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:</p>
			</td>
			<td style="vertical-align: bottom; width: 45%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">August 10, 2023</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/&nbsp;Elizabeth Barrett</p>
			</td>
		</tr>
		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Elizabeth Barrett</b></p>
			</td>
		</tr>
		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Chief Executive Officer</b></p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Principal Executive Officer)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex_532897.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_532897.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt 0pt 0pt 8pt;"><b>Exhibit 31.2</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt;"><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">I, Don Kim, certify that:</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">I have reviewed this quarterly report on Form 10-Q of UroGen Pharma&nbsp;Ltd.;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">3.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(c)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(d)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: top; width: 2.9%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:</p>
			</td>
			<td style="vertical-align: bottom; width: 45%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">August 10, 2023</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/&nbsp;Don Kim</p>
			</td>
		</tr>
		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Don Kim</b></p>
			</td>
		</tr>
		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 5%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Chief Financial Officer</b></p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Principal Financial and Accounting Officer)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex_532898.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_532898.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In connection with the Quarterly Report of UroGen Pharma&nbsp;Ltd. (the &#8220;Company&#8221;) on Form 10-Q for the period ended <a data-tblloc="5x1" data-tblname="176673" data-tblv="7" id="led176673F2022351649186765816">June 30, 2023</a> as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Elizabeth Barrett, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Arial, Helvetica, sans-serif;">

		<tr style="vertical-align: top; font-family: Arial, Helvetica, sans-serif;">
			<td style="width: 36pt; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="width: 36pt; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(1)</p>
			</td>
			<td style="width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Arial, Helvetica, sans-serif;">

		<tr style="vertical-align: top; font-family: Arial, Helvetica, sans-serif;">
			<td style="width: 36pt; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="width: 36pt; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(2)</p>
			</td>
			<td style="width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 50%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: August 10, 2023</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/&nbsp;Elizabeth Barrett</p>
			</td>
		</tr>
		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 50%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Elizabeth Barrett</b></p>
			</td>
		</tr>
		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 50%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Chief Executive Officer</b></p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Principal Executive Officer)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex_532899.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>ex_532899.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 32.2</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In connection with the Quarterly Report of UroGen Pharma&nbsp;Ltd. (the &#8220;Company&#8221;) on Form 10-Q for the period ended <a data-tblloc="5x1" data-tblname="176673" data-tblv="7" id="led176673F2022351649186785876">June 30, 2023</a> as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Don Kim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Arial, Helvetica, sans-serif;">

		<tr style="vertical-align: top; font-family: Arial, Helvetica, sans-serif;">
			<td style="width: 36pt; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="width: 36pt; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(1)</p>
			</td>
			<td style="width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Arial, Helvetica, sans-serif;">

		<tr style="vertical-align: top; font-family: Arial, Helvetica, sans-serif;">
			<td style="width: 36pt; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="width: 36pt; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(2)</p>
			</td>
			<td style="width: auto; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 50%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: August 10, 2023</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/&nbsp;Don Kim</p>
			</td>
		</tr>
		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 50%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Don Kim</b></p>
			</td>
		</tr>
		<tr style="font-family: Arial, Helvetica, sans-serif;">
			<td style="vertical-align: bottom; width: 50%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 3%; font-family: Arial, Helvetica, sans-serif;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%; font-family: Arial, Helvetica, sans-serif;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Chief Financial Officer</b></p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Principal Financial and Accounting Officer)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>urgn-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:34PM UTC 2023-08-09--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:urgn="http://www.urogen.com/20230630" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.urogen.com/20230630">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.urogen.com/20230630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flow-unaudited" roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-business-and-nature-of-operations" roleURI="http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Business and Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-presentation" roleURI="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies" roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-other-financial-information" roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Other Financial Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inventories" roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-fair-value-measurements" roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-investments" roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-property-and-equipment" roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-prepaid-forward-obligation" roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Prepaid Forward Obligation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-longterm-debt" roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Long-term Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-leases" roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-revenue-from-product-sales" roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Revenue From Product Sales</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-license-and-collaboration-agreements" roleURI="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-shareholders-equity" roleURI="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 14 - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-sharebased-compensation" roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 15 - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes" roleURI="http://www.urogen.com/20230630/role/statement-note-16-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 16 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-related-parties" roleURI="http://www.urogen.com/20230630/role/statement-note-17-related-parties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 17 - Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-commitments-and-contingencies" roleURI="http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 18 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-subsequent-events" roleURI="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 19 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 3 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-other-financial-information-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 4 - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inventories-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 5 - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-fair-value-measurements-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 6 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-investments-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 7 - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-property-and-equipment-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 8 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-prepaid-forward-obligation-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 9 - Prepaid Forward Obligation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-longterm-debt-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 10 - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-leases-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 11 - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-revenue-from-product-sales-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 12 - Revenue From Product Sales (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-sharebased-compensation-tables" roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 15 - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-presentation-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 2 - Basis of Presentation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inventories-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 5 - Inventories (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inventories-inventories-details" roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 5 - Inventories - Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-investments-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 7 - Investments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-investments-summary-of-marketable-securities-details" roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 7 - Investments - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" roleURI="http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-property-and-equipment-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 8 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-property-and-equipment-property-and-equipment-details" roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 8 - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-prepaid-forward-obligation-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 9 - Prepaid Forward Obligation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-longterm-debt-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 10 - Long-term Debt (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-longterm-debt-long-term-debt-details" roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 10 - Long-term Debt - Long Term Debt (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-leases-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 11 - Leases (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-leases-components-of-lease-cost-details" roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 11 - Leases - Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-leases-amounts-of-assets-and-liabilities-details" roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 11 - Leases - Amounts of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-leases-supplemental-information-related-to-leases-details" roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note 11 - Leases - Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-leases-maturities-of-lease-liabilities-details" roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note 11 - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note 11 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-revenue-from-product-sales-net-product-sales-details" roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note 12 - Revenue From Product Sales - Net Product Sales (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">061 - Disclosure - Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-license-and-collaboration-agreements-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">062 - Disclosure - Note 13 - License and Collaboration Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-shareholders-equity-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">063 - Disclosure - Note 14 - Shareholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-sharebased-compensation-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">064 - Disclosure - Note 15 - Share-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">065 - Disclosure - Note 15 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">066 - Disclosure - Note 16 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-subsequent-events-details-textual" roleURI="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">067 - Disclosure - Note 19 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="urgn_AccruedClinicalExpense" name="AccruedClinicalExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_AccruedFinancingOnPrepaidForwardObligation" name="AccruedFinancingOnPrepaidForwardObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="urgn_AccruedResearchAndDevelopmentExpense" name="AccruedResearchAndDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_AccruedSalesReserve" name="AccruedSalesReserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_AccruedSalesReserveCurrent" name="AccruedSalesReserveCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_AccruedSellingGeneralAndAdministrativeExpense" name="AccruedSellingGeneralAndAdministrativeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_AssetsAndLiabilitiesLesseeTableTextBlock" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" name="CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" name="CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" name="CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" name="CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare" name="ClassOfWarrantsOrRightsIssuancePricePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="urgn_CollaborationAgreementTerm" name="CollaborationAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_CompanyOfficesInIsraelMember" name="CompanyOfficesInIsraelMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_ComputersAndSoftwareMember" name="ComputersAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_DebtInstrumentCapitalizedCostsAndDiscounts" name="DebtInstrumentCapitalizedCostsAndDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_DebtInstrumentLIBORFloor" name="DebtInstrumentLIBORFloor" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="urgn_DebtInstrumentPaidAndPayableAmount" name="DebtInstrumentPaidAndPayableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" name="DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" name="DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_FinancingOnPrepaidForwardObligation" name="FinancingOnPrepaidForwardObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_FurnitureMember" name="FurnitureMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_GovernmentSponsoredProgramsReservesMember" name="GovernmentSponsoredProgramsReservesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_InterestAndOtherIncomeNet" name="InterestAndOtherIncomeNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="urgn_InventoryCurrentAndNoncurrentNet" name="InventoryCurrentAndNoncurrentNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="urgn_JelmytoMember" name="JelmytoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" name="LeaseAgreementForOfficeInLosAngelesCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" name="LeaseAgreementForOfficeInPrincetonNewJerseyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" name="LessorOperatingLeasePaymentToBeReceivedAfterNextYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="urgn_LondonInterbankOfferedRateLibor1Member" name="LondonInterbankOfferedRateLibor1Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_MDAndersonMember" name="MDAndersonMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_ManufacturingEquipmentMember" name="ManufacturingEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_MonographCapitalPartnersMember" name="MonographCapitalPartnersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_NonCashNewLeaseLiabilities" name="NonCashNewLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_OtherFinancialInformationTextBlock" name="OtherFinancialInformationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_OtherReservesMember" name="OtherReservesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_PharmakonLoanMember" name="PharmakonLoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_PlacementAgentsAndFinancialAdvisorsFees" name="PlacementAgentsAndFinancialAdvisorsFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_PrefundedWarrantMember" name="PrefundedWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" name="PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" name="PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_PrepaidForwardAgreementMinimumFutureCashFlows" name="PrepaidForwardAgreementMinimumFutureCashFlows" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate" name="PrepaidForwardAgreementMinimumFutureCashFlowsRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="urgn_PrepaidForwardObligation" name="PrepaidForwardObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_PrepaidForwardObligationDisclosureTextBlock" name="PrepaidForwardObligationDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" name="PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_PrepaidForwardObligationPolicyPolicyTextBlock" name="PrepaidForwardObligationPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_ProceedsFromPrepaidForwardArrangementNet" name="ProceedsFromPrepaidForwardArrangementNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="urgn_ProceedsFromPrepaidForwardObligation" name="ProceedsFromPrepaidForwardObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_RTWInvestmentsMember" name="RTWInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_SalesBetween200MillionAnd300MillionMember" name="SalesBetween200MillionAnd300MillionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" name="SalesBetween200MillionAnd300MillionWithFDAApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_SalesOfUpTo200MillionMember" name="SalesOfUpTo200MillionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_SalesOver300MillionMember" name="SalesOver300MillionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_SalesOver300MillionWithFDAApprovalMember" name="SalesOver300MillionWithFDAApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_SalesReserveAccruals" name="SalesReserveAccruals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="urgn_SalesReserveUtilization" name="SalesReserveUtilization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_SalesUpTo200MillionWithFDAApprovalMember" name="SalesUpTo200MillionWithFDAApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" name="ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_ScheduleOfSalesReservesTableTextBlock" name="ScheduleOfSalesReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_SecuredLongTermDebtAdditionalDraw" name="SecuredLongTermDebtAdditionalDraw" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="urgn_SecuredLongTermDebtFirstTranche" name="SecuredLongTermDebtFirstTranche" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="urgn_SecuredOvernightFinancingRateSofrMember" name="SecuredOvernightFinancingRateSofrMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_ShareOptionPlanMember" name="ShareOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_The2019InducementPlanMember" name="The2019InducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_UGN102Member" name="UGN102Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_UroGenPharmaIncMember" name="UroGenPharmaIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-10-longterm-debt-long-term-debt-details" name="statement-statement-note-10-longterm-debt-long-term-debt-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-10-longterm-debt-tables" name="statement-statement-note-10-longterm-debt-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details" name="statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-11-leases-components-of-lease-cost-details" name="statement-statement-note-11-leases-components-of-lease-cost-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details" name="statement-statement-note-11-leases-maturities-of-lease-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details" name="statement-statement-note-11-leases-supplemental-information-related-to-leases-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-11-leases-tables" name="statement-statement-note-11-leases-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" name="statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details" name="statement-statement-note-12-revenue-from-product-sales-net-product-sales-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" name="statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-12-revenue-from-product-sales-tables" name="statement-statement-note-12-revenue-from-product-sales-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" name="statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-15-sharebased-compensation-tables" name="statement-statement-note-15-sharebased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-3-significant-accounting-policies-tables" name="statement-statement-note-3-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" name="statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" name="statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" name="statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-4-other-financial-information-tables" name="statement-statement-note-4-other-financial-information-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-5-inventories-inventories-details" name="statement-statement-note-5-inventories-inventories-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-5-inventories-tables" name="statement-statement-note-5-inventories-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" name="statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-6-fair-value-measurements-tables" name="statement-statement-note-6-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details" name="statement-statement-note-7-investments-summary-of-marketable-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-7-investments-tables" name="statement-statement-note-7-investments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" name="statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details" name="statement-statement-note-8-property-and-equipment-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-8-property-and-equipment-tables" name="statement-statement-note-8-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" name="statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-note-9-prepaid-forward-obligation-tables" name="statement-statement-note-9-prepaid-forward-obligation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="urgn_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>urgn-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:34PM UTC 2023-08-09--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:label="urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FinancingOnPrepaidForwardObligation" xlink:label="urgn_FinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InterestAndOtherIncomeNet" xlink:label="urgn_InterestAndOtherIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpenseLongTermDebt" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="urgn_FinancingOnPrepaidForwardObligation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="urgn_InterestAndOtherIncomeNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedClinicalExpense" xlink:label="urgn_AccruedClinicalExpense" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedResearchAndDevelopmentExpense" xlink:label="urgn_AccruedResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSalesReserveCurrent" xlink:label="urgn_AccruedSalesReserveCurrent" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="urgn_AccruedClinicalExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="urgn_AccruedResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="urgn_AccruedSalesReserveCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InterestAndOtherIncomeNet" xlink:label="urgn_InterestAndOtherIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_InterestAndOtherIncomeNet" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_InterestAndOtherIncomeNet" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details" xlink:href="urgn-20230630.xsd#statement-note-5-inventories-inventories-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InventoryCurrentAndNoncurrentNet" xlink:label="urgn_InventoryCurrentAndNoncurrentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_InventoryCurrentAndNoncurrentNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="urgn_InventoryCurrentAndNoncurrentNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:href="urgn-20230630.xsd#statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Investments" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Investments" xlink:to="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:label="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="urgn_PrepaidForwardObligation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-components-of-lease-cost-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:label="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:href="urgn-20230630.xsd#statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>urgn-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:34PM UTC 2023-08-09--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies" xlink:href="urgn-20230630.xsd#statement-note-18-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-17-related-parties" xlink:href="urgn-20230630.xsd#statement-note-17-related-parties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-17-related-parties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales" xlink:href="urgn-20230630.xsd#statement-note-12-revenue-from-product-sales" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements" xlink:href="urgn-20230630.xsd#statement-note-6-fair-value-measurements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_OtherFinancialInformationTextBlock" xlink:label="urgn_OtherFinancialInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="urgn_OtherFinancialInformationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations" xlink:href="urgn-20230630.xsd#statement-note-1-business-and-nature-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-document-and-entity-information" xlink:href="urgn-20230630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation" xlink:href="urgn-20230630.xsd#statement-note-2-basis-of-presentation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies" xlink:href="urgn-20230630.xsd#statement-note-3-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories" xlink:href="urgn-20230630.xsd#statement-note-5-inventories" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments" xlink:href="urgn-20230630.xsd#statement-note-7-investments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-investments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation" xlink:href="urgn-20230630.xsd#statement-note-9-prepaid-forward-obligation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_JelmytoMember" xlink:label="urgn_JelmytoMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:label="urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_RTWInvestmentsMember" xlink:label="urgn_RTWInvestmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOfUpTo200MillionMember" xlink:label="urgn_SalesOfUpTo200MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionMember" xlink:label="urgn_SalesOver300MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionWithFDAApprovalMember" xlink:label="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:label="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UGN102Member" xlink:label="urgn_UGN102Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_RTWInvestmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesOfUpTo200MillionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="urgn_JelmytoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesOver300MillionMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="urgn_UGN102Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt" xlink:href="urgn-20230630.xsd#statement-note-10-longterm-debt" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LondonInterbankOfferedRateLibor1Member" xlink:label="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredOvernightFinancingRateSofrMember" xlink:label="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases" xlink:href="urgn-20230630.xsd#statement-note-11-leases" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CompanyOfficesInIsraelMember" xlink:label="urgn_CompanyOfficesInIsraelMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:label="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:label="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UroGenPharmaIncMember" xlink:label="urgn_UroGenPharmaIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="urgn_CompanyOfficesInIsraelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="urgn_UroGenPharmaIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements" xlink:href="urgn-20230630.xsd#statement-note-13-license-and-collaboration-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MDAndersonMember" xlink:label="urgn_MDAndersonMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_MDAndersonMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity" xlink:href="urgn-20230630.xsd#statement-note-14-shareholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation" xlink:href="urgn-20230630.xsd#statement-note-15-sharebased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareOptionPlanMember" xlink:label="urgn_ShareOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_The2019InducementPlanMember" xlink:label="urgn_The2019InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="urgn_ShareOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="urgn_The2019InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-16-income-taxes" xlink:href="urgn-20230630.xsd#statement-note-16-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-16-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events" xlink:href="urgn-20230630.xsd#statement-note-19-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MonographCapitalPartnersMember" xlink:label="urgn_MonographCapitalPartnersMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrefundedWarrantMember" xlink:label="urgn_PrefundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="urgn_PrefundedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_MonographCapitalPartnersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies" xlink:href="urgn-20230630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:label="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:label="urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables" xlink:href="urgn-20230630.xsd#statement-note-3-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-tables" xlink:href="urgn-20230630.xsd#statement-note-5-inventories-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables" xlink:href="urgn-20230630.xsd#statement-note-6-fair-value-measurements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-tables" xlink:href="urgn-20230630.xsd#statement-note-7-investments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables" xlink:href="urgn-20230630.xsd#statement-note-9-prepaid-forward-obligation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:label="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables" xlink:href="urgn-20230630.xsd#statement-note-10-longterm-debt-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-tables" xlink:href="urgn-20230630.xsd#statement-note-11-leases-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables" xlink:href="urgn-20230630.xsd#statement-note-12-revenue-from-product-sales-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfSalesReservesTableTextBlock" xlink:label="urgn_ScheduleOfSalesReservesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_ScheduleOfSalesReservesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables" xlink:href="urgn-20230630.xsd#statement-note-15-sharebased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual" xlink:href="urgn-20230630.xsd#statement-note-2-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual" xlink:href="urgn-20230630.xsd#statement-note-3-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual" xlink:href="urgn-20230630.xsd#statement-note-5-inventories-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual" xlink:href="urgn-20230630.xsd#statement-note-7-investments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual" xlink:href="urgn-20230630.xsd#statement-note-9-prepaid-forward-obligation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_JelmytoMember" xlink:label="urgn_JelmytoMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" xlink:label="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" xlink:label="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementMinimumFutureCashFlows" xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlows" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate" xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" xlink:label="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ProceedsFromPrepaidForwardArrangementNet" xlink:label="urgn_ProceedsFromPrepaidForwardArrangementNet" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ProceedsFromPrepaidForwardObligation" xlink:label="urgn_ProceedsFromPrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_RTWInvestmentsMember" xlink:label="urgn_RTWInvestmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOfUpTo200MillionMember" xlink:label="urgn_SalesOfUpTo200MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionMember" xlink:label="urgn_SalesOver300MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionWithFDAApprovalMember" xlink:label="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:label="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UGN102Member" xlink:label="urgn_UGN102Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_RTWInvestmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesOfUpTo200MillionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="urgn_JelmytoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesOver300MillionMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="urgn_UGN102Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ProceedsFromPrepaidForwardObligation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ProceedsFromPrepaidForwardArrangementNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardAgreementMinimumFutureCashFlows" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardObligation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual" xlink:href="urgn-20230630.xsd#statement-note-10-longterm-debt-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentLIBORFloor" xlink:label="urgn_DebtInstrumentLIBORFloor" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LondonInterbankOfferedRateLibor1Member" xlink:label="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredLongTermDebtAdditionalDraw" xlink:label="urgn_SecuredLongTermDebtAdditionalDraw" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredLongTermDebtFirstTranche" xlink:label="urgn_SecuredLongTermDebtFirstTranche" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredOvernightFinancingRateSofrMember" xlink:label="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecuredLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_SecuredLongTermDebtFirstTranche" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_SecuredLongTermDebtAdditionalDraw" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DebtInstrumentLIBORFloor" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual" xlink:href="urgn-20230630.xsd#statement-note-11-leases-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CompanyOfficesInIsraelMember" xlink:label="urgn_CompanyOfficesInIsraelMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:label="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:label="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UroGenPharmaIncMember" xlink:label="urgn_UroGenPharmaIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="urgn_CompanyOfficesInIsraelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="urgn_UroGenPharmaIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubleaseIncome" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual" xlink:href="urgn-20230630.xsd#statement-note-13-license-and-collaboration-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CollaborationAgreementTerm" xlink:label="urgn_CollaborationAgreementTerm" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MDAndersonMember" xlink:label="urgn_MDAndersonMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_MDAndersonMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CollaborationAgreementTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual" xlink:href="urgn-20230630.xsd#statement-note-14-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual" xlink:href="urgn-20230630.xsd#statement-note-15-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareOptionPlanMember" xlink:label="urgn_ShareOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_The2019InducementPlanMember" xlink:label="urgn_The2019InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="urgn_ShareOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="urgn_The2019InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual" xlink:href="urgn-20230630.xsd#statement-note-16-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual" xlink:href="urgn-20230630.xsd#statement-note-19-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ClassOfWarrantsOrRightsIssuancePricePerShare" xlink:label="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MonographCapitalPartnersMember" xlink:label="urgn_MonographCapitalPartnersMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PlacementAgentsAndFinancialAdvisorsFees" xlink:label="urgn_PlacementAgentsAndFinancialAdvisorsFees" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrefundedWarrantMember" xlink:label="urgn_PrefundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="urgn_PrefundedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_MonographCapitalPartnersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PlacementAgentsAndFinancialAdvisorsFees" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:href="urgn-20230630.xsd#statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" xlink:label="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FinancingOnPrepaidForwardObligation" xlink:label="urgn_FinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardObligation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_FinancingOnPrepaidForwardObligation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details" xlink:href="urgn-20230630.xsd#statement-note-10-longterm-debt-long-term-debt-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentCapitalizedCostsAndDiscounts" xlink:label="urgn_DebtInstrumentCapitalizedCostsAndDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentPaidAndPayableAmount" xlink:label="urgn_DebtInstrumentPaidAndPayableAmount" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PharmakonLoanMember" xlink:label="urgn_PharmakonLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="urgn_PharmakonLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DebtInstrumentCapitalizedCostsAndDiscounts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DebtInstrumentPaidAndPayableAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:href="urgn-20230630.xsd#statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ComputersAndSoftwareMember" xlink:label="urgn_ComputersAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FurnitureMember" xlink:label="urgn_FurnitureMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LaboratoryEquipmentMember" xlink:label="urgn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ManufacturingEquipmentMember" xlink:label="urgn_ManufacturingEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_FurnitureMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ManufacturingEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:href="urgn-20230630.xsd#statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSalesReserve" xlink:label="urgn_AccruedSalesReserve" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_GovernmentSponsoredProgramsReservesMember" xlink:label="urgn_GovernmentSponsoredProgramsReservesMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_OtherReservesMember" xlink:label="urgn_OtherReservesMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesReserveAccruals" xlink:label="urgn_SalesReserveAccruals" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesReserveUtilization" xlink:label="urgn_SalesReserveUtilization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="urgn_GovernmentSponsoredProgramsReservesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="urgn_OtherReservesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedSalesReserve" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_SalesReserveAccruals" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_SalesReserveUtilization" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:label="urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NonCashNewLeaseLiabilities" xlink:label="urgn_NonCashNewLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="urgn_NonCashNewLeaseLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FinancingOnPrepaidForwardObligation" xlink:label="urgn_FinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InterestAndOtherIncomeNet" xlink:label="urgn_InterestAndOtherIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="urgn_FinancingOnPrepaidForwardObligation" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpenseLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="urgn_InterestAndOtherIncomeNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedClinicalExpense" xlink:label="urgn_AccruedClinicalExpense" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedResearchAndDevelopmentExpense" xlink:label="urgn_AccruedResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSalesReserveCurrent" xlink:label="urgn_AccruedSalesReserveCurrent" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedSalesReserveCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedClinicalExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InterestAndOtherIncomeNet" xlink:label="urgn_InterestAndOtherIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_InterestAndOtherIncomeNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details" xlink:href="urgn-20230630.xsd#statement-note-5-inventories-inventories-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InventoryCurrentAndNoncurrentNet" xlink:label="urgn_InventoryCurrentAndNoncurrentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_InventoryCurrentAndNoncurrentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:href="urgn-20230630.xsd#statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Investments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ComputersAndSoftwareMember" xlink:label="urgn_ComputersAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FurnitureMember" xlink:label="urgn_FurnitureMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LaboratoryEquipmentMember" xlink:label="urgn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ManufacturingEquipmentMember" xlink:label="urgn_ManufacturingEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_FurnitureMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ManufacturingEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:label="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="urgn_PrepaidForwardObligation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriatedMember" xlink:label="us-gaap_RetainedEarningsAppropriatedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsAppropriatedMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-components-of-lease-cost-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubleaseIncome" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:label="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:href="urgn-20230630.xsd#statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_JelmytoMember" xlink:label="urgn_JelmytoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="urgn_JelmytoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:href="urgn-20230630.xsd#statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details" xlink:href="urgn-20230630.xsd#statement-note-7-investments-summary-of-marketable-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:href="urgn-20230630.xsd#statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>urgn-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:34PM UTC 2023-08-09--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DocumentAndEntityInformation" xlink:label="urgn_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="urgn_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DocumentAndEntityInformation" xlink:to="urgn_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="urgn_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="urgn_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-significant-accounting-policies-policies" xlink:label="urgn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-significant-accounting-policies-policies" xlink:to="urgn_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-3-significant-accounting-policies-tables" xlink:label="urgn_statement-statement-note-3-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-3-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-3-significant-accounting-policies-tables" xlink:to="urgn_statement-statement-note-3-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-4-other-financial-information-tables" xlink:label="urgn_statement-statement-note-4-other-financial-information-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-4-other-financial-information-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Other Financial Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-4-other-financial-information-tables" xlink:to="urgn_statement-statement-note-4-other-financial-information-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-5-inventories-tables" xlink:label="urgn_statement-statement-note-5-inventories-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-5-inventories-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-5-inventories-tables" xlink:to="urgn_statement-statement-note-5-inventories-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities within one year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SecuredLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SecuredLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_SecuredLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-6-fair-value-measurements-tables" xlink:label="urgn_statement-statement-note-6-fair-value-measurements-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-6-fair-value-measurements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Fair Value Measurements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-6-fair-value-measurements-tables" xlink:to="urgn_statement-statement-note-6-fair-value-measurements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-7-investments-tables" xlink:label="urgn_statement-statement-note-7-investments-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-7-investments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-7-investments-tables" xlink:to="urgn_statement-statement-note-7-investments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-8-property-and-equipment-tables" xlink:label="urgn_statement-statement-note-8-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-8-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-8-property-and-equipment-tables" xlink:to="urgn_statement-statement-note-8-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-9-prepaid-forward-obligation-tables" xlink:label="urgn_statement-statement-note-9-prepaid-forward-obligation-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-9-prepaid-forward-obligation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Prepaid Forward Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-9-prepaid-forward-obligation-tables" xlink:to="urgn_statement-statement-note-9-prepaid-forward-obligation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-10-longterm-debt-tables" xlink:label="urgn_statement-statement-note-10-longterm-debt-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-10-longterm-debt-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Long-term Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-10-longterm-debt-tables" xlink:to="urgn_statement-statement-note-10-longterm-debt-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PharmakonLoanMember" xlink:label="urgn_PharmakonLoanMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_PharmakonLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Loan [Member]</link:label>
    <link:label xlink:label="urgn_PharmakonLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Pharmakon loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PharmakonLoanMember" xlink:to="urgn_PharmakonLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-tables" xlink:label="urgn_statement-statement-note-11-leases-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-11-leases-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-11-leases-tables" xlink:to="urgn_statement-statement-note-11-leases-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-12-revenue-from-product-sales-tables" xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Revenue From Product Sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-12-revenue-from-product-sales-tables" xlink:to="urgn_statement-statement-note-12-revenue-from-product-sales-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-15-sharebased-compensation-tables" xlink:label="urgn_statement-statement-note-15-sharebased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-15-sharebased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-15-sharebased-compensation-tables" xlink:to="urgn_statement-statement-note-15-sharebased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:label="urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:to="urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:label="urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:to="urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:label="urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:to="urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-5-inventories-inventories-details" xlink:label="urgn_statement-statement-note-5-inventories-inventories-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-5-inventories-inventories-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Inventories - Inventories (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-5-inventories-inventories-details" xlink:to="urgn_statement-statement-note-5-inventories-inventories-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:label="urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:to="urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details" xlink:label="urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Investments - Summary of Marketable Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details" xlink:to="urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:label="urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:to="urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:label="urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Property and Equipment - Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:to="urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:label="urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:to="urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-10-longterm-debt-long-term-debt-details" xlink:label="urgn_statement-statement-note-10-longterm-debt-long-term-debt-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-10-longterm-debt-long-term-debt-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Long-term Debt - Long Term Debt (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-10-longterm-debt-long-term-debt-details" xlink:to="urgn_statement-statement-note-10-longterm-debt-long-term-debt-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-components-of-lease-cost-details" xlink:label="urgn_statement-statement-note-11-leases-components-of-lease-cost-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-11-leases-components-of-lease-cost-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Leases - Components of Lease Cost (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-11-leases-components-of-lease-cost-details" xlink:to="urgn_statement-statement-note-11-leases-components-of-lease-cost-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:label="urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Leases - Amounts of Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:to="urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:label="urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Leases - Supplemental Information Related to Leases (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:to="urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:label="urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Leases - Maturities of Lease Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:to="urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:label="urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:to="urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Revenue From Product Sales - Net Product Sales (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:to="urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:to="urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:label="urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:type="locator"/>
    <link:label xlink:label="urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:to="urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatements" xlink:label="urgn_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="urgn_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NotesToFinancialStatements" xlink:to="urgn_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="urgn_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="urgn_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USTreasuryAndGovernmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</link:label>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee related accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SecuredDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued other expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseImpairmentLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseImpairmentLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseImpairmentLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubleaseIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SubleaseIncome</link:label>
    <link:label xlink:label="us-gaap_SubleaseIncome-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:label xlink:label="us-gaap_SubleaseIncome-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Investments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Investments</link:label>
    <link:label xlink:label="us-gaap_Investments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecurities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee related accrued expenses</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statements of Comprehensive Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseCost</link:label>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccounting-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate of operating leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCostTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term of operating leases (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term debt at closing of Pharmakon loan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LessorOperatingLeasePaymentsToBeReceived</link:label>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</link:label>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options into ordinary shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options into ordinary shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InventoryCurrentAndNoncurrentNet" xlink:label="urgn_InventoryCurrentAndNoncurrentNet" xlink:type="locator"/>
    <link:label xlink:label="urgn_InventoryCurrentAndNoncurrentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_InventoryCurrentAndNoncurrentNet</link:label>
    <link:label xlink:label="urgn_InventoryCurrentAndNoncurrentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label xlink:label="urgn_InventoryCurrentAndNoncurrentNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of inventory, net of allowances, classified as both current and noncurrent.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_InventoryCurrentAndNoncurrentNet" xlink:to="urgn_InventoryCurrentAndNoncurrentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money market funds, unrealized gains</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on cash and cash equivalents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtTerm</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Shareholders' Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Money market funds, unrealized loss</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on cash and cash equivalents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:to="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total assets at fair value, unrealized losses</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on cash cash equivalents and shorterm investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total assets at fair value, unrealized gains</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on cash cash equivalents and short term investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total assets at fair value, fair value</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value portion of cash cash equivalents and short term investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedInvestmentsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted deposit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseLongTermDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on long-term debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLongTermDebt" xlink:to="us-gaap_InterestExpenseLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiabilityCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid forward obligation</link:label>
    <link:label xlink:label="urgn_PrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Forward Obligation</link:label>
    <link:label xlink:label="urgn_PrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Carrying value of prepaid forward obligation as of December 31, 2021</link:label>
    <link:label xlink:label="urgn_PrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Carrying value of prepaid forward obligation as of December 31, 2022</link:label>
    <link:label xlink:label="urgn_PrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of the prepaid forward obligation as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrepaidForwardObligation" xlink:to="urgn_PrepaidForwardObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InterestAndOtherIncomeNet" xlink:label="urgn_InterestAndOtherIncomeNet" xlink:type="locator"/>
    <link:label xlink:label="urgn_InterestAndOtherIncomeNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income (expense), net</link:label>
    <link:label xlink:label="urgn_InterestAndOtherIncomeNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest and other income (expense), net</link:label>
    <link:label xlink:label="urgn_InterestAndOtherIncomeNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of interest and other income, net of expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_InterestAndOtherIncomeNet" xlink:to="urgn_InterestAndOtherIncomeNet-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FinancingOnPrepaidForwardObligation" xlink:label="urgn_FinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:label xlink:label="urgn_FinancingOnPrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing on prepaid forward obligation</link:label>
    <link:label xlink:label="urgn_FinancingOnPrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Financing on prepaid forward obligation</link:label>
    <link:label xlink:label="urgn_FinancingOnPrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of financing on the preapid forward obligation during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_FinancingOnPrepaidForwardObligation" xlink:to="urgn_FinancingOnPrepaidForwardObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of discount on long-term debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets at fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</link:label>
    <link:label xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization (accretion) on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Director [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds, fair value</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 23,498,617 and 23,129,953 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, par value (in ILS per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ProceedsFromPrepaidForwardArrangementNet" xlink:label="urgn_ProceedsFromPrepaidForwardArrangementNet" xlink:type="locator"/>
    <link:label xlink:label="urgn_ProceedsFromPrepaidForwardArrangementNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_ProceedsFromPrepaidForwardArrangementNet</link:label>
    <link:label xlink:label="urgn_ProceedsFromPrepaidForwardArrangementNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Prepaid Forward Arrangement, Net</link:label>
    <link:label xlink:label="urgn_ProceedsFromPrepaidForwardArrangementNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash inflow from prepaid forward arrangement, net of transaction costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ProceedsFromPrepaidForwardArrangementNet" xlink:to="urgn_ProceedsFromPrepaidForwardArrangementNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures of Non-Cash Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:label="urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:label xlink:label="urgn_AccruedFinancingOnPrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued financing on prepaid forward obligation</link:label>
    <link:label xlink:label="urgn_AccruedFinancingOnPrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of prepaid financing on prepaid forward obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:to="urgn_AccruedFinancingOnPrepaidForwardObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfSalesReservesTableTextBlock" xlink:label="urgn_ScheduleOfSalesReservesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_ScheduleOfSalesReservesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Sales Reserves [Table Text Block]</link:label>
    <link:label xlink:label="urgn_ScheduleOfSalesReservesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure for the schedule of sales reserves.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ScheduleOfSalesReservesTableTextBlock" xlink:to="urgn_ScheduleOfSalesReservesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesReserveAccruals" xlink:label="urgn_SalesReserveAccruals" xlink:type="locator"/>
    <link:label xlink:label="urgn_SalesReserveAccruals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals</link:label>
    <link:label xlink:label="urgn_SalesReserveAccruals-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of sales reserve accruals during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SalesReserveAccruals" xlink:to="urgn_SalesReserveAccruals-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesReserveUtilization" xlink:label="urgn_SalesReserveUtilization" xlink:type="locator"/>
    <link:label xlink:label="urgn_SalesReserveUtilization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Utilizations</link:label>
    <link:label xlink:label="urgn_SalesReserveUtilization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of utilization of sales reserve during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SalesReserveUtilization" xlink:to="urgn_SalesReserveUtilization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_GovernmentSponsoredProgramsReservesMember" xlink:label="urgn_GovernmentSponsoredProgramsReservesMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_GovernmentSponsoredProgramsReservesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Sponsored Programs Reserves [Member]</link:label>
    <link:label xlink:label="urgn_GovernmentSponsoredProgramsReservesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to government sponsored programs reserves.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_GovernmentSponsoredProgramsReservesMember" xlink:to="urgn_GovernmentSponsoredProgramsReservesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:label="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="locator"/>
    <link:label xlink:label="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</link:label>
    <link:label xlink:label="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label xlink:label="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredOvernightFinancingRateSofrMember" xlink:label="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_SecuredOvernightFinancingRateSofrMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label xlink:label="urgn_SecuredOvernightFinancingRateSofrMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate based on U.S. Treasury repurchases between banks.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SecuredOvernightFinancingRateSofrMember" xlink:to="urgn_SecuredOvernightFinancingRateSofrMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LondonInterbankOfferedRateLibor1Member" xlink:label="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="locator"/>
    <link:label xlink:label="urgn_LondonInterbankOfferedRateLibor1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) 1 [Member]</link:label>
    <link:label xlink:label="urgn_LondonInterbankOfferedRateLibor1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate at which a bank borrows funds from other banks in the London interbank market.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LondonInterbankOfferedRateLibor1Member" xlink:to="urgn_LondonInterbankOfferedRateLibor1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_OtherReservesMember" xlink:label="urgn_OtherReservesMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_OtherReservesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Reserves [Member]</link:label>
    <link:label xlink:label="urgn_OtherReservesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to other reserves.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OtherReservesMember" xlink:to="urgn_OtherReservesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSalesReserveCurrent" xlink:label="urgn_AccruedSalesReserveCurrent" xlink:type="locator"/>
    <link:label xlink:label="urgn_AccruedSalesReserveCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued sales reserves</link:label>
    <link:label xlink:label="urgn_AccruedSalesReserveCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of accrued sales reserve classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedSalesReserveCurrent" xlink:to="urgn_AccruedSalesReserveCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:label="urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrepaidForwardObligationPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Forward Obligation Policy [Policy Text Block]</link:label>
    <link:label xlink:label="urgn_PrepaidForwardObligationPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure for accounting policy for prepaid forward obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:to="urgn_PrepaidForwardObligationPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life [Table Text Block]</link:label>
    <link:label xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the useful life of property, plant and equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ManufacturingEquipmentMember" xlink:label="urgn_ManufacturingEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_ManufacturingEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label xlink:label="urgn_ManufacturingEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents manufacturing equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ManufacturingEquipmentMember" xlink:to="urgn_ManufacturingEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FurnitureMember" xlink:label="urgn_FurnitureMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_FurnitureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture [Member[</link:label>
    <link:label xlink:label="urgn_FurnitureMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents furniture.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_FurnitureMember" xlink:to="urgn_FurnitureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ClassOfWarrantsOrRightsIssuancePricePerShare" xlink:label="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare" xlink:type="locator"/>
    <link:label xlink:label="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_ClassOfWarrantsOrRightsIssuancePricePerShare</link:label>
    <link:label xlink:label="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrants or Rights, Issuance Price Per Share (in dollars per share)</link:label>
    <link:label xlink:label="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance price per share for class of warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare" xlink:to="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PlacementAgentsAndFinancialAdvisorsFees" xlink:label="urgn_PlacementAgentsAndFinancialAdvisorsFees" xlink:type="locator"/>
    <link:label xlink:label="urgn_PlacementAgentsAndFinancialAdvisorsFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_PlacementAgentsAndFinancialAdvisorsFees</link:label>
    <link:label xlink:label="urgn_PlacementAgentsAndFinancialAdvisorsFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement Agents and Financial Advisors Fees</link:label>
    <link:label xlink:label="urgn_PlacementAgentsAndFinancialAdvisorsFees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of fees of placement agents and financial advisors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PlacementAgentsAndFinancialAdvisorsFees" xlink:to="urgn_PlacementAgentsAndFinancialAdvisorsFees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:label="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities Policy [Policy Text Block]</link:label>
    <link:label xlink:label="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for cash, cash equivalents and marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:to="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrefundedWarrantMember" xlink:label="urgn_PrefundedWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrefundedWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded Warrant [Member]</link:label>
    <link:label xlink:label="urgn_PrefundedWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents pre-funded warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrefundedWarrantMember" xlink:to="urgn_PrefundedWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LaboratoryEquipmentMember" xlink:label="urgn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="urgn_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents laboratory equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LaboratoryEquipmentMember" xlink:to="urgn_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ComputersAndSoftwareMember" xlink:label="urgn_ComputersAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_ComputersAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:label xlink:label="urgn_ComputersAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents computers and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ComputersAndSoftwareMember" xlink:to="urgn_ComputersAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_OtherFinancialInformationTextBlock" xlink:label="urgn_OtherFinancialInformationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_OtherFinancialInformationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Information [Text Block]</link:label>
    <link:label xlink:label="urgn_OtherFinancialInformationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for other financial information.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OtherFinancialInformationTextBlock" xlink:to="urgn_OtherFinancialInformationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsAndShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total assets at fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Deficit:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:label="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:type="locator"/>
    <link:label xlink:label="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear</link:label>
    <link:label xlink:label="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label xlink:label="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lease payment to be received by lessor for operating lease after the next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:to="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at Beginning of Period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 18)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSalesReserve" xlink:label="urgn_AccruedSalesReserve" xlink:type="locator"/>
    <link:label xlink:label="urgn_AccruedSalesReserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_AccruedSalesReserve</link:label>
    <link:label xlink:label="urgn_AccruedSalesReserve-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="urgn_AccruedSalesReserve-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="urgn_AccruedSalesReserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of accrued sales reserve.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedSalesReserve" xlink:to="urgn_AccruedSalesReserve-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedResearchAndDevelopmentExpense" xlink:label="urgn_AccruedResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="urgn_AccruedResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label xlink:label="urgn_AccruedResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of accrued research and development expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedResearchAndDevelopmentExpense" xlink:to="urgn_AccruedResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GrossProfit</link:label>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedClinicalExpense" xlink:label="urgn_AccruedClinicalExpense" xlink:type="locator"/>
    <link:label xlink:label="urgn_AccruedClinicalExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued clinical expenses</link:label>
    <link:label xlink:label="urgn_AccruedClinicalExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance date of accrued clinical expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedClinicalExpense" xlink:to="urgn_AccruedClinicalExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Obsolescence</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued selling, general and administrative expenses</link:label>
    <link:label xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of accrued selling, general and administrative expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:to="urgn_AccruedSellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="locator"/>
    <link:label xlink:label="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities after one year through three years</link:label>
    <link:label xlink:label="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:to="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issuance cost related to at-the-market issuances</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_RTWInvestmentsMember" xlink:label="urgn_RTWInvestmentsMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_RTWInvestmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RTW Investments [Member]</link:label>
    <link:label xlink:label="urgn_RTWInvestmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RTW Investments (&#8220;RTW&#8221;).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_RTWInvestmentsMember" xlink:to="urgn_RTWInvestmentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:label="urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrepaidForwardObligationDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Forward Obligation Disclosure [Text Block]</link:label>
    <link:label xlink:label="urgn_PrepaidForwardObligationDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the prepaid forward obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:to="urgn_PrepaidForwardObligationDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOfUpTo200MillionMember" xlink:label="urgn_SalesOfUpTo200MillionMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_SalesOfUpTo200MillionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales of Up to $200 Million [Member]</link:label>
    <link:label xlink:label="urgn_SalesOfUpTo200MillionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents sales of up to $200 million.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SalesOfUpTo200MillionMember" xlink:to="urgn_SalesOfUpTo200MillionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_SalesBetween200MillionAnd300MillionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Between $200 Million and $300 Million [Member]</link:label>
    <link:label xlink:label="urgn_SalesBetween200MillionAnd300MillionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents sales between $200 million and $300 million.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SalesBetween200MillionAnd300MillionMember" xlink:to="urgn_SalesBetween200MillionAnd300MillionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionMember" xlink:label="urgn_SalesOver300MillionMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_SalesOver300MillionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Over $300 Million [Member]</link:label>
    <link:label xlink:label="urgn_SalesOver300MillionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents sales over $300 million.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SalesOver300MillionMember" xlink:to="urgn_SalesOver300MillionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" xlink:label="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales</link:label>
    <link:label xlink:label="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Forward Agreement, Future Cash Flows, Increase in Percentage of Net Sales</link:label>
    <link:label xlink:label="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in percentage of net sales for future cash flows under the prepaid forward agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" xlink:to="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ProceedsFromPrepaidForwardObligation" xlink:label="urgn_ProceedsFromPrepaidForwardObligation" xlink:type="locator"/>
    <link:label xlink:label="urgn_ProceedsFromPrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_ProceedsFromPrepaidForwardObligation</link:label>
    <link:label xlink:label="urgn_ProceedsFromPrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Prepaid Forward Obligation</link:label>
    <link:label xlink:label="urgn_ProceedsFromPrepaidForwardObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash inflow for prepaid forward obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ProceedsFromPrepaidForwardObligation" xlink:to="urgn_ProceedsFromPrepaidForwardObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" xlink:label="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales</link:label>
    <link:label xlink:label="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales</link:label>
    <link:label xlink:label="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of net sales for future cash payments under the prepaid forward agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" xlink:to="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UGN102Member" xlink:label="urgn_UGN102Member" xlink:type="locator"/>
    <link:label xlink:label="urgn_UGN102Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UGN-102 [Member]</link:label>
    <link:label xlink:label="urgn_UGN102Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents UGN-102.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_UGN102Member" xlink:to="urgn_UGN102Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementMinimumFutureCashFlows" xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlows" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlows-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_PrepaidForwardAgreementMinimumFutureCashFlows</link:label>
    <link:label xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlows-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Forward Agreement, Minimum Future Cash Flows</link:label>
    <link:label xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlows-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum amount of future cash flows under the prepaid forward agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrepaidForwardAgreementMinimumFutureCashFlows" xlink:to="urgn_PrepaidForwardAgreementMinimumFutureCashFlows-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" xlink:label="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths</link:label>
    <link:label xlink:label="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Forward Obligation, Expected Cash Flows in Next Twelve Months</link:label>
    <link:label xlink:label="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of expected cash flows in the next twelve months for the prepaid forward obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" xlink:to="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriatedMember" xlink:label="us-gaap_RetainedEarningsAppropriatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAppropriatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings, Appropriated [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAppropriatedMember" xlink:to="us-gaap_RetainedEarningsAppropriatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:label="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Activity in the Carrying Value of the Prepaid Forward Liability [Table Text Block]</link:label>
    <link:label xlink:label="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of activity in the carrying value of the prepaid forward liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:to="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options into ordinary shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:label="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_SalesUpTo200MillionWithFDAApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Up to $200 Million with FDA Approval [Member]</link:label>
    <link:label xlink:label="urgn_SalesUpTo200MillionWithFDAApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents sales up to $200 million with FDA approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:to="urgn_SalesUpTo200MillionWithFDAApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Between $200 Million and $300 Million with FDA Approval [Member]</link:label>
    <link:label xlink:label="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents sales between $200 million and $300 million with FDA approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:to="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionWithFDAApprovalMember" xlink:label="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_SalesOver300MillionWithFDAApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Over $300 Million with FDA Approval [Member]</link:label>
    <link:label xlink:label="urgn_SalesOver300MillionWithFDAApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents sales over $300 million with FDA approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:to="urgn_SalesOver300MillionWithFDAApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_JelmytoMember" xlink:label="urgn_JelmytoMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_JelmytoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jelmyto [Member]</link:label>
    <link:label xlink:label="urgn_JelmytoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Jelmyto.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_JelmytoMember" xlink:to="urgn_JelmytoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:label="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Agreement for Office in Los Angeles, California [Member]</link:label>
    <link:label xlink:label="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the lase agreement for office in Los Angeles, California.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:to="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:label="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Agreement for Office in Princeton, New Jersey [Member]</link:label>
    <link:label xlink:label="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents lease agreement for office in Princeton, New Jersey.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:to="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_AssetsAndLiabilitiesLesseeTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label xlink:label="urgn_AssetsAndLiabilitiesLesseeTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of lessee's assets and liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="urgn_AssetsAndLiabilitiesLesseeTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UroGenPharmaIncMember" xlink:label="urgn_UroGenPharmaIncMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_UroGenPharmaIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UroGen Pharma Inc. [Member]</link:label>
    <link:label xlink:label="urgn_UroGenPharmaIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents UroGen Pharma Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_UroGenPharmaIncMember" xlink:to="urgn_UroGenPharmaIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Information Related to Leases [Table Text Block]</link:label>
    <link:label xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of supplemental information related to leases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MonographCapitalPartnersMember" xlink:label="urgn_MonographCapitalPartnersMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_MonographCapitalPartnersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monograph Capital Partners [Member]</link:label>
    <link:label xlink:label="urgn_MonographCapitalPartnersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Monograph Capital Partners.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MonographCapitalPartnersMember" xlink:to="urgn_MonographCapitalPartnersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MDAndersonMember" xlink:label="urgn_MDAndersonMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_MDAndersonMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MD Anderson [Member]</link:label>
    <link:label xlink:label="urgn_MDAndersonMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents MD Anderson.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MDAndersonMember" xlink:to="urgn_MDAndersonMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareOptionPlanMember" xlink:label="urgn_ShareOptionPlanMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_ShareOptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Option Plan [Member]</link:label>
    <link:label xlink:label="urgn_ShareOptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding a share option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ShareOptionPlanMember" xlink:to="urgn_ShareOptionPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:type="locator"/>
    <link:label xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage</link:label>
    <link:label xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Individual Voting Powers, Percentage</link:label>
    <link:label xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the individual voting powers percentage that serves as the threshold beyond which certain pricing criteria will apply.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:type="locator"/>
    <link:label xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower</link:label>
    <link:label xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Percentage of Purchase Price for Individuals Having More than Ten Percent of Combined Voting Power</link:label>
    <link:label xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding the 2017 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CollaborationAgreementTerm" xlink:label="urgn_CollaborationAgreementTerm" xlink:type="locator"/>
    <link:label xlink:label="urgn_CollaborationAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_CollaborationAgreementTerm</link:label>
    <link:label xlink:label="urgn_CollaborationAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Term (Year)</link:label>
    <link:label xlink:label="urgn_CollaborationAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The term of the collaboration agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CollaborationAgreementTerm" xlink:to="urgn_CollaborationAgreementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NonCashNewLeaseLiabilities" xlink:label="urgn_NonCashNewLeaseLiabilities" xlink:type="locator"/>
    <link:label xlink:label="urgn_NonCashNewLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label xlink:label="urgn_NonCashNewLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount include in supplemental disclosures of non-cash activities for new lease liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NonCashNewLeaseLiabilities" xlink:to="urgn_NonCashNewLeaseLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentCarryingAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value of Pharmakon loan as of December 31, 2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentCapitalizedCostsAndDiscounts" xlink:label="urgn_DebtInstrumentCapitalizedCostsAndDiscounts" xlink:type="locator"/>
    <link:label xlink:label="urgn_DebtInstrumentCapitalizedCostsAndDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_DebtInstrumentCapitalizedCostsAndDiscounts</link:label>
    <link:label xlink:label="urgn_DebtInstrumentCapitalizedCostsAndDiscounts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Capitalized costs and discounts</link:label>
    <link:label xlink:label="urgn_DebtInstrumentCapitalizedCostsAndDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents capitalized costs and discounts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DebtInstrumentCapitalizedCostsAndDiscounts" xlink:to="urgn_DebtInstrumentCapitalizedCostsAndDiscounts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentPaidAndPayableAmount" xlink:label="urgn_DebtInstrumentPaidAndPayableAmount" xlink:type="locator"/>
    <link:label xlink:label="urgn_DebtInstrumentPaidAndPayableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_DebtInstrumentPaidAndPayableAmount</link:label>
    <link:label xlink:label="urgn_DebtInstrumentPaidAndPayableAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts paid</link:label>
    <link:label xlink:label="urgn_DebtInstrumentPaidAndPayableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of paid and payable related to debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DebtInstrumentPaidAndPayableAmount" xlink:to="urgn_DebtInstrumentPaidAndPayableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredLongTermDebtAdditionalDraw" xlink:label="urgn_SecuredLongTermDebtAdditionalDraw" xlink:type="locator"/>
    <link:label xlink:label="urgn_SecuredLongTermDebtAdditionalDraw-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_SecuredLongTermDebtAdditionalDraw</link:label>
    <link:label xlink:label="urgn_SecuredLongTermDebtAdditionalDraw-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Long Term Debt, Additional Draw</link:label>
    <link:label xlink:label="urgn_SecuredLongTermDebtAdditionalDraw-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents additional draw under the secured long term debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SecuredLongTermDebtAdditionalDraw" xlink:to="urgn_SecuredLongTermDebtAdditionalDraw-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate" xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate" xlink:type="locator"/>
    <link:label xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate</link:label>
    <link:label xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Forward Agreement, Minimum Future Cash Flows, Rate (Rate)</link:label>
    <link:label xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the rate related to minimum future cash flow.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate" xlink:to="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredLongTermDebtFirstTranche" xlink:label="urgn_SecuredLongTermDebtFirstTranche" xlink:type="locator"/>
    <link:label xlink:label="urgn_SecuredLongTermDebtFirstTranche-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_SecuredLongTermDebtFirstTranche</link:label>
    <link:label xlink:label="urgn_SecuredLongTermDebtFirstTranche-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Long Term Debt, First Tranche</link:label>
    <link:label xlink:label="urgn_SecuredLongTermDebtFirstTranche-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the first tranche related to secured long term debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SecuredLongTermDebtFirstTranche" xlink:to="urgn_SecuredLongTermDebtFirstTranche-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CompanyOfficesInIsraelMember" xlink:label="urgn_CompanyOfficesInIsraelMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_CompanyOfficesInIsraelMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Offices in Israel [Member]</link:label>
    <link:label xlink:label="urgn_CompanyOfficesInIsraelMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents company offices in Israel</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_CompanyOfficesInIsraelMember" xlink:to="urgn_CompanyOfficesInIsraelMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentLIBORFloor" xlink:label="urgn_DebtInstrumentLIBORFloor" xlink:type="locator"/>
    <link:label xlink:label="urgn_DebtInstrumentLIBORFloor-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_DebtInstrumentLIBORFloor</link:label>
    <link:label xlink:label="urgn_DebtInstrumentLIBORFloor-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, LIBOR Floor</link:label>
    <link:label xlink:label="urgn_DebtInstrumentLIBORFloor-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the debt instrument, LIBOR floor.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DebtInstrumentLIBORFloor" xlink:to="urgn_DebtInstrumentLIBORFloor-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_The2019InducementPlanMember" xlink:label="urgn_The2019InducementPlanMember" xlink:type="locator"/>
    <link:label xlink:label="urgn_The2019InducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2019 Inducement Plan [Member]</link:label>
    <link:label xlink:label="urgn_The2019InducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2019 Inducement Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_The2019InducementPlanMember" xlink:to="urgn_The2019InducementPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" xlink:label="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" xlink:type="locator"/>
    <link:label xlink:label="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable</link:label>
    <link:label xlink:label="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts paid and payable (1)</link:label>
    <link:label xlink:label="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of decrease in prepaid forward obligation from amounts paid and payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" xlink:to="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per ordinary share - basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Uncertain tax positions liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of right of use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Shareholders' Deficit</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized cost basis</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>urgn-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:34PM UTC 2023-08-09--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies" xlink:href="urgn-20230630.xsd#statement-note-18-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-17-related-parties" xlink:href="urgn-20230630.xsd#statement-note-17-related-parties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-17-related-parties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales" xlink:href="urgn-20230630.xsd#statement-note-12-revenue-from-product-sales" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements" xlink:href="urgn-20230630.xsd#statement-note-6-fair-value-measurements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_OtherFinancialInformationTextBlock" xlink:label="urgn_OtherFinancialInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="urgn_OtherFinancialInformationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations" xlink:href="urgn-20230630.xsd#statement-note-1-business-and-nature-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-document-and-entity-information" xlink:href="urgn-20230630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation" xlink:href="urgn-20230630.xsd#statement-note-2-basis-of-presentation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies" xlink:href="urgn-20230630.xsd#statement-note-3-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories" xlink:href="urgn-20230630.xsd#statement-note-5-inventories" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments" xlink:href="urgn-20230630.xsd#statement-note-7-investments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-investments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation" xlink:href="urgn-20230630.xsd#statement-note-9-prepaid-forward-obligation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_JelmytoMember" xlink:label="urgn_JelmytoMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:label="urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_RTWInvestmentsMember" xlink:label="urgn_RTWInvestmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOfUpTo200MillionMember" xlink:label="urgn_SalesOfUpTo200MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionMember" xlink:label="urgn_SalesOver300MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionWithFDAApprovalMember" xlink:label="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:label="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UGN102Member" xlink:label="urgn_UGN102Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="urgn_RTWInvestmentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesOfUpTo200MillionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="urgn_JelmytoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesOver300MillionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="urgn_UGN102Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="urgn_PrepaidForwardObligationDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt" xlink:href="urgn-20230630.xsd#statement-note-10-longterm-debt" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LondonInterbankOfferedRateLibor1Member" xlink:label="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredOvernightFinancingRateSofrMember" xlink:label="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SecuredDebtMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases" xlink:href="urgn-20230630.xsd#statement-note-11-leases" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CompanyOfficesInIsraelMember" xlink:label="urgn_CompanyOfficesInIsraelMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:label="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:label="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UroGenPharmaIncMember" xlink:label="urgn_UroGenPharmaIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="urgn_CompanyOfficesInIsraelMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="urgn_UroGenPharmaIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements" xlink:href="urgn-20230630.xsd#statement-note-13-license-and-collaboration-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MDAndersonMember" xlink:label="urgn_MDAndersonMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="urgn_MDAndersonMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity" xlink:href="urgn-20230630.xsd#statement-note-14-shareholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation" xlink:href="urgn-20230630.xsd#statement-note-15-sharebased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareOptionPlanMember" xlink:label="urgn_ShareOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_The2019InducementPlanMember" xlink:label="urgn_The2019InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="urgn_ShareOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="urgn_The2019InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-16-income-taxes" xlink:href="urgn-20230630.xsd#statement-note-16-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-16-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events" xlink:href="urgn-20230630.xsd#statement-note-19-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MonographCapitalPartnersMember" xlink:label="urgn_MonographCapitalPartnersMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NotesToFinancialStatementsAbstract" xlink:label="urgn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrefundedWarrantMember" xlink:label="urgn_PrefundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="urgn_PrefundedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="urgn_MonographCapitalPartnersMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies" xlink:href="urgn-20230630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:label="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:label="urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-significant-accounting-policies-policies" xlink:label="urgn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_PrepaidForwardObligationPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables" xlink:href="urgn-20230630.xsd#statement-note-3-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-3-significant-accounting-policies-tables" xlink:label="urgn_statement-statement-note-3-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-3-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-4-other-financial-information-tables" xlink:label="urgn_statement-statement-note-4-other-financial-information-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-4-other-financial-information-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-tables" xlink:href="urgn-20230630.xsd#statement-note-5-inventories-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-5-inventories-tables" xlink:label="urgn_statement-statement-note-5-inventories-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-5-inventories-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables" xlink:href="urgn-20230630.xsd#statement-note-6-fair-value-measurements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-6-fair-value-measurements-tables" xlink:label="urgn_statement-statement-note-6-fair-value-measurements-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-6-fair-value-measurements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-tables" xlink:href="urgn-20230630.xsd#statement-note-7-investments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-7-investments-tables" xlink:label="urgn_statement-statement-note-7-investments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-7-investments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-8-property-and-equipment-tables" xlink:label="urgn_statement-statement-note-8-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-8-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables" xlink:href="urgn-20230630.xsd#statement-note-9-prepaid-forward-obligation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:label="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-9-prepaid-forward-obligation-tables" xlink:label="urgn_statement-statement-note-9-prepaid-forward-obligation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-9-prepaid-forward-obligation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables" xlink:href="urgn-20230630.xsd#statement-note-10-longterm-debt-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-10-longterm-debt-tables" xlink:label="urgn_statement-statement-note-10-longterm-debt-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-10-longterm-debt-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-tables" xlink:href="urgn-20230630.xsd#statement-note-11-leases-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-tables" xlink:label="urgn_statement-statement-note-11-leases-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-11-leases-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables" xlink:href="urgn-20230630.xsd#statement-note-12-revenue-from-product-sales-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ScheduleOfSalesReservesTableTextBlock" xlink:label="urgn_ScheduleOfSalesReservesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-12-revenue-from-product-sales-tables" xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-12-revenue-from-product-sales-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="urgn_ScheduleOfSalesReservesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables" xlink:href="urgn-20230630.xsd#statement-note-15-sharebased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-15-sharebased-compensation-tables" xlink:label="urgn_statement-statement-note-15-sharebased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-15-sharebased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual" xlink:href="urgn-20230630.xsd#statement-note-2-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual" xlink:href="urgn-20230630.xsd#statement-note-3-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual" xlink:href="urgn-20230630.xsd#statement-note-5-inventories-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual" xlink:href="urgn-20230630.xsd#statement-note-7-investments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual" xlink:href="urgn-20230630.xsd#statement-note-9-prepaid-forward-obligation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_JelmytoMember" xlink:label="urgn_JelmytoMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales" xlink:label="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales" xlink:label="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementMinimumFutureCashFlows" xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlows-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate" xlink:label="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths" xlink:label="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ProceedsFromPrepaidForwardArrangementNet" xlink:label="urgn_ProceedsFromPrepaidForwardArrangementNet-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ProceedsFromPrepaidForwardObligation" xlink:label="urgn_ProceedsFromPrepaidForwardObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_RTWInvestmentsMember" xlink:label="urgn_RTWInvestmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:label="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOfUpTo200MillionMember" xlink:label="urgn_SalesOfUpTo200MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionMember" xlink:label="urgn_SalesOver300MillionMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesOver300MillionWithFDAApprovalMember" xlink:label="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:label="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UGN102Member" xlink:label="urgn_UGN102Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="urgn_RTWInvestmentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesOfUpTo200MillionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="urgn_JelmytoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesBetween200MillionAnd300MillionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesOver300MillionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesUpTo200MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="urgn_UGN102Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="urgn_SalesOver300MillionWithFDAApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ProceedsFromPrepaidForwardObligation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ProceedsFromPrepaidForwardArrangementNet-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardAgreementMinimumFutureCashFlows-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardObligation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual" xlink:href="urgn-20230630.xsd#statement-note-10-longterm-debt-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentLIBORFloor" xlink:label="urgn_DebtInstrumentLIBORFloor-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LondonInterbankOfferedRateLibor1Member" xlink:label="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredLongTermDebtAdditionalDraw" xlink:label="urgn_SecuredLongTermDebtAdditionalDraw-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredLongTermDebtFirstTranche" xlink:label="urgn_SecuredLongTermDebtFirstTranche-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SecuredOvernightFinancingRateSofrMember" xlink:label="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SecuredDebtMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="urgn_LondonInterbankOfferedRateLibor1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="urgn_SecuredOvernightFinancingRateSofrMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecuredLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_SecuredLongTermDebtFirstTranche-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_SecuredLongTermDebtAdditionalDraw-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DebtInstrumentLIBORFloor-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual" xlink:href="urgn-20230630.xsd#statement-note-11-leases-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CompanyOfficesInIsraelMember" xlink:label="urgn_CompanyOfficesInIsraelMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:label="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:label="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_UroGenPharmaIncMember" xlink:label="urgn_UroGenPharmaIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="urgn_CompanyOfficesInIsraelMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="urgn_UroGenPharmaIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubleaseIncome-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual" xlink:href="urgn-20230630.xsd#statement-note-13-license-and-collaboration-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CollaborationAgreementTerm" xlink:label="urgn_CollaborationAgreementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MDAndersonMember" xlink:label="urgn_MDAndersonMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="urgn_MDAndersonMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CollaborationAgreementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual" xlink:href="urgn-20230630.xsd#statement-note-14-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual" xlink:href="urgn-20230630.xsd#statement-note-15-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ShareOptionPlanMember" xlink:label="urgn_ShareOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_The2019InducementPlanMember" xlink:label="urgn_The2019InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="urgn_ShareOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="urgn_The2019InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual" xlink:href="urgn-20230630.xsd#statement-note-16-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual" xlink:href="urgn-20230630.xsd#statement-note-19-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ClassOfWarrantsOrRightsIssuancePricePerShare" xlink:label="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_MonographCapitalPartnersMember" xlink:label="urgn_MonographCapitalPartnersMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NoteToFinancialStatementDetailsTextual" xlink:label="urgn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PlacementAgentsAndFinancialAdvisorsFees" xlink:label="urgn_PlacementAgentsAndFinancialAdvisorsFees-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrefundedWarrantMember" xlink:label="urgn_PrefundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="urgn_PrefundedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="urgn_MonographCapitalPartnersMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_ClassOfWarrantsOrRightsIssuancePricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PlacementAgentsAndFinancialAdvisorsFees-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:href="urgn-20230630.xsd#statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable" xlink:label="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable-n8" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FinancingOnPrepaidForwardObligation" xlink:label="urgn_FinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation-4" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation-5" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:label="urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardObligation-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_FinancingOnPrepaidForwardObligation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_PrepaidForwardObligation-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details" xlink:href="urgn-20230630.xsd#statement-note-10-longterm-debt-long-term-debt-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentCapitalizedCostsAndDiscounts" xlink:label="urgn_DebtInstrumentCapitalizedCostsAndDiscounts-n8" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtInstrumentPaidAndPayableAmount" xlink:label="urgn_DebtInstrumentPaidAndPayableAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PharmakonLoanMember" xlink:label="urgn_PharmakonLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-10-longterm-debt-long-term-debt-details" xlink:label="urgn_statement-statement-note-10-longterm-debt-long-term-debt-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-10-longterm-debt-long-term-debt-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="urgn_PharmakonLoanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DebtInstrumentCapitalizedCostsAndDiscounts-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DebtInstrumentPaidAndPayableAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:href="urgn-20230630.xsd#statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ComputersAndSoftwareMember" xlink:label="urgn_ComputersAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FurnitureMember" xlink:label="urgn_FurnitureMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LaboratoryEquipmentMember" xlink:label="urgn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ManufacturingEquipmentMember" xlink:label="urgn_ManufacturingEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:label="urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="urgn_ComputersAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="urgn_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="urgn_FurnitureMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="urgn_ManufacturingEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:href="urgn-20230630.xsd#statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSalesReserve" xlink:label="urgn_AccruedSalesReserve-4" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSalesReserve" xlink:label="urgn_AccruedSalesReserve-5" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_GovernmentSponsoredProgramsReservesMember" xlink:label="urgn_GovernmentSponsoredProgramsReservesMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_OtherReservesMember" xlink:label="urgn_OtherReservesMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesReserveAccruals" xlink:label="urgn_SalesReserveAccruals" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_SalesReserveUtilization" xlink:label="urgn_SalesReserveUtilization" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="urgn_GovernmentSponsoredProgramsReservesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="urgn_OtherReservesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedSalesReserve-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_SalesReserveAccruals" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_SalesReserveUtilization" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedSalesReserve-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:label="urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_NonCashNewLeaseLiabilities" xlink:label="urgn_NonCashNewLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="urgn_AccruedFinancingOnPrepaidForwardObligation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="urgn_NonCashNewLeaseLiabilities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FinancingOnPrepaidForwardObligation" xlink:label="urgn_FinancingOnPrepaidForwardObligation-n8" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InterestAndOtherIncomeNet" xlink:label="urgn_InterestAndOtherIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="urgn_FinancingOnPrepaidForwardObligation-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpenseLongTermDebt-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="urgn_InterestAndOtherIncomeNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedClinicalExpense" xlink:label="urgn_AccruedClinicalExpense" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedResearchAndDevelopmentExpense" xlink:label="urgn_AccruedResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSalesReserveCurrent" xlink:label="urgn_AccruedSalesReserveCurrent" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:label="urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:label="urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedSalesReserveCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedClinicalExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_AccruedSellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:href="urgn-20230630.xsd#statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InterestAndOtherIncomeNet" xlink:label="urgn_InterestAndOtherIncomeNet-3" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:label="urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_InterestAndOtherIncomeNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details" xlink:href="urgn-20230630.xsd#statement-note-5-inventories-inventories-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_InventoryCurrentAndNoncurrentNet" xlink:label="urgn_InventoryCurrentAndNoncurrentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-5-inventories-inventories-details" xlink:label="urgn_statement-statement-note-5-inventories-inventories-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-5-inventories-inventories-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_InventoryCurrentAndNoncurrentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:href="urgn-20230630.xsd#statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:label="urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Investments-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:href="urgn-20230630.xsd#statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ComputersAndSoftwareMember" xlink:label="urgn_ComputersAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_FurnitureMember" xlink:label="urgn_FurnitureMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LaboratoryEquipmentMember" xlink:label="urgn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_ManufacturingEquipmentMember" xlink:label="urgn_ManufacturingEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:label="urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="urgn_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="urgn_ComputersAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="urgn_FurnitureMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="urgn_ManufacturingEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:label="urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear" xlink:label="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:label="urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_PrepaidForwardObligation" xlink:label="urgn_PrepaidForwardObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="urgn_PrepaidForwardObligation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" xlink:href="urgn-20230630.xsd#statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriatedMember" xlink:label="us-gaap_RetainedEarningsAppropriatedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsAppropriatedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-components-of-lease-cost-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-components-of-lease-cost-details" xlink:label="urgn_statement-statement-note-11-leases-components-of-lease-cost-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-11-leases-components-of-lease-cost-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubleaseIncome-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:label="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:label="urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:href="urgn-20230630.xsd#statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_JelmytoMember" xlink:label="urgn_JelmytoMember" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:label="urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="urgn_JelmytoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:href="urgn-20230630.xsd#statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:label="urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details" xlink:href="urgn-20230630.xsd#statement-note-7-investments-summary-of-marketable-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:label="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure-1" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details" xlink:label="urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:href="urgn-20230630.xsd#statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:label="urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:href="urgn-20230630.xsd#statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="urgn-20230630.xsd#urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:label="urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647667680752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001668243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UroGen Pharma Ltd. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1460746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Alexander Park Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">768-9780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value NIS 0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">URGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,282,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474971216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,127<span></span>
</td>
<td class="nump">$ 55,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">27,174<span></span>
</td>
<td class="nump">44,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">15,505<span></span>
</td>
<td class="nump">12,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">4,988<span></span>
</td>
<td class="nump">4,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,723<span></span>
</td>
<td class="nump">11,101<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">81,333<span></span>
</td>
<td class="nump">128,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">910<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted deposit</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">2,107<span></span>
</td>
<td class="nump">2,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">7,970<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2,817<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">95,361<span></span>
</td>
<td class="nump">135,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">16,403<span></span>
</td>
<td class="nump">12,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related accrued expenses</a></td>
<td class="nump">6,721<span></span>
</td>
<td class="nump">8,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,641<span></span>
</td>
<td class="nump">3,276<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">26,765<span></span>
</td>
<td class="nump">23,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardObligation', window );">Prepaid forward obligation</a></td>
<td class="nump">104,507<span></span>
</td>
<td class="nump">98,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">98,296<span></span>
</td>
<td class="nump">97,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Uncertain tax positions liability</a></td>
<td class="nump">3,018<span></span>
</td>
<td class="nump">3,018<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">233,795<span></span>
</td>
<td class="nump">224,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 23,498,617 and 23,129,953 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">493,109<span></span>
</td>
<td class="nump">487,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(631,453)<span></span>
</td>
<td class="num">(577,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Deficit</a></td>
<td class="num">(138,434)<span></span>
</td>
<td class="num">(89,361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Deficit</a></td>
<td class="nump">$ 95,361<span></span>
</td>
<td class="nump">$ 135,619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the prepaid forward obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474973312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in ILS per share)</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued (in shares)</a></td>
<td class="nump">23,498,617<span></span>
</td>
<td class="nump">23,129,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding (in shares)</a></td>
<td class="nump">23,498,617<span></span>
</td>
<td class="nump">23,129,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476033696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 21,139<span></span>
</td>
<td class="nump">$ 16,604<span></span>
</td>
<td class="nump">$ 38,331<span></span>
</td>
<td class="nump">$ 30,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
<td class="nump">4,708<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">18,696<span></span>
</td>
<td class="nump">14,758<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
<td class="nump">26,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">11,584<span></span>
</td>
<td class="nump">12,640<span></span>
</td>
<td class="nump">24,082<span></span>
</td>
<td class="nump">25,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">22,494<span></span>
</td>
<td class="nump">20,833<span></span>
</td>
<td class="nump">46,968<span></span>
</td>
<td class="nump">42,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(15,382)<span></span>
</td>
<td class="num">(18,715)<span></span>
</td>
<td class="num">(37,427)<span></span>
</td>
<td class="num">(40,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_FinancingOnPrepaidForwardObligation', window );">Financing on prepaid forward obligation</a></td>
<td class="num">(5,344)<span></span>
</td>
<td class="num">(5,833)<span></span>
</td>
<td class="num">(10,568)<span></span>
</td>
<td class="num">(11,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense on long-term debt</a></td>
<td class="num">(3,761)<span></span>
</td>
<td class="num">(2,239)<span></span>
</td>
<td class="num">(7,314)<span></span>
</td>
<td class="num">(2,521)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_InterestAndOtherIncomeNet', window );">Interest and other income (expense), net</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(24,082)<span></span>
</td>
<td class="num">(26,659)<span></span>
</td>
<td class="num">(54,274)<span></span>
</td>
<td class="num">(54,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(24,136)<span></span>
</td>
<td class="num">(26,691)<span></span>
</td>
<td class="num">(54,349)<span></span>
</td>
<td class="num">(55,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,136)<span></span>
</td>
<td class="num">(26,691)<span></span>
</td>
<td class="num">(54,349)<span></span>
</td>
<td class="num">(55,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(109)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (24,245)<span></span>
</td>
<td class="num">$ (26,678)<span></span>
</td>
<td class="num">$ (54,396)<span></span>
</td>
<td class="num">$ (55,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
<td class="num">$ (2.33)<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)</a></td>
<td class="nump">23,462,016<span></span>
</td>
<td class="nump">22,703,572<span></span>
</td>
<td class="nump">23,371,878<span></span>
</td>
<td class="nump">22,667,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_FinancingOnPrepaidForwardObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financing on the preapid forward obligation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_FinancingOnPrepaidForwardObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_InterestAndOtherIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other income, net of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_InterestAndOtherIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476152656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings, Appropriated [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">22,462,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 475,698<span></span>
</td>
<td class="num">$ (467,321)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="nump">$ 8,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares (in shares)</a></td>
<td class="nump">264,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,083)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">22,727,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">481,485<span></span>
</td>
<td class="num">(522,404)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(40,913)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">22,682,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">478,646<span></span>
</td>
<td class="num">(495,713)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(17,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares (in shares)</a></td>
<td class="nump">45,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,691)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">22,727,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">481,485<span></span>
</td>
<td class="num">(522,404)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(40,913)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">23,129,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">487,787<span></span>
</td>
<td class="num">(577,104)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(89,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares (in shares)</a></td>
<td class="nump">368,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,349)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">23,498,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">493,109<span></span>
</td>
<td class="num">(631,453)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
<td class="num">(138,434)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">23,440,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">490,744<span></span>
</td>
<td class="num">(607,317)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(116,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares (in shares)</a></td>
<td class="nump">58,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,136)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">23,498,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 493,109<span></span>
</td>
<td class="num">$ (631,453)<span></span>
</td>
<td class="num">$ (154)<span></span>
</td>
<td class="num">$ (138,434)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647475991072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,349)<span></span>
</td>
<td class="num">$ (55,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Obsolescence</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedFinancingOnPrepaidForwardObligation', window );">Accrued financing on prepaid forward obligation</a></td>
<td class="nump">5,982<span></span>
</td>
<td class="nump">8,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization (accretion) on marketable securities</a></td>
<td class="num">(664)<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,508<span></span>
</td>
<td class="nump">5,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of discount on long-term debt</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use assets</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(663)<span></span>
</td>
<td class="num">(480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,801)<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,622)<span></span>
</td>
<td class="num">(2,958)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">4,020<span></span>
</td>
<td class="num">(3,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Employee related accrued expenses</a></td>
<td class="num">(1,536)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(504)<span></span>
</td>
<td class="num">(574)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46,081)<span></span>
</td>
<td class="num">(48,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(24,176)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">34,204<span></span>
</td>
<td class="nump">13,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">9,990<span></span>
</td>
<td class="nump">13,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options into ordinary shares</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost related to at-the-market issuances</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">70,665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (Decrease) in Cash and Cash Equivalents</a></td>
<td class="num">(35,277)<span></span>
</td>
<td class="nump">35,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, Cash Equivalents and Restricted Cash at Beginning of Period</a></td>
<td class="nump">56,220<span></span>
</td>
<td class="nump">45,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">20,943<span></span>
</td>
<td class="nump">81,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_NonCashNewLeaseLiabilities', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedFinancingOnPrepaidForwardObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid financing on prepaid forward obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedFinancingOnPrepaidForwardObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_NonCashNewLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount include in supplemental disclosures of non-cash activities for new lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_NonCashNewLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479323888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Business and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>&#8211;<b> Business and Nature of Operations</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in&#160;<em style="font: inherit;"> April 2004 (</em>&#8220;UPL&#8221;).</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma,&#160;Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in&#160;<em style="font: inherit;"> October 2015&#160;</em>and began operating in&#160;<em style="font: inherit;"> February 2016 (</em>&#8220;UPI&#8221;).</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the &#8220;Company&#8221;) is a biotechnology company dedicated to developing and commercializing&#160;innovative&#160;solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company&#8217;s&#160;<em style="font: inherit;">first</em>&#160;commercial product,&#160;<i>Jelmyto</i>&#160;(mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em>&#160;clinical development of UGN-<em style="font: inherit;">102,</em>&#160;and raising capital to support and expand these activities.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On&#160;<em style="font: inherit;"> April 15, 2020,&#160;</em>the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted expedited approval for&#160;<i>Jelmyto</i>, a&#160;<em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (&#8220;low-grade UTUC&#8221;).&#160;<i>Jelmyto</i>&#160;consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release&#160;<i>RTGel</i>&#160;technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474993008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Accounting [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>&#8211;<b> Basis of Presentation</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company&#8217;s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company&#8217;s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on <em style="font: inherit;"> March 24, 2023.</em></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color:#ffffff;">f $631.5&#160;</span>million and $577.1&#160;million as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan.&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for the next <em style="font: inherit;">12</em> months from the date the financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a&#160;going&#160;concern. The Company&#8217;s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from <i>Jelmyto</i> product sales and develop UGN-<em style="font: inherit;">102.</em>&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">26,</em> <em style="font: inherit;">2023,</em> the Company entered into a private placement transaction with certain institutional and other accredited investors pursuant to which the Company agreed to sell its ordinary shares and pre-funded warrants to purchase ordinary shares to the investors, for aggregate&#160;gross proceeds of $120.0 million.&#160; See Note <em style="font: inherit;">19</em> for further discussion regarding the private placement transaction.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on the Company's cash, cash equivalents and marketable securities as of <em style="font: inherit;"> June 30, 2023, </em>together with management&#8217;s cash flow projections and the net proceeds to the Company from its private placement transaction in <em style="font: inherit;"> July 2023, </em>the Company believes that it has sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these financial statements. The Company will&#160;need to raise additional capital in the future. There can be&#160;<em style="font: inherit;">no</em>&#160;assurances that the Company will be able to secure such additional financing if at all, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is&#160;<em style="font: inherit;">not</em>&#160;successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647566545792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">3</em> </b>&#8211;<b> Significant Accounting Policies</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Principles of Consolidation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company's condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Functional Currency</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The U.S. dollar (&#8220;Dollar&#8221;) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the condensed consolidated statements of operations as &#8220;Interest and other income (expense), net.&#8221;</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cash and Cash Equivalents; Marketable Securities</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company presents all highly liquid investments with an original maturity of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents. Cash and cash equivalents generally consist of money market funds and bank money market accounts and are stated at cost, which approximates fair value.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents and marketable securities totaled $55.3&#160;million as of <em style="font: inherit;"> June 30, 2023</em>. The Company accounts for its investments, which include&#160;cash equivalents and marketable securities,&#160;as available-for-sale in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic <em style="font: inherit;">320,</em> &#8220;Investments &#8212; Debt and Equity Securities&#8221;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#8217; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certain short-term investments are valued using models or other valuation methodologies that use Level <em style="font: inherit;">2</em> inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has <em style="font: inherit;">not</em> been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash is related primarily to cash held to secure corporate credit cards; restricted deposits are related to cash held to secure leases.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the United States. Deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than <em style="font: inherit;">not</em> that the deferred taxes will <em style="font: inherit;">not</em> be realized in the foreseeable future.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company follows a <em style="font: inherit;">two</em>-step approach in recognizing and measuring uncertain tax positions. After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-<em style="font: inherit;">not</em> chance of being sustained), ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">30</em>-<em style="font: inherit;">7</em> requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than <em style="font: inherit;">50%</em> likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. See Note <em style="font: inherit;">16</em>&#160;for further discussion related to income taxes.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Inventory</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For <i>Jelmyto</i>, the Company commenced capitalization of inventory at the receipt of FDA approval.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories<i>.</i></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i></i></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment are depreciated over the following useful lives (in years):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Useful Lives</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computers and software</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c101505219">3</span></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3 - 6.5</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5 - 16.5</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2 - 10</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note <em style="font: inherit;">8</em> for further discussion regarding property and equipment.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Prepaid Forward Obligation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is party to a transaction with RTW Investments (the &#8220;RTW Transaction&#8221;) in which the Company received funds to support the continued launch of <i>Jelmyto</i> and the development of UGN-<em style="font: inherit;">102</em> in return for tiered, future cash payments based on net sales of <i>Jelmyto</i> and UGN-<em style="font: inherit;">102,</em> if approved by the FDA. The net proceeds received under the RTW Transaction were recognized as a long-term liability. The Company recognizes the current cash payable amounts under the arrangement within other current liabilities on the condensed consolidated balance sheets. The subsequent measurement for the liability follows the accounting&#160;principles defined in ASC Topic <em style="font: inherit;">835</em>-<em style="font: inherit;">30,</em> &#8220;Imputation of Interest&#8221;. See Note <em style="font: inherit;">9</em> for further discussion related to the prepaid forward obligation.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Long-Term Debt</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is party to a loan agreement with funds managed by Pharmakon Advisors, L.P. (&#8220;Pharmakon&#8221;). The Company recognizes interest expense in current earnings, and accrued interest within other current liabilities on the condensed consolidated balance sheets. The Company recognizes capitalized financing expenses as a direct offset to the long-term debt on the Company's condensed consolidated balance sheets, and amortizes them over the term of the debt using the effective interest method. See Note <em style="font: inherit;">10</em> for further discussion related to long-term debt.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Leases</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has <em style="font: inherit;">no</em> finance leases.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company accounts for leases in accordance with ASC Topic <em style="font: inherit;">842,</em> &#8220;Leases&#8221;<i>.</i> The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right-of-use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s lease terms <em style="font: inherit;"> may </em>include options to extend the lease. The lease extensions are included in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise that option.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Because most of the Company&#8217;s leases do <em style="font: inherit;">not</em> provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ROU assets for operating leases are periodically reviewed for impairment losses under ASC <em style="font: inherit;">360</em>-<em style="font: inherit;">10,</em> &#8220;Property, Plant, and Equipment&#8221;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Revenue</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Product sales from <i>Jelmyto</i> are recognized as revenue under ASC <em style="font: inherit;">606</em> at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of <i>Jelmyto</i> are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. Net revenue recognized includes gross revenue and management&#8217;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to <em style="font: inherit;">340b</em> drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company&#8217;s copay assistance program, and Medicare refund for discarded drug, which are estimated based on the Company&#8217;s historical experience.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Research and Development Expenses</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to <em style="font: inherit;">third</em> parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when such development milestone results are achieved.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Selling,</i></b> <b><i>General and Administrative Expenses</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses consist&#160;primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services&#160;and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by <em style="font: inherit;">third</em> parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Share-Based Compensation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#8220;RSU&#8221;) equaled the closing price of the Company&#8217;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic <em style="font: inherit;">718,</em> &#8220;Compensation&#8212;Stock Compensation&#8221;.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Net Loss per Ordinary Share</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i></i></b></p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Recently Adopted Issued Pronouncements</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are <em style="font: inherit;">not</em> applicable to the Company.</p><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479427808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_OtherFinancialInformationTextBlock', window );">Other Financial Information [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">4</em> </b>&#8211;<b> Other Financial Information</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Accounts Payable and Accrued Expenses</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable and accrued expenses consisted&#160;of the following as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>&#160;(in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,659</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">5,527</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued sales reserves</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,721</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">618</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,054</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,853</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued research and development expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,003</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,285</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,836</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,609</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued other expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,130</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">491</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,403</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,383</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Interest and Other Income (Expense), Net</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest and other income (expense), net consisted of the following as of <em style="font: inherit;"> June 30, 2023 </em>and <em style="font: inherit;">2022</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,080</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense), net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(45</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">98</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total interest and other income (expense), net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,035</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">126</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OtherFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OtherFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479314928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">5</em> </b>&#8211;<b> Inventories</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inventories consisted of the following as of&#160;<em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">5,363</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,676</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,072</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,019</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,435</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,695</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 2%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p> </td><td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup>&#160;$2.4&#160;million and $2.4&#160;million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;"> December 31, 2022, </em>respectively. Changes in non-current assets are reflected on the condensed consolidated statements of cash flows within the caption of other non-current assets.&#160;</p> </td></tr>
</tbody></table>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479484768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">6</em> </b>&#8211;<b> Fair Value Measurements</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As a basis for considering such assumptions, a <em style="font: inherit;">three</em>-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;">&#160;</td><td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Level <em style="font: inherit;">1:</em></p> </td><td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;">&#160;</td><td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Level <em style="font: inherit;">2:</em></p> </td><td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are <em style="font: inherit;">not</em> active.</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-family: Arial, Helvetica, sans-serif;"><td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;">&#160;</td><td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Level <em style="font: inherit;">3:</em></p> </td><td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The carrying amounts of the Company&#8217;s cash, restricted cash, other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these assets and liabilities.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The carrying value of the prepaid forward obligation (See Note <em style="font: inherit;">9</em> - Prepaid Forward Obligation) approximates its fair value.&#160;The Company estimated&#160;the fair value of the prepaid forward obligation using Level <em style="font: inherit;">3</em> inputs, including internally developed financial forecasts and management's estimate of&#160;probability of success related to product candidates, and determined&#160;that the effective interest rate in the obligation approximates market rates for loans with similar terms and risk characteristics.&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company estimated the fair value of&#160;long-term debt (see Note <em style="font: inherit;">10</em> - Long-Term Debt)&#160;using the income approach with Level <em style="font: inherit;">3</em> inputs. The Company estimated future floating rate interest payments using a forward curve of a <em style="font: inherit;">three</em>-month benchmark rate, and estimated fair value based on publicly available data reported in the financial statements of publicly traded venture lending companies. Based on a reasonable range of yields for debt instruments of similar tenor in a similar industry, the Company determined that the carrying value of the long-term debt on the Company's balance sheet approximates its fair value.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">No</em> transfers between levels have occurred during the periods presented.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets measured at fair value on a recurring basis based on Level <em style="font: inherit;">1</em> and Level <em style="font: inherit;">2</em> fair value measurement criteria as of <em style="font: inherit;"> June 30, 2023</em> are as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements Using</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Quoted Prices</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Significant</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">in Active</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Balance as of</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Markets for</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Observable</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Identical Assets</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Inputs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Assets:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Cash equivalents</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Money market funds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">596</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">596</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Marketable securities</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">18,915</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">18,915</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">6,485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">6,485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">2,011</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">2,011</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">7,733</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,733</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">35,144</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,915</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,229</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Total assets at fair value</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">35,740</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">19,511</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">16,229</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets measured at fair value on a recurring basis based on Level <em style="font: inherit;">1</em> and Level <em style="font: inherit;">2</em> fair value measurement criteria as of <em style="font: inherit;"> December 31, 2022</em> are as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements Using</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Quoted Prices</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Significant</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">in Active</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Balance as of</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Markets for</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Observable</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Identical Assets</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Inputs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">28,693</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">28,693</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,387</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,387</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">9,392</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">9,392</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,084</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,084</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,556</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,693</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,863</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s investments in U.S. government bonds and money market funds are measured based on publicly available quoted market prices for identical securities as of <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023</em> and <em style="font: inherit;"> December 31, 2022. </em>The Company's investments in corporate bonds, commercial paper and certificates of deposits are measured based on quotes from market makers for similar items in active markets.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479531312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">7</em> </b>&#8211;<b>&#160;Investments</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table summarizes the Company&#8217;s investments as of <em style="font: inherit;"> June 30, 2023</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Amortized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Cost Basis</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Gains</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Losses</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 48%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Cash equivalents</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">596</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">596</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Marketable securities:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">18,991</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(76</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">18,915</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">6,548</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(63</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">6,485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,014</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(3</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,011</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">7,745</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(13</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">7,733</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,298</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(155</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,144</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets at fair value</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,894</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(155</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,740</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company classifies its investments as available-for-sale, and they consist entirely of debt securities. As of <em style="font: inherit;"> June 30, 2023</em>, the amortized cost of investments included an immaterial amount of accrued interest. As of <em style="font: inherit;"> June 30, 2023</em>, marketable securities were&#160;in a net unrealized loss position.&#160;Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss.&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of&#160;<em style="font: inherit;"> June 30, 2023</em>, the aggregate fair value of investments held by the Company in an unrealized loss position was $33.9 million&#160;which consisted of&#160;<em style="font: inherit;">38</em> securities.&#160;The unrealized loss was primarily driven by rising interest rates. The Company does <em style="font: inherit;">not</em> expect to settle the debentures at a price less than the amortized cost basis of the investment; the Company expects to recover the entire amortized cost basis of the security. In accordance with the Company&#8217;s general investment strategy, the Company does <em style="font: inherit;">not</em> intend to sell the investments before maturity. As of&#160;<em style="font: inherit;"> June 30, 2023</em>, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and <em style="font: inherit;">no</em> allowance for credit losses were recognized in the period.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s investments&#160;as of <em style="font: inherit;"> June 30, 2023</em> mature at various dates through <em style="font: inherit;"> January 2026. </em>The fair values of investments&#160;by contractual maturity consist of the following (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturities within one year</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">27,770</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">44,556</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturities after one year through three years</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,970</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,740</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,556</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</p>
   <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479329376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">8</em> </b>&#8211;<b> Property and Equipment</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, consists of the following as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">456</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">452</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,195</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,168</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">610</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">602</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">617</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">617</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">607</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">608</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,447</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,575</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,150</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">910</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,297</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciation and amortization expense was $0.2&#160;million and $0.4 million for the&#160;<em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em> and $0.2&#160;million and $0.4 million for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em>.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479435008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Prepaid Forward Obligation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardObligationDisclosureTextBlock', window );">Prepaid Forward Obligation Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">9</em> </b>&#8211;<b> Prepaid Forward Obligation</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2021, </em>the Company entered into a prepaid forward agreement with RTW Investments (&#8220;RTW&#8221;). Under the terms of the RTW Transaction, the Company received $75.0 million (<span style="background-color:#ffffff;">$72.4</span>&#160;million net of transaction&#160;costs) to support the continued launch of <i>Jelmyto</i> and the development of UGN-<em style="font: inherit;">102.</em> In return for the transferred funds, RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of <i>Jelmyto</i> in an amount equal to: (i) 9.5% of annual net sales up to <em style="font: inherit;">$200</em> million, (ii) 3.0% of annual net sales for annual net sales between <em style="font: inherit;">$200</em> million and <em style="font: inherit;">$300</em> million, and (iii) 1.0% of annual net sales for annual net sales above <em style="font: inherit;">$300</em> million. If certain revenue thresholds for <i>Jelmyto</i> aggregate worldwide annual net sales are <em style="font: inherit;">not</em> met, the future cash payments to RTW with respect to <i>Jelmyto</i> annual net sales up to <em style="font: inherit;">$200</em> million will increase by 3.5%, and <em style="font: inherit;"> may </em>decrease back to <em style="font: inherit;">9.5%</em> dependent on the Company meeting certain subsequent <i>Jelmyto</i> aggregate worldwide annual net sales thresholds. The&#160;rate in effect for the <em style="font: inherit;">six</em>&#160;months ended <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023</em>&#160;for annual net sales up to $200 million was 13.0%.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, subject to FDA approval of UGN-<em style="font: inherit;">102,</em> RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of UGN-<em style="font: inherit;">102</em> in an amount equal to: (i) 2.5% of annual net sales up to <em style="font: inherit;">$200</em> million, (ii) 1.0% of annual net sales for annual net sales between <em style="font: inherit;">$200</em> million and <em style="font: inherit;">$300</em> million, and (iii) 0.5% of annual net sales for annual net sales above <em style="font: inherit;">$300</em> million. If the Company does <em style="font: inherit;">not</em> receive FDA approval for UGN-<em style="font: inherit;">102</em> by a specified date, the future cash payments to RTW with respect to aggregate worldwide annual net sales of <i>Jelmyto</i> across all <i>Jelmyto</i> annual net sales tiers will increase by 1.5%. &#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the prepaid forward agreement, the Company will be required to make payments of amounts owed to RTW each calendar quarter, through and until the quarter in which the aggregate cash payments received by RTW are equal to or greater than <em style="font: inherit;">$300</em> million. As security for the payment and fulfilment of these amounts throughout the arrangement, the Company has granted RTW a <em style="font: inherit;">first</em> priority security interest in <i>Jelmyto</i> and UGN-<em style="font: inherit;">102,</em> including the regulatory approvals, intellectual property, material agreements, proceeds and accounts receivable related to these products.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In&#160;<em style="font: inherit;"> May 2021</em><i>,</i>&#160;following the receipt of necessary regulatory approvals, the Company received the $75.0&#160;million prepaid forward payment ($72.4&#160;million net of transaction costs) from RTW and recognized an associated prepaid forward obligation liability. Each period the Company makes a payment to RTW, an expense is recognized related to financing on the prepaid forward obligation based on an imputed rate derived from the expected future payments. Management reassesses the effective rate each period based on the current carrying value of the obligation and the revised estimated future payments. Changes in future payments from previous estimates are included in&#160;future financing expense.&#160;The Company does <span style="-sec-ix-hidden:c101505494">not</span> expect to make any principal payments in the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table shows the activity with respect to the carrying value of the prepaid forward liability for the year ended <em style="font: inherit;"> December 31, 2022 </em>and for the <em style="font: inherit;">six</em>&#160;months ended <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023,</em> in thousands:</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 87%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of prepaid forward obligation as of December 31, 2021</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">85,713</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">21,559</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amounts paid and payable (1)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,349</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Carrying value of prepaid forward obligation as of December 31, 2022</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">98,923</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Financing on prepaid forward obligation</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">10,568</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Amounts paid and payable (1)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(4,984</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of prepaid forward obligation as of June 30, 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">104,507</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">(<em style="font: inherit;">1</em>)</sup> $2.7&#160;million and $2.3&#160;million&#160;of the Amounts paid and payable are included as current portion of the prepaid forward obligation within other current liabilities on the condensed consolidated balance sheets as of <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023</em>&#160;and <em style="font: inherit;"> December 31, 2022, </em>respectively.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardObligationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the prepaid forward obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardObligationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479356240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">10</em> &#8211; Long-Term Debt</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On&#160;<em style="font: inherit;"> March 7,&#160;</em><em style="font: inherit;">2022,</em>&#160;the Company entered into a loan&#160;agreement with Pharmakon&#160;for a&#160;senior secured term loan of up to $100&#160;million in&#160;<em style="font: inherit;">two</em>&#160;tranches. The&#160;<em style="font: inherit;">first</em>&#160;tranche of $75&#160;million was funded in&#160;<em style="font: inherit;"> March 2022. </em>The <em style="font: inherit;">second</em> tranche of&#160;$25&#160;million was funded in&#160;<em style="font: inherit;"> December 2022. </em>The facility will mature&#160;<span style="-sec-ix-hidden:c101505520">five</span>&#160;years from initial funding and can be prepaid in whole at the Company's&#160;discretion, at any time, subject to prepayment premiums and make-whole amounts.&#160;The loan will require interest-only payments for the&#160;<em style="font: inherit;">first</em>&#160;<em style="font: inherit;">48</em>&#160;months followed by principal and interest payments with interest accruing using&#160;<em style="font: inherit;">3</em>-month London Inter-Bank Offered Rate (&#8220;LIBOR&#8221;) (with a&#160;1.25% floor) plus&#160;8.25%. On <em style="font: inherit;"> June 29, 2023, </em>the loan agreement with Pharmakon was amended to replace&#160;the benchmark governing the interest rate with a rate based on the secured overnight financing rate ("SOFR") published by the Federal Reserve Bank of New York.&#160; Effective <em style="font: inherit;"> July 2023, </em>the loan&#160;will accrue interest using a benchmark rate of <em style="font: inherit;">3</em>-month SOFR plus a&#160;0.26161% adjustment. The Company is <em style="font: inherit;">not</em> required to maintain any financial covenants.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company incurred financing expenses of $4.2 million which are recognized as a direct offset to the long-term debt on the Company's condensed consolidated balance sheets. These debt issuance costs are&#160;amortized over the term of the debt using the&#160;effective interest method, and are&#160;recorded in the condensed consolidated statements of operations as "Interest expense".</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table shows the activity with respect to the carrying value of the long-term debt, in thousands:</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 81%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt at closing of Pharmakon loan</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">100,000</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized costs and discounts</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(4,217</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">8,438</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amounts paid</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,685</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Carrying value of Pharmakon loan as of December 31, 2022</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">97,537</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Interest expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">7,314</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Amounts paid</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(6,555</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of Pharmakon loan as of June 30, 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">98,296</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479355008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">11</em>&#160;</b>&#8211;<b> Leases </b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Operating Leases</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company had&#160;the following office and laboratory facility leases as of <em style="font: inherit;"> June 30, 2023</em>:</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> April 2016, </em>UPL signed an addendum to its <em style="font: inherit;"> November 2014 </em>lease agreement for the Company&#8217;s&#160;offices located in Israel, in order to increase the office space rented and to extend the rent period for an additional <em style="font: inherit;">three</em> years until <em style="font: inherit;"> August 2022. </em>In&#160;<em style="font: inherit;"> July 2022,&#160;</em>the Company signed a lease extension agreement for the Company&#8217;s&#160;offices located in Israel, extending the term of the lease through&#160;<em style="font: inherit;"> September 2025.&#160;&#160;</em>The Company's remaining contractual obligation under this lease is approximately $0.6&#160;million as of <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023.</em>&#160;</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> April 2018, </em>UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was <em style="font: inherit;"> July 10, 2018 </em>and terminates in <em style="font: inherit;"> March 2024. </em>The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company&#8217;s remaining contractual obligation under this lease is approximately $0.2&#160;million as of <em style="font: inherit;"> June 30, 2023</em>. In <em style="font: inherit;"> November 2019, </em>UPI entered into a sublease for this office space, with a lease commencement date of&#160;<em style="font: inherit;"> January 1, 2020 </em>and continuing until the end of the lease term in <em style="font: inherit;"> March 2024. </em>The subtenants exercised their early access clause and moved into the premises at the end of <em style="font: inherit;"> November 2019.&#160;</em>The remaining rental payments to be received over the lease term is approximately $0.2&#160;million as of <em style="font: inherit;"> June 30, 2023</em>. The Company accounts for the sublease as an operating lease in accordance with ASC <em style="font: inherit;">842.</em></p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8226;</p> </td><td style="width: auto;"> <p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> November 2019, </em>UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was <em style="font: inherit;"> November 29, 2019&#160;</em>with an original lease term of 38 months, expiring <em style="font: inherit;"> January 31, 2023. </em>In <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">2022,</em> the Company signed a lease extension for the Princeton office, extending the term of the lease through <em style="font: inherit;"> January 31, 2026.&#160;</em>The Company&#8217;s remaining contractual obligation under this lease is approximately $1.5&#160;million as of <em style="font: inherit;"> June 30, 2023</em>.</p> </td></tr>
</tbody></table>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, the Company has other operating office equipment and vehicle leases. The Company&#8217;s operating leases <em style="font: inherit;"> may </em>require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company&#8217;s leases do <em style="font: inherit;">not</em> contain any residual value guarantees or material restrictive covenants. The Company&#8217;s leases expire at various dates from <em style="font: inherit;">2023</em>&#160;through <em style="font: inherit;">2026,</em> with varying renewal and termination options.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The components of lease cost for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em>&#160;and <em style="font: inherit;">2022</em>&#160;were as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">257</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">257</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">516</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(56</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(56</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(112</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(112</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Variable lease cost</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">220</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">220</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">411</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">440</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The amounts recognized as of <em style="font: inherit;"> June 30, 2023</em> and&#160;<em style="font: inherit;"> December 31, 2022</em> were as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Right-of-use assets</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">2,107</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">2,452</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,209</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,586</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">910</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">941</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> June 30, 2023</em>, <em style="font: inherit;">no</em> impairment losses have been recognized.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Supplemental information related to leases for the <em style="font: inherit;">six</em> months ended&#160;<em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;">2022</em> is as follows (in thousands, except for lease terms and discount rate amounts):</p> &#160;

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">587</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">590</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Right-of-use assets obtained in exchange for new operating lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">95</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">1,419</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term of operating leases (in years)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2.23</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">3.01</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate of operating leases</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">10.16</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">9.93</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> June 30, 2023</em>,&#160;maturities of lease liabilities were as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Leases</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">581</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">923</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">811</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">52</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027 and thereafter</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,367</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: Interest</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(248</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,119</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Subleases</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> June 30, 2023</em>, undiscounted cash flows to be received under the Company&#8217;s operating sublease on an annual basis were as follows (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating Leases</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 14%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">49</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025 and thereafter</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479475008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Revenue From Product Sales<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">12</em>&#160;</b>&#8211;<b> Revenue From Product Sales</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net product sales consist of the following for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;">2022</em> (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Jelmyto</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">21,139</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">16,604</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">38,331</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">30,168</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">Net revenue recognized includes gross revenue and management&#8217;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to&#160;<em style="font: inherit;">340b</em>&#160;drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company&#8217;s copay assistance program, and Medicare refund for discarded drug, which are estimated based on the Company&#8217;s historical experience. Reserves related to items that are contractually able to be net settled are recognized as contra accounts receivable while other remaining reserves are recognized within other current liabilities on the condensed consolidated balance sheets.&#160;The following table shows the activity with respect to sales reserves for period ended&#160;of <em style="font: inherit;"> June 30, 2023</em>&#160;(in thousands):</p>
   <p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Reserves related to government sponsored programs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other reserves</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total accrued sales reserves</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 43%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance as of December 31, 2022</b></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">847</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,437</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accruals</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">5,392</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">6,052</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">11,444</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Utilizations</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,182</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,756</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,938</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance as of June 30, 2023</b></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">800</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,143</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,943</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479359824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">13</em>&#160;</b>&#8211;<b> License and Collaboration Agreements</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Agenus Agreement</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> November 2019, </em>the Company entered into a license agreement with Agenus Inc., pursuant to which Agenus granted to the Company an exclusive, worldwide (<em style="font: inherit;">not</em> including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus&#8217;s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary monoclonal antibody of Agenus known as <em style="font: inherit;">AGEN1884</em> (zalifrelimab), an anti-CTLA-<em style="font: inherit;">4</em> antagonist, for the treatment of cancers of the urinary tract via intravesical delivery. UGN-<em style="font: inherit;">301</em> is a formulation of zalifrelimab administered using <i>RTGel</i>&#160;technology&#160;that is in Phase <em style="font: inherit;">1</em> clinical&#160;development for high-grade non-muscle invasive bladder cancer ("high-grade NMIBC").&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>MD Anderson Agreement</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> January 2021, </em>the Company announced that it entered into a <span style="-sec-ix-hidden:c101505661">three</span>-year strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-<em style="font: inherit;">201</em> and UGN-<em style="font: inherit;">301</em>&#160;as an investigational treatment for high-grade NMIBC. Pursuant to the agreement, the Company has made&#160;bi-annual payments totaling $2.0 million to MD Anderson to fund the collaboration, recognized evenly over the associated period through research and development expenses. In <em style="font: inherit;"> July 2022, </em>the Company determined that it had achieved the objectives that it established when the agreement was initiated, and notified MD Anderson that it was exercising its right to conclude the collaboration in <em style="font: inherit;">2022</em> as the Company did <em style="font: inherit;">not</em> foresee initiating further development activities as part of the collaboration, although the Company will continue to collaborate on existing joint projects. As a result of this notification, the Company is <em style="font: inherit;">not</em> responsible for any further&#160;fixed bi-annual funding payments in <em style="font: inherit;">2023,</em> although the Company will be responsible for costs related to existing joint projects to the extent they&#160;exceed the payments already made to MD Anderson.&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479469408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">14</em>&#160;</b>&#8211;<b> Shareholders</b>&#8217;<b> Equity </b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company had 100.0 million ordinary shares authorized for issuance as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>. The Company had 23.5&#160;million and 23.1&#160;million ordinary shares issued and outstanding as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>, respectively. Each ordinary share is entitled to <em style="font: inherit;">one</em> vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors (the &#8220;Board&#8221;). Since its inception, the Board has <em style="font: inherit;">not</em> declared any dividends.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647471561920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">15</em>&#160;</b>&#8211;<b> Share-Based Compensation</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> October 2010, </em>the Board approved a share option plan (the <em style="font: inherit;">"2010</em> Plan") for grants to Company employees, consultants, directors, and other service providers. Subsequently, in <em style="font: inherit;"> March 2017, </em>the Board adopted the <em style="font: inherit;">2017</em> Equity Incentive Plan (the <em style="font: inherit;">"2017</em> Plan" and, together with the <em style="font: inherit;">2010</em> Plan, the "Plans"), which was approved by the shareholders in <em style="font: inherit;"> April 2017. </em>The <em style="font: inherit;">2017</em> Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance share awards, performance cash awards, and other forms of share awards to the Company's employees, directors and consultants.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The grant of options to Israeli employees under the Plans is subject to the terms stipulated by Section <em style="font: inherit;">102</em> of the Israeli Income Tax Ordinance (&#8220;Section <em style="font: inherit;">102&#8221;</em>). The option grants are subject to the track chosen by the Company, either the &#8220;regular income&#8221; track or the &#8220;capital gains&#8221; track, as set out in Section <em style="font: inherit;">102.</em> The Company registered the Plans under the capital gains track, which offers more favorable tax rates to the employees. As a result, and pursuant to the terms of Section <em style="font: inherit;">102,</em> the Company is <em style="font: inherit;">not</em> allowed to claim as an expense for tax purposes the amounts credited to the employees in respect of options granted to them under the Plans, including amounts recorded as salary benefits in the Company&#8217;s accounts, with the exception of the work-income benefit component, if any, determined on grant date. For non-employees and for non-Israeli employees, the Plans is&#160;subject to Section <em style="font: inherit;">3</em>(i) of the Israeli Income Tax Ordinance.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employees are typically granted stock options and/or restricted stock units&#160;("RSUs"), upon commencement of employment. Also, eligible employees <em style="font: inherit;"> may </em>receive an annual grant of options or RSUs. Non-employee members of the Board typically receive a grant of stock options upon initial appointment to the Board, and/or stock options annually. The term of any option granted under the Plans cannot exceed 10 years. Options shall <em style="font: inherit;">not</em> have an exercise price less than 100% of the fair market value of the Company&#8217;s ordinary shares on the grant date, and generally vest over a period of <span style="-sec-ix-hidden:c101505697">three</span> years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall <em style="font: inherit;">not</em> be less than 110% of the fair market value of an ordinary share&#160;on the date of grant.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the <em style="font: inherit;">first</em> anniversary of grant, and in either equal quarterly or annual amounts for the <span style="-sec-ix-hidden:c101505703">two</span> years following the <em style="font: inherit;">one</em>-year anniversary of the grant date. Options generally vest in a 33% increment upon the <em style="font: inherit;">first</em> anniversary of the grant date, and in either equal quarterly or annual amounts for the <span style="-sec-ix-hidden:c101505707">two</span> years following the <em style="font: inherit;">one</em>-year anniversary of the grant date.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The expected volatility is based on a mix of the Company&#8217;s historical volatility, and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted. The expected term is the length of time until the expected dates of exercising the options and is estimated for employees using the simplified method due to insufficient specific historical information of employees&#8217; exercise behavior, and for non-employees, and directors using the contractual term.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The maximum number of ordinary shares that was initially authorized for issuance under the <em style="font: inherit;">2017</em> Plan was&#160;1,400,000.&#160;On <em style="font: inherit;"> January 1, 2018, </em>the share reserve increased by 250,167 to 1,650,167 shares. On <em style="font: inherit;"> October 12, 2018, </em>the Company increased the number&#160;of ordinary shares authorized for issuance under the <em style="font: inherit;">2017</em> Plan by 1,900,000 to 3,550,167 shares. On <em style="font: inherit;"> June 8, 2020, </em>the Company&#8217;s shareholders approved an increase to the number&#160;of&#160;ordinary shares authorized for issuance under&#160;the <em style="font: inherit;">2017</em> Plan by 400,000 to 3,950,167 shares. On <em style="font: inherit;"> June 7, 2021, </em>the Company&#8217;s shareholders approved an increase to the number&#160;of ordinary shares authorized for issuance under the <em style="font: inherit;">2017</em> Plan by 400,000 to 4,350,167 shares. On <em style="font: inherit;"> June 8, 2022, </em>the Company's shareholders approved an increase to the number&#160;of ordinary shares authorized for issuance under the <em style="font: inherit;">2017</em>&#160;Plan by 400,000 to 4,750,167 shares.&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> May 2019, </em>the Company adopted the UroGen Pharma Ltd. <em style="font: inherit;">2019</em> Inducement Plan (the &#8220;Inducement Plan&#8221;). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to inducement awards. The only persons eligible to receive grants under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule <em style="font: inherit;">5635</em>(c)(<em style="font: inherit;">4</em>) and the related guidance under Nasdaq IM&#160;<em style="font: inherit;">5635</em>-<em style="font: inherit;">1,</em>&#160;including individuals who were <em style="font: inherit;">not</em> previously an employee or director of the Company or are following a bona fide period of&#160;non-employment,&#160;in each case as an inducement material to such individual&#8217;s agreement to enter into employment with the Company. In <em style="font: inherit;"> December 2021, </em>the Board approved a 300,000 increase in the share reserve of the Inducement Plan.&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> June 30, 2023</em><span style="background-color:#ffffff;">, </span>3,493,724&#160;<span style="background-color:#ffffff;">ordinary shares are subject to outstanding awards under the Company's share-based compensation plans and 941,759&#160;ordinary shares remain available for future awards.</span></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table illustrates the effect of share-based compensation on the condensed consolidated statements of operations (in thousands):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">496</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">673</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,021</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,398</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,726</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,150</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,487</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,374</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total share-based compensation expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,222</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,823</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,508</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,772</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The total unrecognized compensation cost of options and RSUs at <em style="font: inherit;"> June 30, 2023</em> is&#160;$12.6&#160;million with a weighted average recognition period of 2.0&#160;years.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647481120112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">16</em>&#160;</b>&#8211;<b> Income Taxes </b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is taxed under Israeli tax laws. As of <em style="font: inherit;"> June 30, 2023</em>, the Company continues to maintain a full valuation allowance against deferred tax assets for all jurisdictions. In evaluating the need for a valuation allowance, the Company considers all sources of taxable income available to realize the deferred tax asset, including the future reversal of existing temporary differences, forecasts of future taxable income, and tax planning strategies. The Company has cumulative global pretax losses for the years ended <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em>&#160;and&#160;<em style="font: inherit;">2020,</em> and for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em>. The Company will continue to assess the extent to which its deferred tax assets <em style="font: inherit;"> may </em>be realized in the future and will adjust the valuation allowance as needed.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has a liability for uncertain tax positions of $3.0&#160;million as of <em style="font: inherit;"> June 30, 2023</em>, for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of <em style="font: inherit;"> June 30, 2023</em>, the Company&#8217;s liability for uncertain tax positions includes $1.1&#160;million of accrued interest and penalties.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company operates on a global basis and is subject to tax laws and regulations in the United States&#160;and Israel. The estimate of the Company&#8217;s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that <em style="font: inherit;"> may </em>result from its uncertain tax positions. Based upon the information currently available, the Company does <em style="font: inherit;">not</em> reasonably expect changes in its existing uncertain tax positions in the next <em style="font: inherit;">12</em> months and has recorded the gross uncertain tax positions as a long-term liability.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479356240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">17</em>&#160;</b>&#8211;<b> Related Parties</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">There were <em style="font: inherit;">no</em> related party transactions for the&#160;<em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em> or <em style="font: inherit;">2022</em>.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479356240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">18</em>&#160;</b>&#8211;<b> Commitments and Contingencies </b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>. The Company does <em style="font: inherit;">not</em> anticipate recognizing any significant losses relating to these arrangements.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Leases</i></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">See Note <em style="font: inherit;">11</em>&#160;for further discussion regarding lease commitments.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479469408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 19 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">19</em>&#160;</b>&#8211;<b> Subsequent Events</b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">26,</em> <em style="font: inherit;">2023,</em> the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional and other accredited investors (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to sell and issue to the Purchasers 12,579,156 ordinary shares of the Company (&#8220;Shares&#8221;) (or in lieu of Shares,&#160;pre-funded&#160;warrants to purchase ordinary shares of the Company) at a purchase price of $9.54 per Share (or $9.539 for each ordinary share underlying a&#160;pre-funded&#160;warrant), in a private placement transaction (the &#8220;Private Placement&#8221;) for aggregate gross proceeds of $120.0 million, before deducting fees to placement agents and financial advisors and before other expenses payable by the Company. Each&#160;pre-funded&#160;warrant has&#160;an exercise price of $0.001 per ordinary share, subject to customary adjustments, became&#160;exercisable upon original issuance and will <em style="font: inherit;">not</em> expire until exercised in full. The&#160;pre-funded&#160;warrants <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be exercised if the aggregate number of ordinary shares beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation. The aggregate fee payable by the Company to placement agents and financial advisors is&#160;$3.6 million, plus the reimbursement of certain expenses.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Monograph Capital Partners I, L.P. (&#8220;Monograph&#8221;), a life sciences venture firm that is affiliated with Fred Cohen, M.D., a director of the Company, purchased 1,572,327 of the Shares in the Private Placement, for an aggregate purchase price of $15.0&#160;million. Dr.&#160;Cohen is the Chair and Chief Investment Officer of Monograph.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476052112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Principles of Consolidation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company's condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Functional Currency</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The U.S. dollar (&#8220;Dollar&#8221;) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the condensed consolidated statements of operations as &#8220;Interest and other income (expense), net.&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cash and Cash Equivalents; Marketable Securities</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company presents all highly liquid investments with an original maturity of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents. Cash and cash equivalents generally consist of money market funds and bank money market accounts and are stated at cost, which approximates fair value.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents and marketable securities totaled $55.3&#160;million as of <em style="font: inherit;"> June 30, 2023</em>. The Company accounts for its investments, which include&#160;cash equivalents and marketable securities,&#160;as available-for-sale in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic <em style="font: inherit;">320,</em> &#8220;Investments &#8212; Debt and Equity Securities&#8221;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#8217; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certain short-term investments are valued using models or other valuation methodologies that use Level <em style="font: inherit;">2</em> inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has <em style="font: inherit;">not</em> been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash is related primarily to cash held to secure corporate credit cards; restricted deposits are related to cash held to secure leases.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the United States. Deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than <em style="font: inherit;">not</em> that the deferred taxes will <em style="font: inherit;">not</em> be realized in the foreseeable future.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company follows a <em style="font: inherit;">two</em>-step approach in recognizing and measuring uncertain tax positions. After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-<em style="font: inherit;">not</em> chance of being sustained), ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">30</em>-<em style="font: inherit;">7</em> requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than <em style="font: inherit;">50%</em> likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. See Note <em style="font: inherit;">16</em>&#160;for further discussion related to income taxes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Inventory</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For <i>Jelmyto</i>, the Company commenced capitalization of inventory at the receipt of FDA approval.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories<i>.</i></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment are depreciated over the following useful lives (in years):</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Useful Lives</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computers and software</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c101505219">3</span></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3 - 6.5</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5 - 16.5</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2 - 10</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note <em style="font: inherit;">8</em> for further discussion regarding property and equipment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardObligationPolicyPolicyTextBlock', window );">Prepaid Forward Obligation Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Prepaid Forward Obligation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is party to a transaction with RTW Investments (the &#8220;RTW Transaction&#8221;) in which the Company received funds to support the continued launch of <i>Jelmyto</i> and the development of UGN-<em style="font: inherit;">102</em> in return for tiered, future cash payments based on net sales of <i>Jelmyto</i> and UGN-<em style="font: inherit;">102,</em> if approved by the FDA. The net proceeds received under the RTW Transaction were recognized as a long-term liability. The Company recognizes the current cash payable amounts under the arrangement within other current liabilities on the condensed consolidated balance sheets. The subsequent measurement for the liability follows the accounting&#160;principles defined in ASC Topic <em style="font: inherit;">835</em>-<em style="font: inherit;">30,</em> &#8220;Imputation of Interest&#8221;. See Note <em style="font: inherit;">9</em> for further discussion related to the prepaid forward obligation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Long-Term Debt</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is party to a loan agreement with funds managed by Pharmakon Advisors, L.P. (&#8220;Pharmakon&#8221;). The Company recognizes interest expense in current earnings, and accrued interest within other current liabilities on the condensed consolidated balance sheets. The Company recognizes capitalized financing expenses as a direct offset to the long-term debt on the Company's condensed consolidated balance sheets, and amortizes them over the term of the debt using the effective interest method. See Note <em style="font: inherit;">10</em> for further discussion related to long-term debt.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Leases</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has <em style="font: inherit;">no</em> finance leases.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company accounts for leases in accordance with ASC Topic <em style="font: inherit;">842,</em> &#8220;Leases&#8221;<i>.</i> The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right-of-use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s lease terms <em style="font: inherit;"> may </em>include options to extend the lease. The lease extensions are included in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise that option.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Because most of the Company&#8217;s leases do <em style="font: inherit;">not</em> provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ROU assets for operating leases are periodically reviewed for impairment losses under ASC <em style="font: inherit;">360</em>-<em style="font: inherit;">10,</em> &#8220;Property, Plant, and Equipment&#8221;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Revenue</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Product sales from <i>Jelmyto</i> are recognized as revenue under ASC <em style="font: inherit;">606</em> at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of <i>Jelmyto</i> are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. Net revenue recognized includes gross revenue and management&#8217;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to <em style="font: inherit;">340b</em> drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company&#8217;s copay assistance program, and Medicare refund for discarded drug, which are estimated based on the Company&#8217;s historical experience.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Research and Development Expenses</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to <em style="font: inherit;">third</em> parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when such development milestone results are achieved.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Selling,</i></b> <b><i>General and Administrative Expenses</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses consist&#160;primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services&#160;and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by <em style="font: inherit;">third</em> parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Share-Based Payment Arrangement, Director [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Share-Based Compensation</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#8220;RSU&#8221;) equaled the closing price of the Company&#8217;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic <em style="font: inherit;">718,</em> &#8220;Compensation&#8212;Stock Compensation&#8221;.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Net Loss per Ordinary Share</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive.</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Recently Adopted Issued Pronouncements</i></b></p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are <em style="font: inherit;">not</em> applicable to the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardObligationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure for accounting policy for prepaid forward obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardObligationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479531312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Property, Plant and Equipment, Useful Life [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Useful Lives</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computers and software</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c101505219">3</span></td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3 - 6.5</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5 - 16.5</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2 - 10</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479366336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,659</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">5,527</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued sales reserves</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,721</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">618</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,054</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,853</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued research and development expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,003</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,285</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,836</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,609</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued other expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,130</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">491</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,403</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,383</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Income and Interest Expense Disclosure [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,080</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense), net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(45</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">98</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total interest and other income (expense), net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,035</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">126</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479391552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials <sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">5,363</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,676</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,072</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,019</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,435</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,695</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479409920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements Using</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Quoted Prices</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Significant</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">in Active</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Balance as of</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Markets for</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Observable</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Identical Assets</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Inputs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Assets:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Cash equivalents</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Money market funds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">596</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">596</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Marketable securities</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">18,915</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">18,915</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">6,485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">6,485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">2,011</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;">2,011</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">7,733</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,733</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">35,144</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,915</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,229</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Total assets at fair value</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">35,740</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">19,511</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">16,229</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td></tr>
</tbody></table>

    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurements Using</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Quoted Prices</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Significant</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">in Active</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Balance as of</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Markets for</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Observable</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Identical Assets</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Inputs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 1)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">(Level 2)</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">28,693</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">28,693</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,387</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,387</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">9,392</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">9,392</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,084</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,084</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,556</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,693</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,863</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474244944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Amortized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Cost Basis</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Gains</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Losses</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 48%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Cash equivalents</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">596</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">596</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Marketable securities:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">U.S. government</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">18,991</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(76</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">18,915</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">6,548</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(63</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">6,485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,014</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(3</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,011</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">7,745</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(13</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">7,733</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total marketable securities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,298</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(155</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,144</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets at fair value</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,894</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(155</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,740</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturities within one year</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">27,770</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">44,556</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturities after one year through three years</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,970</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,740</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,556</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479439728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">456</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">452</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,195</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,168</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">610</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">602</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">617</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">617</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing equipment</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">607</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">608</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">4,447</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,575</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,150</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">910</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,297</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479427808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Prepaid Forward Obligation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock', window );">Schedule of Activity in the Carrying Value of the Prepaid Forward Liability [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 87%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of prepaid forward obligation as of December 31, 2021</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">85,713</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing on prepaid forward obligation</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">21,559</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amounts paid and payable (1)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,349</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Carrying value of prepaid forward obligation as of December 31, 2022</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">98,923</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Financing on prepaid forward obligation</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">10,568</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Amounts paid and payable (1)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(4,984</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of prepaid forward obligation as of June 30, 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">104,507</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of activity in the carrying value of the prepaid forward liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474235856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 81%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt at closing of Pharmakon loan</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">100,000</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized costs and discounts</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(4,217</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">8,438</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amounts paid</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,685</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Carrying value of Pharmakon loan as of December 31, 2022</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">97,537</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Interest expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">7,314</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Amounts paid</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(6,555</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carrying value of Pharmakon loan as of June 30, 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">98,296</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476150784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">257</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">257</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">485</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">516</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(56</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(56</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(112</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">(112</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Variable lease cost</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">220</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">220</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">411</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">440</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Assets and Liabilities, Lessee [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Right-of-use assets</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">2,107</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">2,452</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,209</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,586</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">910</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">941</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Information Related to Leases [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">587</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">590</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">Right-of-use assets obtained in exchange for new operating lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">95</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">1,419</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term of operating leases (in years)</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2.23</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">3.01</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate of operating leases</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">10.16</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">9.93</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Leases</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">581</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">923</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">811</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">52</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027 and thereafter</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">2,367</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: Interest</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(248</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,119</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Operating Leases</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 14%;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remainder of 2023</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">49</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025 and thereafter</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474954976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Revenue From Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Jelmyto</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">21,139</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">16,604</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">38,331</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">30,168</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_ScheduleOfSalesReservesTableTextBlock', window );">Schedule of Sales Reserves [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Reserves related to government sponsored programs</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Other reserves</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Total accrued sales reserves</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 43%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance as of December 31, 2022</b></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">847</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,437</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accruals</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">5,392</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">6,052</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">11,444</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Utilizations</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,182</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,756</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,938</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance as of June 30, 2023</b></p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">800</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,143</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,943</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ScheduleOfSalesReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for the schedule of sales reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ScheduleOfSalesReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479560768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">496</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">673</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,021</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">1,398</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,726</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,150</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,487</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,374</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total share-based compensation expense</p> </td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,222</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,823</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,508</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,772</td><td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647477329088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Basis of Presentation (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (631,453)<span></span>
</td>
<td class="num">$ (577,104)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479497456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-Term Investments</a></td>
<td class="nump">$ 55.3<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647471544080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember', window );">Computers and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_FurnitureMember', window );">Furniture [Member[ | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_FurnitureMember', window );">Furniture [Member[ | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">16 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ManufacturingEquipmentMember', window );">Manufacturing Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ManufacturingEquipmentMember', window );">Manufacturing Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (Year)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_FurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_FurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476065504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 4,659<span></span>
</td>
<td class="nump">$ 5,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedSalesReserveCurrent', window );">Accrued sales reserves</a></td>
<td class="nump">2,721<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedClinicalExpense', window );">Accrued clinical expenses</a></td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedResearchAndDevelopmentExpense', window );">Accrued research and development expenses</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedSellingGeneralAndAdministrativeExpense', window );">Accrued selling, general and administrative expenses</a></td>
<td class="nump">2,836<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">3,130<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 16,403<span></span>
</td>
<td class="nump">$ 12,383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedClinicalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance date of accrued clinical expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedClinicalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of accrued research and development expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedSalesReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of accrued sales reserve classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedSalesReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of accrued selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474788912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_InterestAndOtherIncomeNet', window );">Total interest and other income (expense), net</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 1,035<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_InterestAndOtherIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other income, net of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_InterestAndOtherIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474970368">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Inventories (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventory, Raw Materials, Net of Reserves</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,363<span></span>
</td>
<td class="nump">$ 4,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventory, Raw Materials, Net of Reserves</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">$1.5 million and $1.0 million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474765072">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Inventories - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,363<span></span>
</td>
<td class="nump">$ 4,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,072<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_InventoryCurrentAndNoncurrentNet', window );">Total inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,435<span></span>
</td>
<td class="nump">$ 6,695<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">$1.5 million and $1.0 million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_InventoryCurrentAndNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory, net of allowances, classified as both current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_InventoryCurrentAndNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476495280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 35,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">18,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">6,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">7,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">35,144<span></span>
</td>
<td class="nump">$ 44,556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">35,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">18,915<span></span>
</td>
<td class="nump">28,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">19,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">16,229<span></span>
</td>
<td class="nump">15,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">16,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">18,915<span></span>
</td>
<td class="nump">28,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | US Treasury and Government [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">18,915<span></span>
</td>
<td class="nump">28,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | US Treasury and Government [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">6,485<span></span>
</td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">6,485<span></span>
</td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">7,733<span></span>
</td>
<td class="nump">4,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 7,733<span></span>
</td>
<td class="nump">$ 4,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479713184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Investments (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position</a></td>
<td class="nump">$ 33.9<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476309248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Investments - Summary of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,127<span></span>
</td>
<td class="nump">$ 55,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost basis</a></td>
<td class="nump">35,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">35,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total assets at fair value</a></td>
<td class="nump">35,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Total assets at fair value, unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax', window );">Total assets at fair value, unrealized losses</a></td>
<td class="num">(155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure', window );">Total assets at fair value, fair value</a></td>
<td class="nump">35,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost basis</a></td>
<td class="nump">18,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">18,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost basis</a></td>
<td class="nump">6,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">6,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost basis</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost basis</a></td>
<td class="nump">7,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">7,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Money market funds, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax', window );">Money market funds, unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, fair value</a></td>
<td class="nump">$ 596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on cash cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on cash cash equivalents and shorterm investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of cash cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479660304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturities within one year</a></td>
<td class="nump">$ 27,770<span></span>
</td>
<td class="nump">$ 44,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree', window );">Maturities after one year through three years</a></td>
<td class="nump">7,970<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">$ 35,740<span></span>
</td>
<td class="nump">$ 44,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474873920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Property and Equipment (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647469778688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,485<span></span>
</td>
<td class="nump">$ 4,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,575)<span></span>
</td>
<td class="num">(3,150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">910<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember', window );">Computers and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,195<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_FurnitureMember', window );">Furniture [Member[</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ManufacturingEquipmentMember', window );">Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 607<span></span>
</td>
<td class="nump">$ 608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_FurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_FurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647471286656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Prepaid Forward Obligation (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardObligation', window );">Prepaid Forward Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,507<span></span>
</td>
<td class="nump">$ 98,923<span></span>
</td>
<td class="nump">$ 85,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardObligation', window );">Prepaid Forward Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember', window );">RTW Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_ProceedsFromPrepaidForwardObligation', window );">Proceeds from Prepaid Forward Obligation</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_ProceedsFromPrepaidForwardArrangementNet', window );">Proceeds from Prepaid Forward Arrangement, Net</a></td>
<td class="nump">$ 72,400<span></span>
</td>
<td class="nump">$ 72,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementMinimumFutureCashFlows', window );">Prepaid Forward Agreement, Minimum Future Cash Flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate', window );">Prepaid Forward Agreement, Minimum Future Cash Flows, Rate (Rate)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths', window );">Prepaid Forward Obligation, Expected Cash Flows in Next Twelve Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember', window );">RTW Investments [Member] | Sales of Up to $200 Million [Member] | Jelmyto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales', window );">Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales', window );">Prepaid Forward Agreement, Future Cash Flows, Increase in Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember', window );">RTW Investments [Member] | Sales Between $200 Million and $300 Million [Member] | Jelmyto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales', window );">Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember', window );">RTW Investments [Member] | Sales Over $300 Million [Member] | Jelmyto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales', window );">Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember', window );">RTW Investments [Member] | Sales Up to $200 Million with FDA Approval [Member] | UGN-102 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales', window );">Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember', window );">RTW Investments [Member] | Sales Between $200 Million and $300 Million with FDA Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales', window );">Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember', window );">RTW Investments [Member] | Sales Over $300 Million with FDA Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales', window );">Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales', window );">Prepaid Forward Agreement, Future Cash Flows, Increase in Percentage of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in percentage of net sales for future cash flows under the prepaid forward agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales for future cash payments under the prepaid forward agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardAgreementMinimumFutureCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of future cash flows under the prepaid forward agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardAgreementMinimumFutureCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the rate related to minimum future cash flow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the prepaid forward obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expected cash flows in the next twelve months for the prepaid forward obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ProceedsFromPrepaidForwardArrangementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from prepaid forward arrangement, net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ProceedsFromPrepaidForwardArrangementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ProceedsFromPrepaidForwardObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow for prepaid forward obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ProceedsFromPrepaidForwardObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=urgn_RTWInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=urgn_SalesOfUpTo200MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=urgn_SalesOfUpTo200MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=urgn_JelmytoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=urgn_JelmytoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=urgn_SalesBetween200MillionAnd300MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=urgn_SalesBetween200MillionAnd300MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=urgn_SalesOver300MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=urgn_SalesOver300MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=urgn_SalesUpTo200MillionWithFDAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=urgn_SalesUpTo200MillionWithFDAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=urgn_UGN102Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=urgn_UGN102Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=urgn_SalesOver300MillionWithFDAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=urgn_SalesOver300MillionWithFDAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474929440">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardObligation', window );">Carrying value of prepaid forward obligation as of December 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,923<span></span>
</td>
<td class="nump">$ 85,713<span></span>
</td>
<td class="nump">$ 85,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_FinancingOnPrepaidForwardObligation', window );">Financing on prepaid forward obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,344<span></span>
</td>
<td class="nump">$ 5,833<span></span>
</td>
<td class="nump">10,568<span></span>
</td>
<td class="nump">$ 11,659<span></span>
</td>
<td class="nump">21,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable', window );">Amounts paid and payable (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PrepaidForwardObligation', window );">Carrying value of prepaid forward obligation as of December 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 104,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,923<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">$2.7 million and $2.3 million of the Amounts paid and payable are included as current portion of the prepaid
forward obligation within other current liabilities on the condensed consolidated balance sheets as of June 30,
2023 and December 31, 2022, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in prepaid forward obligation from amounts paid and payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_FinancingOnPrepaidForwardObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financing on the preapid forward obligation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_FinancingOnPrepaidForwardObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PrepaidForwardObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the prepaid forward obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PrepaidForwardObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476294480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Long-term Debt (Details Textual) - Secured Debt [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Secured Long-Term Debt, Noncurrent</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_SecuredLongTermDebtFirstTranche', window );">Secured Long Term Debt, First Tranche</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_SecuredLongTermDebtAdditionalDraw', window );">Secured Long Term Debt, Additional Draw</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Long-Term Debt, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_DebtInstrumentLIBORFloor', window );">Debt Instrument, LIBOR Floor</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">London Interbank Offered Rate (LIBOR) 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Overnight Financing Rate (SOFR) [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26161%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DebtInstrumentLIBORFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the debt instrument, LIBOR floor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DebtInstrumentLIBORFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_SecuredLongTermDebtAdditionalDraw">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents additional draw under the secured long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_SecuredLongTermDebtAdditionalDraw</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_SecuredLongTermDebtFirstTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the first tranche related to secured long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_SecuredLongTermDebtFirstTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=urgn_LondonInterbankOfferedRateLibor1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=urgn_LondonInterbankOfferedRateLibor1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=urgn_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=urgn_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476683184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Long-term Debt - Long Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="nump">$ 3,761<span></span>
</td>
<td class="nump">$ 2,239<span></span>
</td>
<td class="nump">$ 7,314<span></span>
</td>
<td class="nump">$ 2,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="nump">3,761<span></span>
</td>
<td class="nump">$ 2,239<span></span>
</td>
<td class="nump">7,314<span></span>
</td>
<td class="nump">$ 2,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=urgn_PharmakonLoanMember', window );">Pharmakon Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long-term debt at closing of Pharmakon loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_DebtInstrumentCapitalizedCostsAndDiscounts', window );">Capitalized costs and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_DebtInstrumentPaidAndPayableAmount', window );">Amounts paid</a></td>
<td class="num">(6,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value of Pharmakon loan as of December 31, 2022</a></td>
<td class="nump">$ 98,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DebtInstrumentCapitalizedCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents capitalized costs and discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DebtInstrumentCapitalizedCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DebtInstrumentPaidAndPayableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of paid and payable related to debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DebtInstrumentPaidAndPayableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=urgn_PharmakonLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=urgn_PharmakonLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647471346848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Leases (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=urgn_CompanyOfficesInIsraelMember', window );">Company Offices in Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember', window );">Lease Agreement for Office in Los Angeles, California [Member] | UroGen Pharma Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating Lease, Impairment Loss</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember', window );">Lease Agreement for Office in Princeton, New Jersey [Member] | UroGen Pharma Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">38 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=urgn_CompanyOfficesInIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=urgn_CompanyOfficesInIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=urgn_UroGenPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=urgn_UroGenPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647471488416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Leases - Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
<td class="nump">$ 516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, Cost</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476672240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Leases - Amounts of Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 2,107<span></span>
</td>
<td class="nump">$ 2,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647480194112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Leases - Supplemental Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of operating leases (Year)</a></td>
<td class="text">2 years 2 months 23 days<span></span>
</td>
<td class="text">3 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of operating leases</a></td>
<td class="nump">10.16%<span></span>
</td>
<td class="nump">9.93%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647471487136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Leases - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">2027 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479494672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2024</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear', window );">2025 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, Operating Lease, Payment to be Received</a></td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after the next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474871920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Revenue From Product Sales - Net Product Sales (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 21,139<span></span>
</td>
<td class="nump">$ 16,604<span></span>
</td>
<td class="nump">$ 38,331<span></span>
</td>
<td class="nump">$ 30,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=urgn_JelmytoMember', window );">Jelmyto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 21,139<span></span>
</td>
<td class="nump">$ 16,604<span></span>
</td>
<td class="nump">$ 38,331<span></span>
</td>
<td class="nump">$ 30,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=urgn_JelmytoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=urgn_JelmytoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647470025696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedSalesReserve', window );">Balance</a></td>
<td class="nump">$ 1,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_SalesReserveAccruals', window );">Accruals</a></td>
<td class="nump">11,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_SalesReserveUtilization', window );">Utilizations</a></td>
<td class="num">(8,938)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedSalesReserve', window );">Balance</a></td>
<td class="nump">3,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=urgn_GovernmentSponsoredProgramsReservesMember', window );">Government Sponsored Programs Reserves [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedSalesReserve', window );">Balance</a></td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_SalesReserveAccruals', window );">Accruals</a></td>
<td class="nump">5,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_SalesReserveUtilization', window );">Utilizations</a></td>
<td class="num">(5,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedSalesReserve', window );">Balance</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=urgn_OtherReservesMember', window );">Other Reserves [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedSalesReserve', window );">Balance</a></td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_SalesReserveAccruals', window );">Accruals</a></td>
<td class="nump">6,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_SalesReserveUtilization', window );">Utilizations</a></td>
<td class="num">(3,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_AccruedSalesReserve', window );">Balance</a></td>
<td class="nump">$ 3,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AccruedSalesReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of accrued sales reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AccruedSalesReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_SalesReserveAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales reserve accruals during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_SalesReserveAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_SalesReserveUtilization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of utilization of sales reserve during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_SalesReserveUtilization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=urgn_GovernmentSponsoredProgramsReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=urgn_GovernmentSponsoredProgramsReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=urgn_OtherReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=urgn_OtherReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647474783280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - License and Collaboration Agreements (Details Textual) - MD Anderson [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_CollaborationAgreementTerm', window );">Collaboration Agreement, Term (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=urgn_MDAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=urgn_MDAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479521488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 14 - Shareholders' Equity (Details Textual) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">23,498,617<span></span>
</td>
<td class="nump">23,129,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647477445664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Share-based Compensation (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2022</div></th>
<th class="th"><div>Jun. 07, 2021</div></th>
<th class="th"><div>Jun. 08, 2020</div></th>
<th class="th"><div>Oct. 12, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,493,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=urgn_ShareOptionPlanMember', window );">Share Option Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage', window );">Share-based Compensation Arrangement By Share-based Payment Award, Individual Voting Powers, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember', window );">Two Thousand Seventeen Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="nump">4,750,167<span></span>
</td>
<td class="nump">4,350,167<span></span>
</td>
<td class="nump">3,950,167<span></span>
</td>
<td class="nump">3,550,167<span></span>
</td>
<td class="nump">1,650,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">250,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=urgn_The2019InducementPlanMember', window );">The 2019 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Share Option Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Share Option Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower', window );">Share-based Compensation Arrangement By Share-based Payment Award, Percentage of Purchase Price for Individuals Having More than Ten Percent of Combined Voting Power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the individual voting powers percentage that serves as the threshold beyond which certain pricing criteria will apply.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=urgn_ShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=urgn_ShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=urgn_The2019InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=urgn_The2019InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647476314544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 2,222<span></span>
</td>
<td class="nump">$ 2,823<span></span>
</td>
<td class="nump">$ 4,508<span></span>
</td>
<td class="nump">$ 5,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 1,726<span></span>
</td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="nump">$ 3,487<span></span>
</td>
<td class="nump">$ 4,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647479597648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 16 - Income Taxes (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139647477422640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 19 - Subsequent Events (Details Textual) - Subsequent Event [Member]<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 26, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Monograph Capital Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_ClassOfWarrantsOrRightsIssuancePricePerShare', window );">Class of Warrants or Rights, Issuance Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="nump">12,579,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_urgn_PlacementAgentsAndFinancialAdvisorsFees', window );">Placement Agents and Financial Advisors Fees | $</a></td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Monograph Capital Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="nump">1,572,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ClassOfWarrantsOrRightsIssuancePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance price per share for class of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ClassOfWarrantsOrRightsIssuancePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PlacementAgentsAndFinancialAdvisorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fees of placement agents and financial advisors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PlacementAgentsAndFinancialAdvisorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=urgn_MonographCapitalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=urgn_MonographCapitalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=urgn_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>urgn20230630_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:urgn="http://www.urogen.com/20230630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="urgn-20230630.xsd" xlink:type="simple"/>
    <context id="d_2023-01-01_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-08-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="i_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsAppropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOfUpTo200MillionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesOfUpTo200MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesBetween200MillionAnd300MillionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesBetween200MillionAnd300MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOver300MillionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesOver300MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_CounterpartyNameAxis-RTWInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-UGN102Member_StatementScenarioAxis-SalesUpTo200MillionWithFDAApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:UGN102Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesUpTo200MillionWithFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesBetween200MillionAnd300MillionWithFDAApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesBetween200MillionAnd300MillionWithFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesOver300MillionWithFDAApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">urgn:SalesOver300MillionWithFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-05-01_2021-05-31_CounterpartyNameAxis-RTWInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:RTWInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="d_2022-03-07_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember_VariableRateAxis-LondonInterbankOfferedRateLibor1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">urgn:LondonInterbankOfferedRateLibor1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2023-07-31_LongtermDebtTypeAxis-SecuredDebtMember_SubsequentEventTypeAxis-SubsequentEventMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">urgn:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="i_2022-01-01_DebtInstrumentAxis-PharmakonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">urgn:PharmakonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_LeaseContractualTermAxis-CompanyOfficesInIsraelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:CompanyOfficesInIsraelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2020-10-01_2020-10-31_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInLosAngelesCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInLosAngelesCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInLosAngelesCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2019-11-29_LeaseContractualTermAxis-LeaseAgreementForOfficeInPrincetonNewJerseyMember_LegalEntityAxis-UroGenPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInPrincetonNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInPrincetonNewJerseyMember_LegalEntityAxis-UroGenPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">urgn:LeaseAgreementForOfficeInPrincetonNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:UroGenPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_ProductOrServiceAxis-JelmytoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_ProductOrServiceAxis-JelmytoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_ProductOrServiceAxis-JelmytoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_ProductOrServiceAxis-JelmytoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">urgn:JelmytoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:GovernmentSponsoredProgramsReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:GovernmentSponsoredProgramsReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:GovernmentSponsoredProgramsReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">urgn:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-01-31_CounterpartyNameAxis-MDAndersonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:MDAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_CounterpartyNameAxis-MDAndersonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:MDAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2017-03-31_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="d_2018-01-01_2018-01-01_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="i_2018-01-01_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="d_2018-10-12_2018-10-12_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-12</startDate>
            <endDate>2018-10-12</endDate>
        </period>
    </context>
    <context id="i_2018-10-12_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-12</instant>
        </period>
    </context>
    <context id="d_2020-06-08_2020-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-08</startDate>
            <endDate>2020-06-08</endDate>
        </period>
    </context>
    <context id="i_2020-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-08</instant>
        </period>
    </context>
    <context id="d_2021-06-07_2021-06-07_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-07</startDate>
            <endDate>2021-06-07</endDate>
        </period>
    </context>
    <context id="i_2021-06-07_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-07</instant>
        </period>
    </context>
    <context id="d_2022-06-08_2022-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="i_2022-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i_2019-05-31_PlanNameAxis-The2019InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:The2019InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="d_2021-12-01_2021-12-31_PlanNameAxis-The2019InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">urgn:The2019InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <context id="i_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-26</instant>
        </period>
    </context>
    <context id="i_2023-07-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:PrefundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-26</instant>
        </period>
    </context>
    <context id="d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:MonographCapitalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <context id="d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">urgn:MonographCapitalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="ILSPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2023-01-01_2023-06-30"
      id="thunderdome-EntityCentralIndexKey">0001668243</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2023-01-01_2023-06-30"
      id="thunderdome-EntityRegistrantName">UroGen Pharma Ltd. </dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2023-01-01_2023-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2023-01-01_2023-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2023-01-01_2023-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2023-01-01_2023-06-30">2023</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-06-30"
      id="c101504776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2022-12-31"
      id="c101504777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c101504781"
      unitRef="ILSPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c101504782"
      unitRef="ILSPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c101504783"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c101504784"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c101504785"
      unitRef="Share">23498617</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c101504787"
      unitRef="Share">23498617</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c101504786"
      unitRef="Share">23129953</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c101504788"
      unitRef="Share">23129953</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504890"
      unitRef="USD">490744000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101504891"
      unitRef="USD">-607317000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101504892"
      unitRef="USD">-45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31"
      decimals="-3"
      id="c101504893"
      unitRef="USD">-116554000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101504896"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504897"
      unitRef="USD">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101504916"
      unitRef="USD">-24136000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504918"
      unitRef="USD">-24136000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101504926"
      unitRef="USD">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504927"
      unitRef="USD">478646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101504928"
      unitRef="USD">-495713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c101504930"
      unitRef="USD">-17074000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101504933"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504934"
      unitRef="USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504937"
      unitRef="USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101504948"
      unitRef="USD">13000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504949"
      unitRef="USD">13000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504982"
      unitRef="USD">487787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101504983"
      unitRef="USD">-577104000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101504984"
      unitRef="USD">-107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504985"
      unitRef="USD">-89361000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101504988"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504989"
      unitRef="USD">814000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101505008"
      unitRef="USD">-54349000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505010"
      unitRef="USD">-54349000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101505018"
      unitRef="USD">61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101505019"
      unitRef="USD">475698000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101505020"
      unitRef="USD">-467321000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c101505022"
      unitRef="USD">8413000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101505025"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101505026"
      unitRef="USD">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505029"
      unitRef="USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember"
      id="c101505219">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <urgn:PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths
      contextRef="i_2023-06-30_CounterpartyNameAxis-RTWInvestmentsMember"
      decimals="-3"
      id="c101505494"
      unitRef="USD">0</urgn:PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths>
    <us-gaap:LongTermDebtTerm
      contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember"
      id="c101505520">P5Y</us-gaap:LongTermDebtTerm>
    <urgn:CollaborationAgreementTerm
      contextRef="d_2021-01-01_2021-01-31_CounterpartyNameAxis-MDAndersonMember"
      id="c101505661">P3Y</urgn:CollaborationAgreementTerm>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="-8"
      id="c101505676"
      unitRef="Share">100000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember"
      id="c101505697">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      id="c101505703">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c101505707">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="d_2023-01-01_2023-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2023-01-01_2023-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2023-01-01_2023-06-30">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2023-01-01_2023-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2023-01-01_2023-06-30">001-38079</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2023-01-01_2023-06-30">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2023-01-01_2023-06-30">98-1460746</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2023-01-01_2023-06-30">400 Alexander Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2023-01-01_2023-06-30">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2023-01-01_2023-06-30">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2023-01-01_2023-06-30">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2023-01-01_2023-06-30">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2023-01-01_2023-06-30">768-9780</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2023-01-01_2023-06-30">Ordinary Shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2023-01-01_2023-06-30">URGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2023-01-01_2023-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2023-01-01_2023-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2023-01-01_2023-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2023-01-01_2023-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2023-01-01_2023-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2023-01-01_2023-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2023-01-01_2023-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2023-08-07" decimals="INF" unitRef="Share">30282880</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504727"
      unitRef="USD">20127000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504728"
      unitRef="USD">55408000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504729"
      unitRef="USD">27174000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504730"
      unitRef="USD">44556000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504731"
      unitRef="USD">816000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504732"
      unitRef="USD">813000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504733"
      unitRef="USD">15505000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504734"
      unitRef="USD">12704000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504735"
      unitRef="USD">4988000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504736"
      unitRef="USD">4325000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504737"
      unitRef="USD">12723000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504738"
      unitRef="USD">11101000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504739"
      unitRef="USD">81333000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504740"
      unitRef="USD">128907000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c101504742"
      unitRef="USD">910000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504743"
      unitRef="USD">1297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504744"
      unitRef="USD">224000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504745"
      unitRef="USD">223000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504746"
      unitRef="USD">2107000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504747"
      unitRef="USD">2452000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c101504748"
      unitRef="USD">7970000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504749"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504750"
      unitRef="USD">2817000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c101504751"
      unitRef="USD">2740000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504752"
      unitRef="USD">95361000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504753"
      unitRef="USD">135619000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504756"
      unitRef="USD">16403000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504757"
      unitRef="USD">12383000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504758"
      unitRef="USD">6721000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504759"
      unitRef="USD">8257000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504760"
      unitRef="USD">3641000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504761"
      unitRef="USD">3276000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504762"
      unitRef="USD">26765000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504763"
      unitRef="USD">23916000</us-gaap:LiabilitiesCurrent>
    <urgn:PrepaidForwardObligation
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504765"
      unitRef="USD">104507000</urgn:PrepaidForwardObligation>
    <urgn:PrepaidForwardObligation
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504766"
      unitRef="USD">98923000</urgn:PrepaidForwardObligation>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504767"
      unitRef="USD">98296000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504768"
      unitRef="USD">97537000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504769"
      unitRef="USD">1209000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504770"
      unitRef="USD">1586000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504771"
      unitRef="USD">3018000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504772"
      unitRef="USD">3018000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504773"
      unitRef="USD">233795000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c101504774"
      unitRef="USD">224980000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504779"
      unitRef="USD">64000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504780"
      unitRef="USD">63000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504789"
      unitRef="USD">493109000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504790"
      unitRef="USD">487787000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504791"
      unitRef="USD">-631453000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504792"
      unitRef="USD">-577104000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504793"
      unitRef="USD">-154000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504794"
      unitRef="USD">-107000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504795"
      unitRef="USD">-138434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504796"
      unitRef="USD">-89361000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504797"
      unitRef="USD">95361000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101504798"
      unitRef="USD">135619000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504799"
      unitRef="USD">21139000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504800"
      unitRef="USD">16604000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504801"
      unitRef="USD">38331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504802"
      unitRef="USD">30168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504803"
      unitRef="USD">2443000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504804"
      unitRef="USD">1846000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504805"
      unitRef="USD">4708000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504806"
      unitRef="USD">3371000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504807"
      unitRef="USD">18696000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504808"
      unitRef="USD">14758000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504809"
      unitRef="USD">33623000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504810"
      unitRef="USD">26797000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504812"
      unitRef="USD">11584000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-4"
      id="c101504813"
      unitRef="USD">12640000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504814"
      unitRef="USD">24082000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504815"
      unitRef="USD">25336000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504816"
      unitRef="USD">22494000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504817"
      unitRef="USD">20833000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504818"
      unitRef="USD">46968000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504819"
      unitRef="USD">42133000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504820"
      unitRef="USD">-15382000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504821"
      unitRef="USD">-18715000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504822"
      unitRef="USD">-37427000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504823"
      unitRef="USD">-40672000</us-gaap:OperatingIncomeLoss>
    <urgn:FinancingOnPrepaidForwardObligation
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504824"
      unitRef="USD">5344000</urgn:FinancingOnPrepaidForwardObligation>
    <urgn:FinancingOnPrepaidForwardObligation
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504825"
      unitRef="USD">5833000</urgn:FinancingOnPrepaidForwardObligation>
    <urgn:FinancingOnPrepaidForwardObligation
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504826"
      unitRef="USD">10568000</urgn:FinancingOnPrepaidForwardObligation>
    <urgn:FinancingOnPrepaidForwardObligation
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504827"
      unitRef="USD">11659000</urgn:FinancingOnPrepaidForwardObligation>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504828"
      unitRef="USD">3761000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504829"
      unitRef="USD">2239000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504830"
      unitRef="USD">7314000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504831"
      unitRef="USD">2521000</us-gaap:InterestExpenseLongTermDebt>
    <urgn:InterestAndOtherIncomeNet
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504832"
      unitRef="USD">405000</urgn:InterestAndOtherIncomeNet>
    <urgn:InterestAndOtherIncomeNet
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504833"
      unitRef="USD">128000</urgn:InterestAndOtherIncomeNet>
    <urgn:InterestAndOtherIncomeNet
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504834"
      unitRef="USD">1035000</urgn:InterestAndOtherIncomeNet>
    <urgn:InterestAndOtherIncomeNet
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504835"
      unitRef="USD">126000</urgn:InterestAndOtherIncomeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504836"
      unitRef="USD">-24082000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504837"
      unitRef="USD">-26659000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504838"
      unitRef="USD">-54274000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504839"
      unitRef="USD">-54726000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504840"
      unitRef="USD">54000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504841"
      unitRef="USD">32000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504842"
      unitRef="USD">75000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504843"
      unitRef="USD">357000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504844"
      unitRef="USD">-24136000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504845"
      unitRef="USD">-26691000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504846"
      unitRef="USD">-54349000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504847"
      unitRef="USD">-55083000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504849"
      unitRef="USD">-24136000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504850"
      unitRef="USD">-26691000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504851"
      unitRef="USD">-54349000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504852"
      unitRef="USD">-55083000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504854"
      unitRef="USD">-109000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504855"
      unitRef="USD">13000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504856"
      unitRef="USD">-47000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504857"
      unitRef="USD">-31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504858"
      unitRef="USD">-24245000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504859"
      unitRef="USD">-26678000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504860"
      unitRef="USD">-54396000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101504861"
      unitRef="USD">-55114000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c101504862"
      unitRef="USDPerShare">-1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c101504863"
      unitRef="USDPerShare">-1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c101504864"
      unitRef="USDPerShare">-2.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c101504865"
      unitRef="USDPerShare">-2.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c101504866"
      unitRef="Share">23462016</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c101504867"
      unitRef="Share">22703572</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c101504868"
      unitRef="Share">23371878</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c101504869"
      unitRef="Share">22667825</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101504888"
      unitRef="Share">23440521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101504889"
      unitRef="USD">64000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101504895"
      unitRef="Share">58096</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      id="c101504898"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      id="c101504899"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504900"
      unitRef="USD">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504903"
      unitRef="USD">2222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504906"
      unitRef="USD">2222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101504911"
      unitRef="USD">-109000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101504912"
      unitRef="USD">-109000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101504919"
      unitRef="Share">23498617</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101504920"
      unitRef="USD">64000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504921"
      unitRef="USD">493109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101504922"
      unitRef="USD">-631453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101504923"
      unitRef="USD">-154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101504924"
      unitRef="USD">-138434000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101504925"
      unitRef="Share">22682221</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101504929"
      unitRef="USD">-69000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101504932"
      unitRef="Share">45670</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504940"
      unitRef="USD">2823000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504943"
      unitRef="USD">2823000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101504953"
      unitRef="USD">-26691000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101504955"
      unitRef="USD">-26691000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101504956"
      unitRef="Share">22727891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101504957"
      unitRef="USD">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504958"
      unitRef="USD">481485000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101504959"
      unitRef="USD">-522404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101504960"
      unitRef="USD">-56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c101504961"
      unitRef="USD">-40913000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101504980"
      unitRef="Share">23129953</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101504981"
      unitRef="USD">63000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101504987"
      unitRef="Share">368664</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      id="c101504990"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      id="c101504991"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504992"
      unitRef="USD">815000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101504995"
      unitRef="USD">4508000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101504998"
      unitRef="USD">4508000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2023-01-01_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101505003"
      unitRef="USD">-47000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505004"
      unitRef="USD">-47000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101505011"
      unitRef="Share">23498617</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101505012"
      unitRef="USD">64000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101505013"
      unitRef="USD">493109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101505014"
      unitRef="USD">-631453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101505015"
      unitRef="USD">-154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505016"
      unitRef="USD">-138434000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101505017"
      unitRef="Share">22462995</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101505021"
      unitRef="USD">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101505024"
      unitRef="Share">264896</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101505032"
      unitRef="USD">5772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505035"
      unitRef="USD">5772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      id="c101505037"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      id="c101505038"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      id="c101505039"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101505040"
      unitRef="USD">-31000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505041"
      unitRef="USD">-31000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101505045"
      unitRef="USD">-55083000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505047"
      unitRef="USD">-55083000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c101505048"
      unitRef="Share">22727891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c101505049"
      unitRef="USD">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c101505050"
      unitRef="USD">481485000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember"
      decimals="-3"
      id="c101505051"
      unitRef="USD">-522404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c101505052"
      unitRef="USD">-56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c101505053"
      unitRef="USD">-40913000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505059"
      unitRef="USD">-54349000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505060"
      unitRef="USD">-55083000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505062"
      unitRef="USD">426000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505063"
      unitRef="USD">449000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InventoryWriteDown
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505064"
      unitRef="USD">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505065"
      unitRef="USD">265000</us-gaap:InventoryWriteDown>
    <urgn:AccruedFinancingOnPrepaidForwardObligation
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505066"
      unitRef="USD">5982000</urgn:AccruedFinancingOnPrepaidForwardObligation>
    <urgn:AccruedFinancingOnPrepaidForwardObligation
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505067"
      unitRef="USD">8359000</urgn:AccruedFinancingOnPrepaidForwardObligation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505068"
      unitRef="USD">664000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505069"
      unitRef="USD">-169000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505070"
      unitRef="USD">4508000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505071"
      unitRef="USD">5772000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505072"
      unitRef="USD">759000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505073"
      unitRef="USD">403000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-4"
      id="c101505074"
      unitRef="USD">440000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505075"
      unitRef="USD">483000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505077"
      unitRef="USD">663000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c101505078"
      unitRef="USD">480000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505079"
      unitRef="USD">2801000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505080"
      unitRef="USD">-122000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505081"
      unitRef="USD">1622000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505082"
      unitRef="USD">2958000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505083"
      unitRef="USD">77000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505084"
      unitRef="USD">444000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-4"
      id="c101505085"
      unitRef="USD">4020000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505086"
      unitRef="USD">-3454000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505087"
      unitRef="USD">-1536000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c101505088"
      unitRef="USD">-520000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505089"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505090"
      unitRef="USD">-704000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505091"
      unitRef="USD">-504000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505092"
      unitRef="USD">-574000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505093"
      unitRef="USD">-46081000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505094"
      unitRef="USD">-48195000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505096"
      unitRef="USD">24176000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505097"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505098"
      unitRef="USD">34204000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505099"
      unitRef="USD">13533000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505100"
      unitRef="USD">38000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505101"
      unitRef="USD">88000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-4"
      id="c101505102"
      unitRef="USD">9990000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505103"
      unitRef="USD">13445000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505105"
      unitRef="USD">814000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505106"
      unitRef="USD">16000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505107"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505108"
      unitRef="USD">70793000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505109"
      unitRef="USD">-0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505110"
      unitRef="USD">144000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505111"
      unitRef="USD">814000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505112"
      unitRef="USD">70665000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505113"
      unitRef="USD">-35277000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505114"
      unitRef="USD">35915000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c101505115"
      unitRef="USD">56220000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c101505116"
      unitRef="USD">45586000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505117"
      unitRef="USD">20943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-06-30"
      decimals="-3"
      id="c101505118"
      unitRef="USD">81501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <urgn:NonCashNewLeaseLiabilities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505120"
      unitRef="USD">95000</urgn:NonCashNewLeaseLiabilities>
    <urgn:NonCashNewLeaseLiabilities
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505121"
      unitRef="USD">1419000</urgn:NonCashNewLeaseLiabilities>
    <us-gaap:NatureOfOperations contextRef="d_2023-01-01_2023-06-30" id="c2444542">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Business and Nature of Operations&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Nature of Operations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;UroGen Pharma Ltd. is an Israeli company incorporated in&#160;&lt;em style="font: inherit;"&gt; April 2004 (&lt;/em&gt;&#x201c;UPL&#x201d;).&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;UroGen Pharma,&#160;Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in&#160;&lt;em style="font: inherit;"&gt; October 2015&#160;&lt;/em&gt;and began operating in&#160;&lt;em style="font: inherit;"&gt; February 2016 (&lt;/em&gt;&#x201c;UPI&#x201d;).&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;UPL and UPI (together the &#x201c;Company&#x201d;) is a biotechnology company dedicated to developing and commercializing&#160;innovative&#160;solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company&#x2019;s&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;commercial product,&#160;&lt;i&gt;Jelmyto&lt;/i&gt;&#160;(mitomycin) for pyelocalyceal solution, formerly known as UGN-&lt;em style="font: inherit;"&gt;101,&lt;/em&gt;&#160;clinical development of UGN-&lt;em style="font: inherit;"&gt;102,&lt;/em&gt;&#160;and raising capital to support and expand these activities.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; April 15, 2020,&#160;&lt;/em&gt;the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) granted expedited approval for&#160;&lt;i&gt;Jelmyto&lt;/i&gt;, a&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (&#x201c;low-grade UTUC&#x201d;).&#160;&lt;i&gt;Jelmyto&lt;/i&gt;&#160;consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release&#160;&lt;i&gt;RTGel&lt;/i&gt;&#160;technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.&lt;/p&gt;
  </us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccounting contextRef="d_2023-01-01_2023-06-30" id="c2444543">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Basis of Presentation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and Article &lt;em style="font: inherit;"&gt;10&lt;/em&gt; of Regulation S-&lt;em style="font: inherit;"&gt;X.&lt;/em&gt; Accordingly, they do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company&#x2019;s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company&#x2019;s Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; as filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on &lt;em style="font: inherit;"&gt; March 24, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company has experienced net losses since its inception and has an accumulated deficit o&lt;span style="background-color:#ffffff;"&gt;f $631.5&#160;&lt;/span&gt;million and $577.1&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan.&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months from the date the financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments relating to the carrying amounts and classification of assets and liabilities that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be necessary should the Company be unable to continue as a&#160;going&#160;concern. The Company&#x2019;s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from &lt;i&gt;Jelmyto&lt;/i&gt; product sales and develop UGN-&lt;em style="font: inherit;"&gt;102.&lt;/em&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; July&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;26,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company entered into a private placement transaction with certain institutional and other accredited investors pursuant to which the Company agreed to sell its ordinary shares and pre-funded warrants to purchase ordinary shares to the investors, for aggregate&#160;gross proceeds of $120.0 million.&#160; See Note &lt;em style="font: inherit;"&gt;19&lt;/em&gt; for further discussion regarding the private placement transaction.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Based on the Company's cash, cash equivalents and marketable securities as of &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;together with management&#x2019;s cash flow projections and the net proceeds to the Company from its private placement transaction in &lt;em style="font: inherit;"&gt; July 2023, &lt;/em&gt;the Company believes that it has sufficient cash and cash equivalents to fund its operations beyond &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year from the issuance of these financial statements. The Company will&#160;need to raise additional capital in the future. There can be&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;assurances that the Company will be able to secure such additional financing if at all, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:BasisOfAccounting>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c101505137"
      unitRef="USD">-631500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c101505138"
      unitRef="USD">-577100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-7"
      id="c101505146"
      unitRef="USD">120000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444544">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company's condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Functional Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The U.S. dollar (&#x201c;Dollar&#x201d;) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the condensed consolidated statements of operations as &#x201c;Interest and other income (expense), net.&#x201d;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents; Marketable Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company presents all highly liquid investments with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased as cash equivalents. Cash and cash equivalents generally consist of money market funds and bank money market accounts and are stated at cost, which approximates fair value.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash and cash equivalents and marketable securities totaled $55.3&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;. The Company accounts for its investments, which include&#160;cash equivalents and marketable securities,&#160;as available-for-sale in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic &lt;em style="font: inherit;"&gt;320,&lt;/em&gt; &#x201c;Investments &#x2014; Debt and Equity Securities&#x201d;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#x2019; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certain short-term investments are valued using models or other valuation methodologies that use Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted cash is related primarily to cash held to secure corporate credit cards; restricted deposits are related to cash held to secure leases.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; enter into any investment transaction for trading or speculative purposes.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s product sales are recognized through the Company's arrangement with a single customer, a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any credit losses related to this customer and has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently recognized any allowance for doubtful accounts.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the United States. Deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that the deferred taxes will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company follows a &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-step approach in recognizing and measuring uncertain tax positions. After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-&lt;em style="font: inherit;"&gt;not&lt;/em&gt; chance of being sustained), ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-&lt;em style="font: inherit;"&gt;30&lt;/em&gt;-&lt;em style="font: inherit;"&gt;7&lt;/em&gt; requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. See Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt;&#160;for further discussion related to income taxes.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For &lt;i&gt;Jelmyto&lt;/i&gt;, the Company commenced capitalization of inventory at the receipt of FDA approval.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment are depreciated over the following useful lives (in years):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Useful Lives&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computers and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c101505219"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;3 - 6.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;5 - 16.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Manufacturing equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;2 - 10&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; for further discussion regarding property and equipment.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Prepaid Forward Obligation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company is party to a transaction with RTW Investments (the &#x201c;RTW Transaction&#x201d;) in which the Company received funds to support the continued launch of &lt;i&gt;Jelmyto&lt;/i&gt; and the development of UGN-&lt;em style="font: inherit;"&gt;102&lt;/em&gt; in return for tiered, future cash payments based on net sales of &lt;i&gt;Jelmyto&lt;/i&gt; and UGN-&lt;em style="font: inherit;"&gt;102,&lt;/em&gt; if approved by the FDA. The net proceeds received under the RTW Transaction were recognized as a long-term liability. The Company recognizes the current cash payable amounts under the arrangement within other current liabilities on the condensed consolidated balance sheets. The subsequent measurement for the liability follows the accounting&#160;principles defined in ASC Topic &lt;em style="font: inherit;"&gt;835&lt;/em&gt;-&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &#x201c;Imputation of Interest&#x201d;. See Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; for further discussion related to the prepaid forward obligation.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Long-Term Debt&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company is party to a loan agreement with funds managed by Pharmakon Advisors, L.P. (&#x201c;Pharmakon&#x201d;). The Company recognizes interest expense in current earnings, and accrued interest within other current liabilities on the condensed consolidated balance sheets. The Company recognizes capitalized financing expenses as a direct offset to the long-term debt on the Company's condensed consolidated balance sheets, and amortizes them over the term of the debt using the effective interest method. See Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; for further discussion related to long-term debt.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; finance leases.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company accounts for leases in accordance with ASC Topic &lt;em style="font: inherit;"&gt;842,&lt;/em&gt; &#x201c;Leases&#x201d;&lt;i&gt;.&lt;/i&gt; The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right-of-use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s lease terms &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include options to extend the lease. The lease extensions are included in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise that option.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Because most of the Company&#x2019;s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;ROU assets for operating leases are periodically reviewed for impairment losses under ASC &lt;em style="font: inherit;"&gt;360&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &#x201c;Property, Plant, and Equipment&#x201d;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Product sales from &lt;i&gt;Jelmyto&lt;/i&gt; are recognized as revenue under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of &lt;i&gt;Jelmyto&lt;/i&gt; are recognized through the Company's arrangement with a single customer, a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party national specialty distributor. Net revenue recognized includes gross revenue and management&#x2019;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to &lt;em style="font: inherit;"&gt;340b&lt;/em&gt; drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company&#x2019;s copay assistance program, and Medicare refund for discarded drug, which are estimated based on the Company&#x2019;s historical experience.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when such development milestone results are achieved.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Selling,&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;General and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Selling, general and administrative expenses consist&#160;primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services&#160;and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#x201c;RSU&#x201d;) equaled the closing price of the Company&#x2019;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic &lt;em style="font: inherit;"&gt;718,&lt;/em&gt; &#x201c;Compensation&#x2014;Stock Compensation&#x201d;.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Ordinary Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Issued Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; applicable to the Company.&lt;/p&gt;&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508147">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company's condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2023-01-01_2023-06-30" id="c101508148">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508149">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Functional Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The U.S. dollar (&#x201c;Dollar&#x201d;) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the condensed consolidated statements of operations as &#x201c;Interest and other income (expense), net.&#x201d;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <urgn:CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508150">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents; Marketable Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company presents all highly liquid investments with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased as cash equivalents. Cash and cash equivalents generally consist of money market funds and bank money market accounts and are stated at cost, which approximates fair value.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash and cash equivalents and marketable securities totaled $55.3&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;. The Company accounts for its investments, which include&#160;cash equivalents and marketable securities,&#160;as available-for-sale in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic &lt;em style="font: inherit;"&gt;320,&lt;/em&gt; &#x201c;Investments &#x2014; Debt and Equity Securities&#x201d;. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders&#x2019; equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certain short-term investments are valued using models or other valuation methodologies that use Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted cash is related primarily to cash held to secure corporate credit cards; restricted deposits are related to cash held to secure leases.&lt;/p&gt;</urgn:CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c101505156"
      unitRef="USD">55300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2023-01-01_2023-06-30" id="c101508151">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; enter into any investment transaction for trading or speculative purposes.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s product sales are recognized through the Company's arrangement with a single customer, a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any credit losses related to this customer and has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently recognized any allowance for doubtful accounts.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508152">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the United States. Deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that the deferred taxes will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company follows a &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-step approach in recognizing and measuring uncertain tax positions. After concluding that a particular filing position can be recognized (i.e., has a more-likely-than-&lt;em style="font: inherit;"&gt;not&lt;/em&gt; chance of being sustained), ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-&lt;em style="font: inherit;"&gt;30&lt;/em&gt;-&lt;em style="font: inherit;"&gt;7&lt;/em&gt; requires that the amount of benefit recognized be measured using a methodology based on the concept of cumulative probability. Under this methodology, the amount of benefit recorded represents the largest amount of tax benefit that is greater than &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; likely to be realized upon settlement with a taxing authority that has full knowledge of all relevant information. See Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt;&#160;for further discussion related to income taxes.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508153">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs.&#160;For &lt;i&gt;Jelmyto&lt;/i&gt;, the Company commenced capitalization of inventory at the receipt of FDA approval.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company values its inventory at the lower of cost or net realizable value.&#160;The Company measures inventory approximating actual cost under a &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508154">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment are depreciated over the following useful lives (in years):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Useful Lives&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computers and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c101505219"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;3 - 6.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;5 - 16.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Manufacturing equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;2 - 10&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; for further discussion regarding property and equipment.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444545">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Useful Lives&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computers and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c101505219"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;3 - 6.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;5 - 16.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 84%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Manufacturing equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;2 - 10&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember"
      id="c101505221">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MaximumMember"
      id="c101505223">P6Y6M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember_RangeAxis-MinimumMember"
      id="c101505224">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember_RangeAxis-MaximumMember"
      id="c101505226">P16Y6M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember_RangeAxis-MinimumMember"
      id="c101505227">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember_RangeAxis-MaximumMember"
      id="c101505229">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <urgn:PrepaidForwardObligationPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508155">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Prepaid Forward Obligation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company is party to a transaction with RTW Investments (the &#x201c;RTW Transaction&#x201d;) in which the Company received funds to support the continued launch of &lt;i&gt;Jelmyto&lt;/i&gt; and the development of UGN-&lt;em style="font: inherit;"&gt;102&lt;/em&gt; in return for tiered, future cash payments based on net sales of &lt;i&gt;Jelmyto&lt;/i&gt; and UGN-&lt;em style="font: inherit;"&gt;102,&lt;/em&gt; if approved by the FDA. The net proceeds received under the RTW Transaction were recognized as a long-term liability. The Company recognizes the current cash payable amounts under the arrangement within other current liabilities on the condensed consolidated balance sheets. The subsequent measurement for the liability follows the accounting&#160;principles defined in ASC Topic &lt;em style="font: inherit;"&gt;835&lt;/em&gt;-&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &#x201c;Imputation of Interest&#x201d;. See Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; for further discussion related to the prepaid forward obligation.&lt;/p&gt;</urgn:PrepaidForwardObligationPolicyPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508156">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Long-Term Debt&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company is party to a loan agreement with funds managed by Pharmakon Advisors, L.P. (&#x201c;Pharmakon&#x201d;). The Company recognizes interest expense in current earnings, and accrued interest within other current liabilities on the condensed consolidated balance sheets. The Company recognizes capitalized financing expenses as a direct offset to the long-term debt on the Company's condensed consolidated balance sheets, and amortizes them over the term of the debt using the effective interest method. See Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; for further discussion related to long-term debt.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508157">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; finance leases.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company accounts for leases in accordance with ASC Topic &lt;em style="font: inherit;"&gt;842,&lt;/em&gt; &#x201c;Leases&#x201d;&lt;i&gt;.&lt;/i&gt; The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right-of-use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s lease terms &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include options to extend the lease. The lease extensions are included in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise that option.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Because most of the Company&#x2019;s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;ROU assets for operating leases are periodically reviewed for impairment losses under ASC &lt;em style="font: inherit;"&gt;360&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &#x201c;Property, Plant, and Equipment&#x201d;, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508158">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Product sales from &lt;i&gt;Jelmyto&lt;/i&gt; are recognized as revenue under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the treating physician. All product sales of &lt;i&gt;Jelmyto&lt;/i&gt; are recognized through the Company's arrangement with a single customer, a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party national specialty distributor. Net revenue recognized includes gross revenue and management&#x2019;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to &lt;em style="font: inherit;"&gt;340b&lt;/em&gt; drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company&#x2019;s copay assistance program, and Medicare refund for discarded drug, which are estimated based on the Company&#x2019;s historical experience.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2023-01-01_2023-06-30" id="c101508159">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when such development milestone results are achieved.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508160">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Selling,&lt;/i&gt;&lt;/b&gt; &lt;b&gt;&lt;i&gt;General and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Selling, general and administrative expenses consist&#160;primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services&#160;and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="d_2023-01-01_2023-06-30" id="c101508161">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (&#x201c;RSU&#x201d;) equaled the closing price of the Company&#x2019;s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic &lt;em style="font: inherit;"&gt;718,&lt;/em&gt; &#x201c;Compensation&#x2014;Stock Compensation&#x201d;.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508162">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Ordinary Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-06-30" id="c101508163">&lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Issued Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; applicable to the Company.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <urgn:OtherFinancialInformationTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444546">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Other Financial Information&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Payable and Accrued Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accounts payable and accrued expenses consisted&#160;of the following as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;(in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accounts payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;4,659&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;5,527&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued sales reserves&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,721&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;618&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued clinical expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,054&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,853&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,003&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,285&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued selling, general and administrative expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,836&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,609&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued other expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,130&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;491&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total accounts payable and accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,403&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,383&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Interest and Other Income (Expense), Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest and other income (expense), net consisted of the following as of &lt;em style="font: inherit;"&gt; June 30, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,080&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;28&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other income (expense), net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(45&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;98&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total interest and other income (expense), net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,035&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;126&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
  </urgn:OtherFinancialInformationTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444547">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accounts payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;4,659&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;5,527&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued sales reserves&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,721&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;618&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued clinical expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,054&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,853&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,003&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,285&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued selling, general and administrative expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,836&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,609&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued other expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,130&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;491&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total accounts payable and accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,403&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,383&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505236"
      unitRef="USD">4659000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505237"
      unitRef="USD">5527000</us-gaap:AccountsPayableCurrent>
    <urgn:AccruedSalesReserveCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505238"
      unitRef="USD">2721000</urgn:AccruedSalesReserveCurrent>
    <urgn:AccruedSalesReserveCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505239"
      unitRef="USD">618000</urgn:AccruedSalesReserveCurrent>
    <urgn:AccruedClinicalExpense
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505240"
      unitRef="USD">2054000</urgn:AccruedClinicalExpense>
    <urgn:AccruedClinicalExpense
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505241"
      unitRef="USD">2853000</urgn:AccruedClinicalExpense>
    <urgn:AccruedResearchAndDevelopmentExpense
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505242"
      unitRef="USD">1003000</urgn:AccruedResearchAndDevelopmentExpense>
    <urgn:AccruedResearchAndDevelopmentExpense
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505243"
      unitRef="USD">1285000</urgn:AccruedResearchAndDevelopmentExpense>
    <urgn:AccruedSellingGeneralAndAdministrativeExpense
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505244"
      unitRef="USD">2836000</urgn:AccruedSellingGeneralAndAdministrativeExpense>
    <urgn:AccruedSellingGeneralAndAdministrativeExpense
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505245"
      unitRef="USD">1609000</urgn:AccruedSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c101505246"
      unitRef="USD">3130000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505247"
      unitRef="USD">491000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505248"
      unitRef="USD">16403000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505249"
      unitRef="USD">12383000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444548">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,080&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;28&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other income (expense), net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(45&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;98&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total interest and other income (expense), net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,035&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;126&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-4"
      id="c101505254"
      unitRef="USD">1080000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505255"
      unitRef="USD">28000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505256"
      unitRef="USD">-45000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505257"
      unitRef="USD">98000</us-gaap:NonoperatingIncomeExpense>
    <urgn:InterestAndOtherIncomeNet
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505258"
      unitRef="USD">1035000</urgn:InterestAndOtherIncomeNet>
    <urgn:InterestAndOtherIncomeNet
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505259"
      unitRef="USD">126000</urgn:InterestAndOtherIncomeNet>
    <us-gaap:InventoryDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444549">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Inventories&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Inventories consisted of the following as of&#160;&lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Raw materials &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;5,363&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;4,676&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,072&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,019&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total inventories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,435&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,695&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-family: Arial, Helvetica, sans-serif;"&gt;&lt;td style="vertical-align: top; width: 2%; font-family: Arial, Helvetica, sans-serif;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-family: Arial, Helvetica, sans-serif;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/sup&gt;&#160;$2.4&#160;million and $2.4&#160;million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;respectively. Changes in non-current assets are reflected on the condensed consolidated statements of cash flows within the caption of other non-current assets.&#160;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
  </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444550">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Raw materials &lt;sup style="vertical-align:top;line-height:120%;"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;5,363&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;4,676&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,072&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,019&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total inventories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,435&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,695&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505270"
      unitRef="USD">5363000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505271"
      unitRef="USD">4676000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505272"
      unitRef="USD">2072000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505273"
      unitRef="USD">2019000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <urgn:InventoryCurrentAndNoncurrentNet
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505274"
      unitRef="USD">7435000</urgn:InventoryCurrentAndNoncurrentNet>
    <urgn:InventoryCurrentAndNoncurrentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505275"
      unitRef="USD">6695000</urgn:InventoryCurrentAndNoncurrentNet>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"
      decimals="-5"
      id="c101505262"
      unitRef="USD">2400000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2022-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"
      decimals="-5"
      id="c101505263"
      unitRef="USD">2400000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444551">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;As a basis for considering such assumptions, a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-family: Arial, Helvetica, sans-serif;"&gt;&lt;td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Level &lt;em style="font: inherit;"&gt;1:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-family: Arial, Helvetica, sans-serif;"&gt;&lt;td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Level &lt;em style="font: inherit;"&gt;2:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-family: Arial, Helvetica, sans-serif;"&gt;&lt;td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: 10%; font-family: Arial, Helvetica, sans-serif;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Level &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 89%; font-family: Arial, Helvetica, sans-serif;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The carrying amounts of the Company&#x2019;s cash, restricted cash, other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these assets and liabilities.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The carrying value of the prepaid forward obligation (See Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; - Prepaid Forward Obligation) approximates its fair value.&#160;The Company estimated&#160;the fair value of the prepaid forward obligation using Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs, including internally developed financial forecasts and management's estimate of&#160;probability of success related to product candidates, and determined&#160;that the effective interest rate in the obligation approximates market rates for loans with similar terms and risk characteristics.&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company estimated the fair value of&#160;long-term debt (see Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; - Long-Term Debt)&#160;using the income approach with Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs. The Company estimated future floating rate interest payments using a forward curve of a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month benchmark rate, and estimated fair value based on publicly available data reported in the financial statements of publicly traded venture lending companies. Based on a reasonable range of yields for debt instruments of similar tenor in a similar industry, the Company determined that the carrying value of the long-term debt on the Company's balance sheet approximates its fair value.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; transfers between levels have occurred during the periods presented.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets measured at fair value on a recurring basis based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; fair value measurement criteria as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; are as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurements Using&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Quoted Prices&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Significant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;in Active&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Other&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance as of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Markets for&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Observable&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Identical Assets&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Inputs&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 2)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;596&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;596&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;U.S. government&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;18,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;18,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;2,011&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;2,011&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;7,733&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,733&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Total marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,144&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,229&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Total assets at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;35,740&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;19,511&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,229&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets measured at fair value on a recurring basis based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; fair value measurement criteria as of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; are as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurements Using&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Quoted Prices&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Significant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;in Active&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Other&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance as of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Markets for&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Observable&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Identical Assets&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Inputs&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 2)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;U.S. government&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;28,693&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;28,693&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,387&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,387&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;9,392&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;9,392&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,084&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,084&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;44,556&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;28,693&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,863&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s investments in U.S. government bonds and money market funds are measured based on publicly available quoted market prices for identical securities as of &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022. &lt;/em&gt;The Company's investments in corporate bonds, commercial paper and certificates of deposits are measured based on quotes from market makers for similar items in active markets.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="d_2023-01-01_2023-06-30"
      id="c1F7EBBFA-1B58-42FB-9522-6D14AC70DD5C">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurements Using&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Quoted Prices&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Significant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;in Active&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Other&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance as of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Markets for&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Observable&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Identical Assets&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Inputs&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 2)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;596&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;596&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;U.S. government&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;18,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;18,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;2,011&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px;"&gt;2,011&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;7,733&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,733&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Total marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,144&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,229&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Total assets at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;35,740&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;19,511&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,229&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Fair Value Measurements Using&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Quoted Prices&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Significant&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;in Active&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Other&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance as of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Markets for&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Observable&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Identical Assets&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Inputs&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 1)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(Level 2)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;U.S. government&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;28,693&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;28,693&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,387&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,387&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;9,392&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;9,392&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; text-indent: 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,084&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,084&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;44,556&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;28,693&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,863&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505316"
      unitRef="USD">596000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505317"
      unitRef="USD">596000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505318"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505320"
      unitRef="USD">18915000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505321"
      unitRef="USD">18915000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505322"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505323"
      unitRef="USD">6485000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505324"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505325"
      unitRef="USD">6485000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505326"
      unitRef="USD">2011000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505327"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505328"
      unitRef="USD">2011000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505329"
      unitRef="USD">7733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505330"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505331"
      unitRef="USD">7733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505332"
      unitRef="USD">35144000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505333"
      unitRef="USD">18915000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505334"
      unitRef="USD">16229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-4"
      id="c101505335"
      unitRef="USD">35740000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505336"
      unitRef="USD">19511000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2023-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505337"
      unitRef="USD">16229000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505357"
      unitRef="USD">28693000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505358"
      unitRef="USD">28693000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505359"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505360"
      unitRef="USD">2387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505361"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505362"
      unitRef="USD">2387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c101505363"
      unitRef="USD">9392000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c101505364"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c101505365"
      unitRef="USD">9392000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505366"
      unitRef="USD">4084000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505367"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505368"
      unitRef="USD">4084000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505369"
      unitRef="USD">44556000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505370"
      unitRef="USD">28693000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c101505371"
      unitRef="USD">15863000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444554">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt;&#160;Investments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The following table summarizes the Company&#x2019;s investments as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Cost Basis&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;596&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;596&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Marketable securities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;"&gt;U.S. government&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;18,991&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(76&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;18,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;"&gt;Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;6,548&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(63&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;6,485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,014&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(3&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,011&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;7,745&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(13&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;7,733&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Total marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,298&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(155&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,144&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;35,894&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(155&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;35,740&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company classifies its investments as available-for-sale, and they consist entirely of debt securities. As of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, the amortized cost of investments included an immaterial amount of accrued interest. As of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, marketable securities were&#160;in a net unrealized loss position.&#160;Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss.&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, the aggregate fair value of investments held by the Company in an unrealized loss position was $33.9 million&#160;which consisted of&#160;&lt;em style="font: inherit;"&gt;38&lt;/em&gt; securities.&#160;The unrealized loss was primarily driven by rising interest rates. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to settle the debentures at a price less than the amortized cost basis of the investment; the Company expects to recover the entire amortized cost basis of the security. In accordance with the Company&#x2019;s general investment strategy, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; intend to sell the investments before maturity. As of&#160;&lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; allowance for credit losses were recognized in the period.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s investments&#160;as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; mature at various dates through &lt;em style="font: inherit;"&gt; January 2026. &lt;/em&gt;The fair values of investments&#160;by contractual maturity consist of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Maturities within one year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;27,770&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;44,556&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Maturities after one year through three years&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,970&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;35,740&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;44,556&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444555">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Cost Basis&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;596&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;596&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Marketable securities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;"&gt;U.S. government&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;18,991&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(76&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;18,915&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;"&gt;Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;6,548&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(63&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;6,485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,014&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(3&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,011&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;7,745&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(13&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;7,733&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Total marketable securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,298&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(155&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,144&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;35,894&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(155&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;35,740&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c101505388"
      unitRef="USD">596000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <urgn:CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c101505389"
      unitRef="USD">0</urgn:CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <urgn:CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c101505390"
      unitRef="USD">-0</urgn:CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-06-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c101505391"
      unitRef="USD">596000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505393"
      unitRef="USD">18991000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505394"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505395"
      unitRef="USD">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FinancialInstrumentAxis-USTreasuryAndGovernmentMember"
      decimals="-3"
      id="c101505396"
      unitRef="USD">18915000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505397"
      unitRef="USD">6548000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505398"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505399"
      unitRef="USD">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c101505400"
      unitRef="USD">6485000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember"
      decimals="-3"
      id="c101505401"
      unitRef="USD">2014000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember"
      decimals="-3"
      id="c101505402"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember"
      decimals="-3"
      id="c101505403"
      unitRef="USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CommercialPaperMember"
      decimals="-3"
      id="c101505404"
      unitRef="USD">2011000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505405"
      unitRef="USD">7745000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505406"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505407"
      unitRef="USD">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c101505408"
      unitRef="USD">7733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505409"
      unitRef="USD">35298000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505410"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505411"
      unitRef="USD">155000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505412"
      unitRef="USD">35144000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ShortTermInvestments
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505413"
      unitRef="USD">35894000</us-gaap:ShortTermInvestments>
    <urgn:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505414"
      unitRef="USD">1000</urgn:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax>
    <urgn:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505415"
      unitRef="USD">155000</urgn:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax>
    <urgn:CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c101505416"
      unitRef="USD">35740000</urgn:CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c101505373"
      unitRef="USD">33900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444556">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Maturities within one year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;27,770&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;44,556&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Maturities after one year through three years&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,970&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;35,740&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;44,556&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c101505421"
      unitRef="USD">27770000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505422"
      unitRef="USD">44556000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <urgn:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c101505423"
      unitRef="USD">7970000</urgn:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <urgn:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505424"
      unitRef="USD">0</urgn:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <us-gaap:Investments
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c101505425"
      unitRef="USD">35740000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505426"
      unitRef="USD">44556000</us-gaap:Investments>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444557">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Property and Equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment, consists of the following as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;456&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;452&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,195&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,168&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;610&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;602&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;617&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;617&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Manufacturing equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;607&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;608&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;4,485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;4,447&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,575&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,150&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;910&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,297&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Depreciation and amortization expense was $0.2&#160;million and $0.4 million for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and $0.2&#160;million and $0.4 million for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444558">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;456&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;452&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,195&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,168&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;610&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;602&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;617&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;617&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Manufacturing equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;607&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;608&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;4,485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;4,447&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,575&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,150&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;910&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,297&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c101505441"
      unitRef="USD">456000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c101505442"
      unitRef="USD">452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember"
      decimals="-3"
      id="c101505443"
      unitRef="USD">2195000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputersAndSoftwareMember"
      decimals="-3"
      id="c101505444"
      unitRef="USD">2168000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember"
      decimals="-4"
      id="c101505445"
      unitRef="USD">610000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureMember"
      decimals="-3"
      id="c101505446"
      unitRef="USD">602000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c101505447"
      unitRef="USD">617000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c101505448"
      unitRef="USD">617000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember"
      decimals="-3"
      id="c101505449"
      unitRef="USD">607000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ManufacturingEquipmentMember"
      decimals="-3"
      id="c101505450"
      unitRef="USD">608000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505451"
      unitRef="USD">4485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505452"
      unitRef="USD">4447000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505453"
      unitRef="USD">3575000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c101505454"
      unitRef="USD">3150000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-06-30"
      decimals="-4"
      id="c101505455"
      unitRef="USD">910000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505456"
      unitRef="USD">1297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-5"
      id="c101505428"
      unitRef="USD">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-5"
      id="c101505429"
      unitRef="USD">400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-5"
      id="c101505432"
      unitRef="USD">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-5"
      id="c101505433"
      unitRef="USD">400000</us-gaap:DepreciationDepletionAndAmortization>
    <urgn:PrepaidForwardObligationDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444559">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Prepaid Forward Obligation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; March 2021, &lt;/em&gt;the Company entered into a prepaid forward agreement with RTW Investments (&#x201c;RTW&#x201d;). Under the terms of the RTW Transaction, the Company received $75.0 million (&lt;span style="background-color:#ffffff;"&gt;$72.4&lt;/span&gt;&#160;million net of transaction&#160;costs) to support the continued launch of &lt;i&gt;Jelmyto&lt;/i&gt; and the development of UGN-&lt;em style="font: inherit;"&gt;102.&lt;/em&gt; In return for the transferred funds, RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of &lt;i&gt;Jelmyto&lt;/i&gt; in an amount equal to: (i) 9.5% of annual net sales up to &lt;em style="font: inherit;"&gt;$200&lt;/em&gt; million, (ii) 3.0% of annual net sales for annual net sales between &lt;em style="font: inherit;"&gt;$200&lt;/em&gt; million and &lt;em style="font: inherit;"&gt;$300&lt;/em&gt; million, and (iii) 1.0% of annual net sales for annual net sales above &lt;em style="font: inherit;"&gt;$300&lt;/em&gt; million. If certain revenue thresholds for &lt;i&gt;Jelmyto&lt;/i&gt; aggregate worldwide annual net sales are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; met, the future cash payments to RTW with respect to &lt;i&gt;Jelmyto&lt;/i&gt; annual net sales up to &lt;em style="font: inherit;"&gt;$200&lt;/em&gt; million will increase by 3.5%, and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;decrease back to &lt;em style="font: inherit;"&gt;9.5%&lt;/em&gt; dependent on the Company meeting certain subsequent &lt;i&gt;Jelmyto&lt;/i&gt; aggregate worldwide annual net sales thresholds. The&#160;rate in effect for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;for annual net sales up to $200 million was 13.0%.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In addition, subject to FDA approval of UGN-&lt;em style="font: inherit;"&gt;102,&lt;/em&gt; RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of UGN-&lt;em style="font: inherit;"&gt;102&lt;/em&gt; in an amount equal to: (i) 2.5% of annual net sales up to &lt;em style="font: inherit;"&gt;$200&lt;/em&gt; million, (ii) 1.0% of annual net sales for annual net sales between &lt;em style="font: inherit;"&gt;$200&lt;/em&gt; million and &lt;em style="font: inherit;"&gt;$300&lt;/em&gt; million, and (iii) 0.5% of annual net sales for annual net sales above &lt;em style="font: inherit;"&gt;$300&lt;/em&gt; million. If the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; receive FDA approval for UGN-&lt;em style="font: inherit;"&gt;102&lt;/em&gt; by a specified date, the future cash payments to RTW with respect to aggregate worldwide annual net sales of &lt;i&gt;Jelmyto&lt;/i&gt; across all &lt;i&gt;Jelmyto&lt;/i&gt; annual net sales tiers will increase by 1.5%. &#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In accordance with the prepaid forward agreement, the Company will be required to make payments of amounts owed to RTW each calendar quarter, through and until the quarter in which the aggregate cash payments received by RTW are equal to or greater than &lt;em style="font: inherit;"&gt;$300&lt;/em&gt; million. As security for the payment and fulfilment of these amounts throughout the arrangement, the Company has granted RTW a &lt;em style="font: inherit;"&gt;first&lt;/em&gt; priority security interest in &lt;i&gt;Jelmyto&lt;/i&gt; and UGN-&lt;em style="font: inherit;"&gt;102,&lt;/em&gt; including the regulatory approvals, intellectual property, material agreements, proceeds and accounts receivable related to these products.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In&#160;&lt;em style="font: inherit;"&gt; May 2021&lt;/em&gt;&lt;i&gt;,&lt;/i&gt;&#160;following the receipt of necessary regulatory approvals, the Company received the $75.0&#160;million prepaid forward payment ($72.4&#160;million net of transaction costs) from RTW and recognized an associated prepaid forward obligation liability. Each period the Company makes a payment to RTW, an expense is recognized related to financing on the prepaid forward obligation based on an imputed rate derived from the expected future payments. Management reassesses the effective rate each period based on the current carrying value of the obligation and the revised estimated future payments. Changes in future payments from previous estimates are included in&#160;future financing expense.&#160;The Company does &lt;span style="-sec-ix-hidden:c101505494"&gt;not&lt;/span&gt; expect to make any principal payments in the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The following table shows the activity with respect to the carrying value of the prepaid forward liability for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months ended &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; in thousands:&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 87%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Carrying value of prepaid forward obligation as of December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;85,713&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Financing on prepaid forward obligation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;21,559&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Amounts paid and payable (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Carrying value of prepaid forward obligation as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;98,923&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Financing on prepaid forward obligation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;10,568&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Amounts paid and payable (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,984&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Carrying value of prepaid forward obligation as of June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;104,507&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/sup&gt; $2.7&#160;million and $2.3&#160;million&#160;of the Amounts paid and payable are included as current portion of the prepaid forward obligation within other current liabilities on the condensed consolidated balance sheets as of &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;respectively.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </urgn:PrepaidForwardObligationDisclosureTextBlock>
    <urgn:ProceedsFromPrepaidForwardObligation
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember"
      decimals="-6"
      id="c101505458"
      unitRef="USD">75000000.0</urgn:ProceedsFromPrepaidForwardObligation>
    <urgn:ProceedsFromPrepaidForwardArrangementNet
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember"
      decimals="-5"
      id="c101505459"
      unitRef="USD">72400000</urgn:ProceedsFromPrepaidForwardArrangementNet>
    <urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOfUpTo200MillionMember"
      decimals="3"
      id="c101505461"
      unitRef="Pure">0.095</urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales>
    <urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesBetween200MillionAnd300MillionMember"
      decimals="2"
      id="c101505463"
      unitRef="Pure">0.030</urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales>
    <urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOver300MillionMember"
      decimals="2"
      id="c101505466"
      unitRef="Pure">0.010</urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales>
    <urgn:PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-JelmytoMember_StatementScenarioAxis-SalesOfUpTo200MillionMember"
      decimals="3"
      id="c101505470"
      unitRef="Pure">0.035</urgn:PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales>
    <urgn:PrepaidForwardAgreementMinimumFutureCashFlows
      contextRef="i_2023-06-30_CounterpartyNameAxis-RTWInvestmentsMember"
      decimals="-8"
      id="c101505475"
      unitRef="USD">200000000</urgn:PrepaidForwardAgreementMinimumFutureCashFlows>
    <urgn:PrepaidForwardAgreementMinimumFutureCashFlowsRate
      contextRef="i_2023-06-30_CounterpartyNameAxis-RTWInvestmentsMember"
      decimals="2"
      id="c101505476"
      unitRef="Rate">0.130</urgn:PrepaidForwardAgreementMinimumFutureCashFlowsRate>
    <urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_ProductOrServiceAxis-UGN102Member_StatementScenarioAxis-SalesUpTo200MillionWithFDAApprovalMember"
      decimals="3"
      id="c101505479"
      unitRef="Pure">0.025</urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales>
    <urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesBetween200MillionAnd300MillionWithFDAApprovalMember"
      decimals="2"
      id="c101505481"
      unitRef="Pure">0.010</urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales>
    <urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesOver300MillionWithFDAApprovalMember"
      decimals="3"
      id="c101505484"
      unitRef="Pure">0.005</urgn:PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales>
    <urgn:PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-RTWInvestmentsMember_StatementScenarioAxis-SalesOver300MillionWithFDAApprovalMember"
      decimals="3"
      id="c101505488"
      unitRef="Pure">0.015</urgn:PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales>
    <urgn:ProceedsFromPrepaidForwardObligation
      contextRef="d_2021-05-01_2021-05-31_CounterpartyNameAxis-RTWInvestmentsMember"
      decimals="-6"
      id="c101505492"
      unitRef="USD">75000000.0</urgn:ProceedsFromPrepaidForwardObligation>
    <urgn:ProceedsFromPrepaidForwardArrangementNet
      contextRef="d_2021-05-01_2021-05-31_CounterpartyNameAxis-RTWInvestmentsMember"
      decimals="-5"
      id="c101505493"
      unitRef="USD">72400000</urgn:ProceedsFromPrepaidForwardArrangementNet>
    <urgn:ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444560">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 87%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Carrying value of prepaid forward obligation as of December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;85,713&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Financing on prepaid forward obligation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;21,559&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Amounts paid and payable (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Carrying value of prepaid forward obligation as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;98,923&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Financing on prepaid forward obligation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;10,568&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Amounts paid and payable (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,984&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Carrying value of prepaid forward obligation as of June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;104,507&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </urgn:ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock>
    <urgn:PrepaidForwardObligation
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c101505505"
      unitRef="USD">85713000</urgn:PrepaidForwardObligation>
    <urgn:FinancingOnPrepaidForwardObligation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c101505506"
      unitRef="USD">21559000</urgn:FinancingOnPrepaidForwardObligation>
    <urgn:DecreaseInPrepaidForwardObligationAmountsPaidAndPayable
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c101505507"
      unitRef="USD">8349000</urgn:DecreaseInPrepaidForwardObligationAmountsPaidAndPayable>
    <urgn:PrepaidForwardObligation
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505508"
      unitRef="USD">98923000</urgn:PrepaidForwardObligation>
    <urgn:FinancingOnPrepaidForwardObligation
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505509"
      unitRef="USD">10568000</urgn:FinancingOnPrepaidForwardObligation>
    <urgn:DecreaseInPrepaidForwardObligationAmountsPaidAndPayable
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505510"
      unitRef="USD">4984000</urgn:DecreaseInPrepaidForwardObligationAmountsPaidAndPayable>
    <urgn:PrepaidForwardObligation
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505511"
      unitRef="USD">104507000</urgn:PrepaidForwardObligation>
    <urgn:PrepaidForwardObligation
      contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="c101505500"
      unitRef="USD">2700000</urgn:PrepaidForwardObligation>
    <urgn:PrepaidForwardObligation
      contextRef="i_2022-12-31_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="c101505501"
      unitRef="USD">2300000</urgn:PrepaidForwardObligation>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444561">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; &#x2013; Long-Term Debt&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; March 7,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2022,&lt;/em&gt;&#160;the Company entered into a loan&#160;agreement with Pharmakon&#160;for a&#160;senior secured term loan of up to $100&#160;million in&#160;&lt;em style="font: inherit;"&gt;two&lt;/em&gt;&#160;tranches. The&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;tranche of $75&#160;million was funded in&#160;&lt;em style="font: inherit;"&gt; March 2022. &lt;/em&gt;The &lt;em style="font: inherit;"&gt;second&lt;/em&gt; tranche of&#160;$25&#160;million was funded in&#160;&lt;em style="font: inherit;"&gt; December 2022. &lt;/em&gt;The facility will mature&#160;&lt;span style="-sec-ix-hidden:c101505520"&gt;five&lt;/span&gt;&#160;years from initial funding and can be prepaid in whole at the Company's&#160;discretion, at any time, subject to prepayment premiums and make-whole amounts.&#160;The loan will require interest-only payments for the&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;&lt;em style="font: inherit;"&gt;48&lt;/em&gt;&#160;months followed by principal and interest payments with interest accruing using&#160;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;-month London Inter-Bank Offered Rate (&#x201c;LIBOR&#x201d;) (with a&#160;1.25% floor) plus&#160;8.25%. On &lt;em style="font: inherit;"&gt; June 29, 2023, &lt;/em&gt;the loan agreement with Pharmakon was amended to replace&#160;the benchmark governing the interest rate with a rate based on the secured overnight financing rate ("SOFR") published by the Federal Reserve Bank of New York.&#160; Effective &lt;em style="font: inherit;"&gt; July 2023, &lt;/em&gt;the loan&#160;will accrue interest using a benchmark rate of &lt;em style="font: inherit;"&gt;3&lt;/em&gt;-month SOFR plus a&#160;0.26161% adjustment. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; required to maintain any financial covenants.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company incurred financing expenses of $4.2 million which are recognized as a direct offset to the long-term debt on the Company's condensed consolidated balance sheets. These debt issuance costs are&#160;amortized over the term of the debt using the&#160;effective interest method, and are&#160;recorded in the condensed consolidated statements of operations as "Interest expense".&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The following table shows the activity with respect to the carrying value of the long-term debt, in thousands:&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Long-term debt at closing of Pharmakon loan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Capitalized costs and discounts&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,217&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;8,438&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Amounts paid&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,685&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Carrying value of Pharmakon loan as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;97,537&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Interest expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;7,314&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Amounts paid&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,555&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Carrying value of Pharmakon loan as of June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;98,296&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;&#160;&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:SecuredLongTermDebt
      contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-8"
      id="c101505514"
      unitRef="USD">100000000</us-gaap:SecuredLongTermDebt>
    <urgn:SecuredLongTermDebtFirstTranche
      contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-6"
      id="c101505517"
      unitRef="USD">75000000</urgn:SecuredLongTermDebtFirstTranche>
    <urgn:SecuredLongTermDebtAdditionalDraw
      contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-6"
      id="c101505519"
      unitRef="USD">25000000</urgn:SecuredLongTermDebtAdditionalDraw>
    <urgn:DebtInstrumentLIBORFloor
      contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="4"
      id="c101505524"
      unitRef="Pure">0.0125</urgn:DebtInstrumentLIBORFloor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2022-03-07_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember_VariableRateAxis-LondonInterbankOfferedRateLibor1Member"
      decimals="4"
      id="c101505525"
      unitRef="Pure">0.0825</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2023-07-01_2023-07-31_LongtermDebtTypeAxis-SecuredDebtMember_SubsequentEventTypeAxis-SubsequentEventMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember"
      decimals="7"
      id="c101505527"
      unitRef="Pure">0.0026161</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember"
      decimals="-5"
      id="c101505529"
      unitRef="USD">4200000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444562">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Long-term debt at closing of Pharmakon loan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Capitalized costs and discounts&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,217&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;8,438&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Amounts paid&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,685&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Carrying value of Pharmakon loan as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;97,537&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Interest expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;7,314&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Amounts paid&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,555&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Carrying value of Pharmakon loan as of June 30, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;98,296&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2022-01-01_DebtInstrumentAxis-PharmakonLoanMember"
      decimals="-8"
      id="c101505530"
      unitRef="USD">100000000</us-gaap:DebtInstrumentFaceAmount>
    <urgn:DebtInstrumentCapitalizedCostsAndDiscounts
      contextRef="i_2022-01-01_DebtInstrumentAxis-PharmakonLoanMember"
      decimals="-3"
      id="c101505531"
      unitRef="USD">4217000</urgn:DebtInstrumentCapitalizedCostsAndDiscounts>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="d_2022-01-01_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember"
      decimals="-3"
      id="c101505532"
      unitRef="USD">8438000</us-gaap:InterestExpenseLongTermDebt>
    <urgn:DebtInstrumentPaidAndPayableAmount
      contextRef="i_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember"
      decimals="-3"
      id="c101505533"
      unitRef="USD">6685000</urgn:DebtInstrumentPaidAndPayableAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2022-12-31_DebtInstrumentAxis-PharmakonLoanMember"
      decimals="-3"
      id="c101505534"
      unitRef="USD">97537000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="d_2023-01-01_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember"
      decimals="-3"
      id="c101505535"
      unitRef="USD">7314000</us-gaap:InterestExpenseLongTermDebt>
    <urgn:DebtInstrumentPaidAndPayableAmount
      contextRef="i_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember"
      decimals="-3"
      id="c101505536"
      unitRef="USD">6555000</urgn:DebtInstrumentPaidAndPayableAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2023-06-30_DebtInstrumentAxis-PharmakonLoanMember"
      decimals="-3"
      id="c101505537"
      unitRef="USD">98296000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444563">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; Leases &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company had&#160;the following office and laboratory facility leases as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; April 2016, &lt;/em&gt;UPL signed an addendum to its &lt;em style="font: inherit;"&gt; November 2014 &lt;/em&gt;lease agreement for the Company&#x2019;s&#160;offices located in Israel, in order to increase the office space rented and to extend the rent period for an additional &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years until &lt;em style="font: inherit;"&gt; August 2022. &lt;/em&gt;In&#160;&lt;em style="font: inherit;"&gt; July 2022,&#160;&lt;/em&gt;the Company signed a lease extension agreement for the Company&#x2019;s&#160;offices located in Israel, extending the term of the lease through&#160;&lt;em style="font: inherit;"&gt; September 2025.&#160;&#160;&lt;/em&gt;The Company's remaining contractual obligation under this lease is approximately $0.6&#160;million as of &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; April 2018, &lt;/em&gt;UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was &lt;em style="font: inherit;"&gt; July 10, 2018 &lt;/em&gt;and terminates in &lt;em style="font: inherit;"&gt; March 2024. &lt;/em&gt;The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company&#x2019;s remaining contractual obligation under this lease is approximately $0.2&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;. In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;UPI entered into a sublease for this office space, with a lease commencement date of&#160;&lt;em style="font: inherit;"&gt; January 1, 2020 &lt;/em&gt;and continuing until the end of the lease term in &lt;em style="font: inherit;"&gt; March 2024. &lt;/em&gt;The subtenants exercised their early access clause and moved into the premises at the end of &lt;em style="font: inherit;"&gt; November 2019.&#160;&lt;/em&gt;The remaining rental payments to be received over the lease term is approximately $0.2&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;. The Company accounts for the sublease as an operating lease in accordance with ASC &lt;em style="font: inherit;"&gt;842.&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Arial; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was &lt;em style="font: inherit;"&gt; November 29, 2019&#160;&lt;/em&gt;with an original lease term of 38 months, expiring &lt;em style="font: inherit;"&gt; January 31, 2023. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company signed a lease extension for the Princeton office, extending the term of the lease through &lt;em style="font: inherit;"&gt; January 31, 2026.&#160;&lt;/em&gt;The Company&#x2019;s remaining contractual obligation under this lease is approximately $1.5&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In addition, the Company has other operating office equipment and vehicle leases. The Company&#x2019;s operating leases &lt;em style="font: inherit;"&gt; may &lt;/em&gt;require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company&#x2019;s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; contain any residual value guarantees or material restrictive covenants. The Company&#x2019;s leases expire at various dates from &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;through &lt;em style="font: inherit;"&gt;2026,&lt;/em&gt; with varying renewal and termination options.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The components of lease cost for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;257&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;257&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;516&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Sublease income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(56&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(56&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(112&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(112&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Variable lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;36&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;220&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;220&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;411&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;440&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The amounts recognized as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Right-of-use assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,107&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,452&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Long-term lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,209&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,586&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other current liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;910&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;941&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impairment losses have been recognized.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Supplemental information related to leases for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; is as follows (in thousands, except for lease terms and discount rate amounts):&lt;/p&gt; &#160;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Operating cash flows from operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;587&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;590&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;95&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,419&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average remaining lease term of operating leases (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2.23&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;3.01&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average discount rate of operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;10.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;9.93&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;,&#160;maturities of lease liabilities were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Leases&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Years ending December 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Remainder of 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;581&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;923&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;811&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;52&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027 and thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total future minimum lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Less: Interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(248&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value of lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,119&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Subleases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, undiscounted cash flows to be received under the Company&#x2019;s operating sublease on an annual basis were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating Leases&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Years ending December 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Remainder of 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;126&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;49&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025 and thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;175&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2023-06-30_LeaseContractualTermAxis-CompanyOfficesInIsraelMember"
      decimals="-5"
      id="c101505540"
      unitRef="USD">600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="d_2020-10-01_2020-10-31_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember"
      decimals="-5"
      id="c101505543"
      unitRef="USD">200000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember"
      decimals="-5"
      id="c101505544"
      unitRef="USD">200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubleaseIncome
      contextRef="d_2023-01-01_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember"
      decimals="-5"
      id="c101505545"
      unitRef="USD">200000</us-gaap:SubleaseIncome>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2019-11-29_LeaseContractualTermAxis-LeaseAgreementForOfficeInPrincetonNewJerseyMember_LegalEntityAxis-UroGenPharmaIncMember"
      id="c101505547">P38M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2023-06-30_LeaseContractualTermAxis-LeaseAgreementForOfficeInPrincetonNewJerseyMember_LegalEntityAxis-UroGenPharmaIncMember"
      decimals="-5"
      id="c101505549"
      unitRef="USD">1500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444564">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;257&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;257&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;485&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;516&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Sublease income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(56&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(56&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(112&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;(112&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Variable lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;36&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;220&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;220&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;411&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;440&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101505573"
      unitRef="USD">257000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101505574"
      unitRef="USD">257000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505575"
      unitRef="USD">485000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505576"
      unitRef="USD">516000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101505577"
      unitRef="USD">56000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101505578"
      unitRef="USD">56000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505579"
      unitRef="USD">112000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505580"
      unitRef="USD">112000</us-gaap:SubleaseIncome>
    <us-gaap:VariableLeaseCost
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101505581"
      unitRef="USD">19000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101505582"
      unitRef="USD">19000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505583"
      unitRef="USD">38000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505584"
      unitRef="USD">36000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-4"
      id="c101505585"
      unitRef="USD">220000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-4"
      id="c101505586"
      unitRef="USD">220000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505587"
      unitRef="USD">411000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c101505588"
      unitRef="USD">440000</us-gaap:LeaseCost>
    <urgn:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444565">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Right-of-use assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,107&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,452&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Long-term lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,209&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,586&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other current liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;910&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;941&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </urgn:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505593"
      unitRef="USD">2107000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505594"
      unitRef="USD">2452000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505595"
      unitRef="USD">1209000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505596"
      unitRef="USD">1586000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2023-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember"
      decimals="-4"
      id="c101505597"
      unitRef="USD">910000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-12-31_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember"
      decimals="-3"
      id="c101505598"
      unitRef="USD">941000</us-gaap:OperatingLeaseLiabilityCurrent>
    <urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444566">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Operating cash flows from operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;587&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;590&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;95&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;1,419&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average remaining lease term of operating leases (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2.23&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;3.01&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average discount rate of operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;10.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;9.93&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505606"
      unitRef="USD">587000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-4"
      id="c101505607"
      unitRef="USD">590000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505608"
      unitRef="USD">95000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505609"
      unitRef="USD">1419000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2023-06-30" id="c101505610">P2Y2M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2022-06-30" id="c101505611">P3Y3D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2023-06-30"
      decimals="4"
      id="c101505612"
      unitRef="Pure">0.1016</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2022-06-30"
      decimals="4"
      id="c101505613"
      unitRef="Pure">0.0993</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444567">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Leases&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Years ending December 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Remainder of 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;581&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;923&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;811&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;52&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027 and thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total future minimum lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Less: Interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(248&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value of lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,119&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505617"
      unitRef="USD">581000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505618"
      unitRef="USD">923000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505619"
      unitRef="USD">811000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505620"
      unitRef="USD">52000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <urgn:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505621"
      unitRef="USD">0</urgn:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505622"
      unitRef="USD">2367000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505623"
      unitRef="USD">248000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505624"
      unitRef="USD">2119000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444568">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating Leases&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Years ending December 31,&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 14%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Remainder of 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;126&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;49&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025 and thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 83%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;175&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505627"
      unitRef="USD">126000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505628"
      unitRef="USD">49000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <urgn:LessorOperatingLeasePaymentToBeReceivedAfterNextYear
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505629"
      unitRef="USD">0</urgn:LessorOperatingLeasePaymentToBeReceivedAfterNextYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505630"
      unitRef="USD">175000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444569">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;12&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; Revenue From Product Sales&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net product sales consist of the following for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Jelmyto&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;21,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;16,604&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;38,331&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;30,168&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;Net revenue recognized includes gross revenue and management&#x2019;s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to&#160;&lt;em style="font: inherit;"&gt;340b&lt;/em&gt;&#160;drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company&#x2019;s copay assistance program, and Medicare refund for discarded drug, which are estimated based on the Company&#x2019;s historical experience. Reserves related to items that are contractually able to be net settled are recognized as contra accounts receivable while other remaining reserves are recognized within other current liabilities on the condensed consolidated balance sheets.&#160;The following table shows the activity with respect to sales reserves for period ended&#160;of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;&#160;(in thousands):&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Reserves related to government sponsored programs&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Other reserves&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total accrued sales reserves&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 43%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance as of December 31, 2022&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;590&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;847&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,437&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Accruals&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;5,392&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;6,052&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;11,444&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Utilizations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,182&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,756&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,938&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance as of June 30, 2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,143&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,943&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-size: 10pt; font-family: Arial, Helvetica, sans-serif;"&gt;&#160;&lt;/p&gt;
  </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444570">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Jelmyto&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;21,139&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;16,604&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;38,331&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;30,168&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-04-01_2023-06-30_ProductOrServiceAxis-JelmytoMember"
      decimals="-3"
      id="c101505636"
      unitRef="USD">21139000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-04-01_2022-06-30_ProductOrServiceAxis-JelmytoMember"
      decimals="-3"
      id="c101505637"
      unitRef="USD">16604000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-06-30_ProductOrServiceAxis-JelmytoMember"
      decimals="-3"
      id="c101505638"
      unitRef="USD">38331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-01-01_2022-06-30_ProductOrServiceAxis-JelmytoMember"
      decimals="-3"
      id="c101505639"
      unitRef="USD">30168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <urgn:ScheduleOfSalesReservesTableTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444571">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Reserves related to government sponsored programs&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Other reserves&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total accrued sales reserves&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 43%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance as of December 31, 2022&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;590&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;847&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,437&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Accruals&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;5,392&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;6,052&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;11,444&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Utilizations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,182&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,756&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,938&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance as of June 30, 2023&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,143&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,943&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </urgn:ScheduleOfSalesReservesTableTextBlock>
    <urgn:AccruedSalesReserve
      contextRef="i_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember"
      decimals="-4"
      id="c101505643"
      unitRef="USD">590000</urgn:AccruedSalesReserve>
    <urgn:AccruedSalesReserve
      contextRef="i_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember"
      decimals="-3"
      id="c101505644"
      unitRef="USD">847000</urgn:AccruedSalesReserve>
    <urgn:AccruedSalesReserve
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c101505645"
      unitRef="USD">1437000</urgn:AccruedSalesReserve>
    <urgn:SalesReserveAccruals
      contextRef="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember"
      decimals="-3"
      id="c101505646"
      unitRef="USD">5392000</urgn:SalesReserveAccruals>
    <urgn:SalesReserveAccruals
      contextRef="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember"
      decimals="-3"
      id="c101505647"
      unitRef="USD">6052000</urgn:SalesReserveAccruals>
    <urgn:SalesReserveAccruals
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505648"
      unitRef="USD">11444000</urgn:SalesReserveAccruals>
    <urgn:SalesReserveUtilization
      contextRef="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember"
      decimals="-3"
      id="c101505649"
      unitRef="USD">-5182000</urgn:SalesReserveUtilization>
    <urgn:SalesReserveUtilization
      contextRef="d_2023-01-01_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember"
      decimals="-3"
      id="c101505650"
      unitRef="USD">-3756000</urgn:SalesReserveUtilization>
    <urgn:SalesReserveUtilization
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505651"
      unitRef="USD">-8938000</urgn:SalesReserveUtilization>
    <urgn:AccruedSalesReserve
      contextRef="i_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-GovernmentSponsoredProgramsReservesMember"
      decimals="-5"
      id="c101505652"
      unitRef="USD">800000</urgn:AccruedSalesReserve>
    <urgn:AccruedSalesReserve
      contextRef="i_2023-06-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-OtherReservesMember"
      decimals="-3"
      id="c101505653"
      unitRef="USD">3143000</urgn:AccruedSalesReserve>
    <urgn:AccruedSalesReserve
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c101505654"
      unitRef="USD">3943000</urgn:AccruedSalesReserve>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444572">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;13&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; License and Collaboration Agreements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;Agenus Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;the Company entered into a license agreement with Agenus Inc., pursuant to which Agenus granted to the Company an exclusive, worldwide (&lt;em style="font: inherit;"&gt;not&lt;/em&gt; including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus&#x2019;s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary monoclonal antibody of Agenus known as &lt;em style="font: inherit;"&gt;AGEN1884&lt;/em&gt; (zalifrelimab), an anti-CTLA-&lt;em style="font: inherit;"&gt;4&lt;/em&gt; antagonist, for the treatment of cancers of the urinary tract via intravesical delivery. UGN-&lt;em style="font: inherit;"&gt;301&lt;/em&gt; is a formulation of zalifrelimab administered using &lt;i&gt;RTGel&lt;/i&gt;&#160;technology&#160;that is in Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; clinical&#160;development for high-grade non-muscle invasive bladder cancer ("high-grade NMIBC").&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;i&gt;MD Anderson Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; January 2021, &lt;/em&gt;the Company announced that it entered into a &lt;span style="-sec-ix-hidden:c101505661"&gt;three&lt;/span&gt;-year strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-&lt;em style="font: inherit;"&gt;201&lt;/em&gt; and UGN-&lt;em style="font: inherit;"&gt;301&lt;/em&gt;&#160;as an investigational treatment for high-grade NMIBC. Pursuant to the agreement, the Company has made&#160;bi-annual payments totaling $2.0 million to MD Anderson to fund the collaboration, recognized evenly over the associated period through research and development expenses. In &lt;em style="font: inherit;"&gt; July 2022, &lt;/em&gt;the Company determined that it had achieved the objectives that it established when the agreement was initiated, and notified MD Anderson that it was exercising its right to conclude the collaboration in &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; as the Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; foresee initiating further development activities as part of the collaboration, although the Company will continue to collaborate on existing joint projects. As a result of this notification, the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; responsible for any further&#160;fixed bi-annual funding payments in &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; although the Company will be responsible for costs related to existing joint projects to the extent they&#160;exceed the payments already made to MD Anderson.&#160;&#160;&lt;/p&gt;
  </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="d_2023-01-01_2023-06-30_CounterpartyNameAxis-MDAndersonMember"
      decimals="-6"
      id="c101505664"
      unitRef="USD">2000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444573">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;14&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; Shareholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company had 100.0 million ordinary shares authorized for issuance as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;. The Company had 23.5&#160;million and 23.1&#160;million ordinary shares issued and outstanding as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, respectively. Each ordinary share is entitled to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors (the &#x201c;Board&#x201d;). Since its inception, the Board has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; declared any dividends.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-06-30"
      decimals="-8"
      id="c101505670"
      unitRef="Share">100000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c101505671"
      unitRef="Share">23500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c101505672"
      unitRef="Share">23100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444574">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;15&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; October 2010, &lt;/em&gt;the Board approved a share option plan (the &lt;em style="font: inherit;"&gt;"2010&lt;/em&gt; Plan") for grants to Company employees, consultants, directors, and other service providers. Subsequently, in &lt;em style="font: inherit;"&gt; March 2017, &lt;/em&gt;the Board adopted the &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; Equity Incentive Plan (the &lt;em style="font: inherit;"&gt;"2017&lt;/em&gt; Plan" and, together with the &lt;em style="font: inherit;"&gt;2010&lt;/em&gt; Plan, the "Plans"), which was approved by the shareholders in &lt;em style="font: inherit;"&gt; April 2017. &lt;/em&gt;The &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance share awards, performance cash awards, and other forms of share awards to the Company's employees, directors and consultants.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The grant of options to Israeli employees under the Plans is subject to the terms stipulated by Section &lt;em style="font: inherit;"&gt;102&lt;/em&gt; of the Israeli Income Tax Ordinance (&#x201c;Section &lt;em style="font: inherit;"&gt;102&#x201d;&lt;/em&gt;). The option grants are subject to the track chosen by the Company, either the &#x201c;regular income&#x201d; track or the &#x201c;capital gains&#x201d; track, as set out in Section &lt;em style="font: inherit;"&gt;102.&lt;/em&gt; The Company registered the Plans under the capital gains track, which offers more favorable tax rates to the employees. As a result, and pursuant to the terms of Section &lt;em style="font: inherit;"&gt;102,&lt;/em&gt; the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; allowed to claim as an expense for tax purposes the amounts credited to the employees in respect of options granted to them under the Plans, including amounts recorded as salary benefits in the Company&#x2019;s accounts, with the exception of the work-income benefit component, if any, determined on grant date. For non-employees and for non-Israeli employees, the Plans is&#160;subject to Section &lt;em style="font: inherit;"&gt;3&lt;/em&gt;(i) of the Israeli Income Tax Ordinance.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employees are typically granted stock options and/or restricted stock units&#160;("RSUs"), upon commencement of employment. Also, eligible employees &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive an annual grant of options or RSUs. Non-employee members of the Board typically receive a grant of stock options upon initial appointment to the Board, and/or stock options annually. The term of any option granted under the Plans cannot exceed 10 years. Options shall &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an exercise price less than 100% of the fair market value of the Company&#x2019;s ordinary shares on the grant date, and generally vest over a period of &lt;span style="-sec-ix-hidden:c101505697"&gt;three&lt;/span&gt; years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be less than 110% of the fair market value of an ordinary share&#160;on the date of grant.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; anniversary of grant, and in either equal quarterly or annual amounts for the &lt;span style="-sec-ix-hidden:c101505703"&gt;two&lt;/span&gt; years following the &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-year anniversary of the grant date. Options generally vest in a 33% increment upon the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; anniversary of the grant date, and in either equal quarterly or annual amounts for the &lt;span style="-sec-ix-hidden:c101505707"&gt;two&lt;/span&gt; years following the &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-year anniversary of the grant date.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The expected volatility is based on a mix of the Company&#x2019;s historical volatility, and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted. The expected term is the length of time until the expected dates of exercising the options and is estimated for employees using the simplified method due to insufficient specific historical information of employees&#x2019; exercise behavior, and for non-employees, and directors using the contractual term.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The maximum number of ordinary shares that was initially authorized for issuance under the &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; Plan was&#160;1,400,000.&#160;On &lt;em style="font: inherit;"&gt; January 1, 2018, &lt;/em&gt;the share reserve increased by 250,167 to 1,650,167 shares. On &lt;em style="font: inherit;"&gt; October 12, 2018, &lt;/em&gt;the Company increased the number&#160;of ordinary shares authorized for issuance under the &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; Plan by 1,900,000 to 3,550,167 shares. On &lt;em style="font: inherit;"&gt; June 8, 2020, &lt;/em&gt;the Company&#x2019;s shareholders approved an increase to the number&#160;of&#160;ordinary shares authorized for issuance under&#160;the &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; Plan by 400,000 to 3,950,167 shares. On &lt;em style="font: inherit;"&gt; June 7, 2021, &lt;/em&gt;the Company&#x2019;s shareholders approved an increase to the number&#160;of ordinary shares authorized for issuance under the &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; Plan by 400,000 to 4,350,167 shares. On &lt;em style="font: inherit;"&gt; June 8, 2022, &lt;/em&gt;the Company's shareholders approved an increase to the number&#160;of ordinary shares authorized for issuance under the &lt;em style="font: inherit;"&gt;2017&lt;/em&gt;&#160;Plan by 400,000 to 4,750,167 shares.&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; May 2019, &lt;/em&gt;the Company adopted the UroGen Pharma Ltd. &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Inducement Plan (the &#x201c;Inducement Plan&#x201d;). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to inducement awards. The only persons eligible to receive grants under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule &lt;em style="font: inherit;"&gt;5635&lt;/em&gt;(c)(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) and the related guidance under Nasdaq IM&#160;&lt;em style="font: inherit;"&gt;5635&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1,&lt;/em&gt;&#160;including individuals who were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; previously an employee or director of the Company or are following a bona fide period of&#160;non-employment,&#160;in each case as an inducement material to such individual&#x2019;s agreement to enter into employment with the Company. In &lt;em style="font: inherit;"&gt; December 2021, &lt;/em&gt;the Board approved a 300,000 increase in the share reserve of the Inducement Plan.&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;As of &lt;/span&gt;&lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;&lt;span style="background-color:#ffffff;"&gt;, &lt;/span&gt;3,493,724&#160;&lt;span style="background-color:#ffffff;"&gt;ordinary shares are subject to outstanding awards under the Company's share-based compensation plans and 941,759&#160;ordinary shares remain available for future awards.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The following table illustrates the effect of share-based compensation on the condensed consolidated statements of operations (in thousands):&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;496&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;673&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,021&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,398&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Selling, general and administrative expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,726&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,150&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,487&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,374&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total share-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,222&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,823&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,508&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,772&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The total unrecognized compensation cost of options and RSUs at &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; is&#160;$12.6&#160;million with a weighted average recognition period of 2.0&#160;years.&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MaximumMember"
      id="c101505694">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MinimumMember"
      decimals="0"
      id="c101505696"
      unitRef="Pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember"
      decimals="1"
      id="c101505698"
      unitRef="Pure">0.10</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage>
    <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-ShareOptionPlanMember_RangeAxis-MinimumMember"
      decimals="1"
      id="c101505700"
      unitRef="Pure">1.10</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="c101505701"
      unitRef="Pure">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-EmployeeStockOptionMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="c101505705"
      unitRef="Pure">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2017-03-31_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505710"
      unitRef="Share">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2018-01-01_2018-01-01_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505711"
      unitRef="Share">250167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2018-01-01_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505712"
      unitRef="Share">1650167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2018-10-12_2018-10-12_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505714"
      unitRef="Share">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2018-10-12_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505715"
      unitRef="Share">3550167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2020-06-08_2020-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505717"
      unitRef="Share">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505718"
      unitRef="Share">3950167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2021-06-07_2021-06-07_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505720"
      unitRef="Share">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2021-06-07_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505721"
      unitRef="Share">4350167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2022-06-08_2022-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505723"
      unitRef="Share">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2022-06-08_PlanNameAxis-TwoThousandSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="c101505724"
      unitRef="Share">4750167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2019-05-31_PlanNameAxis-The2019InducementPlanMember"
      decimals="INF"
      id="c101505726"
      unitRef="Share">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2021-12-01_2021-12-31_PlanNameAxis-The2019InducementPlanMember"
      decimals="INF"
      id="c101505732"
      unitRef="Share">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c101505733"
      unitRef="Share">3493724</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c101505734"
      unitRef="Share">941759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444575">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Arial, Helvetica, sans-serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six Months Ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; width: 44%;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;496&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;673&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,021&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;1,398&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Selling, general and administrative expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,726&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,150&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,487&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,374&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt; &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total share-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,222&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,823&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,508&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,772&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c101505750"
      unitRef="USD">496000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c101505751"
      unitRef="USD">673000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c101505752"
      unitRef="USD">1021000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c101505753"
      unitRef="USD">1398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c101505754"
      unitRef="USD">1726000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-04-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-4"
      id="c101505755"
      unitRef="USD">2150000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c101505756"
      unitRef="USD">3487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c101505757"
      unitRef="USD">4374000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c101505758"
      unitRef="USD">2222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="-3"
      id="c101505759"
      unitRef="USD">2823000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c101505760"
      unitRef="USD">4508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="-3"
      id="c101505761"
      unitRef="USD">5772000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c101505736"
      unitRef="USD">12600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2023-01-01_2023-06-30" id="c101505737">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444576">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;16&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; Income Taxes &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;UroGen Pharma Ltd. is taxed under Israeli tax laws. As of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, the Company continues to maintain a full valuation allowance against deferred tax assets for all jurisdictions. In evaluating the need for a valuation allowance, the Company considers all sources of taxable income available to realize the deferred tax asset, including the future reversal of existing temporary differences, forecasts of future taxable income, and tax planning strategies. The Company has cumulative global pretax losses for the years ended &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; and for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;. The Company will continue to assess the extent to which its deferred tax assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be realized in the future and will adjust the valuation allowance as needed.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company has a liability for uncertain tax positions of $3.0&#160;million as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;, the Company&#x2019;s liability for uncertain tax positions includes $1.1&#160;million of accrued interest and penalties.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company operates on a global basis and is subject to tax laws and regulations in the United States&#160;and Israel. The estimate of the Company&#x2019;s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result from its uncertain tax positions. Based upon the information currently available, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; reasonably expect changes in its existing uncertain tax positions in the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months and has recorded the gross uncertain tax positions as a long-term liability.&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-06-30"
      decimals="-6"
      id="c101505767"
      unitRef="USD">3000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2023-06-30"
      decimals="-5"
      id="c101505768"
      unitRef="USD">1100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444577">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;17&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; Related Parties&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; related party transactions for the&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; or &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;.&lt;/p&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444578">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;18&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; Commitments and Contingencies &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these arrangements is unknown as of &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate recognizing any significant losses relating to these arrangements.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;See Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt;&#160;for further discussion regarding lease commitments.&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2023-01-01_2023-06-30" id="c2444579">
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;19&lt;/em&gt;&#160;&lt;/b&gt;&#x2013;&lt;b&gt; Subsequent Events&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; July&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;26,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional and other accredited investors (the &#x201c;Purchasers&#x201d;), pursuant to which the Company agreed to sell and issue to the Purchasers 12,579,156 ordinary shares of the Company (&#x201c;Shares&#x201d;) (or in lieu of Shares,&#160;pre-funded&#160;warrants to purchase ordinary shares of the Company) at a purchase price of $9.54 per Share (or $9.539 for each ordinary share underlying a&#160;pre-funded&#160;warrant), in a private placement transaction (the &#x201c;Private Placement&#x201d;) for aggregate gross proceeds of $120.0 million, before deducting fees to placement agents and financial advisors and before other expenses payable by the Company. Each&#160;pre-funded&#160;warrant has&#160;an exercise price of $0.001 per ordinary share, subject to customary adjustments, became&#160;exercisable upon original issuance and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expire until exercised in full. The&#160;pre-funded&#160;warrants &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be exercised if the aggregate number of ordinary shares beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation. The aggregate fee payable by the Company to placement agents and financial advisors is&#160;$3.6 million, plus the reimbursement of certain expenses.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Monograph Capital Partners I, L.P. (&#x201c;Monograph&#x201d;), a life sciences venture firm that is affiliated with Fred Cohen, M.D., a director of the Company, purchased 1,572,327 of the Shares in the Private Placement, for an aggregate purchase price of $15.0&#160;million. Dr.&#160;Cohen is the Chair and Chief Investment Officer of Monograph.&lt;/p&gt;
   &lt;p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c101505781"
      unitRef="Share">12579156</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c101505782"
      unitRef="USDPerShare">9.54</us-gaap:SharesIssuedPricePerShare>
    <urgn:ClassOfWarrantsOrRightsIssuancePricePerShare
      contextRef="i_2023-07-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c101505783"
      unitRef="USDPerShare">9.539</urgn:ClassOfWarrantsOrRightsIssuancePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-7"
      id="c101505784"
      unitRef="USD">120000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-07-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c101505785"
      unitRef="USDPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <urgn:PlacementAgentsAndFinancialAdvisorsFees
      contextRef="d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c101505788"
      unitRef="USD">3600000</urgn:PlacementAgentsAndFinancialAdvisorsFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c101506847"
      unitRef="Share">1572327</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-6"
      id="c101506848"
      unitRef="USD">15000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c101505270"
          xlink:label="c101505270"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c101505271"
          xlink:label="c101505271"
          xlink:type="locator"/>
        <link:footnote id="f77a016e4-dc74-4be3-af47-01f1c1cc61c6" xlink:label="f77a016e4-dc74-4be3-af47-01f1c1cc61c6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">$1.5 million and $1.0 million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c101505270"
          xlink:to="f77a016e4-dc74-4be3-af47-01f1c1cc61c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c101505271"
          xlink:to="f77a016e4-dc74-4be3-af47-01f1c1cc61c6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c101505510"
          xlink:label="c101505510"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c101505507"
          xlink:label="c101505507"
          xlink:type="locator"/>
        <link:footnote id="fdbc58e92-bcbc-4c05-93c1-815a65a63318" xlink:label="fdbc58e92-bcbc-4c05-93c1-815a65a63318" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">$2.7 million and $2.3 million of the Amounts paid and payable are included as current portion of the prepaid
forward obligation within other current liabilities on the condensed consolidated balance sheets as of June 30,
2023 and December 31, 2022, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c101505510"
          xlink:to="fdbc58e92-bcbc-4c05-93c1-815a65a63318"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c101505507"
          xlink:to="fdbc58e92-bcbc-4c05-93c1-815a65a63318"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MIT.L.W%6^TH4V\-@F<$VS9]?DV^'0IP,P+AG #X,P,H PGH&D,, H@R@J&<
M/0R@Z@Q^SP#O,,!3!B#2,X =!K"F]L_%:BJ]3$0RORJ+)Z>LHZ5:_::QJQDM
M"YSF=6?=BE+^-Y7CQ'Q1Y&O9)WSMR'=5D:7K1,B#6R%?9 .)RBGNG=M-4O)-
MD:UY6?WD+/E]NDJ%\_)+GNS7J0Q_Y4R=+[=+Y^6+5\X+)\V=WS?%ODKR=74U
M$S+)>JK9ZI#0^^>$<&]"VZWLN%M1K+XZ?WWDVSM>_FV06=AEWJUE9K)UD\RY
M2=+U5":U2':ID,<6T:5=]#,7\EJ5Y8F2,D_SA^JU\VZW*XM=F395LRA'9]+]
MM/C@O!.B3._V(KG+N",*F7@I';"IQG;5WPMYOMUA,]D?QR;!QR;!C0[MT7F?
M9$F^XLY+6<6J[H7JE9,(V0BK-PY!KQWL8F1R^EG5:U3K6]SC'&/*<!AZ5[/'
M4R^MT]<WU[?5+EGQZXF\>U:\?.23^8\_(.;^;/(04BR"%(N!Q#H>DJ.'9)"'
M0WQ[5F(GOC&D.*:'4-]C8= -6^IA4\I\@A6YR!"'E2:)]9B (G(,ZE2%'JM"
MK56)OO%RE5:\OLL5N_J&4<G[E[SVBG*=YO)1>^CWT]8W58SJG<YH$#*E:M9D
MQO8YI%@$*18#B74<]8Z.>B".FESTM Y3V][3?$9*FRZMZ8VU!5(L-B3/S)</
M.Q:;68O=+ RF]<IN[:R*K5SN5DE=<E-QK4HC3V7!M%/Q?!\K3D#.&$&*Q6?2
M[WCA'[WPK5Y\$AM>-B[(M5J]]'_DLO'EL7QN9T5EOF]9)<UGY9C\ -)9 NE$
MOE;@*5&NY=@>T_$@.'H06#WX3:)@76M3J:TCQ_8_I-@RT OA>6Y E&<TY)SQ
MV3D[]0^/]0\O6:C^NL_E@L=M%CS8Y$UH6*CZV ]"]?YOG7YLW2'%(DBQ&$BL
MXR%R6R1UARY5SSIWD.JL597GP.(0<VHO#1 -U">W(6[J26)QJ7(E& .5M5YL
M"J)NV+=B12?$CBYI\H])>5S5FTN%#%W. HS5U?C"GL#8-@=5BT#58BBUKI4M
M5Z-A8#W(/CR@TW7BIG[ *%,[78^;TM#SD7K/-P6R4.UT0Q#R79_V='J+K,C.
MK%!T=IBF4Q:/^:Y:/6LVH]L>4BT"58NAU+J^MM"-8*C;Z"75+@/-1YW&D78%
M@-(SJ%ILS[];\Q:+D9V+QZ":76KL6A7IW(D#3%1#0+D95"T^=P9=2UIX1G9Z
MOHC8[)JCO8%46X*J14BG9/7Y%-MCNKZT((WL)&VC./O0T>6'5%LB ]%BQE2(
MB4!GC<_/VK6A96EDA^E+80[I;-E#<_8$1I<?4BT"58NAU+I6MEB.AG'Y(/O"
M >M<'=C-1*?']1"=*5 C.D.0A>AP"[QX&/!:]M>,I<(Z8F*"ZOTUY3ZYL"<P
M>H<-4BT"58NAU+I6MG".A\'Y(/N0WNF:<3JTT\#W U_I=$/<U/-]I'6Z*1"Y
MBEQLB@I"PGINZOAD)]E.O%!(AW7F)"Q@C*KU@]U:AMU;AMU<_C]VEW'+ZAB&
MU8UFZEN[ZJ,:ZP@O;_CJ17 !UAJW#Z"$8F/:7L]%U/(SMO/S&):S2XU=L&(=
M3:GGJKO^H'-&H&KQN3/H6M+B-;;C]44L9]<<[0VDVA)4+<(Z04^I]M"Q!W6=
M:2D;VRG;1G/VH:,- (5IK*/MU*.$ANH#'71G^ORL71M:J,9VJ!Y <\1HD8Z7
M6*83,.2KCPA0F 95BT#58BBUKI4MF.-A8#[(OD!?XVIK-!W8:4B0&ZJ/%<.F
M,2.(JK03F0*11]7;C2F*!++9>WJ]Q5U\T3;TZ1:/N5B&?6A"J>MI.W3V!$;W
M.NA.-*A:#*76_=)DB^9D\%[T6?N(82]:[75BV(L.79^J2UE#W)2Y/E'O>I$I
MD&I?G30$(<0\KZ?52<N[Q,Z[4#Q'=.#T E?[ J4]F[%]#ZH6@:K%4&I=7UM.
M)S"<;O12WZE6M^B(CN^(JEM"]A1'X!R44'PF[6ZM3[Z9;4?G,3AGEQJ[8B4Z
MGF*,U>]1@LX9@:K%Y\Z@:TE+V,1.V!?AG%USM#>@7Q8'58N(#M%3;;T6GXOJ
M>M.B-K&CM@WH[$-'6P!*U,2 MY@BPM0G.NC>]?E9NS:T7$WL7'TIT!&=,'N
MSI[ Z/*#;DZ#JL50:ETK6S8GP]A\D'W^@$6N'F,$.D.<&>A,@3K0&:-,0#<[
M^;UD_?M9N;)_2.4")^/W<J3[QI?-63[_)/7Y0!2[YB>4=X40Q;9YN^')FI=U
M@/S_?5&([P?UKS*//PR>_P=02P,$%     @ D$ *5]9IJ6HY!P  ]AX  !@
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M2!!RT]'!>%NXR6$X?W_.724RG$5\01S:9XSF;]^,3I.+(V0G/=G),?3YH9K
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M-A#^*P=UZ#; LU[LN%EB&XC3=FN!;D;3;@.&?:"ELT2$(E62LN-_OSM*45U
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M=16![49:M_&F"6-D9SP-I;"LZ%< 6A:@^[VA+M)OV,#PNV+]/U!+ P04
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M^=*Z%;\F.G-MZVK^N#1(+9X6X/>Y@XWC%SJ@?V_X_?\!4$L#!!0    ( )!
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MT*/AABV]TJ@L@/;7DN[U-+$._+N_^ Y02P,$%     @ D$ *5^E^DPF, @
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M%D#[:TD?GVYB#^C_S2S^!U!+ P04    " "00 I7B#*2.1\#    !P  &0
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M-V!]87B8]P<?H/_H+?X'4$L#!!0    ( )! "E=LH53SW0,  %4)   9
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M9>D:]L."WCVHG0#M+Q4UR';B#'0OJ=G?4$L#!!0    ( )! "E<QU^GQPP,
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M_6E)3=4+9W-(@;*&D%QU60MI*P[],@6I+'RJ$#:J;I@\ )=YJS46I.\S(G>
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M1[W8T3'V]" O6X29UDP67BE<<I,)91J-\/,1GRW,A<J>?KWFP/$G]@7Q/^5
M2Y2->3F!6PE+M<5JC9H2%'\:@%069C=7RW@\'L&(,A?#_>,-"HCA[A)F5!7:
M')(ZB@63#4T(E^)X +:D*\?FP8M&^(O$5T#B^=W/E</@M1"'!\U1H2[\"#"0
MJ4;:MD_ZTW[*S-KF>C%O1]0=TP67!@1N"!J=?#P-0+=MWVZLJGVKK96EQO7+
MDB8E:F= ]QM%T>TV[H%^]J9_ 5!+ P04    " "00 I7%^;*Z&8"  !A!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R%5-]OTS 0_E=.08(7:-*D
M&]-H(ZW[(4 :FM8!#X@'-[DVUAQ?9E_6E;\>VTE#D4IY27SG^SY_=^?S=$/F
MT5:(#"^UTG865<S->1S;HL):V!$UJ-W.BDPMV)EF'=O&H"@#J%9QFB2G<2VD
MCO)I\-V9?$HM*ZGQSH!MZUJ8[1P5;6;1.-HY[N6Z8N^(\VDCUKA _MK<&6?%
M TLI:]16D@:#JUET,3Z?3WQ\"/@F<6/WUN S61(]>N-3.8L2+P@5%NP9A/L]
MXR4JY8F<C*>>,QJ.],#]]8[])N3N<ED*BY>DOLN2JUET%D&)*]$JOJ?-1^SS
M.?%\!2D;OK#I8C-W8M%:IKH'.[N6NON+E[X.>X"SY!^ M >D07=W4%!Y)5CD
M4T,;,#[:L?E%2#6@G3BI?5,6;-RN=#C.OQ CC"?P#A:5,%B1*M'8-W#]U$K>
M3F-V9_C(N.CYYAU?^@^^4[@ES96%:UUB^3<^=MH&@>E.X#P]2OBYU2/(DK>0
M)FEVA"\;$LX"7W8D80M,<".UT(44"A8L&-U%8WLHWXYN<IC.S\RY;42!L\@-
MA47SC%'^^M7X-/EP1.QD$#LYQIYW78 ?#_C",%=4//X\)/$HR6&)N[[O=[UO
M.CQ4")=4-T)OH1(EC)-DE+C+IY2?(S*EJYS9@O50"Z+EBHS\A26X-P*DM:VK
M*X*P0"MP[<.A?7"%!=9+-)"-@R?][SZY;4T,AXH9[UW[&LTZ#+>%@EK-W00,
MWN']N.C&YD]X]_C<"K.6VH+"E8,FH_<G$9ANH#N#J0E#M"1V(QF6E7L#T?@
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M?:.E=^SUX/;NFQN\25A38^7,5$A&%C."(&-$]#1D5\J9A"'.C5PKT0NVXON
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MB>]AEV[JM BVC;?CS :^:^-GS3\WY$2 S^>6ZV.S$ .[WZ7IOU!+ P04
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M;#5U\3[@%\?6[.W!5;)1ZM$9W[-E$#E!*# EQ\#LLL4+%,(161E//6<PI'3
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MC4YF*0'5UVH_,;+Q];&2QE:;'U;V>T/E NS^6MJ<&2;N@/'#S/\"4$L#!!0
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M1\<##V1;]]J.%K6K-4NA3>5RS=(\%2AM@)E?"9-P7<<NT#\^V4]02P,$%
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M'Q;4HE&[ -I?*'KSVXE+T#;]R5]02P,$%     @ D$ *5XHI;7=N!   "0P
M !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULM5;;;N,V$/V5@?:"!'"L
MBR5;SMH&DFR+;I'L&DFZBZ+H RV-;2$2J9)4G/Q]AY2MV!M%21\*&#1)<89G
MSEPXDXV0=VJ-J.&AR+F:.FNMRU/75<D:"Z;ZHD1.7Y9"%DS34JY<54IDJ14J
M<C?PO*%;L(P[LXG=F\O91%0ZSSC.):BJ*)A\/,=<;*:.[^PVKK/56IL-=S8I
MV0IO4/]1SB6MW$9+FA7(528X2%Q.G3/_]#PVY^V![QENU-X<C"4+(>[,XDLZ
M=3P#"'-,M-' Z.\>+S#/C2*"\<]6I]-<:03WYSOMOUK;R98%4W@A\A]9JM=3
M)W8@Q26K<GTM-K_AUI[(Z$M$KNP(F_KL:.1 4BDMBJTP(2@R7O^SART/>P*Q
M]X) L!4(+.[Z(HOR,]-L-I%B ]*<)FUF8DVUT@0NX\8I-UK2UXSD].RKT B^
M#R=PB62<@J-;MLA1'4]<3>K-(3?9JCJO504OJ!K"E>!ZK> 7GF)Z*.\2K 9;
ML,-V'G0J_+WB?1AX/0B\8-"A;]#8.K#Z!AVV*JCM:S.OE@[;I4UVG*J2)3AU
M*/P5RGMT9A_?^4/O4P>VL,$6=FF?6?9[<"&4AK\L1+C%!PWGN4CN_FY#VZFO
M'>WM6B(>> ENLH?##2(=+>G-Q+!OAF!O]JU$R73&5Y ;X) 8W.\AB$;-&,81
MC9$_A)MJ49_*>"(*A*-H",>[T?>#I[_O3&;6]CVM_MC\!C$,AD9WX#5C2'%+
M8^A!AP.BQ@%1IP/.E$*M@/$4+@E#EF<Z0]6CM* /^$:?=%[1[I.&YL^88+%
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M^B-Z<63=>-8++4K;["V$IM;13M?4JZ,T!^C[4E 3M%V8"YKN?_8O4$L#!!0
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M.TUNL.%8NY^$Q@<X?ZG=.$;#3_?X-[._4$L#!!0    ( )! "E=F9/9F[@(
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M^*#< ;N?2MLF5A/7==9_&@:_ 5!+ P04    " "00 I7,?,&M-\"  !3"
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M&0J>'V_)Z<D9.2&,DZ="K!4JU-C5R&Q.=K.6[Z;A"S[A^[[F%R3TSDG@!>&
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M<NV^L*I] P^24AM9U&"*H,A%]6=/=1XV .W.'D!8 \*7@&@/H%,#.G\+B&I
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MP'R^W*//(IN:/[,I^XYOF$C2N0SJ"3JUU;,E9Z7\A_O\AP[S<%A1SQM/O.!
M/["'AO&/]O&/X'KD8L4%U:OR#7M0Z#Y=27<++B0?Z--6OI:<E=(?[],?.\@W
MKL@W],>'ZH$=- Q_L@]_ JO'A H7X4SK)Q%?: U77(;PU ,]VFK7DK-2\M[
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M0AL"_/W6^"D,3ACJ\4GF?P%02P,$%     @ D$ *5[X&%94<!0  AQ\  !D
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M0>0,@80"G0*G80LSD-()D8V_O68P_*4C[L]?U6]]=LJRY!9F6OX1*ZPFP9>
MK:#DC<1[W7Z'/L_8Z15:6O_+VAX;!:QH+.JZ)Y.#6JANY"]]'_8(H_0$(>X)
M\4<)24](?-#.F8\UY\BGN=$M,PY-:F[B>^/9E$8H=XH+-+0KB(?3WQJ!9>PS
M^\7-,R!?2F +*!HC4("E]5LN#'OBLJ%*ER=@RQV;:86&#J7ADD#H=G;L?$Y8
M(>T%"3TNYNS\[(*=,:'80Z4;R]7*YB%2"N<E+'K'-YWC^(3CGXVZ9$GTB<51
MG!RAS]ZGSZ$@^LC3X[?TD'HW-# >&AA[O?2$7I_5=:$56%$VK8#M@)MCT3JM
M*Z_E+MAV&F=9%N7A=C_!(2I-Q^.K ?7&:#(833YJE)<(9O#)L#*Z65=NA&[I
MZ+%T\N,]5]G7 ^N'H.BX[72PG;YK^T$C?5%";<$BO1YXU%IZT+!DG*7_>SM$
M'6MKN'>9W$-&7_Q:*,LDE,2++C,*9[K'H2M0;_S]6FJDV^JG%;VG8!R ]DM-
M=ZPOW)4=7NCI/U!+ P04    " "00 I75+PV(6$"  !.!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T.2YX;6RE56U/VS 0_BNGB \@,=(FI6,HC42;3MLD
MIHJ7[;-)KHV%8P?;H;!?O[,3LL):5&U?$M_YGN=\%]^39*WTO2D1+3Q50II)
M4%I;GX>AR4NLF#E1-4K:62I=,4NF7H6FUL@*#ZI$& T&X[!B7 9IXGT+G2:J
ML8)+7&@P354Q_3Q%H=:38!B\.*[XJK3.$:9)S59XC?:V7FBRPIZEX!5*PY4$
MC<M)<#$\G\<NW@?\X+@V&VMPE=PI=>^,K\4D&+@#H<#<.@9&KT><H1".B([Q
MT'$&?4H'W%R_L'_VM5,M=\S@3(F?O+#E)#@+H, E:X2]4NLOV-5SZOAR)8Q_
MPKJ-_7@:0-X8JZH.3">HN&S?[*GKPP9@N L0=8#H+6"T Q!W@'C?#*,.,-HW
MPVD'\*6';>V^<1FS+$VT6H-VT<3F%K[['DW]XM+=DVNK:9<3SJ;?E44X@P^P
MT'3WM'T&)@N8/S2\IMM@X3!#R[@P<(-/MF'BB$)OKS,X/#B" ^ 2;DK5&,*8
M)+1T'L<:YEWN:9L[VI$[ADLE;6E@+@LLMN"S]_'C=_ A]:%O1O32C&GT+N&W
M1IY /#B&:!#%6\XSVQ\>;2OG_[+/_SG[JV;$_<V(/=]H!U^&)#PY9VZ>CX$L
M@>UHT_VXJ)2V_)??V_;=6^:Q9W9*]9B2;B7AXV8O]XC)_HX91>/7,?,M,:-/
M?4Q;>K@Q(!7JE5<F [EJI&T[TGM[\;OP,__&/QV>SX9;_!F)9:MM?^A;I;UD
M>L6E 8%+2C4X<=JD6_5J#:MJ/YYWRM*P^V5)@H_:!=#^4M&(=H9+T/]"TM]0
M2P,$%     @ D$ *5SBFC*UC P  U T  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3 N>&ULK5==;]HP%/TK5E9-K=0V'X3P,4!:8=4ZK1,JZ_90[<&$"UA-
MXM1VH-VOGQW2D(#)2I47B)-[3\ZY)S>^Z:TI>^1+ (&>PR#B?6,I1-PU3>XO
M(<3\DL80R2MSRD(LY)(M3!XSP+,T*0Q,Q[(\,\0D,@:]]-R8#7HT$0&)8,P0
M3\(0LY<K".BZ;]C&ZXD[LE@*=<(<]&*\@ F(^WC,Y,K,468DA(@3&B$&\[[Q
MV>X.;5<EI!&_"*QYX1@I*5-*']7B9M8W+,4( O"%@L#R;P5#" *%)'D\9:!&
M?D^56#Q^1;].Q4LQ4\QA2(/?9":6?:-MH!G,<1*(.[K^"IF@IL+S:<#37[3.
M8BT#^0D7-,R2)8.01)M__)P5HI @A>H3G"S!>6M"(TMHI$(WS%)9(RSPH,?H
M&C$5+='405J;-%NJ(9&R<2*8O$IDGAC\H )0&UV@,9./!A,O"$<S].4I(;$T
M2QR^<#H"@4G SV3(_62$3D_.T DB$?JYI F7L;QG"DE0W<;T,S)7&S+. 3+?
MDN@2-:QSY%A.0Y,^K$X?@2_3[33=*:>;LBQY;9R\-DZ*YQ[ *RF'5^7G:,$H
MUZK;P'DIG.J?U<!UV\V>N2IJT 6YK3RHQ+21,VU4,OT.G'=E2_A)F 18P$P^
MR;*K?8(WO2+YXY R0?ZF)W3<-S=H%FA=-)JM7?*Z*+MIZ=F[.7OW776.0.B8
MNGL<.K:UPW,_QG8Z!XK<S&DVJXN,IY1A0=E+H0T>;B&< ONC(UH)I][/71YC
M'_J&M(H#6X$Q^/C!]JQ/ND>_)K"2<B]7[M7;"-Y>^=VFMV.1+L;1.]3*>;8J
M>0YI&"<"&$^)3NA<K#&#2H\J 8_UJ":PDO9VKKU=KT?MO?H[=F>WWW5!7EOO
M4B=GVJED>IVPB(AD:\R#CEXEQK'&U 16DFM;VRW6JM>:#*]8=F_O%:<+L@XT
MD%T8!^S_["1R)EK28(9NPIC1%2BJO+*%JA&/M:HNM++^[99OU[SG9WAEKUJ[
M7E4'E;EN-WV[>M>_Q5$REW-PPDBT>..>5 UYM%DUH94+L)T;[/<-#H?-<O>&
M+\_:,TL7M/O.,PLCM_K>N<5L02*. IC++.NR);UFFT^(S4+0.)W"IU3(F3X]
M7,K/+F J0%Z?4SF)9PLUV.<?<H-_4$L#!!0    ( )! "E?SKH#K#@8  %$Q
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;+6;:V_B.!2&_XK%5JL9
MJ5.2<"M=BM22>'=&VT[5R\Z'U7YPR0&B26+6,=!*^^/7"6ENI(:TIU\@"3Z/
M';_VB?TJC#9<_(P6 )(\!7X8G;<64B[/VNUHNH" 12=\":'Z9<9%P*0Z%?-V
MM!3 W"0H\-N68?3; ?/"UGB47+L1XQ%?2=\+X4:0:!4$3#Q?@L\WYRVS]7+A
MUILO9'RA/1XMV1SN0#XL;X0Z:V<4UPL@C#P>$@&S\]:%>4:M7AR0E/C+@TU4
M.";QK3QR_C,^^>J>MXRX1>##5,8(IK[6, '?CTFJ'?^FT%969QQ8/'ZAT^3F
MU<T\L@@FW/_AN7)QWCIM$1=F;.7+6[[Y ](;2AHXY7Z4?))-6M9HD>DJDCQ(
M@U4+ B_<?K.GM",* 8I3'V"E 58UH/M*0"<-Z!P:T$T#NH<&]-* WJ$!_32@
MG_3]MK.2GK:99..1X!LBXM**%A\D<B71JH.],!Y9=U*H7ST5)\?77 (9DB_D
M1L"2>2Y1>FV8<,GW1]^;LT3]3S9(YOD1N8<GN6+^9U7\X<XFGXX^DR/BA>1^
MP5<1"]UHU):J33&Y/4WKO]S6;[U2OTFN>"@7$7%"%]QR?%O=2W9#ULL-75I:
MX!5[)AWSF%B&9=8T9[(O6ISHPFU]^+=5J,*-)+Q3$^[HPVV89K5;->'T\'!3
MTY6=;&QT$E[W%=[K0Z).9RTK3I!GT9)-X;RE,F $8@VM\:^_F'WCMSJ5,&'V
M%M9/8'&F78]-H]LS!J/VNJC-;K'AZ3"6L5B*[I8Z[0W,O%2II[M93W>U/?U=
M+D"0R4H(""7YTV./GN])#R+R]Q4$CR#^J>MQ+;-ICV/";$R8@PFC2+"2RKU,
MY1[B?-*RFJJ+";.WL%YA"E@#PZC,IM[./+$ZU4(4J5DE-?J9&GVM&K?W/\C7
M< V15 LEJ9]I6E)3+3!A-B;,P811)%A)VT&F[6#/3.-3 #<B,\$#S=*F3NO!
MSL =](SJR)T<5,K6MK*I.I@PB@0KJ7.:J7/Z#G4NA&#A'.))>4RN0=9I=+K;
M^U9W1Z.#2MG:MC;5"!-&D6 EC8:91L-&SZJ+N8!4DRLO]()50.A*K@20"8L6
MA*H=:NWJ7UM+T\R)";.'NP\HP]B9P@YFG10)5E+4-/*MGH&NZ3&Y96J'^"G^
M_%R[O=/6V51A5)J=TN*O3&3CQ*PLZ1W42BD6K2QR83]OOG&1>4R<IR5,);@%
M?>/M^[7:UI/[#?AK2'?CM4)KZVTL-";-3FG%R5R=QZ@54BQ:660K%]EZT]J5
M_$?NF*^VC7Q&'I9$<G*DDIJ:W;X?&SF%8M_ #Y[5[[I5K[X1C17'I-FH- >5
M1K%HY<&1NS9F,]NFD.:+Z?V&/2>#YYC<@)BJ(S:'>-RH)==V$-4."527)Z69
M9BD_&\->98F&6JN#2J-8M++8N7%DZIVC \5.G^5?PZD %D&<]9NHCNHTI;2J
MZIT=U5%=)%0:Q:*55<^-)%/O).W-_Y<@-P!A.?VST"5'G7<\#U M*52:C4IS
M4&D4BU8>++G/9>J-K@]]'J Z8RFMLEXW.M7$@&IZH=(H%JVL=>Y[F7KC:V]B
M^+X&\;XD@&E#35!I-BK-0:51+%IY8.26F[G/<_O )(#I>DU26C4)F-4D@.K;
MH=(H%JVL=6[=F7KO;F\2J-D:;CRI5HGV!;E8+@5?,[\8]?#[]1?3L/1Y =7I
M0Z79J#0'E4:Q:.67)7)/T'JS)_CNO*"ONNF02&G5;8-5W3:@UNJ@TB@6K2QV
M[@U:>F\0:=OP>JZH'06HOB$JS4:E.:@TBD4KCY7<8K3T%N.')@948S&E[5LP
MH%;JH-(H%JVL=>X86GK'\ V[AH8Y -4V1*79J#0'E4:Q:.5QD9N+%HJY^+8<
M@.HI6O6>HK&S.$#U%%%I%(M6%COW%*UF;Z=]B).L;T-CU7NUJIL[JJ.:@Z@T
MBD7;JMXNO D>@)@G[^Q'9,I7H=R^0YU=S?X7<)&\#5^Y?FF>3;9O]^>8[9\-
MKIB8>V%$?)@II'$R4#<@MN_O;T\D7R;OFS]R*7F0'"Z N2#B NKW&>?RY22N
M(/L7Q?A_4$L#!!0    ( )! "E?$7S&Q_0,  !4.   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4R+GAM;+57;6_;-A#^WE]!:,&0 $WT+LN>;2#QVU:T6]"L
MW8=A'VB)MHE2HD;2=OWO=Z1EU99E)46S+S9YNN?N>,^1//:W7'R1*T(4^IJQ
M7 ZLE5)%S[9ELB(9EG>\(#E\67"18053L;1E(0A.#2ACMN<XD9UAFEO#OI$]
MBF&?KQ6C.7D42*ZS#(O= V%\.[!<ZR#X2)<KI07VL%_@)7DBZE/Q*&!F5U92
MFI%<4IXC018#Z][MS6*M;Q0^4[*51V.D5S+G_(N>_)8.+$<'1!A)E+: X6]#
M1H0Q;0C"^+>T:54N-?!X?+ ^-6N'M<RQ)"/._J*I6@VLV$(I6> U4Q_Y]E=2
MKB?4]A+.I/E%VU+7L5"REHIG)1@BR&B^_\=?RSP< 5S_ L K 5X=$%X ^"7
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M*=/]G[M=(__0].GN?(4=S]OZF&T&#/<(&-D,&%N"5<P^*<T^^<!LW2Q?S#B
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MYJFZ9'K%I2%3.5%&AT>4>-VT_V9B5>4[Z$)9ZL=^6-"+B=H%T'ZNJ(NV$W=
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M1/:MLY]HT73M:BDT-K]N6.+;!J39@,\+@2UKF)@..+Z_LG=02P,$%     @
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MP<< "BQ9*^Q:[;]@7X\WF"MA_!?V?6X40-X:J^H>3 YJ+KN1/?3G< "(XS<
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M2'1W"[O JL9W_E99ND=^6M'#A=HET'ZIJ/O[P%VFX2G,G@!02P,$%     @
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MNXA["3\*=0;#P2G$43PXI.<?\-K!(P\?]L@9=@T<>K[1$WQ/M.J4.T0E'/]
M02>'JM[/.H0'!AYJU[P7Z$SGW%0BQ6G KF*0MA@DSY\-QM&;GF1'7;*C7EG7
MS"@HS?TE7>"63:ARV<*,2*A-F_F<&T[L#V U7"$YJP-^P!>;\RUU^X:O\J5*
M:R+,3N$]:7/P9O:*^?]4F[HU9&-/YKQUF\23<+M?C'#O,RZ1-M[=#*2Z5K;Y
MHKO5SD!GWC?"O^&-^RX%;0IE0.*:H='9*W83:ARMF5A=>5-8:<L6XX<Y_P20
M7 #OKS4;0SMQ!W2_E>0/4$L#!!0    ( )! "E>1N_7%( (  .H$   9
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M_%%9G(PF5Q?1Y0L+QX!1/)F,DQ<.Z$$GNEO@,],;+@T1L+;4<'AI-71[LMH
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M'!9?%]2=TR1OP,\_Q3';_,@[V&Z3??%_4$L#!!0    ( )! "E=[!YL&20,
M ,$+   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;*U6:V_3,!3]*U9
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M-<4>&X0.P.]+CEU1/= )FJY]\AM02P,$%     @ D$ *5W)#0#$" @  ) 0
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M%V;4;@*]7RFZ=%4==X>KK^"S?P%02P,$%     @ D$ *5^V;W5Y@ P  -!4
M  T   !X;"]S='EL97,N>&ULW5C13MLP%/V5*, $TD2:!M)FM)6V2DB3M@D)
M'O:&W,9I+3E.YKBLY7&?L\_:E\PW3I.T^%:%AT'7"F+[^)Q[?'V3& :%6G%Z
M.Z=4.<N4BV+HSI7*/WA>,9W3E!3G64Z%1I),ID3IKIQY12XIB0L@I=SK=CJA
MEQ(FW-% +-+K5!7.-%L(-73[]9!C+I_CH>N'%ZYCY,993(?N_>F['XM,71T[
MYGKT_NBH<W]VM3U^6@)GKF<5O;2+_OGUNRU[WFDK-^#I&L7DPST\;XH?[RO=
MVTMZAS(FW-\4+F>?:!W#.\%HD86F[3=,Z"#D7L=.[FSQ.SLD_/U2O3/7)B=>
M58^C09*)IBP#UPSHZ"2ES@/A0W=,.)M(!JR$I(ROS' 7!J89SZ2C]/V@[?@P
M4CP:V#<]N%4JG92)3):Q303S>U)-WP+6/3#(.*\-=ETS,!KD1"DJQ;7NE)/+
MP2>04[7O5KEV.)-DY7<OW8907G20229C*NLPOKL>&@TX3<".9+,Y7%66>P J
ME:6Z$3,RRP0I/:P954/+3BGGM_ <^9YL:"^3UKZ6A2'JIC94-8V,Z8!^6\UH
MMV4O7J3KY.PA4Y\6>CFB[$.UT!M)$[8L^\ND-H"I^[@ZR7.^^LC93*34+'[O
M@*,!6?.<>2;9HXX&I3+5 U2ZS@.5BDW;(S\ER>_H4JW+:9G@GKL'Z/G?YGE&
M!96$MTWKVG_+67ZQXZ#W6I;+I\JV8:O'ZG#PUDU>'H+)\!!,'D1-]@_!9'0
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M _'M<:"F[)P@@%W%O&%W,(Y$$89 +=IK- R1[(3PM>\/=I<$0139$<#L#H(
M0^!NQ!', 7C D" HWX-;[R-O_9[RFO^3COX"4$L#!!0    ( )! "E>7BKL<
MP    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$
M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E
MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M^X,\TZH6RHJ:P3>K&UD#1\T^\8:K2K  ,D4@TP-"_IL&D!D"F1T$<N9PX-0
M,D<@\P-"1I$L$,CBD)!9 %DBD.5^(;] =F0).V*?>BN5L)9Q:.9?>-<;P?0B
M@#Q&((\)(%,'R:VT@,5NC;!PSG8&>H<POB-@S(!Q)A^4A).X2YE5I7M(F>HA
M@#Q!($\(('. O.F6PK +J2#S2-Z\)O0PET^P9#XAP"P \U(]PI%@76%#-E0T
M>S:-9RN![8)+P^YYTPMV+;B%]N+.##$QU21[=HW'/'X-H>W<T5$(,<,D>U:,
M9WL';%";K:!R>O$YY_/W7JZV0X@Y)MFS9#SFB<<4*RYK=J'-$S<UNYDW\H&'
MF)AEDCUK9IW!)\!YI=7#$92,+3L7\RB,F& 2$L,XQ5Q!,XD;,N:4A$(JB;/*
M5P%9!IKQA=&M>R?KONK"DC'!M))0>"5Q8KF"$Z"<\(WE#+H9?*Y-]!9B8DDH
MS)(XM<R6W(BE;FIA[&^^57<O8?V-B26E$$M2;"B/YGQ=GK5P3<O#)I-BCDDI
M').4/GM7NA7LCC]'#2=%>S$4:DF.?<-I?$E[RZ'[&P-B?DDI_)(XP<"3;>5:
M?J_-!HJQ$!/S2TKAE\0)9M;/K?C>NT[VY\<M4Z>86](]NV5W+<MNH3-3;3UP
M3#$IA6*&:N^H.YABQDDIC#-4?<>8F'%2"N-L5=_L]SL.%/:/$!+S34KAFZ$R
M/!Y+P82340AGJPS?%<L,TTU&H9NA>CR.)>:=C,([0_5XC(F.GY'8YVT]_OK8
M0TS,/AF)?7Z5Y3O?2LP]&4F_9J ^CQ\WYIZ,I'LS4%+&F)A[LH,.H86]G0QS
M3W;(4;1HS#3#[)-1V&<0,P\'R3'[Y!3V&2PXPFCFF']R"O\,8D;1Q/R34_CG
M35UT+CHN&\ON0DS,/SF%?[8Q?VV%F.@,#H5_!@NXZ-W$+)136.A- ;?SH6,6
MRBDLM(WI.I9MR\U+F-YSS$(YA84<YC4WWR"&\.]L)JK>2#=^$&%B%LHI+#18
M$$?O)F:AG,)"@YAAWBPP"Q44%AJLV\-H%IB%"@H+#6)&T<0L5)",ONWJ7OBD
M%&)B%BH.U0M:[P@Q,0L5Y+V@GZE=/'=]B(FN)"#I"P68?FASI97/\SK$Q"Q4
M$$_UP)>/K:N)?8?C8XB)6:@@F?F),&?]:M7X"5S>A)B8A0J2F9\(\]JMRUB[
M,GKHF(4*DIF?"/,?54OK.T.B#I>Y8!8J2:9^AH83HM4XF(5*DJF?(<S00B5F
MH9+$0@.SDM&H1XE9J"2QT-"L9%AOEIB%2A(+#8TA1>\F9J&2Q$)#F-&[B:YH
M(['0]NSI3[.'F)B%2A(+[9S^<ZPA)F:ATEMH[ ^V'TYKL9!*U%_@+RSLKWA3
MW1KF/M9+DO+"+1-8]$US!OMNU)7F]699\69)](?_ %!+ P04    " "00 I7
M%MUK%"8"  !C*   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+
M3N- %(7AK41> )6ZKT"+,.H)4\0&K%!YB"2.7&X!N^\H#))C]: GR&=DE2U?
M_Z-/5MF/+V7?#KON6+>[4YU]'O;'NFRVPW#ZE5)=;<NAK7?=J1S/5]9=?VB'
M\[+?I%.[>F\W)<E\'JF_G=$\/=[.G+U^G<K_3.S6Z]VJ_.Y6?P[E./QC</KH
M^O>Z+65H9J]MORG#LDF?^^OIFBZ'?'>>W,R>WY9-__R6FS1UD$"03!^D$*33
M!QD$V?1!#D$^?5! 4$P?M("@Q?1!]Q!T/WW0 P0]3!^4YRCCG"!IA#6!UAFY
MS@1>9P0[$XB=D>Q,8'9&M#.!VAG9S@1N9X0[$\B=D>Y,8'=&O#.!WH)Z"X'>
M@GH+@=XR>MDFT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'0
M6U%O)=!;46\ET%M1;R706T>;)01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$
M>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'K;:+.;0&]#O8U ;T.]C4!O0[V-
M0&]#O8U ;T.]C4!O1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U ;Q]]K"30VU%O
M)]#;46\GT-M1;R?0VU%O)] [4.\@T#M0[R#0.U#O(- [4.\@T#M0[R#0.U#O
M(- [1C^;$.@=J'<0Z!VH=_RDWG7XVI=Z[?E>X_-_DNKA?&^Y/OZR_#Z)$BXN
M.*?;BOKT%U!+ P04    " "00 I7X>Q>$?0!  "B)P  $P   %M#;VYT96YT
M7U1Y<&5S72YX;6S-VLM.PS 0!=!?J;)%C>LG#]%N@"VPX =,,J51D]BR72A_
MCY,"$@@J4)&XFT:M[;D3CW16/;][]A0GVZ[MX[Q8I>3/&(O5BCH;2^>ISRM+
M%SJ;\M?PP+RMUO:!F)C-#*M<GZA/TS34*!;GE[2TFS9-KK;YY]BX?EX$:F,Q
MN=AM'++FA?6^;2J;\CI[[.M/*=/7A#*?'/?$5>/C4=Y0L"\3AI7O U[/W3Q2
M"$U-DUL;TK7M\BZV;5E,SRW%<G^)+WITRV534>VJ39>/E-$'LG5<$:6N+7=%
MC_8GIWS#M/OD!^>/9?8%YIVWP?F8)Q;H]W%O(QE.3WTN1"$U^U_Q/3&7/OC]
M:)AV3?4/L_/U/KFP'N<1V?@X_(X_SOB]_B_[$"!]2) ^%$@?&J0/ ]+',4@?
M)R!]G(+TP6<HC:"(RE%(Y2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*%%D%
MBJP"15:!(JM D56@R"I09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR2A19
M)8JL"D56A2*K0I%5H<BJ4&15*+(J%%D5BJP*15:%(JM&D56CR*I19-4HLFH4
M636*K!I%5HTBJT:15:/(:E!D-2BR&A19#8JL!D56@R*K09'5H,AJ_E/6>^?6
M?QP_/LO.-OU;/AO_FK=X 5!+ 0(4 Q0    ( )! "E<'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MD$ *5V.;P7WO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ D$ *5YE<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "00 I7WDN.
M$.<%   /'P  &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ D$ *5SAL#["H!@  FQP  !@
M ("!*PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( )!
M"E>;5H_G;P(  'X&   8              " @0D5  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " "00 I70>KY'#T&   E&P  &
M        @(&N%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ D$ *5\M6O4C?!P  )#P  !@              ("!(1X  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( )! "E?6::EJ.0<  /8>   8
M              " @38F  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " "00 I7NQHY:JD#  #1!P  &               @(&E+0  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ D$ *5Q%K\%O; P
M8P@  !@              ("!A#$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( )! "E>F28"1>1   $,L   8              " @94U
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "00 I7\1FR
M4T,#   #"   &0              @(%$1@  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( )! "E?I?I,)C (  +D%   9
M  " @;Y)  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
MD$ *5]S\$VQ;!@  ,Q   !D              ("!@4P  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " "00 I7#UV0I/8#  #9"   &0
M            @($34P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( )! "E>(,I(Y'P,    '   9              " @4!7  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ D$ *5VRA5//= P
M50D  !D              ("!EEH  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " "00 I7,=?I\<,#  !$"   &0              @(&J
M7@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( )! "E?&
MOXO@"04  & ,   9              " @:1B  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ D$ *5_R,]\RG P  [P<  !D
M     ("!Y&<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )! "E?F,2-J,P(  /($   9              "
M@>5[  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ D$ *
M5]+5HN<0 P  J@8  !D              ("!3WX  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " "00 I7G93]B?("  !!!@  &0
M        @(&6@0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( )! "E=1I/N4XA$  +<V   9              " @;^$  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ D$ *5[NY8C9R @  4@4
M !D              ("!V)8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " "00 I7*WK=53X#  "P!P  &0              @(&!F0
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( )! "E<R1C=8
M:0(  #P%   9              " @?:<  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ D$ *5QWPU2B) P  CP@  !D
M ("!EI\  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "0
M0 I7(66,:8,#  #Z!P  &0              @(%6HP  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( )! "E>NS"K=R0(  /T%   9
M          " @1"G  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#
M%     @ D$ *5^7LF#ZJ @  B 8  !D              ("!$*H  'AL+W=O
M<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "00 I7VI1]/[0"
M!@  &0              @('QK   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM
M;%!+ 0(4 Q0    ( )! "E>**6UW;@0   D,   9              " @=RO
M  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ D$ *5X#R
MY[X' P  _08  !D              ("!@;0  'AL+W=O<FMS:&5E=',O<VAE
M970S-BYX;6Q02P$"% ,4    " "00 I7MEMR\;P"   "!@  &0
M    @(&_MP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M )! "E=JR<*LG (  %\'   9              " @;*Z  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ D$ *5W0Z9F/V 0  IP,  !D
M             ("!A;T  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " "00 I79F3V9NX"  ! #   &0              @(&ROP  >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( )! "E<Q\P:TWP(
M %,(   9              " @=?"  !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ D$ *5UYY:M71 @  \ @  !D              ("!
M[<4  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "00 I7
MQ^!B8?L"  "[!P  &0              @('UR   >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( )! "E>0Z#-EV (  "L'   9
M      " @2?,  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ D$ *5Y$%%'*Q!@  4#8  !D              ("!-L\  'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "00 I79B%1'/(!  "> P
M&0              @($>U@  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( )! "E>^!A65' 4  (<?   9              " @4?8  !X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ D$ *5Z#2D0M8
M @  K04  !D              ("!FMT  'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " "00 I75+PV(6$"  !.!@  &0
M@($IX   >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( )!
M"E<XIHRM8P,  -0-   9              " @<'B  !X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ D$ *5_.N@.L.!@  43$  !D
M         ("!6^8  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
M    " "00 I7Q%\QL?T#   5#@  &0              @(&@[   >&PO=V]R
M:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( )! "E=T6I53L@,  #,-
M   9              " @=3P  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL
M4$L! A0#%     @ D$ *5Q<9%HTF!   [A8  !D              ("!O?0
M 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "00 I7F,)3
MG:P$  "L'@  &0              @($:^0  >&PO=V]R:W-H965T<R]S:&5E
M=#4U+GAM;%!+ 0(4 Q0    ( )! "E>+<[]\QP(  .((   9
M  " @?W]  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
MD$ *5Z%9W(V! @  ;P8  !D              ("!^P ! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    " "00 I7@[(I@>8"  "/!P  &0
M            @(&S P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( )! "E?_8%@4B@(  ,L&   9              " @= & 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ D$ *5VMT?#D_ @
M%@4  !D              ("!D0D! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    " "00 I7JHEJ[+$"  "O"   &0              @($'
M# $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( )! "E?7
MXS;%&0,  &L*   9              " @>\. 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ D$ *5[NAPYZA @  8@8  !D
M     ("!/Q(! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )! "E>XYO01B@,  (X+   9              "
M@>PE 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ D$ *
M5^V;W5Y@ P  -!4   T              ( !K2D! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "00 I7EXJ[',     3 @  "P              @ $X+0$
M7W)E;',O+G)E;'-02P$"% ,4    " "00 I7J<]X&F\%  "6+0  #P
M        @ $A+@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ D$ *5Q;=
M:Q0F @  8R@  !H              ( !O3,! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ D$ *5^'L7A'T 0  HB<  !,
M     ( !&S8! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $P 3 #+%
&0#@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>179</ContextCount>
  <ElementCount>263</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flow (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Business and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations</Role>
      <ShortName>Note 1 - Business and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation</Role>
      <ShortName>Note 2 - Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies</Role>
      <ShortName>Note 3 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-4-other-financial-information</Role>
      <ShortName>Note 4 - Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-5-inventories</Role>
      <ShortName>Note 5 - Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements</Role>
      <ShortName>Note 6 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-7-investments</Role>
      <ShortName>Note 7 - Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment</Role>
      <ShortName>Note 8 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Prepaid Forward Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation</Role>
      <ShortName>Note 9 - Prepaid Forward Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-10-longterm-debt</Role>
      <ShortName>Note 10 - Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-11-leases</Role>
      <ShortName>Note 11 - Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Revenue From Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales</Role>
      <ShortName>Note 12 - Revenue From Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 13 - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements</Role>
      <ShortName>Note 13 - License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 14 - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity</Role>
      <ShortName>Note 14 - Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 15 - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation</Role>
      <ShortName>Note 15 - Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 16 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-16-income-taxes</Role>
      <ShortName>Note 16 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 17 - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-17-related-parties</Role>
      <ShortName>Note 17 - Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 18 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies</Role>
      <ShortName>Note 18 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 19 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-19-subsequent-events</Role>
      <ShortName>Note 19 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 3 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 4 - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables</Role>
      <ShortName>Note 4 - Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-4-other-financial-information</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 5 - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-5-inventories-tables</Role>
      <ShortName>Note 5 - Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-5-inventories</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 6 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables</Role>
      <ShortName>Note 6 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 7 - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-7-investments-tables</Role>
      <ShortName>Note 7 - Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-7-investments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 8 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables</Role>
      <ShortName>Note 8 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 9 - Prepaid Forward Obligation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables</Role>
      <ShortName>Note 9 - Prepaid Forward Obligation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 10 - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables</Role>
      <ShortName>Note 10 - Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-10-longterm-debt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 11 - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-11-leases-tables</Role>
      <ShortName>Note 11 - Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-11-leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 12 - Revenue From Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables</Role>
      <ShortName>Note 12 - Revenue From Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 15 - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables</Role>
      <ShortName>Note 15 - Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 2 - Basis of Presentation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual</Role>
      <ShortName>Note 2 - Basis of Presentation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details</Role>
      <ShortName>Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details</Role>
      <ShortName>Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details</Role>
      <ShortName>Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 5 - Inventories (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual</Role>
      <ShortName>Note 5 - Inventories (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-5-inventories-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 5 - Inventories - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details</Role>
      <ShortName>Note 5 - Inventories - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details</Role>
      <ShortName>Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 7 - Investments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual</Role>
      <ShortName>Note 7 - Investments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-7-investments-tables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 7 - Investments - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details</Role>
      <ShortName>Note 7 - Investments - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details</Role>
      <ShortName>Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 8 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual</Role>
      <ShortName>Note 8 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 8 - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details</Role>
      <ShortName>Note 8 - Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 9 - Prepaid Forward Obligation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual</Role>
      <ShortName>Note 9 - Prepaid Forward Obligation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details</Role>
      <ShortName>Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 10 - Long-term Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual</Role>
      <ShortName>Note 10 - Long-term Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 10 - Long-term Debt - Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details</Role>
      <ShortName>Note 10 - Long-term Debt - Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 11 - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual</Role>
      <ShortName>Note 11 - Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-11-leases-tables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 11 - Leases - Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details</Role>
      <ShortName>Note 11 - Leases - Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 11 - Leases - Amounts of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details</Role>
      <ShortName>Note 11 - Leases - Amounts of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note 11 - Leases - Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details</Role>
      <ShortName>Note 11 - Leases - Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note 11 - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details</Role>
      <ShortName>Note 11 - Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note 11 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details</Role>
      <ShortName>Note 11 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note 12 - Revenue From Product Sales - Net Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details</Role>
      <ShortName>Note 12 - Revenue From Product Sales - Net Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details</Role>
      <ShortName>Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Note 13 - License and Collaboration Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual</Role>
      <ShortName>Note 13 - License and Collaboration Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Note 14 - Shareholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual</Role>
      <ShortName>Note 14 - Shareholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Note 15 - Share-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual</Role>
      <ShortName>Note 15 - Share-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Note 15 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details</Role>
      <ShortName>Note 15 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Note 16 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual</Role>
      <ShortName>Note 16 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-16-income-taxes</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="urgn20230630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Note 19 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual</Role>
      <ShortName>Note 19 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.urogen.com/20230630/role/statement-note-19-subsequent-events</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 49 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, urgn:CollaborationAgreementTerm, urgn:PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:LongTermDebtTerm, us-gaap:NetIncomeLoss, us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised, us-gaap:StockholdersEquity -  urgn20230630_10q.htm 8, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="urgn20230630_10q.htm">urgn20230630_10q.htm</File>
    <File>ex_532896.htm</File>
    <File>ex_532897.htm</File>
    <File>ex_532898.htm</File>
    <File>ex_532899.htm</File>
    <File>ex_553803.htm</File>
    <File>ex_557241.htm</File>
    <File>urgn-20230630.xsd</File>
    <File>urgn-20230630_cal.xml</File>
    <File>urgn-20230630_def.xml</File>
    <File>urgn-20230630_lab.xml</File>
    <File>urgn-20230630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="538">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "urgn20230630_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 538,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 179,
   "dts": {
    "calculationLink": {
     "local": [
      "urgn-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "urgn-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "urgn20230630_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "urgn-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "urgn-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "urgn-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 423,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 48,
    "http://www.urogen.com/20230630": 2,
    "http://xbrl.sec.gov/dei/2023": 6,
    "total": 56
   },
   "keyCustom": 48,
   "keyStandard": 215,
   "memberCustom": 28,
   "memberStandard": 26,
   "nsprefix": "urgn",
   "nsuri": "http://www.urogen.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.urogen.com/20230630/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:OtherFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 4 - Other Financial Information",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information",
     "shortName": "Note 4 - Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:OtherFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 5 - Inventories",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.urogen.com/20230630/role/statement-note-5-inventories",
     "shortName": "Note 5 - Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 6 - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements",
     "shortName": "Note 6 - Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 7 - Investments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.urogen.com/20230630/role/statement-note-7-investments",
     "shortName": "Note 7 - Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 8 - Property and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment",
     "shortName": "Note 8 - Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:PrepaidForwardObligationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 9 - Prepaid Forward Obligation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
     "shortName": "Note 9 - Prepaid Forward Obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:PrepaidForwardObligationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 10 - Long-term Debt",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
     "shortName": "Note 10 - Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 11 - Leases",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.urogen.com/20230630/role/statement-note-11-leases",
     "shortName": "Note 11 - Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 12 - Revenue From Product Sales",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales",
     "shortName": "Note 12 - Revenue From Product Sales",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 13 - License and Collaboration Agreements",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
     "shortName": "Note 13 - License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 14 - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity",
     "shortName": "Note 14 - Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 15 - Share-based Compensation",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
     "shortName": "Note 15 - Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 16 - Income Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.urogen.com/20230630/role/statement-note-16-income-taxes",
     "shortName": "Note 16 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 17 - Related Parties",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.urogen.com/20230630/role/statement-note-17-related-parties",
     "shortName": "Note 17 - Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 18 - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies",
     "shortName": "Note 18 - Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 19 - Subsequent Events",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
     "shortName": "Note 19 - Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 3 - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables",
     "shortName": "Note 3 - Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 4 - Other Financial Information (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables",
     "shortName": "Note 4 - Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 5 - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.urogen.com/20230630/role/statement-note-5-inventories-tables",
     "shortName": "Note 5 - Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 6 - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables",
     "shortName": "Note 6 - Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 7 - Investments (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.urogen.com/20230630/role/statement-note-7-investments-tables",
     "shortName": "Note 7 - Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 8 - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables",
     "shortName": "Note 8 - Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "urgn:PrepaidForwardObligationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 9 - Prepaid Forward Obligation (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables",
     "shortName": "Note 9 - Prepaid Forward Obligation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "urgn:PrepaidForwardObligationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "urgn:ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 10 - Long-term Debt (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables",
     "shortName": "Note 10 - Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 11 - Leases (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.urogen.com/20230630/role/statement-note-11-leases-tables",
     "shortName": "Note 11 - Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 12 - Revenue From Product Sales (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables",
     "shortName": "Note 12 - Revenue From Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 15 - Share-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables",
     "shortName": "Note 15 - Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 2 - Basis of Presentation (Details Textual)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual",
     "shortName": "Note 2 - Basis of Presentation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "urgn:CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual",
     "shortName": "Note 3 - Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "urgn:CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
     "shortName": "Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "urgn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details",
     "shortName": "Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details",
     "shortName": "Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "urgn:OtherFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note 5 - Inventories (Details Textual)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual",
     "shortName": "Note 5 - Inventories (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note 5 - Inventories - Inventories (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details",
     "shortName": "Note 5 - Inventories - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
     "shortName": "Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Note 7 - Investments (Details Textual)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual",
     "shortName": "Note 7 - Investments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Note 7 - Investments - Summary of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details",
     "shortName": "Note 7 - Investments - Summary of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details",
     "shortName": "Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Note 8 - Property and Equipment (Details Textual)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual",
     "shortName": "Note 8 - Property and Equipment (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited",
     "shortName": "Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Note 8 - Property and Equipment - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details",
     "shortName": "Note 8 - Property and Equipment - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "urgn:PrepaidForwardObligation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Note 9 - Prepaid Forward Obligation (Details Textual)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual",
     "shortName": "Note 9 - Prepaid Forward Obligation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "urgn:PrepaidForwardObligationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember",
      "decimals": "-5",
      "lang": null,
      "name": "urgn:PrepaidForwardObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "urgn:PrepaidForwardObligation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details",
     "shortName": "Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "urgn:ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock",
       "urgn:PrepaidForwardObligationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "urgn:FinancingOnPrepaidForwardObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecuredLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Note 10 - Long-term Debt (Details Textual)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual",
     "shortName": "Note 10 - Long-term Debt (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2022-03-07_LongtermDebtTypeAxis-SecuredDebtMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecuredLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseLongTermDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Note 10 - Long-term Debt - Long Term Debt (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details",
     "shortName": "Note 10 - Long-term Debt - Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2022-01-01_DebtInstrumentAxis-PharmakonLoanMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Note 11 - Leases (Details Textual)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual",
     "shortName": "Note 11 - Leases (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2020-10-01_2020-10-31_LeaseContractualTermAxis-LeaseAgreementForOfficeInLosAngelesCaliforniaMember_LegalEntityAxis-UroGenPharmaIncMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Note 11 - Leases - Components of Lease Cost (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details",
     "shortName": "Note 11 - Leases - Components of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Note 11 - Leases - Amounts of Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details",
     "shortName": "Note 11 - Leases - Amounts of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "urgn:AssetsAndLiabilitiesLesseeTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30_BalanceSheetLocationAxis-OtherCurrentLiabilitiesMember",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Note 11 - Leases - Supplemental Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details",
     "shortName": "Note 11 - Leases - Supplemental Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "urgn:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Note 11 - Leases - Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details",
     "shortName": "Note 11 - Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2022-01-01_2022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flow (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Note 11 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details",
     "shortName": "Note 11 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Note 12 - Revenue From Product Sales - Net Product Sales (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details",
     "shortName": "Note 12 - Revenue From Product Sales - Net Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30_ProductOrServiceAxis-JelmytoMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "urgn:ScheduleOfSalesReservesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "urgn:AccruedSalesReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details",
     "shortName": "Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "urgn:ScheduleOfSalesReservesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "urgn:AccruedSalesReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30_CounterpartyNameAxis-MDAndersonMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Note 13 - License and Collaboration Agreements (Details Textual)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual",
     "shortName": "Note 13 - License and Collaboration Agreements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30_CounterpartyNameAxis-MDAndersonMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Note 14 - Shareholders' Equity (Details Textual)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual",
     "shortName": "Note 14 - Shareholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Note 15 - Share-based Compensation (Details Textual)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
     "shortName": "Note 15 - Share-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Note 15 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details",
     "shortName": "Note 15 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-04-01_2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Note 16 - Income Taxes (Details Textual)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual",
     "shortName": "Note 16 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "i_2023-06-30",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-07-26_2023-07-26_SubsequentEventTypeAxis-SubsequentEventMember",
      "decimals": "-7",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Note 19 - Subsequent Events (Details Textual)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
     "shortName": "Note 19 - Subsequent Events (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-07-26_2023-07-26_CounterpartyNameAxis-MonographCapitalPartnersMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 1 - Business and Nature of Operations",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations",
     "shortName": "Note 1 - Business and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 2 - Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
     "shortName": "Note 2 - Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 3 - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies",
     "shortName": "Note 3 - Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "urgn20230630_10q.htm",
      "contextRef": "d_2023-01-01_2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 55,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information",
      "http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-17-related-parties",
      "http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-tables",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-investments",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables",
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information",
      "http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-17-related-parties",
      "http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-tables",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-investments",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables",
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r288",
      "r314",
      "r462",
      "r622",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r346",
      "r497",
      "r530",
      "r547",
      "r548",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r614",
      "r615",
      "r631",
      "r638",
      "r643",
      "r650",
      "r708",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r346",
      "r497",
      "r530",
      "r547",
      "r548",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r614",
      "r615",
      "r631",
      "r638",
      "r643",
      "r650",
      "r708",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r211",
      "r499",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r617",
      "r639",
      "r649",
      "r671",
      "r704",
      "r705",
      "r709",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r211",
      "r499",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r617",
      "r639",
      "r649",
      "r671",
      "r704",
      "r705",
      "r709",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r339",
      "r346",
      "r373",
      "r374",
      "r375",
      "r473",
      "r497",
      "r530",
      "r547",
      "r548",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r614",
      "r615",
      "r631",
      "r638",
      "r643",
      "r650",
      "r653",
      "r702",
      "r708",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r339",
      "r346",
      "r373",
      "r374",
      "r375",
      "r473",
      "r497",
      "r530",
      "r547",
      "r548",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r614",
      "r615",
      "r631",
      "r638",
      "r643",
      "r650",
      "r653",
      "r702",
      "r708",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r288",
      "r314",
      "r462",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r188",
      "r347",
      "r667",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r188",
      "r347",
      "r667",
      "r668",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "urgn_AccruedClinicalExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance date of accrued clinical expense.",
        "label": "Accrued clinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpense",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AccruedFinancingOnPrepaidForwardObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepaid financing on prepaid forward obligation.",
        "label": "Accrued financing on prepaid forward obligation"
       }
      }
     },
     "localname": "AccruedFinancingOnPrepaidForwardObligation",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AccruedResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of accrued research and development expense",
        "label": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpense",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AccruedSalesReserve": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of accrued sales reserve.",
        "label": "urgn_AccruedSalesReserve",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "AccruedSalesReserve",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AccruedSalesReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of accrued sales reserve classified as current.",
        "label": "Accrued sales reserves"
       }
      }
     },
     "localname": "AccruedSalesReserveCurrent",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AccruedSellingGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of accrued selling, general and administrative expense.",
        "label": "Accrued selling, general and administrative expenses"
       }
      }
     },
     "localname": "AccruedSellingGeneralAndAdministrativeExpense",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's assets and liabilities.",
        "label": "Assets and Liabilities, Lessee [Table Text Block]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on cash and cash equivalents.",
        "label": "Money market funds, unrealized gains"
       }
      }
     },
     "localname": "CashCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on cash and cash equivalents.",
        "label": "urgn_CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax",
        "negatedLabel": "Money market funds, unrealized loss"
       }
      }
     },
     "localname": "CashCashEquivalentsAccumulatedGrossUnrealizedLossesBeforeTax",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash, cash equivalents and marketable securities.",
        "label": "Cash, Cash Equivalents and Marketable Securities Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on cash cash equivalents and short term investments.",
        "label": "Total assets at fair value, unrealized gains"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on cash cash equivalents and shorterm investments.",
        "label": "urgn_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax",
        "negatedLabel": "Total assets at fair value, unrealized losses"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of cash cash equivalents and short term investments.",
        "label": "urgn_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure",
        "verboseLabel": "Total assets at fair value, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_ClassOfWarrantsOrRightsIssuancePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance price per share for class of warrants or rights.",
        "label": "urgn_ClassOfWarrantsOrRightsIssuancePricePerShare",
        "terseLabel": "Class of Warrants or Rights, Issuance Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsIssuancePricePerShare",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "urgn_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the collaboration agreement.",
        "label": "urgn_CollaborationAgreementTerm",
        "terseLabel": "Collaboration Agreement, Term (Year)"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "urgn_CompanyOfficesInIsraelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents company offices in Israel",
        "label": "Company Offices in Israel [Member]"
       }
      }
     },
     "localname": "CompanyOfficesInIsraelMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_ComputersAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents computers and software.",
        "label": "Computers and Software [Member]"
       }
      }
     },
     "localname": "ComputersAndSoftwareMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_DebtInstrumentCapitalizedCostsAndDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents capitalized costs and discounts.",
        "label": "urgn_DebtInstrumentCapitalizedCostsAndDiscounts",
        "negatedLabel": "Capitalized costs and discounts"
       }
      }
     },
     "localname": "DebtInstrumentCapitalizedCostsAndDiscounts",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_DebtInstrumentLIBORFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the debt instrument, LIBOR floor.",
        "label": "urgn_DebtInstrumentLIBORFloor",
        "terseLabel": "Debt Instrument, LIBOR Floor"
       }
      }
     },
     "localname": "DebtInstrumentLIBORFloor",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_DebtInstrumentPaidAndPayableAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of paid and payable related to debt instrument.",
        "label": "urgn_DebtInstrumentPaidAndPayableAmount",
        "negatedLabel": "Amounts paid"
       }
      }
     },
     "localname": "DebtInstrumentPaidAndPayableAmount",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details": {
       "order": 1.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Maturities after one year through three years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of decrease in prepaid forward obligation from amounts paid and payable.",
        "label": "urgn_DecreaseInPrepaidForwardObligationAmountsPaidAndPayable",
        "negatedLabel": "Amounts paid and payable (1)"
       }
      }
     },
     "localname": "DecreaseInPrepaidForwardObligationAmountsPaidAndPayable",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_FinancingOnPrepaidForwardObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financing on the preapid forward obligation during the period.",
        "label": "Financing on prepaid forward obligation",
        "negatedLabel": "Financing on prepaid forward obligation"
       }
      }
     },
     "localname": "FinancingOnPrepaidForwardObligation",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_FurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents furniture.",
        "label": "Furniture [Member["
       }
      }
     },
     "localname": "FurnitureMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_GovernmentSponsoredProgramsReservesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to government sponsored programs reserves.",
        "label": "Government Sponsored Programs Reserves [Member]"
       }
      }
     },
     "localname": "GovernmentSponsoredProgramsReservesMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_InterestAndOtherIncomeNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest and other income, net of expenses.",
        "label": "Interest and other income (expense), net",
        "totalLabel": "Total interest and other income (expense), net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeNet",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_InventoryCurrentAndNoncurrentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory, net of allowances, classified as both current and noncurrent.",
        "label": "urgn_InventoryCurrentAndNoncurrentNet",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryCurrentAndNoncurrentNet",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_JelmytoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Jelmyto.",
        "label": "Jelmyto [Member]"
       }
      }
     },
     "localname": "JelmytoMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents laboratory equipment.",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_LeaseAgreementForOfficeInLosAngelesCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the lase agreement for office in Los Angeles, California.",
        "label": "Lease Agreement for Office in Los Angeles, California [Member]"
       }
      }
     },
     "localname": "LeaseAgreementForOfficeInLosAngelesCaliforniaMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_LeaseAgreementForOfficeInPrincetonNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents lease agreement for office in Princeton, New Jersey.",
        "label": "Lease Agreement for Office in Princeton, New Jersey [Member]"
       }
      }
     },
     "localname": "LeaseAgreementForOfficeInPrincetonNewJerseyMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "urgn_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease after the next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "urgn_LessorOperatingLeasePaymentToBeReceivedAfterNextYear",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentToBeReceivedAfterNextYear",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_LondonInterbankOfferedRateLibor1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) 1 [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLibor1Member",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_MDAndersonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents MD Anderson.",
        "label": "MD Anderson [Member]"
       }
      }
     },
     "localname": "MDAndersonMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents manufacturing equipment.",
        "label": "Manufacturing Equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_MonographCapitalPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Monograph Capital Partners.",
        "label": "Monograph Capital Partners [Member]"
       }
      }
     },
     "localname": "MonographCapitalPartnersMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_NonCashNewLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount include in supplemental disclosures of non-cash activities for new lease liabilities.",
        "label": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "NonCashNewLeaseLiabilities",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_OtherFinancialInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other financial information.",
        "label": "Other Financial Information [Text Block]"
       }
      }
     },
     "localname": "OtherFinancialInformationTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_OtherReservesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to other reserves.",
        "label": "Other Reserves [Member]"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_PharmakonLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Pharmakon loan.",
        "label": "Pharmakon Loan [Member]"
       }
      }
     },
     "localname": "PharmakonLoanMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_PlacementAgentsAndFinancialAdvisorsFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees of placement agents and financial advisors.",
        "label": "urgn_PlacementAgentsAndFinancialAdvisorsFees",
        "terseLabel": "Placement Agents and Financial Advisors Fees"
       }
      }
     },
     "localname": "PlacementAgentsAndFinancialAdvisorsFees",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_PrefundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents pre-funded warrant.",
        "label": "Pre-funded Warrant [Member]"
       }
      }
     },
     "localname": "PrefundedWarrantMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in percentage of net sales for future cash flows under the prepaid forward agreement.",
        "label": "urgn_PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales",
        "terseLabel": "Prepaid Forward Agreement, Future Cash Flows, Increase in Percentage of Net Sales"
       }
      }
     },
     "localname": "PrepaidForwardAgreementFutureCashFlowsIncreaseInPercentageOfNetSales",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales for future cash payments under the prepaid forward agreement.",
        "label": "urgn_PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales",
        "terseLabel": "Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales"
       }
      }
     },
     "localname": "PrepaidForwardAgreementFutureCashPaymentsPercentageOfNetSales",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_PrepaidForwardAgreementMinimumFutureCashFlows": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of future cash flows under the prepaid forward agreement.",
        "label": "urgn_PrepaidForwardAgreementMinimumFutureCashFlows",
        "terseLabel": "Prepaid Forward Agreement, Minimum Future Cash Flows"
       }
      }
     },
     "localname": "PrepaidForwardAgreementMinimumFutureCashFlows",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rate related to minimum future cash flow.",
        "label": "urgn_PrepaidForwardAgreementMinimumFutureCashFlowsRate",
        "terseLabel": "Prepaid Forward Agreement, Minimum Future Cash Flows, Rate (Rate)"
       }
      }
     },
     "localname": "PrepaidForwardAgreementMinimumFutureCashFlowsRate",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_PrepaidForwardObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the prepaid forward obligation as of the balance sheet date.",
        "label": "Prepaid forward obligation",
        "periodEndLabel": "Carrying value of prepaid forward obligation as of December 31, 2022",
        "periodStartLabel": "Carrying value of prepaid forward obligation as of December 31, 2021",
        "terseLabel": "Prepaid Forward Obligation"
       }
      }
     },
     "localname": "PrepaidForwardObligation",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_PrepaidForwardObligationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the prepaid forward obligation.",
        "label": "Prepaid Forward Obligation Disclosure [Text Block]"
       }
      }
     },
     "localname": "PrepaidForwardObligationDisclosureTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expected cash flows in the next twelve months for the prepaid forward obligation.",
        "label": "urgn_PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths",
        "terseLabel": "Prepaid Forward Obligation, Expected Cash Flows in Next Twelve Months"
       }
      }
     },
     "localname": "PrepaidForwardObligationExpectedCashFlowsInNextTwelveMonths",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_PrepaidForwardObligationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for accounting policy for prepaid forward obligation.",
        "label": "Prepaid Forward Obligation Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PrepaidForwardObligationPolicyPolicyTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_ProceedsFromPrepaidForwardArrangementNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from prepaid forward arrangement, net of transaction costs.",
        "label": "urgn_ProceedsFromPrepaidForwardArrangementNet",
        "terseLabel": "Proceeds from Prepaid Forward Arrangement, Net"
       }
      }
     },
     "localname": "ProceedsFromPrepaidForwardArrangementNet",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_ProceedsFromPrepaidForwardObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow for prepaid forward obligation.",
        "label": "urgn_ProceedsFromPrepaidForwardObligation",
        "terseLabel": "Proceeds from Prepaid Forward Obligation"
       }
      }
     },
     "localname": "ProceedsFromPrepaidForwardObligation",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of property, plant and equipment.",
        "label": "Property, Plant and Equipment, Useful Life [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_RTWInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RTW Investments (\u201cRTW\u201d).",
        "label": "RTW Investments [Member]"
       }
      }
     },
     "localname": "RTWInvestmentsMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_SalesBetween200MillionAnd300MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents sales between $200 million and $300 million.",
        "label": "Sales Between $200 Million and $300 Million [Member]"
       }
      }
     },
     "localname": "SalesBetween200MillionAnd300MillionMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_SalesBetween200MillionAnd300MillionWithFDAApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents sales between $200 million and $300 million with FDA approval.",
        "label": "Sales Between $200 Million and $300 Million with FDA Approval [Member]"
       }
      }
     },
     "localname": "SalesBetween200MillionAnd300MillionWithFDAApprovalMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_SalesOfUpTo200MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents sales of up to $200 million.",
        "label": "Sales of Up to $200 Million [Member]"
       }
      }
     },
     "localname": "SalesOfUpTo200MillionMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_SalesOver300MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents sales over $300 million.",
        "label": "Sales Over $300 Million [Member]"
       }
      }
     },
     "localname": "SalesOver300MillionMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_SalesOver300MillionWithFDAApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents sales over $300 million with FDA approval.",
        "label": "Sales Over $300 Million with FDA Approval [Member]"
       }
      }
     },
     "localname": "SalesOver300MillionWithFDAApprovalMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_SalesReserveAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sales reserve accruals during the period.",
        "label": "Accruals"
       }
      }
     },
     "localname": "SalesReserveAccruals",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_SalesReserveUtilization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of utilization of sales reserve during the period.",
        "label": "Utilizations"
       }
      }
     },
     "localname": "SalesReserveUtilization",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_SalesUpTo200MillionWithFDAApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents sales up to $200 million with FDA approval.",
        "label": "Sales Up to $200 Million with FDA Approval [Member]"
       }
      }
     },
     "localname": "SalesUpTo200MillionWithFDAApprovalMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of activity in the carrying value of the prepaid forward liability.",
        "label": "Schedule of Activity in the Carrying Value of the Prepaid Forward Liability [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfActivityInTheCarryingValueOfThePrepaidForwardLiabilityTableTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_ScheduleOfSalesReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for the schedule of sales reserves.",
        "label": "Schedule of Sales Reserves [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfSalesReservesTableTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental information related to leases.",
        "label": "Schedule of Supplemental Information Related to Leases [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "urgn_SecuredLongTermDebtAdditionalDraw": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents additional draw under the secured long term debt.",
        "label": "urgn_SecuredLongTermDebtAdditionalDraw",
        "terseLabel": "Secured Long Term Debt, Additional Draw"
       }
      }
     },
     "localname": "SecuredLongTermDebtAdditionalDraw",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_SecuredLongTermDebtFirstTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first tranche related to secured long term debt.",
        "label": "urgn_SecuredLongTermDebtFirstTranche",
        "terseLabel": "Secured Long Term Debt, First Tranche"
       }
      }
     },
     "localname": "SecuredLongTermDebtFirstTranche",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "urgn_SecuredOvernightFinancingRateSofrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. Treasury repurchases between banks.",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the individual voting powers percentage that serves as the threshold beyond which certain pricing criteria will apply.",
        "label": "urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage",
        "terseLabel": "Share-based Compensation Arrangement By Share-based Payment Award, Individual Voting Powers, Percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIndividualVotingPowersPercentage",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power.",
        "label": "urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower",
        "terseLabel": "Share-based Compensation Arrangement By Share-based Payment Award, Percentage of Purchase Price for Individuals Having More than Ten Percent of Combined Voting Power"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfPurchasePriceForIndividualsHavingMoreThanTenPercentOfCombinedVotingPower",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "urgn_ShareOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding a share option plan.",
        "label": "Share Option Plan [Member]"
       }
      }
     },
     "localname": "ShareOptionPlanMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_The2019InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the 2019 Inducement Plan.",
        "label": "The 2019 Inducement Plan [Member]"
       }
      }
     },
     "localname": "The2019InducementPlanMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding the 2017 Equity Incentive Plan.",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_UGN102Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents UGN-102.",
        "label": "UGN-102 [Member]"
       }
      }
     },
     "localname": "UGN102Member",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_UroGenPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents UroGen Pharma Inc.",
        "label": "UroGen Pharma Inc. [Member]"
       }
      }
     },
     "localname": "UroGenPharmaIncMember",
     "nsuri": "http://www.urogen.com/20230630",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "urgn_statement-statement-note-10-longterm-debt-long-term-debt-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Long-term Debt - Long Term Debt (Details)"
       }
      }
     },
     "localname": "statement-statement-note-10-longterm-debt-long-term-debt-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-10-longterm-debt-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Long-term Debt"
       }
      }
     },
     "localname": "statement-statement-note-10-longterm-debt-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Leases - Amounts of Assets and Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-leases-amounts-of-assets-and-liabilities-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-11-leases-components-of-lease-cost-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Leases - Components of Lease Cost (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-leases-components-of-lease-cost-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-11-leases-maturities-of-lease-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Leases - Maturities of Lease Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-leases-maturities-of-lease-liabilities-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-11-leases-supplemental-information-related-to-leases-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Leases - Supplemental Information Related to Leases (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-leases-supplemental-information-related-to-leases-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-11-leases-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Leases"
       }
      }
     },
     "localname": "statement-statement-note-11-leases-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-12-revenue-from-product-sales-net-product-sales-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Revenue From Product Sales - Net Product Sales (Details)"
       }
      }
     },
     "localname": "statement-statement-note-12-revenue-from-product-sales-net-product-sales-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Revenue From Product Sales - Sales Reserves Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-12-revenue-from-product-sales-sales-reserves-activity-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-12-revenue-from-product-sales-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Revenue From Product Sales"
       }
      }
     },
     "localname": "statement-statement-note-12-revenue-from-product-sales-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details)"
       }
      }
     },
     "localname": "statement-statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-15-sharebased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Share-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-15-sharebased-compensation-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-3-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-3-significant-accounting-policies-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-other-financial-information-interest-and-other-income-expense-net-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-4-other-financial-information-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Other Financial Information"
       }
      }
     },
     "localname": "statement-statement-note-4-other-financial-information-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-5-inventories-inventories-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Inventories - Inventories (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-inventories-inventories-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-5-inventories-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Inventories"
       }
      }
     },
     "localname": "statement-statement-note-5-inventories-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)"
       }
      }
     },
     "localname": "statement-statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-6-fair-value-measurements-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Fair Value Measurements"
       }
      }
     },
     "localname": "statement-statement-note-6-fair-value-measurements-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-7-investments-summary-of-marketable-securities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Investments - Summary of Marketable Securities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-investments-summary-of-marketable-securities-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-7-investments-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Investments"
       }
      }
     },
     "localname": "statement-statement-note-7-investments-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-8-property-and-equipment-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Property and Equipment - Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-property-and-equipment-property-and-equipment-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-8-property-and-equipment-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Property and Equipment"
       }
      }
     },
     "localname": "statement-statement-note-8-property-and-equipment-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-note-9-prepaid-forward-obligation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Prepaid Forward Obligation"
       }
      }
     },
     "localname": "statement-statement-note-9-prepaid-forward-obligation-tables",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "urgn_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.urogen.com/20230630",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r648"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments",
        "negatedLabel": "Amortization (accretion) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r142",
      "r516"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r30",
      "r75",
      "r146",
      "r512",
      "r535",
      "r536"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r2",
      "r13",
      "r30",
      "r414",
      "r417",
      "r457",
      "r531",
      "r532",
      "r682",
      "r683",
      "r684",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r545",
      "r691",
      "r692",
      "r693",
      "r737",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r48",
      "r49",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to reconcile net loss to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r377",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r6",
      "r54",
      "r83",
      "r306"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of discount on long-term debt"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r144",
      "r170",
      "r197",
      "r205",
      "r209",
      "r250",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r409",
      "r411",
      "r432",
      "r509",
      "r569",
      "r648",
      "r660",
      "r706",
      "r707",
      "r746"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r136",
      "r149",
      "r170",
      "r250",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r409",
      "r411",
      "r432",
      "r648",
      "r706",
      "r707",
      "r746"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsFairValueDisclosure",
        "totalLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
        "negatedLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r220",
      "r258",
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized cost basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r227",
      "r505"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details": {
       "order": 0.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Maturities within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r221",
      "r258",
      "r500",
      "r695"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r217",
      "r258"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r140",
      "r217",
      "r258"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r139",
      "r618"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash equivalents, fair value",
        "verboseLabel": "Money market funds, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r681"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
        "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r34",
      "r85",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period",
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r85"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Increase (Decrease) in Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosures of Non-Cash Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r10",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r119",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r95",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r710",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r58",
      "r510",
      "r556"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r269",
      "r270",
      "r613",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r651",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r691",
      "r692",
      "r737",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Ordinary shares, par value (in ILS per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r65",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Ordinary shares, authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Ordinary shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r65",
      "r557",
      "r575",
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Ordinary shares, outstanding (in shares)",
        "terseLabel": "Common Stock, Shares, Outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r65",
      "r511",
      "r648"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 23,498,617 and 23,129,953 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r31",
      "r154",
      "r156",
      "r161",
      "r501",
      "r521"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r60",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r640",
      "r642",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r79",
      "r170",
      "r250",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r432",
      "r706"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r168",
      "r284",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r300",
      "r307",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r62",
      "r63",
      "r103",
      "r104",
      "r174",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r441",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1",
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r104",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "us-gaap_DebtInstrumentCarryingAmount",
        "terseLabel": "Carrying value of Pharmakon loan as of December 31, 2022"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r55",
      "r57",
      "r285",
      "r441",
      "r634",
      "r635"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Long-term debt at closing of Pharmakon loan"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r174",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r441",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r113",
      "r260",
      "r632"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "us-gaap_DeferredFinanceCostsGross",
        "terseLabel": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r6",
      "r201"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization",
        "terseLabel": "Depreciation, Depletion and Amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r348",
      "r350",
      "r378",
      "r379",
      "r381",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes",
      "http://www.urogen.com/20230630/role/statement-note-17-related-parties",
      "http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements",
      "http://www.urogen.com/20230630/role/statement-note-7-investments",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r162",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r422",
      "r423",
      "r502",
      "r522",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per ordinary share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee related accrued expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r14",
      "r134",
      "r158",
      "r159",
      "r160",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r196",
      "r251",
      "r252",
      "r327",
      "r382",
      "r383",
      "r384",
      "r402",
      "r403",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r457",
      "r531",
      "r532",
      "r533",
      "r545",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r298",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r426",
      "r470",
      "r471",
      "r472",
      "r634",
      "r635",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r298",
      "r340",
      "r345",
      "r426",
      "r470",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r298",
      "r340",
      "r345",
      "r426",
      "r471",
      "r634",
      "r635",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r298",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r470",
      "r471",
      "r472",
      "r634",
      "r635",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r424",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r261",
      "r262",
      "r309",
      "r324",
      "r419",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r520",
      "r632",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r78",
      "r170",
      "r197",
      "r204",
      "r208",
      "r210",
      "r250",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r432",
      "r630",
      "r706"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "us-gaap_GrossProfit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r76",
      "r108",
      "r197",
      "r204",
      "r208",
      "r210",
      "r503",
      "r518",
      "r630"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r268",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r389",
      "r394",
      "r397",
      "r400",
      "r404",
      "r406",
      "r407",
      "r408",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r127",
      "r186",
      "r187",
      "r202",
      "r393",
      "r405",
      "r523"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r391",
      "r392",
      "r397",
      "r398",
      "r399",
      "r401",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities",
        "verboseLabel": "Employee related accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInInventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r670",
      "r685"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "auth_ref": [
      "r110",
      "r131",
      "r132"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest paid or due on all long-term debt.",
        "label": "Interest expense",
        "negatedTerseLabel": "Interest expense on long-term debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-5-inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r90",
      "r620"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details": {
       "order": 0.0,
       "parentTag": "urgn_InventoryCurrentAndNoncurrentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r148",
      "r619",
      "r648"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r138",
      "r147",
      "r263",
      "r264",
      "r266",
      "r498",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r90",
      "r621"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details": {
       "order": 1.0,
       "parentTag": "urgn_InventoryCurrentAndNoncurrentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Raw materials",
        "terseLabel": "Inventory, Raw Materials, Net of Reserves"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Obsolescence"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r81",
      "r200"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details": {
       "order": 1.0,
       "parentTag": "urgn_InterestAndOtherIncomeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "us-gaap_Investments",
        "totalLabel": "Total investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r111",
      "r112",
      "r133",
      "r216",
      "r218",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r447",
      "r647"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "us-gaap_LeaseCost",
        "totalLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r744"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Month)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
        "totalLabel": "Lessor, Operating Lease, Payment to be Received"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.",
        "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r745"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r170",
      "r250",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r410",
      "r411",
      "r412",
      "r432",
      "r555",
      "r629",
      "r660",
      "r706",
      "r746",
      "r747"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r71",
      "r105",
      "r514",
      "r648",
      "r689",
      "r701",
      "r740"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total Liabilities and Shareholders' Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r137",
      "r170",
      "r250",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r410",
      "r411",
      "r412",
      "r432",
      "r648",
      "r706",
      "r746",
      "r747"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Uncertain tax positions liability"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LongTermDebtTerm",
        "terseLabel": "Long-Term Debt, Term (Year)"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r23",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r116",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r77",
      "r87",
      "r109",
      "r135",
      "r152",
      "r155",
      "r160",
      "r170",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r191",
      "r197",
      "r204",
      "r208",
      "r210",
      "r250",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r423",
      "r432",
      "r519",
      "r577",
      "r595",
      "r596",
      "r630",
      "r659",
      "r706"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details": {
       "order": 0.0,
       "parentTag": "urgn_InterestAndOtherIncomeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r197",
      "r204",
      "r208",
      "r210",
      "r630"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r448",
      "r647"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "us-gaap_OperatingLeaseImpairmentLoss",
        "terseLabel": "Operating Lease, Impairment Loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease liabilities",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "us-gaap_OperatingLeaseLiabilityCurrent",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long-term lease liabilities",
        "verboseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r445",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.",
        "label": "Amortization of right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r454",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate of operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r453",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term of operating leases (Year)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r4",
      "r12",
      "r100",
      "r153",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r150",
      "r151",
      "r249"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r648"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-5-inventories",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "negatedLabel": "Issuance cost related to at-the-market issuances"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "us-gaap_PaymentsToAcquireMarketableSecurities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r32",
      "r539"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "us-gaap_ProceedsFromIssuanceOfPrivatePlacement",
        "terseLabel": "Proceeds from Issuance of Private Placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r163",
      "r164",
      "r696"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r15"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options into ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r122",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r92",
      "r141",
      "r517"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r506",
      "r517",
      "r648"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r122",
      "r125",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Useful life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r542",
      "r543",
      "r544",
      "r580",
      "r581",
      "r582",
      "r601",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-17-related-parties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r61",
      "r387",
      "r754"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r679",
      "r687"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [
      "r611",
      "r612"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted deposit"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r68",
      "r99",
      "r513",
      "r534",
      "r536",
      "r540",
      "r558",
      "r648"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAppropriatedMember": {
     "auth_ref": [
      "r42",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.",
        "label": "Retained Earnings, Appropriated [Member]"
       }
      }
     },
     "localname": "RetainedEarningsAppropriatedMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r198",
      "r199",
      "r203",
      "r206",
      "r207",
      "r211",
      "r212",
      "r213",
      "r336",
      "r337",
      "r499"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r129",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r578",
      "r616",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r452",
      "r647"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r23",
      "r43",
      "r44",
      "r54",
      "r55",
      "r57",
      "r59",
      "r97",
      "r98",
      "r634",
      "r636",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r17",
      "r72",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "us-gaap_SecuredLongTermDebt",
        "terseLabel": "Secured Long-Term Debt, Noncurrent"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement, Director [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r106",
      "r107",
      "r680"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Total assets at fair value"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r27",
      "r134",
      "r158",
      "r159",
      "r160",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r196",
      "r251",
      "r252",
      "r327",
      "r382",
      "r383",
      "r384",
      "r402",
      "r403",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r457",
      "r531",
      "r532",
      "r533",
      "r545",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r196",
      "r499",
      "r537",
      "r546",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r578",
      "r579",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-17-related-parties",
      "http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-tables",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-investments",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables",
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r196",
      "r499",
      "r537",
      "r546",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r578",
      "r579",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flow-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited",
      "http://www.urogen.com/20230630/role/statement-note-1-business-and-nature-of-operations",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-long-term-debt-details",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-amounts-of-assets-and-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-maturities-of-lease-liabilities-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-supplemental-information-related-to-leases-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-undiscounted-cash-flows-to-be-received-under-sublease-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-net-product-sales-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-sales-reserves-activity-details",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements",
      "http://www.urogen.com/20230630/role/statement-note-13-license-and-collaboration-agreements-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity",
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-effect-of-sharebased-compensation-on-the-condensed-consolidated-statements-of-operations-details",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes",
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-17-related-parties",
      "http://www.urogen.com/20230630/role/statement-note-18-commitments-and-contingencies",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-useful-lives-of-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-accounts-payable-and-accrued-expense-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-interest-and-other-income-expense-net-details",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-inventories-details",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-tables",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-investments",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-marketable-securities-fair-values-of-marketable-securities-by-contractual-maturity-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-property-and-equipment-details",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-activity-in-the-carrying-value-of-the-prepaid-forward-liability-details",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables",
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r99",
      "r539",
      "r597",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r99",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of options into ordinary shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r27",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of options into ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r65",
      "r69",
      "r70",
      "r89",
      "r559",
      "r575",
      "r598",
      "r599",
      "r648",
      "r660",
      "r689",
      "r701",
      "r740",
      "r758"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Shareholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r169",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r420",
      "r600",
      "r602",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-14-shareholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r450",
      "r647"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "us-gaap_SubleaseIncome",
        "negatedLabel": "Sublease income",
        "terseLabel": "Sublease Income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r440",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r440",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r440",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation",
      "http://www.urogen.com/20230630/role/statement-note-2-basis-of-presentation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events",
      "http://www.urogen.com/20230630/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-tables",
      "http://www.urogen.com/20230630/role/statement-note-11-leases-tables",
      "http://www.urogen.com/20230630/role/statement-note-12-revenue-from-product-sales-tables",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-tables",
      "http://www.urogen.com/20230630/role/statement-note-3-significant-accounting-policies-tables",
      "http://www.urogen.com/20230630/role/statement-note-4-other-financial-information-tables",
      "http://www.urogen.com/20230630/role/statement-note-5-inventories-tables",
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-tables",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-tables",
      "http://www.urogen.com/20230630/role/statement-note-8-property-and-equipment-tables",
      "http://www.urogen.com/20230630/role/statement-note-9-prepaid-forward-obligation-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r309",
      "r324",
      "r419",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r520",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r504",
      "r640",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-6-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.urogen.com/20230630/role/statement-note-7-investments-summary-of-marketable-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r390",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-16-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r118",
      "r120",
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r449",
      "r647"
     ],
     "calculation": {
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-11-leases-components-of-lease-cost-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt",
      "http://www.urogen.com/20230630/role/statement-note-10-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation",
      "http://www.urogen.com/20230630/role/statement-note-15-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r189",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.urogen.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org//940-320/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.8)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org//942-320/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org//946-320/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org//606/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org//808/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org//320/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(4)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org//330/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org//830/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r663": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r664": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r665": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r666": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3)(i))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001437749-23-022879-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-022879-xbrl.zip
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M"3L>B")KOBZ@;^*/''\#4$L#!!0    ( )! "E> L6I!W 0  -P8   -
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MU7B\U;/)E=,\SB-NTN4VSX*\)=5O%S!5XDN-PRXWX]Y9IO9%D28HY\I2;'
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MJOP$V2H!P;B5A 3E8N&)"JR HM;<E3=NH8 J@ZE:(:J4;DL:^LD7Y G\@IZ
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MQELJG3<OHI/!^J\NWUZ4L\$3^+L^E_P%5&SC[_Z$&(M^@>G_ U!+ P04
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MS67DT*3O*XSK3F?^>Y'EX?BBVNG)),S4I9-7G1R?^^M_/-O86'L)R]6;ZCB
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MH+EA*$Q]F'%.4QR.*=: 4EOP"7<7Q*/,=PLA*,Q)-96)4F>$*QO^*VG.-^?
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MY@12B5I=-O'@7(8QI@)YE,43P@.4\92R@IKYQ!D"NKO+*M_AG:_F4&U'&^6
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MM>L(6D/GUAM%CN3(.CG[GL7N:_Q$-SI%GJ A/!+O,=_WS[\8L6)&[-I:VF:
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M\!:"@,V7$POAU1$>RT*FSRU'W-*?L5+F<242*_595F1L/4NC'2FS:L;0G!9
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M']E,S6HM/C+030R NZD(0U]$IPTP=NO51O*$%0XXFL30'.)9@X$1<@7PG;0
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M8O=XC/CN$VV?KC(1!!5:@1%?,F"B1CQ#?H$:<*K/0BWWF\Y)IQ\YRJES%CH
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MA-P#BX7$O!T16DCC7&U%?OSY?^\RKVB.B-@]4!]W3P[ZQ\?JX[O^H'_X!L4
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MYEI5)ZN'U^A]DMOCE5D21K&MOLW/7Z$;FZ6#65@ASXV!\@P-!CXE" C&8,M
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M2IU_G-U=.ZYS>/CI^-WM=^?QX=PY.C@Z=@]^<P].7/?WS\_2^R2'$SHE#G#
MY2=X\&5O$H:S3_O[3T]/;Y^.WP9BO']T<'"X_X_OU_>J[%Y2>!A$/!2+K,+S
M0/AO)1V^'0?S_>3E/A+,*D1"@%Q5-9*WA2H>9?K2\*)8,!1NN)A16>!?54$)
MX/4^OL8Z!^[!H7MTF-:DS\.)G@:^*1#Q&?]3WS[TT/$^OAX02=/BG+"AU#>M
M7A7:EFRH+PHOB@5%F!4<$3E0].%AN5"I._)%XU?%"N%,5-"'-X6BD1CS0B]$
M(AA3_G883%6Y@P_'!UE9Z8X)F:URD;PH-BRK>$[?%(HCEUY89#K1Q?O]^&6^
M**O1'.,XMH:9YIY7-)V,A,.3DY-]]7;/(6$HV" *Z64@IA=T1"(?N(GXOR+B
MLQ&C'HQBGTXI#PL%<J]#(L8T_$&F5,[(D#9V*@QXQU&CEDUG@0@=KJU:)5L\
MU*^#(0F5H:FL@G^Y:3T7'[F'1^[QX5L@O;=OP$4EUG4LR.H*\4\7?[:C731#
M1M3S5=(_-N @9T2,R&?EU:\-""\MI!'=M#C^6(^JQ@C54EPIOT_]4"J[U%[:
MI94TDC8MCC]:2ENR268BY\U>+';:3 O95XR=X0!/*^#(?M^RNY>3@EE_I^75
MK_;X:M'EJRAKT=\5\]8&2L<GZ_'0[-!4L=-44_TM6UK8HMMF9F+S=;*_-N@-
M /+)O@A\NL_I&%UAL['@"U&HA0/B!*>ZPP]E/@CG0:B:4L_2I[,9XZ,@>00/
MT3/XE/J!=W3D*%_A$Q%#I%/O4>S/1#"C(F0 \)PKJ1J8"#H"WP(\+S?U!O[I
MD\%;<%?2(BL$BG.ZDA.J4/]ZR5Y:%_7_94]"9_LTD?JGBS,D_KKB0)5AY"NM
M=%0HCX[6%0JJ,,XZ+--,T'5E@BH2_.!6FL(&'J" PV!M"BYIJ%QJUPN&D?H!
M:V(7_F7APL6Q**:*RIZ#]1[OKIJ<ZIA!\W8S[E+^EOJ*%P\F"\3?#PX.8&5^
MD=#*_SSEGO-5D76NEF0_[Y=HK; 12>K=\-_5[]*X2"HG)>HJ%K%G7J^L7WW-
MY&FJ4#,]#P/N40X-X2\9^,Q3EGI ?+4XD1-*0^G&<TCH HY9X+D1)Y''U#S0
M$@8;DK6%DD. QGW*%/P^3]G"7QE;SEG,EG.OV'+>G,=\.;>*+^<QY>LO/8[:
M*=2=$7P^H2&#3I&O!*LR%[90=F099<Z;VP*C/>S*"L\*2#<8N3C]*N)2S3H
M(.!H M78G+I^(.7+&;3VC-@"W[$9^+(BT@E&SDW&J .,0LD<H\XU,.J\Z8V>
MH=+E! ;K)/ ]*J2+0@Q9^+, UT#;%L;>M<'8?8ZW_W8N8N9Z7!GK=DCDQ!WY
MP=// I..H"T$O6^#H'-@R+D$AGK4H!)Y$%+WT!U$DG$JXRF&DS 2M#CWM$:)
M,0%;J/B *S<FAS U A'XXP=PX*#3?I;PH*:G'XJ'XKRUXS X I]7,C5L\Z0V
M4WU5H[;4_5&K;O2>SY N*O@V1W?'57SL2C;F#*9-@N&4H=I+8WSLSL!<#AG=
M<)PW-V]+[;]IU:[\UB4'SFG&@7.;<+#C 'CG!K $%"YP!^M&1GPK 3J#IFTI
M_D2K>'0F;Y"Z<YE2[T-UF6;>@R;F\%<@-A[AQ:8L*?7P0*M4].^NEM1V7(D?
MW!%APIT3/Z+NE!+L*>75;J;0ZF9M*?=0JUQTTRZ!LO-WI.Q\SU'><45_5$-,
MAA:46VS*ED*/M K]F(S6A-J.*_$W-]G!6\2;5O^*V S?;J;/RE9MJ?98JUIT
MMFX3PFKQ]#4EO.-:/L$US8PPSP57XXD(SPT&/AM;<*9J6[:E[7=:;9\H;2OB
MSF5,W+G)B.^XQ@\/7#_@XY"*J>O1P8;C>:4U6YI]KP^"H)]U#01=I.A< ,5=
M5^>AZX/GL:E7O&S&E@(KHECH2UTK2KNNN"-74%@:@-,Z$L$4YT4O&H:N)/[&
MRJQMVI:"]7$KY5O=Q=2=2Z".\RY2=^Z1^JXK_=CUV1!#_,E6J.^301 ';UTR
M%M3&@LB4B"T@Z"-9RA.[COE(ME-S?#BG&1^[#HEWQ?U*=(G#Q88(T+=I2^'Z
M")9RQHK;FU\5W5U7\/M8&=A[<?8## D+#G9-NY84?:2/:BG?3"G:5;15HD1*
M>]>5_<%E''1!W9 \;SR/EQJSI59]/$MY;%>*GO. ]'9=E1_!B_))DB$7;AQX
MUK1G2Z'Z>);RT.YBDLYM3'+7=?H;&LHIBR-\B7NDMM<HWWSSL+%U6_K6![F4
M(W:^9"#QNG(,[+KV3UP9#21X0_@(UR@;N]JZ%FUI61_<4M[7?4;4^3K?;2>Z
M8;]^\[P 8P*V]+X2^FI("'#>I+]V/0VL,7L#'*G!QN$58RJV *$/I1FDBCAO
M'A0GNXZ+VL0.*Y@PHF +#_K(6T,&28\%3?Z'%=UK6[2E:WUPK918TNNV(17$
MBIX;6[>E<WU\K2;?I->_)EO$BLZU+5K2\[$^O%9*0^EU6Y\Y8D7-38W;TK@^
M\E:=G=(KOSF9Q H 3 C8 H$^6E>?M-(#09]O8D7Y58W:4GA%N&XUEZ77<BD;
MQ8YZRZW9TFM%@&Z9XM+KTR AQ8Z.32C8TGM%;EI]YDN/A:9M:SM :&S>%@HJ
M$MSJ-L=[#-0>J83)-R3,A_%*G\.(^"]R;G.%B"T\K'F.TWES$3/B/,2,[#HH
MFL/J5N&Q/CE;0&E]\K.'S-HZ!%*CR'=]-J>))= N\Q-5OS2BUN3&%N#T\403
MP+G.HV+9N4:68Q.FCU,DR-QU1-;O R68D.Z,+- 14'J'AR("7X4^SU3.KA4L
M6N3#$@K?Z:.=3;M6;HI+Z=S&S"KDG<;,.E]C9GO\&>F=\9 " _$UE''!),$P
M53JGEHRA349L(5 ??6U&X%7"K4)>7#3)DWR3X.\O_^/\H+T5U.^(6G7;ZINV
MA11]B'9EU[5WQVITH]&33=7KFK>E?GW MJQ^/1AV'035N^1$2IJDQ?J,#)C/
M,",Y+0,.2)BOBFZ**RC>6HH^=+R6MX*CG\*A+2CJ8\QUN0#@,2DQU&QUO10C
M+>4Y),Q7!H:(<Y>*D00K>C3K]O^MSF3U3=O"CSY6O9)CT,]D-;J1T71*Q )7
M[/#OGU0%DEV)0R8V$%;,4DN:MH"B#V>7@8*IYXHQC 5\SQAS[C/&>M.1Z5.O
MN.4,(JNU.UBHHR."#'$X0J$0WRQL(>T%.;.%1WTX'9_J89>?$&4U.@<+=20F
M81\*Q>SWJ&W*A+(Z]QE3L84F?<R]+O&JGQ'--/:2$?6V1&VA1A\XKT%-(YQV
M'4:U>7963<Q:E"P!YKT^QMV4VM>;&G/-P;S-YO'GD]QP0MTA$6*!R^]D33Y2
M3\L-I*MY2P[43^'0%B;U4>\&3.*V2RR&P[@###OGB1AIU&"DGI:;2.,-O4-5
MF5QJU<HUMFX+1157#.AR6'MS5J\B/^VO@L8LXZ""B"TXF*<TQP\ #&5\[#PN
MLK1DNQ:ALEE;NC=(>^Y-0(5.,"$UX#3YMHQZ",^D+2M@3L<6&"IRH7-@4'>2
M),R@VZ >PS/9FX)5O9%IG)@#2JO8C+(,%'."MA#3>#$H.I\Q5PB7BLVL'CIE
M3<IH-O/5FU*R37KK5!B49@9;&&I!V1:8*BXA+8#I/L=>(;,GO1LK#,H35X^J
M5&%)?)_1W$3R@N;(E)PM_%3<75K S_>,I^7TU9NB.M!$W(,^11..9W#2#^A)
MM ,#BBD3E,TI?H+6HP(OT(KU;!E*FS%A"V 5=Z46 /:8XW3Y>3^)=FE ,35#
M<8K%J,"KOQ2G/>R,COYA'FGQB1V8M21J"58?*FYF;3B"Z*HLU=*QQ!Y&!AJ-
M_X\L"#R[D<5X?P*8FDC;@E3%K;"-D(K_O4OX6\:->V"M=1V[Y2A02Z*VP%01
M+C:]$[Z/(!G=Z&X9,V8T;$&D(H1<=8M\#PGSD^YV86%.QQ8T*B+,]4?K>WB8
MJHV.1A3<"UA@5Y4(DJUKDP^D+[^ ;<D;>D7&;0&X(BI>"V#7^:K$PR!#9:&;
M9#/>Y$/QR\^"][Z8_HL*E@UE0^.VP%410"]_OJ&WB :7M5M&@ D%6S"H"'UK
MKX??*2Q\WG^6WB<RF^%6A'J6/.&@))+)^AF?T7AC0,$E$F/^S^1@^3DTS$#J
MY'SOGL/)E'[9JWS+<!WC0XD0WN\YB(*0A1$2^R:":/9E#Q7)/C& RYX3 K/I
MDVG 035B<05O4(@])WX^(#[A0R@V%-1C8?H8;#H+O ?5 .. /Q[N[3?+DQQM
MYN,;GJ1L)1E;-[G/?19D-*OQ@G)[=* 7VXOB:<U$;@Q+$#&<G'+O L:C'ZAT
M7+U6F\IV7<<J$)/$84JBE5YMDR3GD1 4/SM<*="R1.?EHCY8CO$WRL$S\P%G
MI]X4+(D,$=!SJH>E<:7N2J^V\('SW*[9-86'5%V'AE/2F1\,_\P$-R_?1F8O
M%"[^DI_"M*6RX&N;&]RUP?\P5C$';,*<"^J+II':8096I'SD@A*?_1O^)(R?
MT5$@0)[G5.B-6NBLZM>2ZAK^HG*SGEEMXS6FJ+9=P[WEJ;7EH35U'=,B_O_*
M8-F\F2Z/(>[=3P(18O9H[ABJA:&U:<-;->+6%7:-@;AYT]LU/G72XL%3=2IB
MN1Q;O\OTC72V<WPBY<WH#R($%)4WXHZ-)Z&\DC+"UF\%@_]1H>)865^L5V<S
MLS1+&JJS2D:"YG>HL@TJU%TF5EV)]OI+369;LTH&4IUR3DGG))K."%_<C$;0
MW_**7TE!J/^=3@=4+&6J+;.9:KQ@"L;T1>2*0BK4  M&(:Q5Z:I4E25>4Z9,
M!CP@<06H%!$^/R<S%L9F$].ED>V+)%%(IC*M5:.KUJ0HQ/75V<W=I1\$0B]D
MX?W&5F((+6YJ)(K\W1+F0<<GUQ7&J<QZ22I*=EE-2W?R=$Z8XA.F<LQ1R2:P
M]$Z%4Q_<0G0!<+C!"M;/WES T],1C,3_HT3<</HP ;'&$_B'TGQ/_0QBW>UL
M\ .)I%>5X;<D2;X(HF7WM:W>M9!>I<&_"(9J% 'W7SFPN,CE=F?=4%^FO:S
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MD, C,E13+'#@SC QD)F/]C4:^I5Z)U(Y9[ (F,=K@EF2G*86FS3-3#,>QB]
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M*@*6 7O'20CTQC2+Q7GR2$2JF/X::">#N<7]DD(R29=4%A3J()KV<XKF&!:
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MY/R2?O\N-#.6C$]VJ/WD+Y_J<Q_(7_^>M8[\-2$#(&_]>]0Z\C:\R5L5(?O
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MI/0N;TW/O!V8Y-; ^L1-C3I5I77,036$(P-*3T(PF(+!!#(:'C*WZKS,PM!
M@'4/QD P!H(Q$(R!8 P$8^ U& ,FIZ);_/M3-$,IC=8H*S%G%PET7F4,M</"
MT.$<X6(S<@)&#A@9A)'/N5#])F3JB#%<7=G9,^JO:C%+)OF-N+U#TWQ^C%AJ
MZFFW^(V M@/:#F@[H.V M@/:?@UHV_K1Z1:2_UPY<UG1 8:KAG $O?4D!+@=
MX+:FW.%6?*H'(=)9BI/CS0G)JPLP)<JN4"%NQV].N> !\WBZ#^ET#IHJ >B8
M!/4))D$P"8))$$R"8!($D^!P30*#HW"4Z3:VT(Q;^^:7:+6]@A&A/(GP[OY%
M.U,'.)HCJ\>(FF  !0.H32WKUE6L@QD0S(!@!@0S()@!P0QX16: Z7GH%@Y_
MYI"QJJH7S>JR>A%YJ*O7#A(;C.@(%AM3%*#Q(4-C2>F;_<LS1;KF'[C([Q;X
M!%&Z2?-Y%=*;S/AOGI:AW 7W-OJZ./U\(:#H@*(#B@XH.J#H@*(/$$7W?7"Z
MA=OOWT49R><%IDLN@].67F?-*(Y@-8B* *4/&4I;S&H7)<XO<L8U3!53@J>J
MZSH&?!SP<<#' 1\'?!SP\0'BXY;GH6/8^S[*JK<]6N)=27=70%?Y^8!P#QGA
M2IS%37<[ZC=L]&Y@T[Y6?=NWY6I5:UZ473R6.;W!&1?YY([43_"8^+*[C.@4
M0U:$G! &*RJC:>V8<B$=$XY9D'BWH2+MP;FQ2[,#<M5Z).<<$_J4SFNTJ4\T
M<BS>3\+I&B?&S'<?--B3P9X,]F2P)X,]&>S)P[4G0?!G3-<6VB-O()?NGF $
M1\NZ0W,@[^Y>8X1(;D>("^39W>N+,)YM(5O'GJ$/$:V?1(T$T^("2U+&1<10
MUMI;9#"D*P^2,4G!J_0*O4I[FEL(AG@\EZX-O3'ZCDX-K=.4H?F<XCK;=C+;
MOG\,LK^,^@:S/)CEP2P/9GDPRX-9?KAF>8LC<6Q&>@LLX]AD^10Q\9K[5+QP
M'\5[3]RWM%>@X[DR5LSH"9;*(5LJ%C,\S[C<D@W&MWP_IS&^%3)V+&3L9$_$
MCK**KJURB\D\3__"R36F*4F$.](@,;2G[P5#(Q@:P= (AD8P-(*A<;B&AJ-C
MU"UR_Q!-1;'EB,Q$10 FXF)%+>(%2C,6"3DJT8,8 /&[X:B.4'PKJ@*6#UA>
M71,LQCAAYUR97#!6HCSF"N*:IFLN>M<9BO&^YGU9%\R@LU.^;L2>R'%RAFB>
MYG-V%,?ELJR"Y*=\4\:IC"=XQV U'(#5<%M.&?ZSY#2<B1>UKIZ<L,_)5;4=
MDNH[_NT&'0-L/33EC8H;W'Z<U)N<0\%<Z\P(="<08\$;G5%JI!2\LW+TJR)G
ML4E?>V6!VY32?LSSX$+QQH4BW7.'YD)Q%\6$L61J('B7:PQCLXUMY];U\S%B
MZ3Q/^90C_BL4QZ3,1:ILM"(97P;,.CJ!6H_OR!W4D;[@& J.(86I<X+80OQ7
MU+9=HTRDG1_ER>V"T.(.T^7>6Q$2V\=\@.!0<>]0"<9E +(!R+Y*(-M60;M%
M>9^J9S]SKKFZ(SK06([0FP$M :D%I*9 !L<H$\;9[0+CXG(;LE=$ W3-!Z==
MZ5'7=Q@K_=;DNNW;N$(7;6[0_1774S1%&?N*"Y'Z42=K2_B!=W3*SZ188/J5
MY.)!;DY??4M<&=P#] CV2;!/O+1/8,$OK>(GYFIV=':8V2GH7?P+L"ZDA4[S
MROBT*Z\A$!;\!\%_T(?_P!3ZN?4;_%S9UUL'1D>_ 6@L1WX# UJ"WR#X#51U
M//"T>'S&_&C-!4GHIG-"Q2W=;SG%*!,I_Y>$L6O"*@F6X/HN0P6K*EA57EI5
M ;4%U'9XJ*V[JG:+XWX1E=6JUW8CE"<1WCVUVQ'2F0[K"-VU(RL O0#TE$!O
M17&<UDX1S 6X4E%Y<K0DM$C_0DI@!^\:@%P <@'(!2 7@)PC(&>JFMT"M\_B
MDKIXNC6:U6^W1F2:I7,;U_/;#.T(P+4G+8"XUP?B&"WVP /_Z9$R_L._3D1&
M/Z8KQ.V!KVC9=,=7UZQW&J_KNM<3NBTF(J%1U<P5C55Z8_UYUBB$H+;CH-9^
M-I&&ZAN\*FF\0 P?S2FN-.)SN91R8=SW,+AQOD:W,<X13<FWG*TX=)BE.)%R
MH6T[#FK=S_$.#^Q(DBA$93L3*B6%Y_^)L^6F(,TY;](&%CY\7>.?\QK^/&R!
M\[(H*1;YYN<9N6<7>4S%DQ87^36WS?C?T1Q/9E]Q456(;:+7YK@NV-P]UF&-
M/\B _3%VQ4'RLEP^FVX#1M0#N";\AN^^SL3O#V*=@<F#W:"G\V7;'LDY^\Y5
M;(&3O3WWE1LO=_<X6^,K;N\O &+1:C@K3#U>:WZVUI2B?%ZM-M]5S1R8]>V5
M7)UXP/M9(//F[O>]ZT+R,T?5S@(9E2H\QL4]QOF'=^^NTBRK?2(?'WZ0TV;<
MV0W!OZ?%XOSTZ&BUHF2-LD[T*\>RQ<YD]FUU1SY 9US=W!I1:TS!0J!JW ]!
M9HMLT-<6N4_7R(Q<@[X6R/WVY>O[=Q_D)#7]?? K0^&ZUNCH'_2Z5I78?U)G
M]>\]?*F_X*3K$V*X(89;$^Q9#%?-B-;#3(R<N[ZQIG3PDTX^5)]8/9R+:OHE
M5;O_B)$/=G39%+"@E3>7[]IM+P*V>;W*';&N;P[D A[09^^5T.KU!S$UQ;V3
MU6Z*M)-P6BK9:$DX]1%VKV13#\5VLJD(5'DGC9U J ^:TJY&,7>GNMUZEO6G
MUF\(Y.ZCC]P9N_&\$ERXNI$["($,_>CCZG4.# "9_^0C\\8.<[?[-)0U:5'6
M!.;)] H@>%38Q)*."C<KPLV* [I9T2YSPAO(:H5+52J+-_#5B%-K:77>X#^;
M[!MG37H#!+O/ B0E$<CN3Z-E]V42(Y#EG_UEN4-V(9#Y7\; O(PS%]?_WK^+
M,I+/"TR7' 5-N]9K@ [GZ)J?&3GA:M\A7^V3)**)0BL7.>-JH=J\%\>3&ZZ
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MYQ9XAR,MS83]^+5W@+,GF0$F;7@'-NU,1]M\3.] 5B=%"DZS'8LBA3 D41^
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MA12$4-;[ =F&X'P(SH?@?*_5G@&'BG<N!0UK)AC,._\ G#<E*O<N&@;GRW[
MVAL_>D?</69W.A#X>1?5:J5&X8:&3XZW=!MGK-Q'=<.T\DT^^)!R7/3B>6OU
M92]<;QTH#[ZW5^A[&_'=Y\<"^34=VFN2ZN9N[]F1G#Q-EE)?F]"V#VZ*X*8(
M;HK@I@AN"D</*D .D[$Y*LP.FS&Z*HQ3/EU809\X1']XAN+)O]O9-N#Q'%DL
MAO0$.^15VB';]]6V7@F^01\?HI":([ ^SJV2BJASX3U;X.0+(4F=2;7U^\K
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M&M-<D*94I* ^(87$20J)#F\1%_O:QXD!6)BD#WPTVLP;J$GN7>*-E;4C9I:
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M-/UWED-FV\])QFV(JEH4^V?<LS*K^)_>\W\6#S+1YHK6BQ4_$Q0GNF]P2&O
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M\I5-J\-$#$/%<%'=G,I7R8:.7)"'AF CLWM3^18%@$4 6,Q+\B#MF Y!@G/
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M*F[L?6>+<V7L*Q":B:4_Q7/C)?UU:!WND4AFI]-T.,>V.;Q43T1&'V,?B+2
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M'IX:-C'($[[,G$UUKX[.!+Z<F;#T_[F<F2H]@')GCNZK!VW)K8(U*X6YW<L
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M2_-1QNX_D[<_G/SQQ[^<_/G-/XD1_)]OWOYX\N.??FCGS(270.;%[>JJYC]
M#(7,AM4 <4+X+%NZ!%[*XS2#57(#T]WB<'?(]'_LFGBI.W9#87%9#@E\,O+X
M(ZOX[\%^NB[98Y;2]-WSYXJFET47 W(&E!;O<E/W3X^@L'=7#RAYSZ'H<(9"
MDF6+M$@;Y?9#!;^%GY=@R0-?$M8%(B4=MI'NRCY9@(7<UW"UB]O+RKOG3S0!
M\Q"6=5&*QH#+YY%>S09?8NL13T/P+0T]N*0#'+.'LPG5F04IPS/@$%ZC'6H-
MOK1E0#6$2 P8LVNM"=V'6%"7F%%9L+J!>"#(?_XD[#\#'E1]ZI )CT%X+P0
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M&U7#7/%9C-*D+[U_XE30JTZJ\;%]@=(1('%=P;,H5:JS!</52K7I:NLJ@PJ
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MB]6OH@1P72W*&W@VJ=JZW-=EME3V8\!^C^%I$SA!PH1,$#*6![^KQ=2S!X3
M*&]1(OQB+9$ZV=>N%W@1CIBL="]JV:<LY]9^I=VM(C@UD&\\[9JW8LW=ZH3'
M8=E2ZZE'K5(@'4&]H$246=/>UN&0)TL1S'3V  IZ7X(RR<_2QZQB975!Z6!6
MF^&G*.>"'H@P%?SU<#'W(/A:(Z9^?XL+D<@(9T"'#FGQ(?-:J&V4XHK*FK/;
M;O7)?O7[ +^D03*&3\10U)@-R8/Y/ZYHC6RN?N2LP$^$](Z8 _2MHD2MY M1
M^!VZ,9!]2?C(!90M]H:Y([BM^<YAP__#Y?4QR1M9^B1B1<"3*.*A!'CM1S1'
M4Z*,?#O0(5@9FCEQANYA*)3Q'D>R1]+E\UMPTE@_R,D'\('WN*4@HV@(08_(
MN-F3L>H6%,-D=B0#S,?NV;^R0^@931N;7NV2&A^)?#<?F#'  _FI!-M>7_&.
M5U<KL'98;?>+:FZ9<5ZSQSB$&1 MF'%W0Q]IL:,W=,D>BFS_>CY5DT_[.Z3I
M-CF_;S%I$)A-U5)]@C,T%8-QW6V;F_4Q*^@E_U&5[Z,>B.2KEQ.&*(W<%$,&
MF$0 C<-#(]1D^B2R31!([ED)F_:L\?PY.1B5!J":U'OD?P?8Q:NGPV58G[_Y
M?F4QWSNGV869$<_V0LHVVQTX^*#(/%O5W#89>?2<'HVZ1BIG]7Y#;"'+S@ -
M;#S#NUR)-<<O#Q97->C$N)U-<PTS)*"+S)/.@WE9\&ON1M!YU-.B_Q4Z+V5T
M]C!I*GLO?0\'@_+C@9:&C_?G'V5<R(_JKLJLEKV3/MMC&2O%18_5&)+(P4SI
M,^E5JKB-3[-'<)^ $W8X6<;@$Z1Y/39U@+09 9N4'? H5K86>1F&9L&8:MA#
M=[MF97U'RXULA3C6M==\ B3#Z0/R_OILC)&1I@^P7DPDS. CP(DT^ "I4\"*
M:"_:DT@BV)'9TSS<&9"FPKF3Y%#EY;(X3[99G>3<W-NPXK96>_'T/\2>!Y,
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M?.4^YPD1G;!==3;$4Q C)!BWG0P;S_85_5+?/='\D7YB1;W6T%2HZ5P&.6J
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MR5'\ASTC\7_\[7USO/P_NZ3D5]3\F9\<K#S.1- 8:<@Z(S-ZOQ(U8$D'ETC
M0;E%AZ3,@$Z>^.-#44LG'BNWS=U?U-XY!X.B?#YGZ7%4E>%7"+[1F-U[V1N!
M CG X80(+"#/JL&$ "K!N<J$^ Q)T6"'W.>BI$OV4&3_$/W?WM&"KK):92Y-
MC$8>;XI90V4H*<!CLHN<K03AV^W#)APXT5N(IT-ZBE.8(='">3WI?7U95'4I
MCH2V)^V9N."IG)T:GV!]G"-3AY*/,1PP0N)V39A7D!<-F&7]Q-^Y99NSI(
M1/[+]W0IGM/(#V].".>3MW'\MSK,Q3#4#5=P>;D$Z")T(,^6&:W.[BOAI5,(
MU/0'V%++RHF]UUGN(),6-+^6-\ CE5B>IC(S)UVX:J,9/S)6V3(IZI>X3;T
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M^W5A<DHE%@30D-D+@,@)Z?6SF\OJK(VF9+^FE&- =E  29A254.%'*@@,B#
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M":I'[VDVLSE3M<*"/UZ^6]Q<Y(P-^H"FQMJ' ._GC!#XNP=N&2AKLPJ$TQ>
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M?.0_\5^VO^+_PRE%^6_^?U!+ P04    " "00 I7;/I8P)](  "HE08 %0
M '5R9VXM,C R,S V,S!?<')E+GAM;.U]6W/C.++F^T;L?ZCM?>9TN:IO-3%]
M3OA:Q[.NDM9V=9^S+Q,4"4D\30%J@)2M_O4+D)(MVP20X 4D(43,I6P#8")Q
MR^_+1.(?__ZX2M]M$&4)P;]^=_*W]]^]0S@B<8(7OW[W[2XXO3N_OO[N'<M"
M'(<IP>C7[S#Y[M__[7_^CW_\KR#XC#"B88;B=[/MN_MECF-$+\@*O?O/L]N;
M=\&[DY._?_QA^N7=M_OS=Q_>?_@8O/\E>/\I"/[M'VF"__B[^)]9R- [+@1F
MQ8^_?K?,LO7?O__^X>'A;X\SFOZ-T,7W']Z___C]OO1WN^+BKW'V5.&P\(_?
MEW]\*OJFZ8>/1=F33Y\^?5_\]:DH2ZH*\D9/OO_/+S=WT1*MPB#!0B.1D(4E
M?V?%+V](%&:%&K5=>"<M(7X*]L4"\:O@Y$/P\>1OCRS^CFO]W;M2=92DZ!;-
MWXG__W9[_>*;.24+A/\6D=7W0NGO?_KX_GM1[GLN<X96"&<!)AD*3GX)>)E5
MDHE?L8"/,/\99WSH^11($..=*[ZUI&C^ZW<Y7>!@WYX0YW_7;"[;KODL8LEJ
MG:+OOC_HTYHBQJL62KSAO]B5%Z)WVK]2(/28(3Y_=UK>RY22Z(46A!AL/]L8
MBOZV()OO8Y04DHA_%"HJU,-_^-<E_URVY4LB3/#^<VDX0^FOW\G^7$J3BLE$
MZ$X_+4ES@Q9A6G[S]#%A%0))2IC(]':>B-_\ZRL?$79/KA+,UTT2IG?[L6*G
M,Y;1,,I>B6-8J[;:YB&;%>LO9\$B#->E[E":L?UOGI6X^\6_SI^GU2F.SP\G
MU47"HI2PG*)[/J/.^*?_>-VQ1HU8[6>%'++1@M<8;P^"#[WTX6G2\TT17?-_
MOEZY^H+]R'L?SE*DD_5%(96<A\?#*8W>$<JMC5^_XQ8+_\L<48KBF_(;TM.U
M."4*0?@'"POA[V*L4?SK=QG-GZ0(:?3FT'G9T*[$]^N0BN,F6B9IO*\]IV1E
MOGT1F&KXASM22\:-0'1C1S?Z^4IJ+<CNM&-GTJB.8*(S&<;>><WT)P +!:R"
MD[&J +K5NS(9(/8$:<>F>E;9/[ZOQ"-MPZ^? XI2@9X#KH>L!N"2-F /8FE$
M\*#*@RH/-L8$-F[+Y3SEJWE[3T/,N"A\LS# M35:\'#*PRD/ISR<\G#*PRD/
MIX8#IVH?Y=:QU >.0S8(YR@0'0[6E,0YW]!8F)K#*DA;]A 67!H/MCS8\F!K
M7&"K6-E7?&$+KDI(\GN2+<]SEI$5HGJD95;=PRP/LSS,\C#+PRP/LSS,&A+,
MJG..V\98/P7S,*'!)DPY%EFA4'2O.!4,\96V'6O8"BB)QU4>5WE<-29<=<67
M]6]B53^+QG1@"E3'(RB/H#R"\@C*(RB/H#R"&@Z",CB\;<.F'P*2+1$-YOO#
M($CPG-!5\3U#Z 1JRQI\,I#&0ZBC@5 2$2=BJCQ]ZOIYHDCM<K-:X\5(X^^!
MOQ?E\9''1QX?>7SD\9''1X/"1W6,*.O!>\$L9WRX6)FC 8<9[U9 Y@%9B^PB
M(N#0$"<9M&@OD,]4)H^9C@8S#<N<'W\/>@(D7XLU/9E/WJSH5Z++"WH Y0&4
M!U >0'D Y0&4!U # %# $]LB9HI)E!?_$# "%1.VGDL)V) -A&0D2B? Z)1_
M/A8B7*7AH@*(5/Z]0VAT+O8ABL)S$K^V=&1_[E*:G(H%=<4739C^%PKI)8XO
M^.!52:8IVJ&4%[M95'Y[BFA"XBO^NRI@J2UK34ZA(YB4;TI:D/& +I*A!&AQ
MN])6801(40M2EK--OH24Y2S(]W_SD'*K/=W>HC6AK_$WH*0%&8OKR(D8/:V0
MLJ(VI.2?4$EV\.<.I=E9M7',#VRV^S^Q.D^D#*"BK"TYQ0DWH??D0<Y32DO:
MDG%*N F3_K]D+3FE]85M25J8]1,ZI623E'FKE;)*BG<N[3D2UU_2:V[>/?X?
MM)6**2G7O7QDM2+X+N-HX6[),0:;Y%F1&SW!548CO%+WDI=F6;D#\@^+$:XT
M.2#%.Y=V* Z*\G.7*T077 F?*7G(EGPXUR&6STUEZ<YEO4I2]#5?S1"5"OBV
MB!6IZ#G?4Q:$RC576:ISV:YQ1"B?YH4I6&Q\YR3GV\M6N:F#:EF0G5M?(BG+
M!G$;,=RM6H70JN*=2WN+%HF@6'#V-5S)55M=K'/I[I8H376+NZI0]Y*MPC0]
MVWF/Y:)5E>I<MOOP\3H6C,T\*9^_T&P^FO)C=S:;RD0$^; D6+YGRXIT*-4=
MBG+*E7#R87:?9)4H6E;$@E27C]$RQ LDV4-4Q3J4CH-,8<_=;5<SDE:(5?EW
M=[R2JN7CO(,)1"L=@YO)1!%PQM#1Z?&VMP0,<1V=*!J5J Q#L$8^N*$1A3\*
MK(J/;J@"YG$":^4'-[0"='"!U?*CBVJ1>-3 2OG)+:6\]4> -?&S6YI0.K;
M2OG%+:4H_)%@E7QR2R5JWR+<3'/*=)41S'!U.&6V&E#%< TY8L8:D()PW3AB
MUP)=\7"].&+9@IS_<*TX8MC"_?=PU3ABWD+#,."*<<3:E4>1PE7AB(VK=K/
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M\/%WA[28N_%W(#N3F%EVKNA$NK\3^*[JBB[JOVGO^BS1L\EZ#.>*[P6ZBVC
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MPS%-LM,N;4+;N.WD?9 2O.!;[RJ(T:RF[TO3BC5\!I+#8[)^?%V:P0&!$=
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MG^BW?#$T%E\TTF$7)D\FH5[2Y[)6!+I\Y.=!AN*#U?>5[R?W#RC=H"\$9TO
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MP0KYP0F%&'."+JPHT*XBYR?!*OAQN"IH;5-I<\K\Y(2^C+T"8]^#?9:4YMR
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MX'#6VBX_5TYZ8-1OHY #L*Z,\Z".4%>=[FPN94?M)M0'K$KC;*D#WN7J1M.
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MC.PK[VZIXTF%&].V]^,4J26(S<Z6D]"+-0F%'H,4;2;%D=:[</C^.KDC;3G
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M#V3LD#1L#-YE_#T:5.RFKS+(-A0CU+ ]6EF6;#Q33]#,;[F79_@3ZPW[ZY_
MG:'8%)>)BEO-VQ-U]UEY@+[ D\#I;%Y^ *GMA\<?&0^[VVAN&'82<<1QP9#A
MD#=1.GK((]-T#-.A>,;B!,#Y_$N-&G77]AH>=;MR0^S05EU5NJUZ:TB;=7G4
MPF-)(U$1%:4C*IW:V?^(1VTRT70=A8!LJ 1^:(0_F"-BR:\$>D7QJ()-8&Q$
M,Q3=5:E*7C5GK,%-Z%3#@P=U[[2*0V3;IHY-H &XA/108:K@ ?ADF[JF>J<S
M9!T/ZA![3/%FV2&_N08ES89 4-RPSEQ0A=&!-$7V*_P-(@5UD?9"]=D1FY=@
M'F+-BCI4VCW:E^I#9:C46TJC7>\W%;'>$]MR!_YK-F'U>O8_TE%W>5:DH^;B
MK."X!A,4YC9!C<ENFLHS](0O3Y)LDV!:II[7/'A^ZBG;OXT\;4O,4-TNSVSP
MN*[)0TT'$Y1N.[4VOC*8W;^QHR]1LRMMG%WV;?$@B45'% \G41N^XZFT$YN=
MP0+&(^SLX,F8'<-$-58/CNT<O=F@"+S+>.3GEYJM ?>QN//E-KP7+KV$?;=-
MU_*^LC.6)SZ[,_*N\Y:<^?=2=@@D^*:I^'VDP0RPM]+( Y7GU[\O'UY9??@L
M^&FY]2EC\^";[8#*QZ,79_,>!L_-KX7=5!=NQ1',7^%=";X'+SE>FHMP;E!7
MLXGQ='70_H3*-MA)9_[KF9X.F@BN!=^QB<BY#HS/'EAC!9A@[^"?<S;O5-B0
M?V7;.;L%R3Z=ZIJ"3/UN[A;.%IUHL&J,-7]AVVAXK[;H'],\@6L[$Z,@:%\F
MQB* MR3&NS$&9FBAQB@%AZGV ]SBN9+@+:KV OTZ6[B5V0"R8UKK\ /-;,+/
MN^?QQPMJF!/-B&HVKI!8:N)XN?<?P7==E%S^5%Z5VZU,Y/:[N8G8Q"_8W$CQ
MYT9*?&Y6/5;%FYNX^GZ_N5G4+TF(D@]441%%R19'"]Z[ME/&C3]^^HQ=\KZJ
M\+(W-#(TWV-%5&V"H0FFL>ACW3",VEF$[\5KZ_0X\A7A)(8]V5JE-W=7=SL2
M:[/WO=R$VSBV*A$QQEY@N2GY\0"K1,[XD57EIFKL<9:*N 6PDE(98U)GT\J-
MV52-@8*LBA(^=%=N@F=F1)25^-SXX##@1DNZ1DO^H-"XRL]@_9^D2Y^K[IS6
M_]D3D:O@2I&3J]+,UO_)[J%R[WAZQ)*2==8DD9:BW(3+0SOF0D2N'2M%3JX=
ML]&.Z1"W6-[QY,:85.Z8<F,V.^]XKG$Q2>;&*3?!\_&.EXGX7%MEY!8M$2BX
M15HQ&&A<Y6>P_D_86<-5=Q[K_^R)R*5MI<C)+:K,UO\I$+=PZ_\43E%Q"R E
M0.YS'&Q'8G$+H )$Y!9 I<C)+8"L+("DB)M45M)RTS/3V/%L,B'L3V2N8 ^8
M^%PQ<QAPA9YM['CVH-@K47&Y*9[5VEA,U@Y/(NERN0F7Q]HX%R)R%5PI<G)5
MFLW:.!WB%LL[GMP8D\J17F[,9AH=ETUFI/V)S(V( R8^-SXX#+C1DFV09$Z@
MP.H"=:FS^/'1'=KT+Q>G[07^FI<;6/Z]X*2/'L2<Z)&C2=/!@W,;T\&S>.NN
M.1'_S7*I^[\&:0==QSKY=_#H3NEV]ZTO4E"XQ!@50,>K4+%N;"DM:5(ZZQR'
MCC=>*0[3FH57O3']\8 E +QR'IJA3=Q)5<B[=LAKJ?MA)VS+.0GGJW:&7Y<F
M[4!Q([]QW&R-F\5)JQYNKEPPQQTW$*C5E3(K ^6R)1&,5$NBI(J1:LN1[[+A
MCF3%817Z#L9TV31J+F&21T^UQ$UVZ"FO[/GJ59IZQ$)3-Z;BE4-#+#"WT:UI
M^,6K!JPB6+&1L6XL<P_)AD&5@VQ!V#(G6[ID2SC:/"SQ*MMC$%GX#\JC%UD/
M/=/?38/.OLO6G]2Y<@W5']X?5[)FL5*\7V??/><6#N?*8GX^9>;9C\$]"W?8
M#UA)%05?L8F_?D;FY(^>FMTE>-!NC+F==R+.))=#AB0"QO#CKT!^V5+&LQOZ
M0O5E/%X;4]>QV061XSE+/&\@3P2DW].),U>9F$OBS%4*YI(X<R7"7$GA_(\K
MS0#34Y/U:^B9Y>(][.$?CT\6>VP&</MFOE#+F"\=B\H=V8$B?I>BYW?>C8T3
M75I0YFT<51;7AV36<"9+ELF2-I(XDU7 O.%,EH=Y=6Y:4PPMH!=TZ#SB0YJC
MT8*[*<L(RHT375I0%M:\*CNNN7G%F:SPYM7!,ME!FU<58K(-KF$\MT<MG(=[
M&9KG;MVE$XWO9J9,K% Y*.9MA7$T<U..LQ;?_RL/:Y70@"LD:Z6_Q* 60E4!
M<].^&UW0J6D'4U)4UBBE3;]^FDL+R+RMHHIB^I#,&<Y@Y?1+'2:#E="HX0R6
MFDE5 J0?N,6<MX%2 H0<DK%1-;@>BBOD0%5WH> :',;C$655L>?R".)*J;!-
M@51^97%]2(8"9[)DF8R'(W/SAC-9(<RKLD>4E0:4>01Q%4_R\W!D;EYQ)JN*
M>76P3';0YE4UF2PM#EF*R+HUG6M#T5V5JO_2G'%T3%=IV*=$B-V5"J6%<X$-
MLPIS!+?:.'N6W:3C[,GMO4-G3QXE5V:\9AZ85CQ]P4.KN;W&&:P2!MEA,MAA
M6UP59+"J1R(6.OBO>/*3AU97VMBH&EQY:'6E57>AX+IS&O6B@BJ%U.7[$2RM
MHQN5BD(L8I1=QH0K9WQ#$??O,R=<1"*4$A-LF[0NY2)4";T;Q5N]%[$V=%')
MEV8-Z$)1,5CU<"IF2L64UJYQJ AZ A9AU++A^J,Y<E[EH-IP^<FX?FSEH.,>
M-;'+3[RXM:]+*S\YQ<K&8S>P=*5C4U>O)U,+%J_,750%ZODW;QA?]=B/$[-"
MG+FI<GFYJ;ES7?;2,B:G96'Y4D5:BO4&H$,,/P)9STT7;K*F,DS!K3SQZ/CP
M]*]KXX7:3H$EJVTY)U&=]XD5-80DB02$L)P+V:%G\WD-VPFOA5.F+MTZIVAP
M)29%7;#2&#GOP58+*3+QML#._";@8_!\<"7XCL^G P^4#ZJK.'?6([5>-,6[
M\S>J3V:.Z=_RZ,!0\9E'A1HR#)3=\RCKZ#C[,7TRI4;CNZ;K0-_J8R[6RZ(F
MU7_9TM3N]Y9(NOBOV4"=\K-3D3C@*W5>*37FDPRZJ,GYH9#\$(=6G#L2U0\O
MU.+<4$QNB*)-M="_'*?#+>9\EZBA$?P Y'QG!+N.=8(7BF("__AV*S:DCR7<
MLH6%1^VN+@:#*3J 9+WZ@-I7X"U.<\KR+@:EJB7^]N>,G>U>S@<I&*@<LOM!
M=MG@X1!-P&H\($BVYY!L<P]L<A1MQZ=H.T&*2O!:GZ*^MSYM.FT[-WX/X\S-
MRGY#4DNFK[(N&PI]'%/JW)B*[*!&0IC?.6-JG;N6!8.YT>2AII<@XGK=:.8;
MN!N'5<@UU=IM/TZZ$F:[0^W6_>/&-)Y!-D\P[C_<HF4' *B*OQ6;5%&]GY/I
MW3!2(PV;RZ0V8 /2;$VE/_X)-I0\U"FZ-KP@&--03>,:M>]0-OZ\&XTH/(&7
M;[2A:8F'0=W8+UR=OR!<.-8LIF:VK,!KLVI>NG5?LP7;\LT6]A%$?4PD/KI#
MFQW)="Y?X*_YG<N_K\.MWR":_X;V/';\\Q7&,][Q:(X*?GHG<^"NF>Z%=T;-
M>VH,$Y-\J7&,C]LX'./C.BEC-C#TD;@KQYKNQ[(UD?\TC1M3+NCF5$#6][WW
M"1LQAO1TZN)Z) &=NK( XR1*1#/EM&CD1"S<LB*P&,2YQ<#6]9Q$2>BSN'RV
MLL)/RCG#B5@LSTM %W8*X!RN6AAS+.M/8'6&Y_YD8P9K%4VA]K5Q;5LR+>B^
MP]*1AHC!+!SW6S>DPE.-2<=&76SXTI%]Q/74.@*R"X-GBWH);DS+&_<U0-4>
M&,]4I_:YK&LC$TQLV5]'W=!G6;]D0_/""BSS&S4\D%\;2JFIO\-\[+Z^4:EV
MLC*900A!U)2F)OA]P,01_#Z@DA;\')\<GQE)QPC;D:./HZ\ 9G$83/@=+HPC
MHPF_!\_&#B5$,2OVZZ)8E_H[ /W>T@R%.J9Q2U]_HY9-9X<,\W6S44J0ST5L
M@(_,E@T<;H<,MQ0T>FM%HW]\PJ-H6$GD$$4"JJZ5N0<H\)RW0L\YI^%^WO*X
M-)22I6&$9<UI6&R3<_,.%J=A5KM6B7K3@UVK@:)@2*Q]:SK41M<S9C";;Y)3
MA6HON*W^=3;_'(90S-/J/DY-PS8MJL*4/EORQ'Z@-LQIT>/K]AF]#Y38<U#X
M7;/D<,&"$@\& 1&C+3RMU^EB+@[** X*8A<DC2<N1BJ%$8T+FK(+FO2C"+C
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M*# 9Z(S$,XMX,R;]5F5+M0D>E=#4=<%HS4_RYT@/(?=;[^:WML=4UP.$D$]
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MI'Y13F(<MMFV(<Y1I5/3UKC83Y$CHT(3M@QUQ!TLVV&IR,#^5O8)?)>*$IK
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MC(0XO"ET6H5._<-!7&@0[Q=OD1B(I6YFR?MYFI"=(RXBU%6T1[L,K%X$'OZ
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M-,$P*]X;")&"=X7,L/1Y\>,X=#S<#[Y=UK\^7 Y^KP^NGBX?3HBLO\HS.Y"
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M/0D/I'>%;J];H!S#' NY8 &$PZ=VMRN(>,0Z)S!4]"QHJ7#0 AR(C?P$ L=
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M >>Z)@\UG1]*X4T?4-/<F-UDS(:!=MQDS7Z?NAL5I;)]D*]BH25P0;U_KXV
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MP^'B2(NLL^>Y,V3ME8&0&#Y#U=NXS)#!SW4/DG'!?Y\*X(4+'WDNS\7)BP3
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M$M/@]%Q5%NF041#ZDWH@L%(^1I/)@'<#=^Q%@6Z;U:NBA/9([*EF3&P&X '
M\@Q_/'MH@J&H8A[A Z]9;&!&3DCJ#0;5D[H2*J[+TRRI(@&OW6*C9TB&OY,Q
MSZ'X;3V7&9.4!5D$@'_!, 13ZE]80>$9G;[*,""T(A%H-3+_[4DA1=0/T2S0
M>%Q>#\#AF2BH4)OX8BE2K28BK)+IGMHKE _J<;U/I'[PF&OM&0=OE,S/PDJA
MZ\_XHLB:L3(6<(!9(M>4TF[9S[8547&9))66T?R"_$V3=>W9%PJ2XYD?JGJ&
MB=P>@U4H RDF\CV&$8[F" WX_R6=.0B3!8LLAOB.Y?#TK!(U'+?QJYQ@@T=
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M(P7IH%RUW;.W\#^,Q)4B[H5KD9C$"<,/MJ*#MM9H%\;VJD"$?8?N\[=PO0U
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M;@2R3VHGYZ6&[!T)-5DA$W]]EL9F8\HE;4:AI[X2CFOZ+LN;O/@2$B)!6FI
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M+;^_D4ZXD5"+;K# 9J1"S.V-9'X41DINUN5KLQ/J;H_U333:B74'0P"".IH
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ML 6$G+NN^5I,A7! ^CEE7M1>.8*?AD"VW?X0@9'FX;"NK46C[]*),XX I/N
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MC#58H7X>/QP;3QYLTD5F6XP):@$#YC;GW)Q@F%Y'G@37:N1(<.L2IOZ\EA7
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MKQUC0?VEJ)3SS!SA8HT@*V2=;\, LEK6>3LK#V"=$M#Z=9VS6NO\I#SFCVF
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M@?%.KT_RO@S^WS5$BQ#G#4*J$Y(=)M(IMBI)-UV4I!O7)#G?9DV2@F,/L]7
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MD0 ,R(I!7;+3G<P/)("K<./W\N$R)XVLG/BWE:&_$\WA5RL>>U;%<95ASI)
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M(4C&GE]+6$8UBR@%X"MW4KPXK<D;G<_!X>>(FZ0,(/,]KO6E;0$4Z!]G!5#
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M,5>+[Z)WLC04W3@]6.WF<=I(=_NZVW<SL]# TUH,.Y?-P?'($A56'%C+J]#
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M$.,AW:"15Y4Q4C_*AK<!.;<_2&V+*?<3RC3<(S!4A4 _XM\HD+1F"7NCM;/
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M^FT00V3;S)%7>(B.>4KU%$S28%4&C)!!EV#5O:8JTJ822J$ 8&1@H'O]H?&
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MN4J"4F$3P0+N05 461C3!U=Q.:4YSX*T&@=A6>5J^2; $SC75M!*4XW=X\W
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MO2P%J6VXFMCV2P=_H$^+[7UF3>QB![4B#>.Y22$6D]H,2=1JC?PPS"O<F*J
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M2%Y_X!\>G_K]PZ,E4T/<T6+D6/OF$WUME[>;H??!2V)5X3/\M6_"D'O,AX6
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MI(I[9!\ZFQ"67QM$DSN*Q6I"I#?ZZ@(Y)VZE,3SU*1 HD0O]ZD"S47;82AA
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M_8D9.A&]E2_J3F]9;RF&P?S/ZL%WK+GZ</7M#[<=B9_6]&@_?/N$7PZ7T^E
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MFVJ&4:M?)UOTBNDC2P2+U^!T;#P7J"<Q.&<0QA-ZYA+P4!!<>&8'I8W3<OW
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M9]R0(;-FYQ,5=^HK2'5@%IK6PB>KI]_^[W<__/1L0B:YG/*4%;(9?TW\[M.
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MO ;)]S_ZW"\$;=4KS.R;R02HHHQ$V@4@$A0!N*(R'0--FFNBXJ0EN:8\"6J
M'.2T-11@?%ST->#>'Q\B9<:VA+'MTP\S8UMF;'M?&-M^OD$"=M;U7*6<H%,$
MY2$>G4,DP<7_;9<.I7GY"\;QL.O7*JKN9XNYK^4.?&A/8&K!O#XLOJ-;VI-+
M7UEJ5KY4HO"VXCH!C1H,#55SQ+ >ZZ;2*$':=$I=)*.0.]'L2\1S?78_;2:Z
M7]UFU$[BG2H62YB'A;*&!R'9N^07&!*7&&+"B.WU20?X_'L$$ZT$6#4@F9MR
M/U'/N16+<[;!6\:Y=J0IE'9Z.=Q)O\9JQ8\TU8C-"L^7S &_WJ*\S &"]$33
MBK07(^2_^3B1&XO:=62ZN=8(:'3:5"^S5^9AUCRE\'(CAM[492UE_&LWP=S+
M"EUP#O'K9MM/F^K!%<R<"(L@^5[UG0$S@KD<AZ-AD5V,#N7\4@)<[Z *NVL.
MH)B_A(&=&K]*WC+E6A:>FIN!R5SF=#VMOKT'YO=7]494!KEKH"+1W,>F<+UI
M'"+V@& G9]2/M7>CO;-^^9'57)%<T]OJVM;1I7/;GX6NZ!:ZDY-=Y7BT8E#<
MI!U.E&3M1<H(\0]YO$$?Q 0O?^G*:N-)0LSV\2'$Y7Z@$3S%@V*]P4I%#E\J
MU/VAXW"V;K=]24YF!,>UB"IA,<98E/B-K9W&S/65O G,O3P2.B1^:9HGJS+6
MVD5SW7? KTRP!L;N$KWEBU7:F#D'NUB"+H1U9J -O=J0YO+@)DMV'0UK/+$-
MSKT7_*NN+%T:!6-%B@CS(8MDL@'+Q?C%PL;%_5?.3&?8:,>YH&#Z4V2UWO0B
M,&-2QXGO?Y+DQ,>_$?[F-9?4MX0GR7^84*CXW&DZ]I2\?(.# R6D[6[QOI/M
MK@V7N<C'GJ[H(GZ_X4G>X+C.B3]*)QPK&4JPU\KRS680*@K*YI*.%2]2?[\5
M=-]O*BY= O;'BRN8!9+Z!<.\.S#30DM[Q]JZ>"<"P.\IZ;2>S9XI/H-87WA:
MC'4$U!'+=M]A^YF8JX='8C-8Z"],E WG(5W@5670RRL"7%@@W?1//7\9>XZ%
M?28>S9!!L*1TPR0F$WA?IPMK^H#D@,Q(P5-O<+ACB3VL,.P91Q?6T91Z%=9M
M4UX/:=XT+;/=?ML<<"QAR>:"DAPAG;T'VG;'7M&G95R3Y;0J"B/VT)2 W.P:
M4*[YZUP[+H"[!G*;$6\!G;TCTSHSF3,WX.DU!H.F1[*7AQF<M;&K)*T%BV;#
M;D@V#T\X2AWOTC5Z-/+K"-GX'(K0\Q>L=\IE9-ILMK6FL9*E+G??\1G!_,U
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M2P@][S",H*,'G@O(DW?\K?[[C\^_=DT03 WB*=DU9->074-P#09'XU;TL1X
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MSE^TW77CJIW X/E*=KO>[41\C/-)N)2M<Q5*TQ+^AG(.>QL($,I5'7IF^(_
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M2ED6(10.LO-/H>S7]=' X@D-\_49-N2$_S@FE+R%8CE[NNSILJ>[L0O$LWY
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M]^.S&EV21*>B6.!Q^>ID]"O7:^#S&AD#G*NK#0$^@9[/?*8CBE93'H9#Q#_
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M><DBT'9JI?=I38,,;X]U2FHCS0 G'N:EU_"XDG7:+T%6I2RDM=1E,KC*[*,
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M]A%^$!>=ZN,Q$:6.)2+)8(?U\ZFFC4^'6HB9[*A!* N$HPNJRY=S'63Q7#B
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MC/_]=GE*!T@!NN>Y3B".]$[65E9HNE8W(A<=KV9"\S$&=8ELK;D(87SLTVS
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M?"7EP*T'EK9>O$"]^F,W3K!EI_WJ/0S2@1_SY:<O*FE$(&8"M#OB>LN?N6(
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M<I>2K]:;HDZW-4F4ABK+D=^#?/S>'$]W,3+=3>MT'[8F(I-.OPAN8DL8B#+
M9KY1F#UU&&?"F$SPY#(_N#?J'&S%"XS'^51^Z0:IW_J00F'$;7W6/N<U)-U0
MI1/S'LS\'5Y)+S5'V;A^)-IM,05YNDOA89O9?8=I-TQPR3 8,80$W2632U.O
M!SW.'E.<,H.?[J0@2'6:,X-!"@\+'7_#U([J@!!"%Z'/_3@=6JNV98EMWQQ,
MF2=_7":638P%311_TPD4.E=M$-0/(ZGD>LN^[/GJCV%3"_-RO<(N^QXN('L
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M32WVC_<?>8_81$*^GMO)N'GG3WAJRI+5Q$'4I4HBD3>BLT0M%8<A[N7OS63
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M#[+C] NWK7,J,P2,"XAW13<V_#$[!EBZB]1$HGV/=3YE)((M@$'&]\7THI=
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M@#!BDC]V#F0IU&4DC9I:'D#RE4;>2^ &BTG&BY4)E#BJ5#+L?<ZOL9.D.8>
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MOPP=):ML0XQLE'4+E72HK6BV!G*W+:L*N%^XJ>-G8@\P?Q]N[L'::V4^%26
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M>OE8NAJWR$Z8LDY%I98C+L^MZ@0MU .DMHI'T<5)&FK0_T]YUTSB[+ K+\K
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MNRLGW=9HL1OT5QU\D^KTXO45G(; &R0NDC7V35Z>,Z)CLGI([H>.%>.!EQ_
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MK9N!>E51EV2?1G?U;8,X!>1O+O)#9.E7:4-<+0WC#PFTL&.YJ?8=;#8BHXN
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M>Y B.CDF7XY^ZV>93TX]Z7M)_X0SWOT4QDA;M:\61L[ ,P:>/9F!9S/P[ K
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MA0C536]9Y*=6C[!N;&>?9%6\U2)9$5B/#;@6W%56+D*C8Z;VZ!I"=]"R4YS
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M"OFR5;Z@5(Q<*+CSL>>?\G\+MQ,SN-'G)?5+\D0#G+-V%JUF8DWE:"=C%^I
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M>%\U,S(X.3<N:'1M4$L! A0#%     @ D$ *5X,73?G;!   ZQ@   T
M         ( !U1   &5X7S4S,C@Y."YH=&U02P$"% ,4    " "00 I7@+%J
M0=P$  #<&   #0              @ ';%0  97A?-3,R.#DY+FAT;5!+ 0(4
M Q0    ( )! "E>MXBQ2]A4  ,=T   -              "  >(:  !E>%\U
M-3,X,#,N:'1M4$L! A0#%     @ D$ *5Q7U@F7X3P  '^0!  T
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M+3(P,C,P-C,P7VQA8BYX;6Q02P$"% ,4    " "00 I7;/I8P)](  "HE08
M%0              @ $@20$ =7)G;BTR,#(S,#8S,%]P<F4N>&UL4$L! A0#
M%     @ D$ *5V+>T?M\N0( <WH9 !0              ( !\I$! '5R9VXR
E,#(S,#8S,%\Q,'$N:'1M4$L%!@     ,  P [P(  *!+!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
